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ABSTRACT
The effects of^% , and in male CBA/H mice have been compared after 
systemic administration in citrate solutions. Each nuclide was administered to three 
groups o f animals at levels o f activity which gave estimated life-time average skeletal 
doses o f about 0.25-0.3 Gy, 0.5-1 Gy and 1-2 Gy.
Statistical modelling by Cox regression showed that, considering all three nuclides 
together, there was a highly significant increase in hazard o f death from osteosarcoma or 
myeloid leukaemia with increasing dose rate. For osteosarcoma, the effect was 
significantly greater for ^^ P^u than Am. The analysis for was statistically consistent 
with no effect o f dose rate. For example, the increase in relative hazard o f death from 
osteosarcoma for an increase in dose rate o f 1 mGy d'* was 4.2 (2.7-6.5) for ^^ P^u, 2.3 
(1.4-3.4) for '^’^ Am and 1.1 (0.4-3.1) for For myeloid leukaemia, there was no 
significant difference between ^^ P^u and "^^ *Amin the efiect o f dose rate. The increase in 
relative hazard fi’om myeloid leukaemia for an increase in dose rate o f 1 mGy d * was 1.8 
(1.1-2.8) for ^^ P^u, 2.0 (1.4-2.9) for ^^ A^m and 1.5 (0.8-2.7) for Significant increases 
in hepatic (^ "“Am) and renal (^ ^^ U) carcinoma were also recorded.
Studies o f the distribution o f the nuclides within the skeleton showed differences in their 
retention in individual bones and within bone. The proportions o f alpha decays occurring 
near to bone surfaces and in bone marrow were in the order: ^^^u> '^"Am>^^^U. For 
osteosarcoma, the relative effectiveness o f the nuclides was consistent with the proportion 
of dose delivered near to endosteal surfaces. For myeloid leukaemia, the greater 
effectiveness of^^^Pu and '^^ ‘Am than was consistent with their accumulation in 
marrow.
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Chapter 1 : Introduction
The skeleton is a major site o f deposition and retention o f the elements, uranium (U), 
plutonium (Pu) and americium (Am), after their entry into the circulation (ICRP, 1979; 
1986). The commonly encountered isotopes o f these elements decay by emission o f alpha- 
particles. The distance travelled by alpha-particles is about 40pm in soft tissues and about 
25pm in bone mineral (Thome, 1977). It is therefore o f critical importance where the 
radionuclides are deposited in bone and how this distribution changes with time. The 
radionuclide distribution determines the radiation dose received by sensitive cells and the 
associated risk o f cancer: irradiation o f bone stem cells can result in the induction o f  
osteosarcoma and the irradiation o f haemopoietic stem cells in red bone marrow can result 
in leukaemia (ICRP, 1979; 1986). Differences in the incidence o f osteosarcoma and 
leukaemia induced by alpha-emitting radioisotopes o f the three elements wiU therefore 
reflect differences in their distribution.
In the studies undertaken for this thesis, the toxicity o f ^^ P^u and '^‘‘Am in mice has 
been compared with the overall objective of relating the incidence and distribution of 
osteosarcoma and incidence o f leukaemia induced by these radionuclides to their 
distribution within the skeleton.
The thesis is presented in four chapters. This first chapter gives an overall introduction 
which considers sources o f exposure to isotopes o f U, Pu and Am, their chemical and 
physical properties and their biokinetic behaviour in the body. A description o f  bone 
structure is given, current dosimetric models used to calculate tissue doses in humans 
following intakes o f radionuchdes are outlined and our present understanding o f the 
biological effects o f radiation and intemaUy-deposited radionuchdes is introduced. The 
review of effects includes experimental data from studies on the induction o f  osteosarcoma
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and leukaemia by incorporated radionuclides and human epidemiological studies on 
exposure to bone-seeking alpha-emitting radionuclides.
Chapter 2 gives details o f methods used in the experimental studies and Chapter 3 presents 
the results. Experiments using CBA/H mice are described which consider the distribution 
and retention o f ^^ P^u and Am in the body and individual bones o f the skeleton; 
autoradiographic studies o f the microdistribution o f ^^ P^u and "^’’Am within bone are 
presented. The results o f a life-time study o f tumour induction by ^^Pu and Am in
CBA/H mice are presented together with statistical analyses o f results.
The results o f the studies are discussed in Chapter 4 in relation to other published work 
and the Chapter concludes with a summary of the overall findings fi*om the work and 
suggestions for further work.
The main objectives o f the studies undertaken were:
#  to quantify the incidence of osteosarcoma, acute myeloid leukaemia, other 
malignancies and aU other lesions in CBA/H mice, comparing the effects of 
exposure to ^^ P^u and '^’‘Am, in each case relating incidence to dose using 
three dose levels;
#  to obtain detailed information on the tissue distribution o f the nuclides and their 
distribution within bone, considering changes in distribution with time;
#  to relate observed incidences o f osteosarcoma and acute myeloid leukaemia to
dose distribution in bone.
Chapter L Introduction 3
1.1. Sources of exposure
The exposure o f people to ionising radiation may occur from either natural or artificial 
sources (UNSCEAR, 1988; 1993). The most likely routes o f accidental intake by workers 
are inhalation and absorption from wounds. Ingestion is uncommon in accidental 
situations but is a likely route o f intake following an accidental release o f radioactivity into 
the environment. Natural, or background radiation, has three main sources: terrestrial 
radiation resulting from the presence o f naturally occurring radionuclides in the soü and 
earth, cosmic radiation arising from outer space and naturally occurring radionuclides 
deposited in the human body via the food chain (Hughes and O’Riordan, 1993; 
UNSCEAR, 1988; 1993). Artificial sources o f radiation include exposure to radioactive 
fall-out from nuclear weapon testing, discharge o f radionuclides to the environment from 
nuclear power stations and reprocessing plants and the possibility o f accidents at nuclear 
facilities or during weapons manufacture (UNSCEAR, 1988; 1993).
Uranium is an alpha emitter and is found naturally in various quantities in most soils and 
rocks (UNSCEAR, 1988). Natural U consists o f three isotopes, ^^"*U (0.0058%), ^^ U^ 
(0.71%) and ^^ *U (99.28%) (Greenwood and Eamshaw, 1994). Their decay produces 
much o f the natural radiation originating from the earth’s crust, leading to population 
exposures from radioisotopes o f U, thorium (Th), radium (Ra), radon (Rn) and their 
daughter radionuclides (Hughes and O’Riordan, 1993; UNSCEAR, 1988; 1993). 
Radium-226 and ^^ T^h are also alpha emitters and are present in varying amounts in all 
rocks, soils and water (UNSCEAR, 1988). Radium-226 decays to ^^ R^n which is a noble 
gas that emits alpha particles and has short-lived alpha and gamma emitting daughters 
(Greenwood and Eamshaw, 1994). Concentrations o f natural radionuclides vary 
according to the underlying rock stmcture and levels o f radioactivity in the United 
Kingdom are highest in Devon, Cornwall and Aberdeen (Hughes and O’Riordan, 1993). 
There are other regions in the world where the terrestrial radiation from U and particularly 
Th substantially exceeds the normal amounts present at the earth’s surface (UNSCEAR, 
1988; 1993). The highest deposits are found in the Monazite sand regions in Kerala, India 
and Brazil (UNSCEAR, 1988). Regions with high natural backgrounds can also be found 
in Italy, France, Iran, Madagascar and Nigeria (Eisenbud, 1987). The Oklo U mines near
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Gabon in West Africa are the sites o f several spent, natural nuclear reactors. High 
concentrations o f depleted U and some U fission products are still present in the rocks in 
the mine (Greenwood and Eamshaw, 1994).
The main use o f U is in the manufacture o f nuclear fuels to generate electric power and to 
manufacture isotopes (UNSCEAR, 1988; 1993). It has also been used in the manufacture 
o f nuclear weapons (UNSCEAR, 1988; 1993). Occupational exposure to U occurs during 
U mining (UNSCEAR, 1988; 1993). The major U  resources in the Westem world are 
those in the United States, Canada, Southem Africa and Australia (UNSCEAR, 1988; 
1993). Uranium miners are exposed to gamma radiation, radon and thoron gases as well 
as radioactive dusts containing isotopes o f U and other radionuclides (Duport and 
Horvath, 1989). Occupational exposure to U may also arise from the preparation of  
nuclear fuel elements, the operation o f nuclear reactors, the fuel reprocessing process and 
waste disposal and storage (Hughes and O’Riordan, 1993; UNSCEAR, 1988; 1993).
Plutonium-239 and Am are alpha-emitting radionuclides produced from ^ ^^ U by multiple 
neutron capture (Lederer et a/., 1967; Hammond, 1993), primarily during the operation of  
nuclear reactors but also via nuclear weapon detonations. Exposure to these radionuclides 
may occur from radioactive fall-out as a result o f nuclear weapon testing and routine or 
accidental discharges from nuclear power stations and reprocessing plants (Hughes and 
O’Riordan, 1993). In addition, there have been a number o f accidents involving exposure 
of individuals to ^^^u and "^*^ Am (Breitenstein and Palmer, 1989; Carbough et al., 1989; 
Doerfel and Oliveria, 1989; Mclnroy et al., 1989; Schlenker et al., 1989).
Atmospheric nuclear testing began in 1945 and many weapons tests were performed 
between 1954 and 1962 (UNSCEAR, 1988; 1993). About 450 atmospheric and 1000 
underground nuclear explosions have occurred (UNSCEAR, 1993). The fall-out from 
these tests has resulted in the internal radiation of individuals by ^H (1.2%), ‘"‘C (70%), 
^Mn, '^ *1, ^^ Fe, »^ Sr, %  (3.2%), %  (5.3%), °^^ Ru (2.2%), ^^ C^s, "^Cs (14%), ‘^ ®Ba,
‘"‘^ Ce (1.4%), ^^ P^u, ^^^u, "^*°Pu, "^*^ Pu and '^^ ‘Am. The radionuclides without individual 
values conqirise less than 1% o f the total present in the fallout (UNSCEAR, 1988; 1993).
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Exposure to radionuclides may arise following their discharge into the environment from 
nuclear power stations and reprocessing plants such as Sellafield. Discharges o f  ^ ^^ Pu and 
from nuclear power stations are extremely low but liquid discharges to the Irish Sea 
from the nuclear fuel reprocessing plant at Sellafield in Cumbria have given cause for 
concern (Hughes et ah, 1989; Hughes and O’Riordan, 1993). The Ministry o f  
Agriculture, Fisheries and Food (MAFF) have identified critical groups o f people in the 
local community who are likely to receive the highest doses because o f their dietary habits 
(Camplin, 1993). Estimated doses for these groups, due largely to Pu isotopes and '^*‘Am 
in fish and shellfish have been progressively reduced over the last 10-15 years as a result o f  
a number o f factors (Camplin, 1992; 1993; Hunt, 1986; 1989; 1990). These were a 
reduction in consumption o f  local shellfish, the use o f a revised lower value for the 
absorption o f ingested Pu and Am to blood and a reduction in discharges. Discharges 
have been further reduced recently by the introduction o f the Enhanced Actinide Removal 
Plant (Hughes and O’Riordan, 1993).
The United States Transuranium Registry maintains records o f workers in the United 
States who have been exposed to radiation. Amongst their records are cases o f workers 
with ^^^u and '^‘‘Am wounds to their hands and bodies and workers who have inhaled Pu 
aerosols (Breitenstein and Palmer, 1989; Carbough et ah, 1989; Mclnroy et a l ,  1989; 
Schlenker et al., 1989). Doerfel and Oliveria (1989) reported on cases o f four workers 
receiving intensive "^^‘Am contamination (external and inhaled) at a German industrial 
research institute.
Nuclear accidents, both at civilian nuclear reactors and military installations have 
contributed to the radiation exposure o f the world's population. The fire in the No 1 pile 
at the graphite reactor at Windscale in 1957, resulted in the release o f a radioactive plume 
containing ^^ Sr, ®^Sr, *°^ Ru, *^ ‘I, ‘^ T^e, '^^ Xe, ‘^ ^Cs, ^^ ®Po and ^^ P^u. The major 
radionuclides released were ^^ I^ (37%), ^^ °Po (37%) and *^ C^s (15%) (Clarke, 1989; Crick 
and Linsley, 1984; Tyror, 1989).
The pressurised water reactor incident at Three Mile Island in Harrisburg, Pennsylvania, 
resulted in the discharge o f  radioactive water, fuel damage and release o f fission products
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into the containment building which led to relatively small external releases o f  ^ K^r, ^^ Sr, 
°^Sr, "'I, '% e, and '^Cs (Behling and Hildebrand, 1986; Tyror, 1989).
The severe 1986 incident at the RBMK reactor at the Chernobyl nuclear power station 60 
miles north o f Kiev in the Ukraine resulted in large releases o f radionuclides including ^^ Kr, 
°^Sr, ^ 0 ,  '%u, ‘®^ Ru, ^^ T^e, '% e, '% s, ^^ C^e, ^^ Ce, ^^Pu,
^^ P^u, '^^ °Pu, '^^ ‘Pu and '^‘^ Cm which contaminated land around the power station and 
led to the necessity for large scale evacuation o f the local population (IAEA, 1986; 
UNSCEAR, 1988).
Of the nuclear incidents outlined above, the incidents at Windscale and Three Mile Island 
caused no acute injuries or fatalities while the Chernobyl incident resulted in 31 early 
fatalities and 203 cases showing acute radiation syndrome. Although assessments o f the 
effect o f releases from Windscale and Three Mile Island indicate that some cancer deaths 
may have resulted in the exposed populations (Crick and Linsley, 1982; Hatch et al.,
1993), the levels o f exposure were too low for the numbers o f excess cancers to be 
detectable by epidemiological studies. However, an increase in childhood thyroid cancer 
was reported within 5 years o f the Chernobyl accident in the Belarus area (Baverstock and 
Cardis, 1996; Kazakov et al., 1992; Prisyazhiuk et al., 1991). The average time between 
exposure and diagnosis appeared to be six years (Cardis and Okeanov, 1996); the tumours 
appeared to be particularly aggressive, metastasising to associated tissue and lung 
(Kazakov et al., 1992). Epidemiological studies are being performed on the populations 
of the Ukraine and Belarus as well as specific studies o f the liquidators who dealt with 
clearing up after the accident (Okeanov et al., 1996).
A variety o f consumer and industrial products contain radioactive materials incorporated 
to utilise the radioactive decay as an energy source and may therefore cause radiation 
exposure o f the general population (NCRP, 1989). Plutonium-238 is used as the energy 
source for cardiac pacemakers and was used in the Apollo lunar missions to power seismic 
and other equipment on the lunar surface. Americium-241 emits a 60 keV gamma-ray and 
has been used as a gamma radiation source to measure the thickness o f metal sheets and o f  
deposited metal coatings, the degree o f soil compaction, sediment concentration in flowing
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streams and to induce X-ray fluorescence in chemical analysis (Choppin et al., 1995a). 
Amercium-241 has been mixed with beryllium to make neutron sources for oil well logging 
and for measuring water content in soils and process streams in industrial plants. It is also 
used extensively in smoke detectors, approximately 37 kBq o f  ^ "**Am is found in domestic 
smoke detectors, where its use depends on the ionisation o f air (Choppin et al., 1995a).
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1.2. Physical and chemical properties of U, Pu and Am
The actinides are the 14 elements which follow actinium in the Periodic Table and include 
U, Pu and Am. None o f the actinide elements have stable isotopes and many decay by 
alpha particle emission. Some isotopes, for example are capable o f spontaneous 
fission which can result in criticality with sufficient mass; ^T u and are thermally 
fissile. Plutonium-239 in solution can be triggered into a chain reaction if a neutron from 
any source, such as cosmic radiation, slows down in the hydrogenous liquid and then has a 
high probability o f fissioning ^^^u by thermal neutron capture. The critical mass for ^^^u 
in homogenous aqueous solutions is 530 g (Cotton and Wilkinson, 1980; Greenwood and 
Eamshaw, 1994).
1.2.1. Uranium
In 1789, Klaproth recognised an unknown element in pitchblende which he attempted to 
isolate. Uranium metal was eventually isolated by Peligot in 1841, who reduced the 
anhydrous chloride with potassium. Uranium Qccurs in numerous minerals eg pitchblende 
and uranite (Hammond, 1993). It is also found in phosphate rock, lignite and monazite 
sands and can be recovered commercially from these sources. Natural U consists o f three 
alpha-emitting isotopes, ^^ U^ and ^^ U^ and has two decay series referred to as (a) the 
uranium series, which originates with ^^ ®U and includes ^^"*U and (b) the actinium series, 
which originates with ^^ U^ (Cotton and Wilkinson, 1980; Greenwood and Eamshaw,
1994).
Uranium is element 92 in the Periodic Table; it is a dense, silvery-white metal which is 
pyrophoric when finely divided (Wilkinson, 1962). It has a density o f 1.9 x lO'^  kg m'^  at 
25°C and a melting point o f 1135°C (Cotton and Wilkinson, 1980; Greenwood and 
Eamshaw, 1994). The metal is a little softer than steel and it is malleable, ductile and 
slightly paramagnetic. It can be prepared by the reduction o f U halides with alkali or 
alkaline earth metals, or by the reduction o f U oxides by carbon, aluminium, calcium or 
magnesium (Katz and Rabinowitz, 1951). Uranium is chemically reactive and oxidises
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when exposed to air causing the metal to become coated with a layer o f black U^Og 
(Latimer, 1952). Uranium metal and most o f its common salts dissolve readily in acids but 
are unaffected by alkahes.
Uranium has 18 known isotopes, all o f which are radioactive, the majority decay be alpha 
particle emission; they have hah-lives ranging from 0.08 seconds to 4.46 xlO* years 
(Hammond, 1993; Choppin et al., 1995b). Natural U is sufficiently radioactive to blacken 
a photographic plate in about an hour. Uranium-233, the isotope used in the studies 
described in this thesis, is produced from ^^ T^h as a result o f neutron capture (Lederer et 
al., 1967):
^^ T^h -  ( w ,y )  ^^ T^h -  P “ -  ^^ P^a P “ -
Uranium-233 has a half-life o f 1.6 x 10^  years and decays by the emission o f an alpha 
particle which has an energy o f 4.824 MeV. It has a specific activity o f 1.9 x 10^  Bq g** 
(0.05 Ci g ') (Hammond, 1993; Choppin et a l ,  1995b).
Uranium in solution has been shown to exist in valence states o f +3, +4, +5 and + 6  
(Cotton and Wilkinson, 1980; Gindler, 1973; Hammond, 1993; Greenwood and 
Eamshaw, 1994). Evidence for the existence o f U^  ^ions in solution comes from the 
reversibility o f the U(III) / U(IV) couple (Gindler, 1973). U^  ^ions undergo slow 
oxidation by water and rapid oxidation by air to U'^  ^(Choppin et al., 1995b). Little work 
has been done on the hydrolysis o f U^  ^in solutions because o f the instability o f the ion. 
Evidence based on pH measurements o f solutions containing U^  ^ions indicates that their 
behaviour is similar to the rare earth 3 + ions (Gindler, 1973). Solutions o f trivalent U can 
be prepared by dissolution of a U trihalide (UCI3 , UF3 , UBr3 , or UI3) or by reduction o f a 
U(IV) or U(VI) solution (Cotton and Wilkinson, 1980). U^  ^solutions are deep red in 
concentrated acid solution or greyish green in less acidic solutions (Someya, 1927).
Confirmation for the existence o f U"*^  ions in solution has been obtained by solvent 
extraction studies (Betts and Leigh, 1950; Rydberg and Rydberg, 1956) and by measuring 
the amount o f acid liberated in the dissolution o f UCI4 (Kraus and Nelson, 1950). U"*^  ions 
are stable in water and undergo slow oxidation in air to U 0 2 ^^  (Choppin et al., 1995b).
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The properties ofU(IV) are similar to Pu(IV), but U(IV) is readily oxidised to 
(NEA, 1988). Solutions o f tetravalent U are green in colour. They can be prepared by 
dissolution o f a tetravalent U salt such as UCI4  or 1 1 (8 0 4 )2 , by the dissolution o f U metal in 
sulphuric or phosphoric acid or by reduction o f a uranyl solution (Gindler, 1973). The 
presence o f U(V) in solution is supported by the reversible nature o f the U(V) / U(VI) 
couple (Gindler, 1973) and disproportion to the U(IV) and U(VI) states readily occurs 
(Bulman, 1980; Choppin et al., 1995b). The hexavalent U 0 2 ^^  ion is the most stable U 
species found in solution at neutral pH (Hoekstra and Katz, 1954; Katz and Seaborg, 
1957). Uranyl solutions are yellow in colour and are readily prepared by dissolving uranyl 
salts eg. as the chloride, halide, nitrate, sulphate or acetate in water or an appropriate 
solvent (Gindler, 1973).
Uranium as uranyl ions (UOg^ )^ forms stable con^lexes with citrate, bicarbonate and other 
organic acids. In the absence o f binding ligands, U(VI) can be hydrolysed by addition o f  
NaOH but is redissolved by addition o f bicarbonate or citrate. In contrast, U(IV) 
hydrolysed by the addition o f NaOH remains insoluble on addition o f binding ligands. 
Uranium is present in blood as U(VI), binding to the iron-transport protein, transferrin, 
with a proportion circulating as U(VI) bicarbonate (Gindler, 1973; Stevens et al., 1980).
1.2.2. Plutonium
Plutonium was the second transuranium element o f the actinide series to be discovered 
after neptunium. The isotope ^^ P^u was first produced in 1940 by Seaborg et al. by 
deuteron bombardment o f U in the 60-in cyclotron at Berkeley, California. Plutonium also 
exists in trace quantities in naturally occurring U ores.
Plutonium is element 94 in the Periodic Table; it is a silvery white metal which has a 
density o f 2.0 x  lO'^kg m'^  at 25°C and a melting point o f about 640°C (Cotton and 
Wilkinson, 1980; Greenwood and Eamshaw, 1994). The metal is warm to touch due to 
the energy given off by alpha decay. It readily oxidises in moist air and takes on a 
yellowish tamish. It is prepared by reduction o f the triftuoride with alkaline earth metals. 
Plutonium readily dissolves in concentrated hydrochloric acid, hydriodic acid or perchloric
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acid with formation of the ion but is insoluble in nitric acid, and is only slowly
attacked by sulphuric acid (Hammond, 1993). At raised temperatures Pu metal reacts with 
oxygen to form oxides, with halogens to form halides, with nitrogen or ammonia to form 
nitrides, with hydrogen to from hydrides and with carbon monoxide to form carbides.
Plutonium has 15 known isotopes, all o f which are radioactive, the majority decaying by 
alpha particle emission; they have half-lives ranging from 0.18 seconds to 76 million years 
(Lederer et aL, 1967; Hammond, 1993). Plutonium-239, is produced from by 
neutron capture as follows:
(w ,Y ) -* -  f i '  -  ^^ N^p -  fi~ -
Plutonium-239 has a 24,390 year half-life and emits alpha particles with a principal energy 
of 5.15 MeV. It has a specific activity o f 2.3 xlO^Bq g'^  (0.062 Ci g'^ ) (Hammond, 1993; 
Choppin flf/., 1995b).
Plutonium can exist in 5 oxidation states (III to VII); the divalent state may also exist in 
certain solid compounds (Taylor, 1973). Pu(VII) is only stable in very strong basic 
solutions (Métivier, 1988). The four common oxidation states (III to VI) are stable in 
acidic solutions and correspond to the ions Pu^ ,^ Pu'*^ , PuOz  ^and PuOz^^  (Hammond,
1993; Métivier, 1988). Plutonium (III) is stable in water and air and oxidises by action o f  
its own a-radiation to Pu(IV) (Choppin et a i ,  1995b). Plutonium (IV) is stable in 
concentrated acids eg. 6 M HNO3 but it disproportionates at lower acidities (Choppin et 
al., 1995b). Plutonium (IV) shows a strong tendency to undergo hydrolysis due to its high 
ionic charge, leading to the formation o f polymers or particles at pH values greater than 
about 2 (Grebenschikova and Davydor, 1961). Hydrolysis can be suppressed by the 
addition o f complexing agents such as citrate to the solutions (Asprey and Penneman,
1962). Plutonium (V), usually found as Pu0 2  ^is most stable at low acidities; it 
disproportionates to Pu(IV) and Pu0 2 ^^  (Pu(VI)). is stable and reduces slowly
under the action o f its own a-radiation (Choppin et al., 1995b).
In neutral solutions the formation of the Pu(IV) state is favoured; biological fluids contain 
ligands and complexing entities that tend to stabilise the Pu(IV) state. Stable Pu
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complexes can be formed with citrate, ascorbate, amino acids and proteins. The stability 
o f these complexes decreases in the order Pu(IV) > Pu(III) > Pu(VI) > Pu(V). It is 
believed that Pu is present as the tetravalent form (Pu(IV)) in mammalian body fluids, 
including blood plasrria, lung fluids, bile or urine (Stover et al., 1968; Taylor, 1973; 
Raymond and Smith, 1981). Taylor (1973) considers it unlikely that uncomplexed Pu ions 
exist in mammalian systems (pH about 7) except in very low concentrations, because an 
excess o f complexing ions, or other binding agents, will be present.
Following the entry o f soluble forms o f Pu into the blood, it is rapidly bound to transferrin, 
a protein that normally transports iron in the body (Popplewell and Boocock, 1968;
Stevens et al., 1968; Stover et a /.,1968; Turner and Taylor, 1968a;b). Association with 
other macromolecules has also been reported and a small proportion may circulate as 
complexes with low molecular weight substances including peptides, sugars, amino acids 
and citrate (Boocock and Popplewell, 1965; 1966; 1968; Popplewell et al., 1975; Stevens 
et al., 1968). A  small amount o f Pu may bind to albumin (Stevens et al., 1968).
1.2.3. Americium
Americium was the fourth transuranium element to be discovered. The isotope "^^ A^m was 
identified by Seaborg et al. in 1944 at the Metallurgy Laboratory (later the Argonne 
National Laboratory) o f the University o f Chicago.
Americium is element 95 in the Periodic Table; it is a silver white metal, more malleable 
than uranium; it has a density o f 1.4 x lO'^  kg m'^  at 25°C and a melting point o f 994°C 
(Cotton and Wilkinson, 1980; Greenwood and Eamshaw, 1994). It tarnishes slowly in air, 
and is produced by reducing the trifluoride with barium vapour at 1000-1200°C or the 
dioxide with lanthanum metal. The chemical properties o f  the Am(III) ion are similar to 
those o f the trivalent rare earths. It is precipitated from solution by hydroxide, fluoride, 
oxalate and phosphate. Americium oxide is insoluble in water, but soluble in acids. 
Americium is known to form 2 hydroxides, Am(OH) 3  and Am(OH) 4  (Penneman et al., 
1961).
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Americium has 13 known isotopes, all o f which are radioactive, they have half-lives 
ranging from 25 mins to 7.8 x 10^  years (Lederer et al., 1967; Hammond, 1993). 
Americium-241 is produced by successive neutron capture reactions by Pu isotopes in a 
nuclear reactor as follows:
^^ P^u -* (a 7 ,y )  ^^ P^u ( « , y )  ^^ P^u A
Americium-241 has a half-life o f 458 years and decays by the emission o f an alpha particle 
with a principal energy o f 5.5 MeV. It has a specific activity o f 1.2 x 10 '^ Bq g'* (3.2 Ci 
g '^ ) (Hammond, 1993; Choppin e ?  a / . ,  1995b).
Americium exists in 5 oxidation states (II to VI). The +2 state has been shown to exist in 
a Cap2  lattice (Cotton and Wilkinson, 1972). The trivalent (HI) state is the most stable in 
solution (ICRP, 1986) and strong oxidation is required to achieve the higher oxidation 
states (Cotton and Wilkinson, 1972). Alkaline solutions are more favourable for the 
stabilisation o f Am(IV) (Cotton and Wilkinson, 1972). The hydroxide is prepared by the 
oxidation o f Am(III) to Am(IV) in alkaline solution in the presence o f sodium hypochlorite 
(Bulman, 1980; Cotton and Wilkinson, 1972). Americium is oxidised to the +5 state in 
aqueous solution. The dioxo cation AmOz  ^is produced by a similar method to the dioxo 
cations o f Pu (Bulman, 1980). Am(V) is unstable in acid medium and disproportionates 
into Am(III) and Am(VI) (Bulman, 1980). Americium (VI) can exist as the dioxo cation 
Am0 2 ^^  which resembles the dioxo cations of other actinides. "^^ 'Am0 2 ^^  is stable and 
reduces fairly rapidly under the action o f its own a-radiation.
The trivalent state is the only one o f importance in biological systems. Am^  ^has a smaller 
ionic potential than the ions o f Pu, it does not hydrolyse below pH 4.5, and shows 
decreasing solubility in the pH range 6.5 to 9, forming insoluble hydroxides or other 
hydroxy species (ICRP, 1986). Taylor (1973) considers it unlikely that uncomplexed Am 
ions exist in m a m m alian  systems (pH about 7) except in very low concentrations, because 
an excess o f complexing ions, or other binding agents will be present.
Americium has been shown to be protein bound in blood plasma (Boocock and 
Popplewell, 1966; Popplewell and Boocock, 1968; Bruenger et al., 1969a;b; Turner and
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Taylor, 1968a). Bruenger et al. (1969a;b) demonstrated that Am was bound to transferrin 
and albumin in canine and human blood. Experiments examining the association o f  
Am(III) to human transferrin showed that the binding was very weak (Chipperfield and 
Taylor, 1968; 1970; 1972). Some Am in the plasma is thought to be associated with a 
smaller molecule, probably citrate (Stradling et al., 1976).
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1.3. The Skeleton
The skeletal system includes bone, bone marrow, cartilage and teeth. Bone is a specialised 
form o f connective tissue, characterized by its rigidity and hardness, with properties of 
growth and renewal similar to other tissues (Gray, 1995). Bone consists o f a mineralized 
matrix produced and maintained by osteoblasts and three other cell types, osteoprogenitor 
cells, osteocytes and osteoclasts (Fawcett, 1986; Gray, 1995). Bone marrow is a soft, 
highly cellular tissue containing blood cell precursors, osteoclast precursors, macrophages 
and adipose cells, contained within the cylindrical cavities o f long bones and in the 
trabecular spaces o f the vertebrae, ribs, sternum and the flat bones o f the cranium and 
pelvis (Fawcett, 1986; Gray, 1995). Cartilage is normally found at the ends o f bone and 
allows bones to move smoothly against one another (Gray, 1995). It is also found at the 
growing ends o f bone and is involved in bone growth, subsequently becoming calcified. 
Most o f the skeleton is first formed as cartilage which is later replaced by bone (Fawcett, 
1986; Ross and Romrell, 1989).
The skeleton can be described as consisting o f two parts: the axial skeleton which includes 
the head bones, vertebrae, ribs and sternum, and the appendicular skeleton which consists 
o f the shoulder girdle, pelvis, arms, legs and hand and feet bones (Gray, 1995). In the 
human there are usually 206 - 208 distinct bones; 80 - 82 in the axial skeleton and 126 in 
the appendicular skeleton (Gray, 1995). The mouse skeleton consists o f about 185 bones; 
about 85 bones in the axial skeleton and about 100 bones in the appendicular skeleton 
(Olds and Olds, 1979).
Bone growth begins pre-natally. Skeletal elements are present at birth, but are immature 
and in^erfectly formed (Gray, 1995). After the primary bone is formed, the second phase 
of bone growth commences; this is termed bone remodelling and refers to the processes by 
which bones alter their size and shape and increase in strength (Gray, 1995). After skeletal 
maturity occurs, bone remodelling refers to bone turnover that replaces existing bone. 
Bone remodelling is carried out throughout life by osteoclasts and osteoblasts on bone 
surfaces, thus maintaining the mechanical competence o f bone and accommodating
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conditioning forces that are applied through locomotion, lifting and the maintenance o f  
posture (Frost, 1980).
1.3.1. Bone matrix
Bone, like other connective tissues, consists o f  cells and extracellular material. Its 
distinguishing feature is the mineralization o f an extracellular organic matrix material 
which results in an extremely hard tissue capable o f  providing support and protection 
(Gray, 1995). Bone consists o f an organic matrix impregnated with inorganic salts and 
permeated by a complex cellular network (Gray, 1995). The matrix o f bone is composed 
o f various proteins, carbohydrates, lipids and other substances. The bulk o f the organic 
material is made up o f a protein, collagen (Triffitt, 1980). The inorganic matter o f  bone 
consists mainly o f submicroscopic deposits o f forms o f calcium phosphate 
[Cajo(P0 4 )6(OH)2] with small amounts o f calcium carbonate, calcium fluoride and 
magnesium chloride (Neuman, 1980; Fawcett, 1986; Ross and Romrell, 1989).
In mature bone, the matrix is moderately hydrated, 10-20% o f its mass being water (Gray, 
1995). Of its dry weight, 60-70% is made up o f inorganic, mineral salts rich in calcium 
and phosphate, 30-40% is collagen and the remainder (about 5%) is non-collagenous 
protein and carbohydrate, mainly conjugated as glycoproteins (Bradbury, 1975; Gray, 
1995). The skeleton contains about 99% o f the total calcium in the body (Parfltt, 1983). 
Calcium in blood and tissue fluids is constantly exchanging with calcium in bone. The 
blood calcium is in equilibrium with that o f  tissue fluid; the microcirculation in bone is 
rapid and calcium from the bone matrix can be mobilized and taken up by the blood as 
needed to maintain appropriate levels m body tissues (Frost, 1980; Parfltt, 1983). The 
calcium content o f newly formed, less well mineralized bone is more labile than older, 
denser tissue and provides a ready reservoir o f calcium ions. However, rapid calcium 
exchange is a feature o f all bone surfaces, whether growing, resorbing or resting (Parfltt, 
1983).
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1.3.2. Bone structure
The structure o f a typical long bone is shown in Figure 1.1. This consists o f a central 
cylindrical shaft, the diaphysis, two terminal articular regions, the epiphyses, and two 
intermediate regions, the metaphyses, which connect the diaphysis and epiphyses (Gray, 
1995). The largest increase in length during bone growth occurs in the metaphyseal 
region. The epiphysis and metaphysis are joined together by a cartilage region, known as 
the epiphyseal plate or growth plate (Gray, 1995). At maturity, the epiphyseal plate is 
reduced in size and is known as the epiphyseal line (Fawcett, 1986; Ross and Romrell, 
1989).
The outer surface o f bone is covered by a fibrous sheath, the periosteum, which consists o f  
an outer thick fibrous connective tissue layer and, during growth, an inner layer containing 
osteoprogenitor cells and osteoblasts (Ross and Romrell, 1989). In the adult, these cells 
revert to a resting form (Fawcett, 1986). The periosteum is abundantly supplied with 
nerves (Moss, 1966) and is penetrated by blood vessels which communicate with the 
Volkmann’s canals and vessels o f the Haversian canals (Fawcett, 1986). Muscle tendons 
and ligaments may attach directly into the compact outer layer o f a bone, or join the outer 
layers o f the periosteum (Moss, 1966).
There are two types o f bone in the adult skeleton which can be distinguished by differences 
in hardness, porosity, and soft-tissue content. These are classified as conq)act (cortical or 
dense) bone and trabecular (cancellous or spongy) bone (Fawcett, 1986). The cut face o f  
conq)act bone appears to be solid, whereas the cut face o f trabecular bone has the 
appearance o f a sponge. Compact bone constitutes about 75% o f the total skeletal mass in 
adult humans but only about 33% of the total bone surfaces (Frost, 1963; Johnson, 1964; 
Parfitt, 1988). It is the hard, dense bone that forms the outer wall o f all bones; most o f the 
compact bone is found in the shafts o f long bones. Trabecular bone provides the 
remaining 25% o f the total skeletal mass and about 67% o f the total bone surfaces (Frost, 
1963; Johnson, 1964; Parfitt, 1988). It is a relatively soft, spongy bone consisting o f a 
3-D network o f curved trabeculae which are 100-150pm thick in humans (Parfitt, 1988)
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Figure 1.1. Diagrammatic section through a typical long bone (Little, 1973).
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and lO-lSpm thick in mice (Cartlidge, 1997). The trabeculae form interconnecting spaces 
o f 500-1000pm diameter, in man (Parfitt, 1988), and 65-1350pm (mean diameter, 290pm) 
in mice (Cartlidge, 1997), which contain either haemopoietic or fatty marrow (Fawcett, 
1986; Ross and Romrell, 1989). The bones o f the axial skeleton and the ends o f the long 
bones (epiphyses) have the largest proportion o f trabecular bone (Fawcett, 1986). Not all 
bone tissue is easily classified as either trabecular or cortical bone as there is otten a zone 
between the two bone types that is intermediate in porosity and surface : volume ratio 
(Parfltt, 1988).
Both trabecular and cortical bone contain spaces known as lacunae. Each lacuna contains 
an osteocyte, which is essentially an osteoblast that has become surrounded by bone matrix 
(Matthews, 1980; Fawcett, 1986; Ross and Romrell, 1989). Radiating in all directions 
tfom each lacuna are slender, branching tubular passages, called canaliculi. These 
penetrate the interstitial substance and join with canaliculi o f neighbouring lacunae. In this 
way, a continuous network o f canaliculi and lacunae is formed throughout the bone, 
allowing communication between cells (Fawcett, 1986; Ross and Romrell, 1989).
Contact bone has a special arrangement o f blood vessels and bone elements forming 
structural units known as osteons or Haversian systems, in humans (Bradbury, 1975; 
Fawcett, 1986; Ross and Romrell, 1989) or vascular channels, in mice (Vaughan, 1973). 
Osteons are cylinders about 200pm in diameter (in humans) which run parallel to the long 
axis o f bone; there is some variation in the shape, direction and size o f these structures 
(Parfitt, 1983; Fawcett, 1986). The osteon contains a central canal about 40pm in 
diameter, containing blood vessels, lymphatics, nerves and connective tissue. The wall o f  
the osteon consists o f concentric lamellae which are about 7pm thick (Parfitt, 1983). 
Haversian c an a ls are connected with one another and communicate with the bone marrow 
and exterior surfaces o f bone via supporting channels called Volkmann’s canals (Bradbury, 
1975; Fawcett, 1986; Ross and Romrell, 1989). These channels are transverse channels 
which are structurally distinct from Haversian canals. They are not surrounded by 
concentrically arranged lamellae but traverse the lamellae around Haversian canals 
(Fawcett, 1986). The Haversian systems, together with Volkmann’s canals supply
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nutrients to the canalicular network, ensuring nutrients are carried to the cells in the 
interior o f compact bone.
The middle portion o f a long bone, the diaphysis, contains the medullary or marrow cavity 
which is filled with haemopoietic marrow or fatty marrow (Bradbury, 1975; Fawcett,
1986; Ross and Romrell, 1989). Haemopoietic marrow is also found in the trabecular 
spaces in the epiphyses (Fawcett, 1986; Ross and Romrell, 1989). The bone marrow 
cavities are lined by a thin layer, the endosteum which resembles the periosteum in its 
bone-forming potential but is much thinner, consisting o f a single layer o f cells without any 
associated connective tissue fibres (Ross and Romrell, 1989). The endosteum contains 
bone-forming (osteoblasts) and bone-resorbing cells (osteoclasts), or resting forms o f  
these cells, known as endosteal cells or bone lining cells, which are capable o f becoming 
active in response to appropriate stimuli (Ross and Romrell, 1989). All bone cavities, 
including the marrow spaces within cortical and trabecular bone, are lined by endosteum 
(Fawcett, 1986).
The blood supply o f long bones is from branches o f  the nutrient artery o f the bone that 
enter the marrow cavity in the diaphysis and epiphysis (Gray, 1995; Ross and Romrell, 
1989). Other blood vessels in the muscle and periosteum surrounding bone may provide 
an additional supply to the metaphysis. The capillary network supplying blood to the bone 
marrow opens into a series o f thm walled sinusoids, which empty into a large central sinus. 
Blood passes through the bone marrow tissue, through the bone tissue and leaves through 
periosteal vessels. The Volkmann’s canals provide the major route for nourishment o f the 
bone tissue itself (Fawcett, 1986; Ross and Romrell, 1989). Bone tissue lacks lyn^hatic 
vessels and only the periosteal tissue has lymphatic drainage (Ross and Romrell, 1989).
1.3.3. Cells o f bone tissue
Bone tissue contains four cell types: osteoprogenitor cells; osteoblasts; osteocytes and 
osteoclasts (Gray, 1995). With the exception o f the osteoclast, these cells may be 
regarded as modulated forms of the same cell because they undergo transformation in 
relation to functional activity (Fawcett, 1986; Gray, 1995; Ross and Romrell, 1989). In
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contrast, osteoclasts originate from a different cell line and are responsible for bone 
resorption, an activity associated with bone remodelling (Fawcett, 1986; Gray, 1995; Ross 
and Romrell, 1989). Figure 1.2 shows the position o f the main types o f bone cells in 
cortical and trabecular bone. When bone undergoes remodelling, the different types o f  
bone cells interact closely together. Osteoclasts selectively resorb formed bone. 
Osteoblasts produce new osteoid, become surrounded by mineralizing bone matrix and are 
transformed into osteocytes.
1.3.3.1. Osteoprogenitor cells
Osteoprogenitor cells are derived from plurq)otential stem cells present in bone marrow 
and other connective tissues which can proliferate and differentiate into osteoblasts prior 
to bone formation (Gray, 1995). The stromal stem cells are o f mesenchymal origin and are 
responsible for all bone formation during early development. There may be two types or 
stages o f osteoprogenitor cells, one totally committed to bone formation (committed 
osteoprogenitors), found associated with bones, and the other (inducible osteoprogenitors) 
which are widely present in connective tissue and probably able to differentiate into 
various connective tissue cells {eg. fibroblasts, myoblasts, pericytes, adipose cells, 
chondroblasts, osteoblasts) depending on the nature o f the mducer. Cells that have 
differentiated in one direction may be able to revert to a proliferative phase and then 
differentiate into osteoblasts. The osteoprogenitor cells are usually regarded as resting 
cells and are found on the innermost layer o f the periosteum, the endosteal lining cells o f  
the marrow cavities, and the lining cells o f the Haversian and Volkmann’s canals (Ross 
and Romrell, 1989).
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1.3.3.2. Osteoblasts
Osteoblasts are differentiated, non-mitotic cells which arise from osteoprogenitor cells 
(Gray, 1995). They are basophilic, roughly cuhoidal mononuclear cells about 15-30pm 
across, with their nucleus at the end o f the cell furthest away from the bone surface and 
are found on the forming surfaces o f growing or remodelling bone where they constitute a 
covering monolayer (Bradbury, 1975; Martin et al., 1993). In relatively quiescent adult 
bones they appear to be present chiefly on the endosteal rather than periosteal surfaces, 
but also occur deep within compact bone where osteons are being remodelled (Gray, 
1995). Osteoblasts are responsible for the synthesis, deposition and mineralization o f bone 
matrix. As the osteoblast secretes the bone matrix o f collagen and proteoglycans it 
becomes completely surrounded by this substance and is transformed into an osteocyte 
occupying a space or lacuna in the bone matrix (Bradbury, 1975; Fawcett, 1986; Ross and 
Romrell, 1989). When not active in bone formation, osteoblasts may also become bone 
lining cells (Bradbury, 1975; Fawcett, 1986; Ross and Romrell, 1989). These flattened 
epithelium like cells are particularly evident on the resting surfaces o f adult bone. On the 
endosteal surface o f marrow cavities they form the outer boundary o f the marrow tissue. 
They are also present on the periosteal surface and line the system o f vascular canals 
within osteons (Gray, 1995). These bone lining cells may play an active role in regulating 
the differentiation of osteoprogenitor cells, control the access o f osteoclasts to the bone 
surface and regulate mineral homeostasis. It has also been suggested on the basis o f in 
vitro experiments that bone lining cells may secrete coUagenase to remove any 
unmineralized matrix and prepare bone surfaces for osteoclastic resorption.
Osteoblasts produce the bone matrix, osteoid, by manufacturing a variety o f proteins 
including collagen, osteocalcin, glycoproteins and mucopolysaccharides (Gray, 1995; 
Pritchard, 1972), some proteoglycans, latent proteases and growth factors (Stevens and 
Lowe, 1992). They are also capable o f synthesising prostaglandins and coUagenase in 
response to stimulators o f bone resorption (Ross and Romrell, 1989).
Chapter I. Introduction 24
There is also much evidence that osteoblasts may play an important though indirect role in 
the hormonal regulation of bone resorption, since they bear receptors for parathyroid 
hormone and other stimulants o f bone resorption (Gray, 1995). During bone deposition 
osteoblasts may inhibit osteoclast activity or fail to stimulate them, but in the presence o f  
bone resorption stimulators, eg. parathyroid hormone (PTH), osteoblasts release various 
intermediaries which activate osteoclasts to remove osseous tissue (Gray, 1995).
1.3.3.3. Osteocytes
Osteocytes are the mature bone cells and are found scattered within spaces (lacuna) in the 
bone matrix (Fawcett, 1986; Gray, 1995). They are derived from osteoblasts which have 
become enclosed in bone matrix and develop long, dendritic processes (canaliculi) which 
act as a communication network between adjacent osteocytes (Fawcett, 1986; Ross and 
RomreU, 1989). Mature osteocytes possess a three-axis ellipsoid cell body, the longest 
axis (about 25pm) running parallel to the surrounding bony lamellae (Gray, 1995). The 
canaliculi contain the cell processes o f the osteocyte. They are about 0.25-0.5pm wide 
and extend from the cell body, forming an extensive network throughout the bone matrix 
providing a route for the difrusion o f nutrients, gases and waste products to and from the 
osteocyte (Atkinson and Hallsworth, 1982). The cytoplasm o f osteocytes is basophilic and 
contains relatively few organelles, including a small amount o f endoplasmic reticulum, a 
few ribosomes and a small Golgi apparatus (Gray, 1995; Ross and Romrell, 1989).
Younger osteocytes appear to be more rounded, and their cytoplasm contains a well- 
developed endoplasmic reticulum and larger Golgi complexes (Gray, 1995; Ross and 
Romrell, 1989). The average lifespan o f an osteocyte varies with the metabolic activity o f  
the bone and the likelihood that it will be remodelled but has been estimated as about 25 
years for human osteocytes (Gray, 1995).
The exact functions o f osteocytes are not clear. However, it is widely assumed that they 
have an essential role in the maintenance o f bone. They have the ability to synthesize, as 
well as resorb bone matrix to a limited extent (Ross and RomreU, 1989). Their death leads 
to the resorption o f the matrix by osteoclast activity (Gray, 1995). By means o f  their 
communications with cells at the bone surface, they may act as local sensors o f the
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mechanical and chemical state o f the bone and initiate resorption or addition o f matrix at 
the surface accordingly. These activities are important in contributing to the homeostasis 
of blood calcium.
1.3.3.4. Osteoclasts
Osteoclasts are large multinucleate cells (20-100pm) which contain a variable number o f  
oval, closely packed nuclei, large numbers o f mitochondria, Golgi bodies and lysosomes, 
and are actively involved in bone resorption (Fawcett, 1986; Ross and Romrell, 1989). 
They are derived from haemopoietic stem cells (pluripotential stem cells) and arise from 
fusion o f mononuclear cells which originate in the bone marrow or other haemopoietic 
tissue, in response to hormonal cues (Ross and Romrell, 1989). As they mature, 
osteoclasts migrate to bone surfaces and are usually found in shallow depressions in the 
bone tissue known as Howship’s lacunae (Bradbury, 1975) where they attach by resorbing 
a small amount o f bone (Fawcett, 1986). The life-span o f an osteoclast nuclei has been 
estimated to be about 16 days, and Jaworski et al. (1981) give in vivo human osteoclast 
survival times o f over 7 weeks.
The surface o f the cell directly in contact with bone at the site o f resorption can be divided 
into two parts: a central region making up the ruffled border which contains numerous 
plasma membrane infoldings forming microvilli type structures, and a smaller ring-like 
perimeter o f cytoplasm, known as the clear zone because it has few cell organelles, which 
demarcates the limits o f  the bone area being resorbed (Bradbury, 1975; Fawcett, 1986; 
Ross and Romrell, 1989). The ruffled border is the site o f resorption and actively frees 
apatite crystals and collagen from the bone tissue. There is evidence o f organic matrix 
destruction by lysosomal and non-lysosomal enzymes. The size o f the ruffled membrane 
varies with hormone levels, increasing when resorption o f bone is stimulated, eg. with 
parathyroid hormone, and disappearing in the presence o f agents which directly inhibit 
resorption, eg. calcitonin (Gray, 1995; Ross and Romrell, 1989). The side o f the 
osteoclast not in contact with the bone surface is smooth, and the nuclei and mitochondria 
are usually found near this outer surface (Bradbury, 1975).
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1.3.4. Bone marrow
Bone marrow is found in the cylindrical cavities o f long bones, the trabecular spaces o f the 
long bones and vertebrae, ribs, sternum and the flat bones o f the cranium and pelvis 
(Fawcett, 1986; Ross and Romrell, 1989). Bone marrow is a soft cellular tissue which is 
responsible for the production o f differentiated blood cells. The haemopoietic stem cells 
give rise to osteoclasts, red blood cells, white blood cells, platelets, and macrophages and 
the stromal system gives rise to fibroblasts, adipocytes, reticular cells and osteogenic cells 
(Ross and Romrell, 1989).
The site o f haemopoiesis changes several times during fetal development, the earliest sites 
are the yolk sac followed by the liver and spleen. At five months o f gestation, the fetal 
bone marrow begins to produce white cells and platelets, while red cell production by bone 
marrow starts at around seven months o f gestation (Stevens and Lowe, 1992). At birth, 
the bone marrow is the main site o f red cell production and almost all bones in the body 
are involved. In the infant, all bones contain haemopoietically active red bone marrow. 
During early childhood, with the rapid increase in bone size, the haemopoietic capacity o f  
the bone marrow expands beyond that needed for normal production o f blood cells and the 
transformation of haemopoietically active red marrow to relatively inactive fatty tissue 
called yellow marrow begins. The yellow marrow retains its haemopoietic capacity and 
can revert to red bone marrow in response to unusual demands for blood cells (Fawcett, 
1986; Ross and Romrell, 1989). By early adulthood, most o f the marrow in long bones is 
inactive and red marrow is found mainly in the vertebrae, ribs, pelvis, cranium, scapulae, 
sternum and the trabeculae o f the upper ends o f the femora and humeri (Hartsock et al., 
1965; Dunnill ef a/., 1967).
1.3.5. Cartilage
Cartilage is a form of connective tissue consisting o f collagen and non-collagenous matrix 
and chrondrocytes (Ross and Romrell, 1989). Cartilage matrix is solid, firm and pliable, 
and can be found between bones and covering the ends o f bones thus allowing bones to
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move smoothly against one another while supporting great weight (Fawcett, 1986). Most 
o f the skeleton is first formed as cartilage, but is later replaced by bone.
Cartilage consists o f cells, chondrocytes, embedded in a gel-like matrix, but unlike other 
connective tissues, cartilage has no blood vessels or nerves (Fawcett, 1986; Ross and 
Romrell, 1989). While bone cells must be near a vascular space because o f the 
impermeability o f bone, cartilage cells receive nutrients through the permeable matrix 
(Marks and Popoff, 1988). There are three types o f cartilage, hyaline cartilage, 
fibrocartilage and elastic cartilage, which are distinguishable by the amount o f gel-like 
matrix and the relative abundance o f collagenous and elastic fibres in the matrix (Fawcett, 
1986; Ross and Romrell, 1989). Hyaline cartilage is found on the articular surfaces o f the 
ends o f the long bones and is also present in the tracheal rings, bronchi, larynx, nose and at 
the ends o f the ribs. Fibrocartilage is associated with the intervertébral discs, certain 
articular cartilages, the symphysis pubis, the ligaments o f joints and sites o f attachment o f  
certain tendons to bones. Elastic cartilage is found primarily in the external ear, the walls 
o f the external auditory and eustachian tubes, and the epiglottis.
1.3.6. Bone growth and remodelling
Bone is a dynamic system where continuous formation and resorption o f bone substance 
occurs in different parts o f the skeleton throughout life. Bone growth begins prenatally, 
with the initial formation o f bone in hyaline cartilage (Gray, 1995). The skeletal elements 
are present at birth, but the skeleton consists o f cartilage and develops into bone by 
endochondral ossification (Gray, 1995; Ham and Cormack, 1979). After bone is formed, 
the second phase o f growth commences and each bone increases in size through a 
continuous process that ceases at skeletal maturity. This process has been characterized in 
long bones (Figure 1.1) where an increase in length is due to continued endochondral bone 
formation at each end o f the long bones (Stevens and Lowe, 1992). An actively 
proliferating plate o f cartilage (the epiphyseal plate) remains across the junction between 
the epiphysis and diaphysis. This plate gives rise to the apposition o f new cartilage to the 
ends o f the diaphysis, which is converted to trabecular bone, leading to a progressive 
increase in length. Activity o f the epiphyseal plate normally ceases after puberty. New
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bone is formed on the diaphyseal sides o f the epiphyseal plate as follows: ( 1 ) cartilage on 
the epiphyseal face o f the epiphyseal plate proliferates to produce columns o f  
chondrocytes embedded in matrix; (2 ) the chondrocytes which are nearest the diaphyseal 
plate become greatly enlarged and begin to produce alkaline phosphate, which facilitates 
calcification o f the matrix; (3) osteoblasts lay down osteoid on the calcified cartilaginous 
trabeculae; (4) the deposited bone is incorporated into the diaphysis; (5) as the bone 
ceases to grow in length, the lower and upper epiphyseal plates disappear, the bone 
marrow cavity becomes continuous throughout the bone and blood vessels o f the 
diaphysis, metaphysis and epiphyses intercommunicate (Fawcett, 1986). The epiphyseal 
plate and the zone o f ossifying cartilaginous matrix trabeculae form the metaphysis. 
Increase in circumference o f the diaphysis is achieved by formation o f new bone on the 
outer surface o f cortical bone which not only increases the diameter o f the diaphysis but 
also increases the thickness o f cortical bone.
After its primary formation, bone is continuously renewed (remodelled) throughout life 
(Frost, 1969) in order to maintain the viability o f the cells and biomechanical conq)etence. 
In adult bone, remodelling refers to a process o f bone turnover that replaces existing bone 
and changes the shape and total amount o f bone very slowly or not at all. It also refers to 
local influences that alter the size and shape o f growing bones and processes which 
increase bone volume (Frost, 1980). Bone remodelling is carried out by osteoclasts and 
osteoblasts and takes place at localized sites on the periosteal, Haversian and endosteal 
surfaces in cortical and trabecular bone (Fawcett, 1986; Frost, 1969; Ross and RomreU, 
1989). This process changes young, newly formed bone into highly organized, secondary 
lameUar bone with Haversian systems. In long bones this also includes longitudinal 
growth, transverse growth and adaptation o f shape (Melsen and Mosekilde, 1988).
The remodelling process involves 6  steps: initiation, activation, resorption, reversal, 
formation and resting. Each bone surface is always in one o f three fimctional states: 
forming, resorbing or resting. Bone-resorbing surfaces are scaUoped by Howship’s lacunae 
which contain osteoblasts and poorly characterised mononuclear ceUs. Bone-forming 
surfaces are covered by osteoid seams and osteoblasts (Fawcett, 1986). The initiation 
phase involves the alteration of the status o f a resting bone surface, which is foUowed by
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the activation process when osteoclast precursors are transformed into osteoclasts and 
attracted to bone surfaces where they begin to resorb bone (Frost, 1969). During the 
resorption phase, the osteoclasts form a "cutting cone", which erodes a canal through 
existing bone removing bone mineral and organic matrix (Parfitt, 1976). This is followed 
by the reversal process, where the osteoclasts are replaced by osteoblasts. The formation 
phase follows, when osteoblasts repair the resorption cavity by laying down osteoid which 
is then converted in to mineralized bone (Melsen and Mosekilde, 1988; Parfitt, 1983). 
Osteoblastic activity may occur at the same site for up to 3 months (Melsen and 
Mosekilde, 1988). At the end o f this phase, osteoblasts are converted to flat inactive 
lining cells and the bone returns to the resting phase, its normal status. Trabecular bone is 
remodelled in the same way as cortical bone (Kragstrup et ah, 1982).
Bone remodelling rates have been estimated by a variety o f indirect methods, such as 
analysis o f the rate o f turnover o f radionuclide labels (Bryant and Loutit, 1961; Rowland, 
1964; Bauer, 1964; Leggett et ah, 1982) or the rate o f change with age in the number o f  
osteons in compact bone (Kerley, 1965; ICRP, 1973). The remodelling rates o f rib and 
ilium (iliac crest) have been studied more directly by a tetracycHne-based histological 
analysis (Frost, 1961; 1963; 1964; 1969; Melsen and Mosekilde, 1978). Indirect estimates 
of bone remodelling based on the turnover rate o f bone-seeking radionuclides in the 
skeleton suggests potentially large variations in cortical remodelling rates in different parts 
of the skeleton (Bryant and Loutit, 1961; Rowland, 1964; Bauer, 1964). Parfitt (1983) 
reviewed data on cortical remodelling rates in adults and concluded that an average value 
of about 3% y  ^ for all cortical bone is reasonably consistent with both direct and indirect 
information. Remodelling rates are less well established for trabecular bone than for 
compact bone. Indirect estimates based on turnover o f bone-seekmg radionuclides depend 
on the biokinetic model employed but are typically in the order o f 10-25% y'^  for adult 
trabecular bone (Leggett et aL, 1982; Parfitt, 1983). About 80% o f the trabecular and 
inner cortical bone surfaces are inactive with respect to bone remodelling compared with 
young growing bone in which most o f the bone surfaces are either forming or resorbing 
(Parfitt, 1983).
Chapter 1. Introduction 30
1.4. Biokinetics of Uranium, Plutonium and Americium
Alpha-emitting radionuclides have a relatively short range, approximately 40pm in soft 
tissue and 25 pm in bone (Thome, 1977) and therefore only pose a risk after they have 
entered the body and are in close proximity to cells in tissues. In order to understand the 
effects o f radiation resulting from the deposition of alpha-emitting actinide isotopes in the 
skeleton and other tissues, it is necessaiy to understand their deposition, redistribution and 
retention characteristics. Some human data are available from the US injection cases 
(Bernard and Struxness, 1957; Durbin, 1972; Langham and Carter, 1951; Langham, 1956; 
Volez et al., 1979), but much o f the available information has been obtained from 
laboratory animal studies. The routes by which radionuclides may enter the body are 
inhalation, ingestion or through wounds. The amounts o f actinides which deposited in 
tissues depended upon the route o f administration and physico-chemical form o f the 
radionuclide being administered. Information from the animal studies and the available 
human data have shown that the skeleton is the major site o f actinide deposition following 
entry into the systemic circulation. This section reviews current knowledge on the 
transport o f radionuclides around the body, distribution in body tissues and within bones. 
Section 5 summarises biokinetic and dosimetric models developed by the International 
Committee on Radiation Protection for the isotopes o f U, Pu and Am. Section 6  discusses 
the effects o f radiation, including effects o f incorporated alpha-emitting nuclides.
1.4.1. Intakes and transport within the body
Following inhalation of a radionuclide and its deposition in the respiratory tract, movement 
from the initial site o f deposition occurs by two con^eting processes, mucociliary 
clearance o f the deposited particles and dissolution followed by absorption to blood. The 
regional deposition o f particles depends on their size. For exan^le, for 10pm diameter 
particles, about three-quarters o f inhaled particles are deposited in the respiratory tract, 
very largely in the exterior nasopharyngeal region (>90%), with very small amounts 
reaching the thoracic airways (about 2%) and alveolar region (about 4%). For 5pm 
diameter particles, about 80% are deposited in the respiratory tract, o f which about 90%
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are deposited in the exterior nasopharyngeal region, and deposition in the thoracic airways 
and alveolar region is about twice that for 10pm particles. For 1 pm diameter particles, 
about half o f those inhaled are deposited in the respiratory tract, with a smaller proportion 
in the exterior nasopharyngeal region (about 70%) and greater deposition in the alveolar 
region (Birchall et al., 1991; Jarvis et al., 1993; Jarvis and Birchall, 1994).
Particle clearance is independent o f the chemical form o f the element but depends on the 
deposition site within the lungs; particles deposited in the major airways clear more rapidly 
than those deposited in the alveoli (ICRP, 1994). In addition to movement o f particles by 
mucociliary clearance, transport through lymphatic vessels may also occur, leading to 
accumulation in regional lymph nodes. Some particles may reach the blood by this route 
and will then be removed from the circulation by uptake into the phagocytic cells o f the 
reticuloendothelial system in the liver, spleen and bone marrow.
Dissolution and absorption to blood depends on the chemical form o f the element and the 
physicochemical characteristics o f the particles (ICRP, 1994). For exanq)le, experimental 
studies on beagle dogs inhaling confounds such as uranium hexaflouride and uranium 
nitrate have shown them to be very soluble, about 90% o f the initial lung burden being 
transported to blood with a half-time o f less than 20 minutes (Eidson, 1994). Plutonium 
nitrate has also been shown to be quite soluble in the respiratory tract; experimental 
studies using beagle dogs (Dagle et al., 1983) and cynomolgous monkeys (Brooks et al., 
1981) have shown absorption values o f 80% and 53%, respectively. Plutonium and Am 
oxides are much less soluble. Experimental studies have shown absorption values o f  
between 1% and 2% following inhalation o f PUO2  in dogs, monkeys and rats (LaBauve et 
fl/., 1990; Stanley a/., 1982).
The level o f absorption o f elements from the gastrointestinal tract varies widely between 
different elements, depending on their chemical nature and the chemical form ingested. 
While elements such as iodine and caesium are almost conq)letely absorbed, the absorption 
o f the soluble forms o f actinide elements Pu and Am has been shown in animal studies to 
be less than 0.1% (ICRP, 1986; Harrison, 1991) and considerably less for Pu oxides 
(ICRP, 1986). Uranium is much more readily absorbed than Pu or Am. Experimental
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studies in animals and human subjects have shown absorption to be in the range 0 . 3  to 6 % 
with an average absorption o f 2% in adult humans (Leggett and Harrison, 1995).
Radionuclides absorbed from the lungs and gastrointestinal tract into body fluids and 
circulated in the bloodstream in a soluble form will distribute in body tissues depending on 
their chemical nature and similarity to elements with a physiological role in the body. 
Calcium and iron, for example, are essential components o f the body and specific pathways 
exist for them which determine their distribution in the body (ICRP, 1980; NE A, 1988). 
Strontium is similar to calcium and is incorporated into bone mineral (ICRP, 1989). 
Uranium, Pu and Am do not have any close elemental analogues with physiological roles 
and they are deposited throughout the body in a pattern determined largely by the affinity 
o f their ions for different tissue components. However, uranyl ions (UOj)^  ^show some 
similarities to Ca^  ^ions and are incorporated into bone mineral (Stevens et al., 1980;
ICRP, 1995a). Plutonium and Am show some similarities to iron in that they bmd to the 
iron-binding plasma protein, transferrin, and to the iron-storage protein, ferritin, in the 
liver (Boocock and Popplewell, 1966; 1968; Bruenger et al,, 1969a;b;c; Popplewell and 
Boocock, 1968; Turner and Taylor, 1968a).
Uranium is transported in the blood either as the hexavalent uranyl ion, (U0 2 )^\ which 
shows weak binding to transferrin, or as U(VI) bicarbonate (Gindler, 1973; Stevens et al.,
1980). Most o f the U circulating in body fluids is rapidly excreted; this is indicative o f  
weak protein binding (Gindler, 1973; Stevens et al., 1980). Uranium behaves similarly to 
calcium and the alkaline earths and the principal site o f retention in the body is the 
skeleton.
Experimental evidence has shown that transferrin is the predominant transport protein in 
the plasma for Pu (Boocock and Popplewell, 1965; Stevens et al., 1968; Turner and 
Taylor, 1968b). Plutonium has also been shown to bind to other proteins including ferritin 
(Boocock et al., 1970; Bruenger et al., 1969c), bone sialoprotein (Chipperfield and 
Taylor, 1968; 1970; 1972) and salivary proteins (Taylor, 1983). Americium has also been 
shown to bind to transferrin (Boocock and Popplewell, 1968; Bruenger et al., 1969a; 
Turner and Taylor, 1968a; Cooper and Gowing, 1981), but the binding is relatively weak.
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A proportion o f each element will also be present in low molecular weight form, probably 
as the citrate complexes, and it is likely that this proportion will be greater for Am than Pu 
because the binding o f Am to transferrin is weaker than that of Pu (Bruenger et al., 
1969a;c; Cooper and Gowing, 1981; Turner and Taylor, 1968a). Uptake o f both elements 
into the liver involves transfer from transferrin to the iron-storage protein, ferritin, in 
hepatocytes (Bruenger et al., 1969a;b;c; Turner and Taylor, 1968). The association o f Pu 
and Am with the longer-term iron-storage protein, haemosiderin, in liver 
reticuloendothelial cells has also been demonstrated (Boocock et al., 1970; Bruenger et 
al., 1969b;c).
Plutonium and Am transfer from circulating transferrin to binding sites on bone surfaces, 
indicating the presence o f molecules on bone surfaces which have a higher binding affinity 
for Pu and Am than transferrin. It has been suggested that these binding molecules are 
glycoproteins or proteoglycans, constituents o f the osteoid layer o f unmineralised new 
bone on growing surfaces (Chipperfield and Taylor, 1968; 1970; 1972; Vaughan, 1973; 
Williams and Peacocke, 1965).
1.4.2. Distribution within the body
The behaviour o f U in the body shows similarities to that o f calcium and the alkaline earth 
elements. The chief sites o f U deposition are the skeleton and the kidney (Durbin and 
Wrenn, 1975). In the skeleton, the uranyl ions replace calcium ions on the surface o f the 
hydroxyapatite crystals o f mineral bone during bone formation (Priest et al., 1982; Stevens 
et a/., 1980). The only significant site o f accumulation o f other than the skeleton is
the kidneys; the toxicity o f natural U is due to its chemical damage to the proximal 
convoluted tubules o f the kidneys (Durbin and Wrenn, 1975; Hursh and Spoor, 1973; 
Neuman, 1951).
Data from human experience with U are sparse. Human intravenous exposures for 
experimental purposes were carried out in 6  hospital patients in the "Rochester study" 
conducted in the late 1940’s (Hursh and Spoor, 1973). Another 8  terminally ill patients 
were injected in the "Boston study" in the mid 1950’s (Bernard and Struxness, 1957).
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These experiments provided information on the distribution and renal effects o f acute 
exposures. Uranium was rapidly excreted and chemically toxic effects to the kidney were 
seen at average renal concentrations o f 2-3 pg U per g o f  renal tissue.
In experiments using soluble U in rats, Neuman et al. (1948a; 1948b; 1953) found that 40 
minutes after injection about 50% had been excreted in the urine, between 25% and 33% 
was deposited in the skeleton, and the remainder was divided equally between the kidneys 
and other soft tissues. At later times, the U deposited in the kidneys was excreted in urine 
and 6  weeks after administration 20-25% o f injected activity was retained in the skeleton.
In other experiments using rats, Durbin and Wrenn (1975) found that 93% o f the U 
remaining in the body 18 months after injection was in the skeleton. In dogs, the skeleton 
accounted for 90% o f the total retention at 8-10 weeks after injection (Tannenbaum et al., 
1951).
Plutonium, in common with other actinide and lanthanide elements, is deposited mainly in 
the liver and skeleton, although small amounts are also deposited in other organs including 
the kidneys and gonads.
Human data concerning the biokinetics o f  ^ ^^ Pu are firom 2 principle sources: terminally iU 
patients who were given small amounts of^^^Pu (Langham and Carter, 1951; Langham, 
1956; Durbin, 1972) and a group o f American workers exposed occupationally during the 
Manhattan Project (Volez et al., 1979). The body distribution o f solubilised ^^ P^u was 
reported as follows: skeleton 45%; liver 45%; other tissues 10%.
Experiments to examine the biokinetics o f Pu citrate have been carried out in mice (Brown 
et al., 1970; Lindenbaum et al., 1968; 1969; Rosenthal and Lindenbaum, 1967; Rosenthal 
et al., 1968; UUberg et al., 1962), in rats (Belyaev, 1962; Carritt et al., 1947; Foreman et 
a l ,  1955; Fried et al., 1959; Hamilton and Scott, 1953; Markley et al., 1964; Rosenthal 
and Schubert, 1957; Schubert et al., 1950; Smith, 1964; Taylor, 1962; White and 
Schubert, 1952), in dogs (Buldakov etal., 1972; Stover eta l., 1959; 1962), in pigs 
(Busted et al., 1962; Smith et al., 1961), in rabbits (Bleaney and Vaughan, 1971) and
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sheep (Buldakov et al., 1970). The distribution varied according to the ultrafilterabUity o f  
the solutions, but generally at early times (approx 7 days) the uptake was greatest in the 
liver (25-80%) with some deposition in the skeleton (20-40%), at approximately 50 days 
the uptake in liver and skeleton was about equal and at later times most o f the activity was 
found in the skeleton (50-80%) with lower retention in the liver (19-30%). Colloidal 
solutions o f Pu were largely retained in the liver owing to the fact that colloidal particles 
are removed by the cells o f the reticuloendothelial system (Markley et ah, 1964; Schubert 
et a l.,\9 6 \) .
Americium, in common with other actinide and lanthanide elements, is deposited mainly in 
the liver and skeleton. The amount o f Am which deposits in the skeleton after entry into 
the blood as a soluble form is very variable. For example, experiments using animals have 
found skeletal uptake o f about 36% in rats (Durbin, 1962; 1973), between 53-78% in rats 
(Sikov and Mahlum, 1972; Taylor et al., 1961), about 70% in dogs (Stevens et al., 1976) 
and 20% in hamsters (McKay e/a/., 1972).
1.4.3. Distribution within bone
Most o f the studies on the distribution o f U in bone were undertaken in the late 1940’s and 
early 1950's before good quantitative autoradiographic techniques had been developed for 
use with undecalcifed bone sections (Neuman et al., 1948a; 1949b; 1953). More recently 
work has been undertaken in rats (Priest et al., 1982) and beagle dogs (Rowland and 
Famham, 1968; 1969; Stevens eta l., 1980).
Autoradiography has shown that initially U deposited on all bone surfaces but was most 
highly concentrated on surfaces in close proximity to the circulation ie. epiphyseal and 
metaphyseal trabeculae, endosteal and periosteal surfaces and vascular canals in cortical 
bone. The highest concentrations o f U were found in areas o f growth and active 
calcification such as the alveolar crests o f the mandible and the primary spongiosa o f the 
long bones (Neuman and Neuman, 1948; Priest et al., 1982; Stevens et al., 1980). There 
was an initial association with the vascular canals. With time, the deposits became 
diffusely distributed throughout compact bone and non-uniform deposits were observed on
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trabecular bone surfaces (Neuman et al., 1948a; 1948b; 1953; Priest et al., 1982; Stevens 
et a l ,  1980). Recent work by Priest et al. (1982) showed that growing bone surfaces, 
identified by their layer o f unmineralized osteoid and lining osteoblasts, accumulated most 
U although other types o f surfaces had some deposits.
Early studies using rats (Neuman et ah, 1948a; 1948b) suggested that once fixed, little 
redistribution o f U within bone occurred. However, more recent studies using rats and 
dogs (Priest et al., 1982; Rowland and Famham, 1968; 1969; Stevens et al., 1980) have 
suggested that U becomes either redistributed or diffused throughout the bone-volume 
producing a distribution pattem similar to that expected for alkaline earth elements (ICRP, 
1973).
Priest et al. (1982) showed that the changes in the distribution o f U caused by bone 
growth and remodelling processes were similar to those described for Pu. Uranium 
appeared to be lost quickest from bones with the highest remodelling rates such as the 
femur, but slowly from bones such as the caudal vertebrae which show little remodelling 
activity. Using microdosimetric methods it was shown the U  deposited onto resting bone 
surfaces is retained there until it was either buried by the deposition o f new bone or 
removed during bone resorption.
The distribution o f Pu within bone has been described by a number o f authors. In 
experiments with mice (Finkel and Biskis, 1962), rats (Arnold, 1951; Arnold and Jee,
1957; Jee and Arnold, 1961; Jee, 1972; Hamilton, 1947; Nenot et al., 1972; Priest and 
Jackson, 1977), dogs (Arnold and Jee, 1959; 1962) and rabbits (Williamson, 1963; 
Vaughan, 1970) autoradiography has shown that Pu was preferentially deposited on 
endosteal bone surfaces. Also, more Pu appeared to be deposited in vertebrae than in 
bones such as the femur. The ratio o f deposits between the periosteal and endosteal 
surfaces was 1:3.6 for beagles (Finkel and Biskis, 1962) and 1:4 for rabbits (Bleaney, 
1969).
Arnold and Jee (1957) first described the effects of growth and remodelling on the 
distribution of Pu in the bones o f rats. The Pu deposits on the bone surfaces were
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removed by osteoclastic activity or buried by layers o f new bone. Local variations in the 
distribution o f Pu on bone surfaces are therefore indicative o f the pattem o f skeletal 
remodelling. (Arnold and Jee, 1957; 1962; Marshall, 1969; Wronski et al., 1980).
Once Pu has deposited on a bone surface, it remains there until osteoclasts resorb the bone 
in the process o f remodelling. Thus, with growth in the length o f bones, the trabeculae are 
continually remodelled with the result that Pu bound to their surfaces is either buried or 
removed by osteoblastic activity (Jee et al., 1969b; Priest and Jackson, 1977) ultimately 
leading to Pu becoming volume distributed in the bone matrix with time. Significant 
amounts o f Pu released from bone destroyed by remodelling, recirculates and is 
redeposited on bone surfaces (Arnold and Jee, 1957) or accumulated in macrophages o f  
the bone marrow (Priest and Jackson, 1977).
With time, burial o f activity deposited on endosteal surfaces occurred which resulted in the 
activity becoming redistributed in bone volume (Jee and Amold, 1961; Schlenker et al., 
1976; Vaughan, 1973). Experiments using juvenile (90 days old) and young adult beagle 
dogs (550 days old) showed rapid burial o f surface deposits in the juvenile dogs which 
resulted in less Pu being found in tissue adjacent to bone surfaces and an increase in long­
term retention (Bmenger et al., 1984; Wronski et al., 1980). In young adult animals, loss 
o f Pu from bone surfaces occurs less rapidly than in growing animals. In the older dogs, 
autoradiographic data showed that a larger fraction o f  the surface deposits remained for 
many years after injection (Jee, 1972; Wronski et al., 1980), consistent with decreasing 
bone turnover rates with increasing age.
Experiments with Am have shown that this radionuclide deposits on all types o f  bone 
surface including the surfaces o f cortical vascular canals (Durbin et al., 1969; Hamilton, 
1947; Nenot et al., 1972; Taylor et a l ,  1961; Taylor, 1972; Williamson, 1963). In long 
bones. Am concentrates along the epiphyseal and metaphyseal surfaces o f the growth plate 
cartilages (Nenot et al., 1972). Less intense deposits were found on the endosteal and 
periosteal surfaces o f the shaft and in the Haversian canals o f cortical bone (Hamilton, 
1948). Americium-241 deposits more evenly on endosteal and periosteal surfaces than 
^^ P^u, although the endosteal surfaces are usually more heavily labelled. The difference
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between the uptake o f Am and other elements was found by WiUiamson (1963) to be 
greatest during the first few minutes after injection. However, preferential deposits o f Am 
were reported on the periosteal surfaces (Lloyd et al., 1972; Taylor, 1962), and on 
surfaces o f the vascular canals within the bone cortex (Taylor et al., 1961; Durbin et al., 
1969). Americium has also been seen to concentrate in the cells o f the dental pulp and in 
dentine (Hammarstrom and Nilsson, 1970).
In young adult dogs, Am was found to have a intensity ratio o f deposits between the 
periosteal and endosteal surfaces o f 1:2 (Finkel and Biskis, 1962). Taylor and Bensted 
(1969) found the uptake o f  ^ "**Am in the skeleton o f rats to be 1.4 times less than that o f  
^^ P^u. As for ^^^u the skeletal uptake o f  ^ "^ *Am was lower in older animals (Mahlum and 
Sikov, 1975; Stevens et al., 1976). Americium appeared to deposit preferentially on the 
resorbing bone surfaces and to a lesser extent on the resting surfaces (Herring et al., 1962; 
Williamson and Vaughan, 1964).
The long-term distribution and redistribution o f Am is similar to that o f Pu (Durbin et al., 
1969; Taylor et al., 1961). The redistribution o f Am due to bone growth and remodelling 
is similar to that described for Pu (Jee et al., 1969a; Howells and Green, 1981; Priest,
1981) in that the deposition o f new bone leads to the burial o f surface deposits o f Am and 
that bone resorption results in their removal (Jee, 1972). Significant amounts o f Am 
released from bone being remodelled recirculate and are redeposited onto bone surfaces. 
Am is also similar to Pu in that it is accumulated in the macrophages o f the bone marrow 
as remodelling occurs (Durbin et al., 1969; Taylor et al., 1961; Taylor, 1972).
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1.5. Bioldnetic and dosimetric models
The internationally recognised models for the calculation o f doses from intakes o f  
radionuclides are those o f the International Commission on Radiological Protection 
(ICRP). The ICRP values o f dose per unit intake are incorporated into legislation in 
Europe and the USA. In Publication 30 (ICRP, 1979), the ICRP reviewed metabolic data 
for each element for use in the calculation o f limits on internal exposure to radionuclides 
by workers for intakes by inhalation or ingestion. General models were given for the 
organs o f intake - the respiratory and gastrointestinal tracts - and element-specific models 
were given for the distribution and retention o f radionuclides following their entry into the 
blood. A model for the behaviour o f bone-seeking radionuclides was also included. 
Recently the lung model was updated in Publication 66 (ICRP, 1994) and now takes into 
account the increased understanding o f the behaviour o f radionuclides in the respiratory 
tract. A revision o f the gastrointestinal model is currently being undertaken.
ICRP has also considered doses to members o f  the public including children, and published 
models and dose coefficients for isotopes o f 31 elements in Publications 56, 67, 69 and 71 
(ICRP, 1989; 1993; 1995a;c). Where sufficient information is available, more 
physiologically realistic models have been included; for exan^le, account is taken o f the 
effects o f bone remodelling on the distribution and retention o f actinide and alkaline earth 
elements (ICRP, 1993; 1995a).
1.5.1. Inhalation - respiratory tract models
The current ICRP model o f the respiratory tract in Publication 66 (ICRP, 1994) is an 
update o f the earlier model used in ICRP Publication 30 (ICRP, 1979), takes into account 
extensive data on the behaviour of inhaled materials that has become available. As in the 
earlier model, deposition and clearance are treated separately. The scope o f the model has 
been extended to apply to all members o f the population and reference values for 3-month- 
old infants, 1-, 5-, 10- and 15-year-old children, and adults are included.
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The main difference in approach is that whereas the ICRP Publication 30 model (ICRP, 
1979) calculates only the average dose to the lungs, the ICRP Publication 66 model 
(ICRP, 1994) calculates doses to specific tissues o f the respiratory tract, and also takes 
account o f differences in radiosensitivity. In the Publication 66 model (ICRP, 1994), the 
respiratory tract is represented by five regions. The extrathoracic (ET) airways are divided 
into ETj, the anterior nasal passage, and ETg, which consists o f the posterior nasal and 
oral passages, the pharynx and larynx. There are three thoracic regions: bronchial (BB: 
trachea, generation 0 and bronchi generations 1-8); bronchiolar (bb: airway generations 9- 
15); and alveolar-interstitial (Al: the gas exchange region). Lynq)hatic tissue is associated 
with the extrathoracic and thoracic airways (LN^ and LN^y, respectively). Reference 
values o f dimensions and scaling factors for subjects o f different ages are specified.
Ventilation, the breathing frequency and tidal volume, is the main factor in the model that 
depends on age and level o f exercise. There are conprehensive data for men, women and 
children. Four activity levels are considered by ICRP which are: sleep, sitting, light 
exercise and heavy exercise, and habit survey data are available for the proportions o f time 
spent m each as a frmction o f age and sex. These parameters can be used to determine 
intake per unit exposure, and are also used with the deposition model to determine 
regional deposition.
Deposition is calculated for each region o f the respiratory tract taking into account both 
inhalation and exhalation. This is done as a function o f particle size, breathing parameters 
and/or work loads, according to the age and sex o f the subject. Groups considered are 3- 
month-old infants, 1-, 5-, and 10-year-old children, male and female 15 year olds and male 
and female adults (30 years) with breathing rates for sleeping, sitting, light and heavy 
exercise, for nose and mouth breathers. Deposition parameters are given for various 
particle sizes (average mean aerodynamic diameter 0.006-100pm). Default deposition 
parameters for individuals are given based on average daily patterns o f activity.
Clearance from the respiratory tract is treated as two competing processes, absorption to 
blood and particle transport out o f the respiratory tract, eg. hy mucociliary clearance. 
Particle transport is treated as a function o f the deposition site in the respiratory tract but
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is assumed to be material independent. Time dependent transport is modelled by 
considering each region as several conq)artments with different clearance half-times. For 
exan^le, the Al region is divided into three compartments which clear to bb with half- 
times o f 35, 700 and 7000 days. Similarly the bb and BB regions have fast and slow 
clearance compartments. Clearance from Al also involves transfer to lymphatic tissue.
For bb, BB and ET, there are con^artments to represent material that is sequestered in 
tissue and transported to lynq)hatic tissue.
Absorption to blood depends on the chemical nature o f the element and the chemical form 
deposited but is taken to be independent o f the deposition site with the exception o f ET i 
for which no absorption is assumed to occur. The model allows for changes in dissolution 
and absorption to blood with time. The use o f material specific dissolution rates is 
encouraged but default values are given. These are Type F (fast). Type M (medium) and 
Type S (slow), which broadly correspond to the ICRP Publication 30 (ICRP, 1979) 
defaults o f Class D, W and Y, respectively. Expressed as approximate half-times for one 
or two components o f clearance, these absorption rates correspond to: Type F -1 0  
minutes (100%); Type M -1 0  minutes (10%), 140 days (90%); Type S - 10 minutes 
(0.1%), 7000 days (99.9%).
The National Councü on Radiation Protection (NCRP) in the United States has also 
developed a new model o f the respiratory tract (Phalen et ah, 1991). As with the ICRP 
Publication 66 model (ICRP, 1994), the NCRP model is intended for application to the 
general public as well as workers. The model can therefore be adjusted to take account o f  
different body sizes, ventilation rates, the effect o f cigarette smoking and other factors.
The respiratory tract is subdivided into four main regions referred to as the naso-oro- 
pharyngo-laryngeal region (NOPL), tracheobronchial (TB), pulmonary (P) and pulmonary 
lymph nodes (LN). The deposition, clearance, and doses resulting from inhaled 
radionuclides are calculated separately for each o f these regions. Clearance data for 
specific chemical forms o f individual radionuclides are provided in an Appendix to the 
NCRP report (Phalen et ah, 1991).
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1.5.2. Ingestion - gastrointestinal tract models
The dosimetric model o f the GI tract in ICRP Publication 30 (ICRP, 1979) was very 
largely based on the work o f Eve (1966) who reviewed data on the transit o f materials 
through the GI tract and other parameters necessary to calculate doses. The model has 
four con^artments: the stomach, small intestine, upper large intestine and lower large 
intestine. The model allows for time-varying input into the stomach and one-way 
interconpartmental transfer with first order kinetics. The absorption o f material from 
blood is taken to occur in the small intestine. The transfer rate coefficients for movement 
of intestinal contents are equal to the reciprocal o f the mean residence times, taken to be 1 
hour for the stomach, 4 hours for the small intestine, 13 hours for the upper large intestine 
and 24 hours for the lower large intestine on the basis o f observed ranges o f 25-120 
minutes, 1-7 hours, 6-22 hours and 15-72 hours, respectively.
Doses are calculated separately for the mucosal layer o f each region o f the GI tract. For 
penetrating radiations, the average dose to the wall o f each region is used as a measure o f  
the dose to the mucosal layer. For non-penetrating radiations, the fraction absorbed by the 
mucosal layer is taken to be equal to 0.5 v/M where M is the mass o f the contents o f that 
section o f the GI tract and v is a factor between 0 and 1 representing the proportion of  
energy reaching sensitive cells. The factor o f 0.5 is introduced because the dose at the 
surface o f the contents will be approximately half that within the contents for non­
penetrating radiations. For p particles, v is taken to be 1 and for a particles, a value o f  
0.01 is used. This value o f 0.01 is arbitrary, the experimental evidence that it is warranted 
being from an acute toxicity study in rats in which LDgg for ingested yttrium-91 was 
estimated as about 12 Gy while a dose to the mucosal surface o f more than 100 times 
greater than from ^^^u had no effect (Sullivan et al., 1960).
In the ICRP Publication 30 (ICRP, 1979) model o f the GI tract, the absorption o f most 
elements is assumed to occur from the small intestine. The level o f absorption varies 
widely between different elements, depending on their chemical nature. For exanq)le, 
iodine and caesium are almost completely absorbed whilst less than 0.1% o f the actinide 
elements Pu and Am are absorbed (Harrison, 1995). The chemical form o f an ingested
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element may affect its absorption in some cases. The general observation is that 
incorporation o f an element into food may lead to greater absorption than ingestion o f  
inorganic forms o f the same element (Harrison, 1995). There is good evidence from 
animal experiments, with supporting human data for some elements, that the absorption o f  
a large number o f elements is greater in newborn mammals than in adults (ICRP, 1989; 
1993; 1995a;c). In Publication 30 (ICRP, 1979) the ICRP recommended values for 
fractional absorption (fj values) o f elements and their radioisotopes, specifically applying 
to occupational exposure o f workers. An Expert Group set up by the Committee on 
Radiation Protection and Public Health o f the Nuclear Energy Agency (NEA), 
Organisation for Economic Cooperation and Development, reviewed data on the 
absorption o f elements with radionuclides considered important in the context of 
environmental exposures o f members o f the public (NEA, 1988). They proposed the use 
o f values greater than the ICRP Publication 30 (ICRP, 1979) values for a number o f  
elements ingested in food and also proposed values for absorption in the first year o f life. 
For absorption values between 0.01 and 0.5 in the adult, an increase by a factor o f two 
was applied as an average for the first year. For values in the adult o f 0.001 or less, an 
increase by a factor o f ten was assumed. Adult values o f between 0.001 and 0.01 were 
rounded to 0.01 by the NEA (NEA, 1988). A similar approach has been adopted by ICRP 
in recommending fj values for infants (ICRP, 1989; 1993; 1995a;c). Unlike the NEA 
(NEA, 1988), the ICRP (1989; 1993; 1995a;c) have specified intermediate values for 
children for a number o f elements (Co, Fe, Sr, Ba, Ra and Pb).
A new dosimetric model for the GI tract is being produced by a Task Group o f ICRP 
Committee 2. This will be based on the transit model developed by Stubbs (1992) using 
the substantial body of recent data obtained using non-invasive scintigraphic procedures. 
The new model will include the oesophagus, take account o f retention o f radionuclides in 
the wall o f the GI tract and reconsider doses to sensitive cells from alpha-emitting 
radionuclides.
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1.5.3. Distribution to tissues and excretion
Radionuclides absorbed from the respiratory and GI tracts into body fluids and circulated 
in blood, are then transferred to tissues depending on their chemical nature. While this 
process is taking place, the radionuclides are regarded as being in the "transfer 
compartment" and are assumed by ICRP to be uniformly distributed throughout the body 
(ICRP, 1977; 1989; 1993; 1995a;c). For U isotopes reaching blood, the assumptions 
made in calculating doses to workers in ICRP Publication 30 (ICRP, 1979), based on 
human and animal data, were that fractions o f 0.2 and 0.023 o f U reaching the "transfer 
compartment" would go to mineral bone and be retained there with half-lives o f 20 and
5,000 days respectively. Retention in the kidneys (0.12) and other soft tissues (0.12) were 
also considered. The remaining fraction o f U reaching blood was assumed to be rapidly 
excreted. For isotopes o f Pu and Am entering the "transfer con^artment" the assumptions 
were that 0.45 would be translocated to bone and 0.45 would translocate to liver. Values 
corresponding to a fractional translocation to the gonads o f 10'^  g’’ were assumed in both 
cases. Plutonium and Am deposited in the liver and skeleton was assumed to be retained 
with a biological half-life o f 40 and 100 years, respectively. Deposits o f Pu and Am in 
gonadal tissue were assumed to be permanently retained. Half-times o f retention in liver 
and bone were subsequently reduced in Publication 48 (ICRP, 1986) to 20 and 50 years, 
respectively.
ICRP Publication 30 (ICRP, 1979) considered only occupational exposure in adults. 
Distribution and retention in body tissues may be age-dependent and in general retention 
half-times tend to be shorter at younger ages. For those radionuclides where sufficient 
data are available, this age dependence has been taken into account in ICRP Publication 
56 ,67 ,69  and 71 models as well as the smaller masses o f body tissues and organs (ICRP, 
1989; 1993; 1995a;c). If insufficient age-specific data are available, then adult biokinetic 
models are adopted for all ages. The age groups considered by ICRP are 3-month-old 
infants, 1-, 5-, 10- and 15- year old children and adults.
For many tissues o f the body, including liver and gonads, doses are calculated assuming 
uniform distribution of radionuclides and sensitive cells. This approach would not be
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acceptable for doses within the skeleton because o f the heterogeneous distribution o f  
radionuclides and sensitive cells.
1.5.4. Bone models
In the ICRP Publication 30 model (ICRP, 1979), the red bone marrow is assumed to be 
the tissue at risk for the induction o f radiation-induced leukaemia. In adults, red bone 
marrow is found in the trabecular or "spongy" bone in the vertebrae and the ends o f the 
long bones. Cortical or compact bone, which makes up the shafts o f the long bone, 
contains only fatty marrow in the adult. The haemopoietic stem cells are assumed to be 
randomly distributed throughout the haemopoietic marrow contained within trabecular 
bone (ICRP, 1968; 1977; 1989; 1993; 1995a;b). The dose to these cells is calculated as an 
average over the marrow contained within trabecular bone cavities.
The Publication 30 model (ICRP, 1979) assumes that the cells at risk for osteosarcoma 
induction are a layer o f cells along endosteal bone surfaces. The specific cells which are at 
risk are unknown, but the osteoprogenitor cells, osteoblasts and lining cells are thought to 
be the most likely targets since they all retain proliferative capacity. The probability o f  
osteoclasts becoming tumour cells is believed to be low (Hashimoto and Jee, 1976). The 
ICRP recommend that the dose should be calculated as an average over tissue up to a 
distance o f 10pm from the bone surfaces (ICRP, 1977).
Radionuclides were classified in ICRP Publication 30 (ICRP, 1979) as bone-surface or 
bone-volume seekers; ^^^u and were classified as bone-surface seeking elements 
and as a bone-volume seeker (ICRP, 1977). That is, ^^^u and '^*'Am were assumed 
to be uniformly distributed on endosteal bone surfaces o f cortical and trabecular bone at all 
times after their deposition in the skeleton and was considered to be uniformly 
distributed throughout bone volume at aU times following deposition in the skeleton. The 
assumption that a radionuclide is either a surface or a volume seeker takes no account o f  
the movement between different skeletal con^onents as a result o f bone turnover and 
growth or the age-related distribution o f red bone marrow.
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Dynamic models taking into account deposition characteristics, burial o f surface deposits, 
transfer o f activity to marrow and recycling to the circulation and between organs have 
been developed by Leggett and his colleagues (Leggett and Eckerman, 1984; Leggett et 
ah, 1982; Leggett, 1985; 1992). These models have been adopted by ICRP (1989; 1993; 
1995) for the main groups o f bone-seeking radionuclides, the alkaline earth elements and 
the actinides. The model for the alkaline earth elements, Ba, Ra and Sr which were 
adopted in ICRP Publication 67 (ICRP, 1993) was revised to include U in Publication 69 
(ICRP, 1995a). The model for the actinides which includes Pu and Am was adopted in 
ICRP Publication 67 (ICRP 1993).
1.5.5. Model for uranium and alkaline earth elements
Figure 1.3 shows the ICRP Publication 69 (ICRP, 1995a) model for the distribution and 
retention o f U. Bone is divided into cortical and trabecular conq)artments, each o f which 
is further divided into bone surface and bone volume. In the model, cortical and trabecular 
bone volume are each assumed to consist o f two subcon^artments, representing relatively 
exchangeable activity and relatively non-exchangeable activity. The relatively 
exchangeable activity is assumed to reside close to bone surfaces, which is treated as a 
uniformly mixed con^artment that exchanges activity with blood plasma. Removal from 
the nonexchangeable bone volume is assumed to occur during resorption.
The model assumes that U entering blood from the respiratory or GI tracts is rapidly taken 
up and retained on bone surfaces as well as in soft tissues, including the kidneys, and a 
proportion is excreted in the urine and faeces. Bone surface deposits o f U migrate to 
exchangeable bone volume within a few days except for a proportion lost to blood. On a 
longer time-scale, U migrates to nonexchangeable bone volume. The model is intended to 
provide reasonably accurate predictions o f the time-dependent activity on bone surfaces 
and in bone volume after injection o f isotopes o f U into plasma, using a minimal number o f  
compartments and first-order transfers between compartments.
Parameter values for the skeleton are based on experimental studies in laboratory animals 
and man. It is assumed that 15% of U leaving the circulation deposits on bone surfaces in
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Figure 1.3. Model for the distribution and retention o f U and alkaline earths (ICRP, 1995).
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Figure 1.4. Model for the distribution and retention o f actinides (ICRP, 1993).
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adult humans. By analogy with the alkaline earths (ICRP, 1993), the ratio o f the amount 
deposited on trabecular surfaces to that deposited on cortical surfaces is assumed to be 
1.25 in the mature skeleton. The removal half-time from bone surfaces is assumed to be 5 
days. It is assumed that one-half goes to an exchangeable bone volume compartment. 
Uranium is assumed to leave the exchangeable bone volume compartment with a half-time 
o f 30 days; this value was derived for Ra (ICRP, 1993) and is consistent with the limited 
data on loss o f U from bone. Based on the small amount o f U retained in the skeleton at 
later times (as indicated by human chronic exposure data) 75% o f U leaving exchangeable 
bone is assumed to return to the bone surface compartment and 25% is assigned to non­
exchangeable bone. Removal from non-exchangeable bone to plasma is at the age- 
dependent rate o f bone turnover, which is different for cortical and trabecular bone (ICRP, 
1989; 1993). In children, initial deposition o f U and the alkaline earth elements in the 
skeleton is greater than in adults and the rate o f bone turnover is also greater.
1.5.6. Model for the actinides
Figure 1.4 shows the ICRP model for actinides as described in ICRP Publication 67 
(ICRP, 1993). Cortical and trabecular bone are considered separately as is associated 
bone marrow. The model assumes that Pu and Am entering blood from the respiratory or 
GI tract are deposited initially on bone surfaces as well as in the liver and other soft 
tissues, and a proportion is excreted in urine or faeces. Bone surface deposits are 
subsequently transferred to bone volume during bone formation and to marrow by bone 
resorption. Plutonium and Am in bone volume may also be transferred to bone marrow by 
bone resorption. The rate o f removal from bone volume at a given age is assumed to be 
equal to the bone resorption rate at that age. The actinides are removed from bone 
marrow to blood over a period o f months and redistributed in the same pattem as the 
original input to blood.
Movement o f material in the body is depicted as a system o f first-order kinetics.
Parameter values for the skeleton are based on experimental studies in man and laboratory 
animals and from cases where accidental intake o f actinides has occurred and are detailed 
in ICRP Publication 67 (ICRP, 1993) individually for each element at the various ages.
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For all ages at injection, liver and bone surfaces combined are assumed to receive 80% of 
Pu and Am leaving the circulation; the division o f this amount between liver and bone 
surfaces varies with age. For Pu, the relative deposition in (a) skeleton and (b) liver are 
set at a:b = 5:3 for adults, whilst for Am the ratio a;b = 3:5. For both Pu and Am a ratio 
a:b o f 7:1 is assigned to the infant and 1-year-old child. Intermediate ratios to those for 1- 
year-old children and adults, a:b = 6:2 for Pu and a:b = 5.3 for Am, are applied to ages 5 
to 15 years.
1.5.7. Dosimetric quantities
When the distribution o f activity in different organs or tissues is known, the resulting 
distribution o f the absorbed energy and absorbed dose, defined as absorbed energy per unit 
mass, can be calculated. For non-penetrating radiations, energy will in most cases be 
deposited largely in the tissue in which the radionuclide is deposited. For penetrating 
radiations, however, it is necessary to take account o f cross-fire between tissues. This is 
done using a "mathematical phantom" which describes the geometric relationship between 
the different tissues and organs o f the body {ie. a phantom which can be described with 
simple mathematical equations). Such phantoms have been developed for different ages 
(Cristy and Eckerman, 1987). Different mathematical methods, including Monte Carlo 
techniques, may then be used to calculate the absorbed dose in a given organ from decays 
taking place in the same or another organ, making the assumption that the radionuclides in 
the source regions are homogeneously distributed. The values obtained are referred to as 
specific effective energies (SEE(T^S)) for a particular radionuclide (Leggett and 
Eckerman, 1984), expressing the energy absorbed in the tissue T per transformation in the 
source organ S (ICRP, 1979; Cristy and Eckerman, 1987).
To provide a tool for the interpretation o f absorbed dose in different organs in terms o f the 
total risk o f cancer and hereditary effects, the ICRP uses the concepts o f equivalent dose 
and effective dose (ICRP, 1979; 1989). Radiation weighting factors take account o f  the 
relative biological effectiveness o f different radiation types in causing malignancy or 
genetic damage. Thus the absorbed dose in Gray (Gy) is multiplied by a radiation 
weighting factor o f 20 for alpha irradiation and 1 for beta and gamma radiations to give
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the equivalent dose in Sievert (Sv).
Table 1.1. Radiation weighting factors (ICRP, 1991).
5 0
T y p e  a n d  e n e r g y  r a n g e R a d i a t i o n  w e i g h t i n g  f a c t o r ,  Wr
P h o t o n s ,  a l l  e n e r g i e s 1
E l e c t r o n s  a n d  m u o n s ,  a l l  e n e r g i e s 1
N e u t r o n s ,  e n e r g y  <  1 0  k e V 5
1 0  k e V  t o  1 0 0  k e V 1 0
>  1 0 0  k e V  t o  2  M e V 2 0
>  2  M e V  t o  2 0  M e V 1 0
>  2 0  M e V 5
P r o t o n s ,  o t h e r  t h a n  r e c o i l  p r o t o n s ,  e n e r g y  >  2  M e V 5
A l p h a  p a r t i c l e s ,  f i s s i o n  f r a g m e n t s ,  h e a v y  n u c l e i 2 0
Thus, the equivalent dose in a tissue T is given by the expression:
• ^T ,R  y o M / e s  kg''^
where is the absorbed dose averaged over the tissue or organ T, due to radiation R.
Since tissues differ in their radiosensitivity, tissue weighting factors are attributed to 
different tissues and organs, taking account o f the incidence o f fatal cancer and hereditary 
effects, weighted for the incidence o f non-fatal disease and years o f life lost (ICRP, 1991).
The effective dose is the sum of the weighted equivalent doses in all the tissues and organs 
o f the body. It is given by the expression:
where H j is the equivalent dose in tissue or organ T and Wj is the weighting factor for 
tissue T.
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Table 1.2. Tissue weighting factors (ICRP, 1991).
T i s s u e  o r  o r g a n T i s s u e  w e i g h t i n g  f a c t o r ,  Wy
G o n a d s 0 . 2 0
R e d  b o n e  m a r r o w 0 . 1 2
C o l o n 0 . 1 2
L u n g 0 . 1 2
S t o m a c h 0 . 1 2
B l a d d e r 0 . 0 5
B r e a s t 0 . 0 5
L i v e r 0 . 0 5
O e s o p h a g u s 0 . 0 5
T h y r o i d 0 . 0 5
S k i n 0 .0 1
B o n e  s u r f a c e 0 .0 1
R e m a i n d e r ’ 0 .0 5 ^
‘ F o r  t h e  p u r p o s e s  o f  c a l c u l a t i o n ,  t h e  r e m a i n d e r  i s  c o m p o s e d  o f  t h e  f o l l o w i n g  a d d i t i o n a l  t i s s u e s  a n d  o r g a n s :  
a d r e n a l s ,  b r a i n ,  u p p e r  l a r g e  i n t e s t i n e ,  s m a l l  i n t e s t i n e ,  k i d n e y ,  m u s c l e ,  p a n c r e a s ,  s p l e e n ,  t h y m u s  a n d  u t e r u s .
^ I n  e x c e p t i o n a l  c a s e s  w h e r e  a  s i n g l e  o n e  o f  t h e  r e m a i n d e r  t i s s u e s  o r  o r g a n s  r e c e i v e s  a n  e q u i v a l e n t  d o s e  i n  
e x c e s s  o f  t h e  h i g h e s t  d o s e  r e c e i v e d  b y  a  t i s s u e  o r  o r g a n  f o r  w h i c h  a  w e i g h t i n g  f a c t o r  i s  s p e c i f i e d ,  t h e n  a  
w e i g h t i n g  f a c t o r  o f 0 . 0 2 5  s h o u l d  b e  a p p l i e d  t o  t i i a t  t i s s u e  o r  o r g a n  a n d  a  w e i g h t i n g  f a c t o r  o f  0 . 0 2 5  t o  t h e  
a v e r a g e  d o s e  i n  t h e  r e s t  o f  t h e  r e m a i n d e r  t i s s u e s .
There are other subsidiary dosimetric quantities which are used in radiation protection. 
Following an intake to the body of a radioactive material, there is a period during which 
the material gives rise to equivalent doses in the tissues o f the body at vaiying rates. The 
time integral o f the equivalent-dose rate is called the "committed equivalent dose", 
where t  is the integration time (in years) following the intake. If t  is not specified, it is 
implied that the value is 50 years for adults and from intake to age 70 years for children. 
The "committed effective dose", E{x), is similarly defined.
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1.6. Effects of radiation
The widespread use o f X-rays and radium in treating disease in the early 1900s led to 
reports o f the biological effects o f radiation, which in turn led to studies o f the biological 
effects o f radiation. Pierre Curie intentionally exposed the skin o f his arm to observe the 
result, Marie Curie developed radiation bums on her fingers as a result o f handling a small 
tube o f radium enclosed in a thin metal box and Henri Becquerel burned the skin on his 
chest by carrying a tube o f radium-bearing barium chloride in his chest pocket (Saunders 
and Kathren, 1983; Stannard, 1988). Albers-Schonberg reported the sterilizing effect o f  
X-rays on male guinea pigs and rabbits in 1903; histological examination showed the testes 
to be atrophic. The effects o f radiation on bone marrow were reported by Heineke (1903) 
who later demonstrated that myelopoiesis was more radiosensitive than erythropoiesis 
(Heineke, 1906). In 1913, Shouse et aL demonstrated that aplasia o f the bone marrow in 
animals was a cause o f death following total-body irradiation. Leukaemia was reported in 
5 radiation workers in 1911 and anaemia in 2 X-ray workers in 1912 (Upton, 1990). Both 
Marie Curie and her daughter Irène Juloit-Curie died o f leukaemia, probably induced by 
prolonged exposure to radiation (Saunders and Kathren, 1983). Theodor Blum, an , 
American dentist, first reported bone changes in the jaws o f women radium dial painters - 
known as "radium jaw" (Blum, 1924). The practice o f pointing the brush between the lips 
to make the point finer led to ingestion and internal contamination with large amounts o f  
^^ R^a and ^^ ®Ra. Nine deaths were reported in radium dial painters between 1922 and 1924 
which were linked to radium exposure (Martland, 1931).
There was a delay o f about 40 years before it became clear from epidemiological studies 
that there was a risk o f radiation-induced cancer from irradiation. This delay can be 
attributed to the fact that radiation-induced cancers are indistinguishable from most other 
cancers arising from other causes and their occurrence can only be identified by a 
statistical analysis o f "excess" incidence over the "natural" incidence. For many cancers 
there is also a long interval, the latency period, between exposure to radiation and the 
appearance o f a tumour. In humans, the latency period may last a number o f years. For 
acute myeloid leukaemia the latency period is about 2 years (Ichimaru et a l ,  1976; 1991) 
and for ^^ '^ Ra induced osteosarcomas the minimum latency period is about 4 years (Speiss
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and Mays, 1970; 1973), and o f the order o f 5-10 years for other cancers. For radiation 
induced leukaemia, the median latency period is about 10 years (Ichimaru et a/., 1976; 
1991; Mettler and Upton, 1995) and may be 20-30 years for bone tumours. An average 
latency period o f 10 years is assumed by ICRP in Publication 60 (ICRP, 1991).
1.6.1. Stochastic and deterministic effects
Radiation from either external sources or internally incorporated radionuclides leads to the 
deposition o f energy in cells. Therefore, even at very low doses, it is possible that 
sufficient energy may be deposited within a cell to result in its modification or death.
Death o f one or a small number o f  cells will, in most cases, have no consequences in a 
tissue or organ, but modifications in single cells such as genetic changes or transformations 
may ultimately lead to the induction o f cancer. These effects have been termed 
"stochastic" by ICRP (1991) and the probability o f their occurrence, but not their severity, 
depends on the radiation dose. There are two types o f stochastic effects: the first occurs 
in somatic cells and may result in the induction o f cancer and the second is termed 
hereditary and occurs as mutations and chromosomal aberrations in germinal tissue cells 
whose frmction is to transmit genetic information. Stochastic effects can be reduced in 
frequency by lowering the dose, but cannot be avoided entirely and are assumed by ICRP 
to occur with low frequency at low doses (ICRP, 1991).
General or localised tissue irradiation at high doses o f  radiation between a few Gy and a 
few tens o f Gy causes cell killing which cannot be compensated for by proliferation o f  
viable cells. The resulting loss o f cells can cause a severe and clinically detectable 
impairment o f frmction in a tissue or organ. There is a threshold below which the loss o f  
cells is too small to detectably in^air tissue or organ frmction and therefore the severity o f  
the observed effects depends on the dose. These effects have been termed "deterministic" 
by ICRP (1991) and include effects such as opacity o f the lens and cosmetically 
unacceptable changes in the skin.
The principal sources o f information on the stochastic effects o f radiation are
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epidemiological studies o f the A-bomb survivors exposed to whole-body irradiation at 
Hiroshima and Nagasaki, patients exposed to external radiation or radiation from internally 
incorporated radionuchdes for medical treatment or diagnosis, and groups o f workers 
exposed to radiation or radioactive substances such as U miners and radium-dial painters 
(ICRP, 1991; KendaU et a l ,  1992).
Data on deterministic effects in man come from: the side effects o f radiotherapy; recorded 
effects on the early radiologists; the effects o f the atomic bombs at Hiroshima and 
Nagasaki in Japan; the consequences o f industrial accidents, some in the nuclear industry 
and some involving radiographic sources; the Marshall islanders and Japanese fishermen 
after the tests at Bikini; and from accident victims, for example at Chernobyl in the USSR 
and Goiânia in Brazil (ICRP, 1991; Saunders et a l ,  1990).
The induction o f osteosarcomas and myeloid leukaemias by ^^ P^u and "^^‘Am and 
osteosarcomas by ^^ U^ have been demonstrated in animal studies; no human data are 
available. Induction o f liver cancer by ^ ^^ Pu has also been demonstrated in animals. Acute 
damage to bone, bone marrow and kidney has been recorded in both animals and humans.
In the following sections, an outline is given o f the tumorigenesis process and information 
is reviewed on radiation-induced osteosarcoma, leukaemia and carcinomas o f liver and 
kidney. In addition, deterministic damage to these tissues is considered.
1.6.2. Mechanisms of radiation tumorigenesis
The development o f cancer is the major late effect resulting from exposure to radiation. 
During the last few years, there has been a substantial increase in knowledge o f cellular 
and molecular mechanisms o f tumorigenesis (Bishop, 1987; Fearon and Vogelstein, 1990; 
Heim and Mitelman, 1989; Knudson, 1986; Scrable et a/., 1990). Of particular importance 
to an understanding o f radiation tumorigenesis is the knowledge that, for the majority o f  
human and animal tumours, the tumour initiation processes probably involve specific 
changes to single target cells in tissue and that tumour development is complex and 
involves multistage clonal growth and evolution before the final malignant state is achieved
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(Bishop, 1987; Sager, 1989; Weinberg, 1991). In this way, multistage tumour 
development and its variation between tumour types may, in part, explain the different 
latent periods seen in radiation-induced tumours o f man and experimental animals. 
Although there is evidence that specific mechanisms for induction can vary amongst 
tumours, the malignant process may be divided into four phases: neoplastic initiation; 
promotion; conversion and progression.
Neoplastic "initiation" encompasses the essentially irreversible cellular damage, which 
although not necessarily expressed immediately, provides the potential in cells for 
neoplastic development. There is good evidence that this initiation process results from 
damage to DNA leading to gene mutations in single target cells in tissues. The critical 
damage is likely to be coincident damage to both DNA strands (DNA double strand 
breaks). Although a proportion o f the double strand damage will be repaired, completely 
error free repair o f this damage, even at low doses, is not expected. Such somatic cell 
mutations are believed to provide cells with some form o f growth or selective advantage 
that they have the potential to evade some o f the normal tissue constraints and proliferate 
to form clones o f pre-neoplastic cells.
Neoplastic "promotion" can be seen as a process where the clones o f pre-neoplastic cells 
receive an abnormal growth stimulus and begin to proliferate in a semi-independent 
manner. Tumour promoting agents vary in structure and origin and range from chemical 
agents to cellular growth factors, hormones and other dietary/environmental factors. Thus 
dormant tumour initiated cells in tissues may be stimulated to proliferate and express their 
pre-neoplastic growth advantage and, in this way, promotion is evidenced by an increase in 
the frequency o f induced neoplasia (Trosko et al., 1990; Yuspa and Poireier, 1988). 
"Conversion" o f these pre-neoplastic cells to a form in which they are committed to 
become frilly malignant is a central feature o f the process o f neoplastic development.
Once the potential for frill malignancy has been established, the subsequent "progression" 
o f the disease may depend upon further gene mutations accumulating within the expanding 
population o f pre-neoplastic cells (Fearon and Vogelstein, 1990). These mutations may, 
for example, block the normal pathways o f terminal cellular differentiation, alter ceU cycle
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controls and response to growth regulating factors, enhance the recruitment o f a blood 
supply or change the mobility o f cells such that they become invasive and metastatic 
(Foulds, 1975; Hart et al., 1989). It is this invasive process that principally provides for 
the fatal effects o f most common tumours.
On this basis, a single mutational event in a critical gene in a single target cell in vivo can 
create the potential for neoplastic development. Thus, a single radiation track transversing 
the nucleus o f an appropriate target cell has a finite probability, although very low, o f  
generating specific damage to DNA that results in a tumour initiating mutation. These 
initiated cells can then develop by multistage processes into an overt malignancy. For 
radiation protection purposes, a progressive increase in risk with increasing dose, with no 
threshold, is assumed (Cox et al., 1995).
Ionising radiation is a relatively well-characterised mutagenic agent in mammalian somatic 
cells (Sankaranarayanan, 1991). Since both tumour initiation and progression are 
characterised by the acquisition o f specific cellular mutations, it may be expected that 
ionising radiation plays a role throughout the malignant process. Radiation is capable o f  
causing tumours in nearly all tissues o f the body, although the observed frequency o f  
tumours following a unit dose varies from one tissue to another.
1.6.3. Osteosarcoma in humans
In man, osteosarcomas are commonly found in young people, mean age 17 years, and. 
chondrosarcomas are seen later in life, mean age 44 years (McCollister Evarts and Rubin, 
1978). Pain is the presenting symptom in more than half o f patients with osteosarcoma or 
chondrosarcoma followed by a swelling or mass in 23-65% and pathologic fracture in 
1-6% (Brostrom et al., 1980; Prichard et al., 1980). Osteosarcomas tend to be o f 3 
histological types: osteoblastic, chondroblastic or fibroblastic, and 50-70% o f bone 
tumours are highly malignant (Brostrom et al., 1980). Bone sarcomas are usually fatal 
because o f métastasés and the 5-yr survival for osteosarcoma is about 30% (Mettler and 
Upton, 1995).
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Bone tumours are staged according to their location in the bone cortex, tumour size, 
amount o f spreading into adjacent soft tissues and the degree o f metastasis. The incidence 
o f the different bone tumours in man is 51%, 23%, 7%, 11% and 8% for osteosarcoma, 
chondrosarcoma, fibrosarcoma, Ewing’s sarcoma and a miscellaneous group o f tumours 
(Dahlin, 1967). Osteosarcoma sites in humans are femur (36-54%), tibia (32-38%), 
humerus (11-14%), fibula (7%), pelvis (7%) and vertebrae (1-2%) (Barwick et al., 1980; 
Brostrom a/., 1980).
Osteosarcoma has been reported following external radiation treatment for tinea capitis 
(UNSCEAR,1977), Hodgkin’s disease (Huvos and Woodard, 1988; Laskin et al., 1988; 
Tucker et al., 1987; 1988; Woodard et al., 1988) and various neoplasms (Arlen et al.,
1971). Tumour induction times ranged from 4-27 years with a median time o f 11 years.
Reviews o f the effects o f whole-body irradiation following the bomb explosions at 
Hiroshima and Nagasaki show no increase in the number o f bone tumours observed 
(ICRP, 1966; Okada et a l ,  1975).
Following World War II, a preparation known as Peteosthor containing short-lived ^^ "^ Ra 
was administered intravenously for therapy o f tuberculosis and ankylosing spondylitis 
(Mays, 1978; Speiss, 1956; Speiss and Mays, 1973; Speiss et a l ,  1962). Radium-224 is 
still used in Germany for treatment o f ankylosing spondylitis. Due to the short physical 
half-life o f  ^ "^^ Ra (3.62 days), most o f the dose was delivered to the endosteal and 
periosteal surfaces o f bone. Increased incidences o f osteosarcoma have been reported in 
these patients (Mays, 1978; Speiss and Mays, 1970; 1973; Schales, 1978) and it was found 
that protraction o f the injections resulted in a higher risk o f bone tumour induction 
(Chemelesky et a l ,  1990). In German patients who received injections o f short-lived 
^^ "^ Ra, the first osteosarcomas were seen 4 years after exposure with an average time o f 10 
years (Speiss and Mays, 1970; 1973).
Between 1915 and 1930 watch dial figures were painted with luminous compounds 
containing ^^ R^a and ^^ R^a by women in the USA and UK. It was a relatively common
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practice to point the brush between the lips to make the point finer. This practice led to 
ingestion and internal contamination with large amounts o f Ra salts. The radioisotopes of 
Ra involved were ^^ R^a and ^^ R^a (Aub et a l ,  1952; Looney et al., 1955; Sharpe, 1974), 
the Ra accumulated in bone, and autopsies conducted 20 years later revealed that o f the 
ingested Ra remaining in the body up to 95% remained in bone (BEIRIV; 1988). There 
are extensive data on the effect o f deposition of^^^Ra or a mixture o f Ra and mesothorium 
in the skeleton of the dial painters and high incidences o f osteosarcoma were observed as 
well as tumours o f the cranial sinuses of the skull (Evans, 1966; Hasterlik et al., 1964).
In the US, there were about 2,000 female dial painters employed and in the UK there were 
about 1,200. These two groups have been followed for their life-spans (ANL, 1977; 
Baverstock and Papworth, 1989; Evans et al., 1972; Rowland et al., 1971). The UK 
group ingested less Ra than their US counterparts (Baverstock and Papworth, 1989). The 
time o f onset for carcinomas o f the cranial sinuses was 19-51 years (median 39 years) and 
for osteosarcoma 7-43 years (median 23 years) (Evans, 1966; Rowland and Stehney,
1978; Rowland et al., 191%; Rowland and Lucas, 1984).
Patients given intravenous injections o f the contrast medium, Thorotrast (^^Th02), for 
diagnostic purposes have been followed by a number o f groups with reference to induction 
of bone tumours. This is because ^^Th decays to ^^'’Ra. Cases o f osteosarcoma induction 
have been reported Andersson and Storm (1992), van Kaick et al. (1986; 1989) and Mori 
et al. (1986; 1989). However, Travis et al. (1992) have concluded that the association 
between Thorotrast and bone tumours is not entirely convincing.
1.6.4 Osteosarcoma in experimental animals
A large number o f experimental animal studies have been undertaken using °^Sr, ^^'‘Ra, 
^^ P^u, Am and other alpha-emitting radionuchdes and these have produced substantial 
data on bone cancer which are summarised in this section. A few experiments have been 
undertaken to examine the effect of X-irradiation upon osteosarcoma induction and these 
have been included for comparison purposes.
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1.6.4.1. X-irradiation
Finkel and Biskis (1968) exposed CFl mice to 2.5, 6.3 and 10 Gy o f 250 kVp X-rays and 
observed osteosarcoma incidences o f about 2%, 6% and 11%, respectively. Fabrikant et 
al. (1972) exposed male Fj (August x Marshall) rats to either a single dose o f 30 Gy X- 
rays (140 kVp), 30 Gy X-rays given in 3 fractions (140 kVp) or 30 Gy X-rays given in 6 
fractions (230 kVp) and observed osteosarcoma incidences o f about 27%, 3% and 27%, 
respectively.
1.6.4.2; Plutonium
Induction o f osteosarcomas by *^*Pu or has been demonstrated in mice (Finkel and 
Biskis, 1962; Humphreys eta l., 1987; Loutit eta l., 1976; Oghiso et al., 1994; 1997; 
Rosenthal and Lindenbaum, 1969; Svoboda et al., 1981; Svoboda and Budenikova, 1990; 
Taylor et al., 1983), hamsters (Benjamin et al., 1976), rats (Bensted et al., 1965;
Buldakov and Lyubchansky, 1970; Fabrikant and Smith, 1964; Fabrikant et al., 1972; 
Langham and Carter, 1951; Moskalev et al., 1969) and dogs (Bruenger et al., 1991; Dagle 
et al., 1996; Jee, 1972; Jee et al., 1976; Mays and Lloyd, 1972; Park, 1987; Taylor et al., 
1981).
Finkel and Biskis (1962) injected 6, 13, 26, 63, 115, 223 and 855 kBq kg‘^  ^^ P^u citrate 
into CFl mice and observed osteosarcoma incidences o f about 4%, 8%, 10%, 20%, 44%, 
21% and 23%; estimated life-span skeletal doses were between 0.4 and 5.6 Gy. At the 
two highest dose levels, relatively fewer tumours were observed but the bones showed 
extensive non-neoplastic damage. They recorded that the majority o f the tumours were 
seen in the spine. Rosenthal and Lindenbaum (1969) examined the effectiveness o f  
polymeric ^^^u (0.32 and 0.55 kBq kg' )^ versus monomeric ^^ P^u (0.22, 0.44 and 0.93 
kBq kg"^ ) in inducing osteosarcomas in CFl female mice. Tumour incidences o f 39% and 
63%, respectively, were observed for polymeric ^^ P^u and 60%, 75% and 82%, 
respectively, were observed for monomeric ^^ P^u. An osteosarcoma incidence o f  1% was 
observed in control mice. The authors concluded that the mice given the monomeric ^^ P^u
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solution appeared to develop more tumours with a shorter induction time. Experiments by 
Humphreys et al. (1987) compared the effect o f single and protracted administration o f  
^^ P^u in female CBA/H mice at levels o f 1.9. 5.6 and 18.5 kBq kg'\ They reported 
osteosarcoma incidences o f 0%, 8% and 30%, respectively, for a single administration o f  
^^ P^u, while for multiple administrations o f  ^ ^^ Pu incidences o f about 2%, 7% and 33%, 
respectively, were observed; no osteosarcomas were seen in controls. They also reported 
the presence o f "early" osteosarcomas which were visible histologically but were not seen 
in X-radiographs o f the animals.
Experiments to examine the effect o f sex on osteosarcoma induction were undertaken by 
Loutit et al. (1976) and Taylor et al. (1983). Loutit et al. (1976) administered ^^ P^u to 
CBA/H mice at dose levels o f 0.4, 1.1 and 3.7 kBq kg'’ and observed osteosarcoma 
incidences o f 0%, 40% and 30%, respectively, for males and 50%, 80% and 60%, 
respectively, for females. In the series o f experiments reported by Taylor et al. (1983) 
groups of 10 week old male and female C57BL/Do mice were given doses o f 0.6, 3.5,
10.6, 32.4 and 106 kBq kg'’ ^^ P^u. Osteosarcoma incidences o f 0%, 0%, 0%, 27% and 
54%, respectively, were induced in male mice, while incidences o f 8%, 8%, 8%, 55% and 
92%, respectively, were observed in female mice. In further studies, 12-13 week old male 
and female albino C57BL/Do mice were given doses o f 0.6, 3.6, 11.8, 33.3 and 108 kBq 
kg ’ of^^^Pu which resulted in osteosarcoma incidences o f 0%, 0%, 0%, 6% and 17%, 
respectively, in males and 0%, 0%, 25%, 56% and 90%, respectively, in female mice. It 
was concluded that female mice were more susceptible to the induction o f osteosarcoma. 
One problem with both o f these studies was the small size o f the experimental groups used 
(10 and 12-16 animals, respectively); no statistical analyses were undertaken.
Svoboda et al. (1981) administered 180 kBq kg ’ ^^ P^u to female ICR mice and observed 
an osteosarcoma incidence o f about 54%; an incidence o f 1.4% was seen in control mice. 
Further studies, where 3, 6 and 12.3 kBq kg ’ ^^ P^u was administered resulted in 
osteosarcoma incidences o f 2%, 3% and 10%, respectively; in these experiments no 
osteosarcomas were seen in control mice (Svoboda and Budenikova, 1990). Oghiso et al. 
(1994) administered 0.5, 1, 5 and 10 kBq kg ’ ^^ P^u to female C3H mice and observed 
osteosarcoma incidences o f about 36%, 60%, 48% and 17%, respectively; calculated
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skeletal doses were 3.1, 5.9, 19.4 and 40.2 Gy. In a further series o f experiments by the 
same authors 0.011, 0.11, 0.63, 1.13, 1.46, 5.41, 7.87 and 11.5 kBq kg ’ ^^ P^u resulted in 
osteosarcoma incidences o f  2%, 14%, 30%, 43%, 96%, 48%, 32% and 20%, respectively; 
skeletal doses were calculated as 0.067 Gy, 0.69 Gy, 2.93 Gy, 4.66 Gy, 6.92 Gy, 17.3 Gy, 
25.5 Gy and 42.4 Gy, respectively (Oghiso et ah, 1997). Benjamin et al. (1976) 
administered 74 kBq kg ’ to hamsters and observed an osteosarcoma incidence o f 25%.
Langham and Carter (1951) injected groups o f rats with 1.2, 1.9 and 2.3 MBq kg ’ of^^^Pu 
which produced osteosarcoma incidences o f 11%, 6% and 10%, respectively. Bensted et 
al. (1965) gave a single administration o f 110 kBq kg ’ of^^^Pu to male F, rats (August x 
Marshall) and observed an osteosarcoma incidence o f about 77%; further studies in which 
239pu was administered in 5 fractionated doses totalling 111 kBq kg ’ produced an 
osteosarcoma incidence o f 58%. The osteosarcomas induced in the rats which had 
received the fractionated doses arose shghtly earlier than those in animals which had 
received a single injection o f  ^ ^^ Pu. These experiments were repeated by Fabrikant et al. 
(1972) using the same strain o f rats and the same dose levels; tumour incidences o f 52% 
following the single administration o f  ^ ^^ Pu and 56% following fractionated doses were 
observed. Although fractionation did not affect the tumour incidence, it appeared to 
shorten the latent period. Moskalev et al. (1969) observed osteosarcoma incidences o f  
about 5%, 16%, 24% and 23% in rats at dose levels o f 24, 48, 93 and 185 kBq kg ’ 
respectively. Buldakov and Lyubchansky (1970) administered 0.27, 0.3, 1.8, 3.7 and 26 
kBq kg ’ ^^^u to rats and observed osteosarcoma incidences o f 1.0%, 1.3%, 1.1%, 3.4% 
and 5%, respectively.
The effect o f age at the time o f injection has been investigated using rats (Fabrikant and 
Smith, 1964). Young rats (7 weeks old) and adult rats (7 months old) were injected with 
110 kBq kg ’ o f  ^ ^^ Pu, resulting in osteosarcoma incidences o f 25% and 5%, respectively.
It was concluded that tumours in the adult rats grew more slowly, were more confined and 
had a lower tendency to invade the surrounding tissue.
Experiments using beagle and St Bernard dogs have been carried out in the US; in all over
1,000 dogs were exposed to various radionuclides. Twelve years after inhalation o f
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^^ P^u02 an osteosarcoma incidence o f 46% was reported by Park (1987); calculated 
cumulative skeletal doses ranged from 0.5 to 4.8 Gy. Dagle et al. (1996) report 
experiments where ^^^u(N0 3 ) 4  was administered to beagle dogs by inhalation, resulting in 
estimated final body depositions o f 0.1, 0.2, 1.3, 6.7 and 43 kBq kg ’ ^^ P^u and 
osteosarcoma incidences o f 10%, 5%, 5%, 45% and 85%, respectively, were observed.
Experiments were performed on beagle dogs by Jee (1972) who gave dose levels o f 0.6, 
1.8, 3.5, 11, 34 and 107 kBq kg' ’ of^^^u, resulting in tumour incidences o f 33%, 69%, 
83%, 100%, 100% and 78%, respectively. Other experiments using beagle dogs gave an 
osteosarcoma incidence o f 33% following the administration o f 0.58 kBq kg ’ ^^ P^u 
(Dougherty, 1971); average bone dose was calculated as 0.78 Gy (Mays and Lloyd, 1972). 
Bruenger et al. (1991) administered 0.58 kBq kg ’ ^^ P^u to beagle dogs and observed an 
osteosarcoma incidence o f about 78%; average skeletal doses were calculated as 0.45 Gy.
Experiments to examine the effect o f age at administration o f  ^ ^^u on osteosarcoma 
induction were undertaken by Bruenger et a/. (1991) who administered 11 kBq kg ’ to 
juvenile dogs (3 months old), young adult dogs (17-19 months old) and mature dogs (60 
months old). They observed osteosarcoma incidences o f 75%, 100% and 89%, 
respectively; average skeletal doses were calculated as 4.2 Gy, 5.3 Gy and 3.0 Gy, 
respectively.
The St. Bernard dog has been reported to be more sensitive than the beagle dog to ^^ P^u- 
induced bone sarcoma formation with a higher spontaneous incidence. Taylor et al.
(1981) administered 0.58-33 kBq k g ’ and observed a 100% incidence o f osteosarcoma.
Jee et al. (1983) compared osteosarcoma induction by ^^ P^u in the beagle and St. Bernard 
dogs; 1.8, 3.5, 11,33 and 40 kBq kg ’ ^^^u was administered to beagle dogs and 3.5 and 
11 kBq kg ’ ^^ P^u was administered to St. Bernard dogs. Osteosarcoma incidences o f  
92%, 83%, 100%, 100% and 89%, respectively, were observed in the beagle dogs and 
100% for each group in the St. Bernard dogs.
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1.6.4.3. Americium
Induction o f osteosarcomas by "^”Am has been demonstrated in mice (Nilsson and 
Broomé-Kaulsson, 1976; Schoeters et aL, 1991; Schoeters and Vanderborght, 1983;
1989; Taylor et al., 1983; Van den Heuvel et al., 1995), rats (Bensted et al., 1965; 
Fabrikant and Smith, 1964; Fabrikant et al., 1972; Filippova et al., 1974; Langham and 
Carter, 1951; Moskalev and Rudnitskaya, 1970; Taylor and Bensted, 1969; Zalikin et al., 
1969) and dogs (Buldakov et ah, 1972; Dougherty, 1972; Lloyd et ah, 1972; 1994; 
Nifatov et ah, 1972).
CBA mice were given doses o f 1.5, 7, 15, 300 and 600 kBq kg ’ "^”Am resulting in 
osteosarcoma incidences o f about 2%, 2%, 4%, 45% and 25%, respectively; no 
osteosarcomas were seen in control mice. Most o f the tumours were seen in the thoracic 
and lumbar vertebrae (Nilsson and Broomé-Kaulsson, 1976). Taylor et al. (1983) 
administered 11,30 and 103 kBq kg ’ "^”Am to 10 week old male and female C57BL/Do 
black mice which resulted in osteosarcoma incidences o f 0%, 9%, and 0%, respectively, in 
male mice and 10%, 25% and 25%, respectively, in female animals. In other experiments, 
12-13 week old male and female C57BL/Do albino mice were given doses o f 0.74, 4.4, 14, 
50 and 129 kBq kg ’ '^’’Am which resulted in osteosarcoma incidences o f 0%, 0%, 0%, 6% 
and 12%, respectively, in male mice and 0%, 0%, 0%, 50% and 60%, respectively, in 
female animals. Female mice appeared to be more sensitive to osteosarcoma induction 
than male mice but small group sizes (12-20) were used for the experiments; no statistical 
analyses were undertaken. Schoeters et a/. (1991) and Schoeters and Vanderborght 
(1983; 1989) reported a series o f experiments in which 22, 58, 190, 373 and 1197 kBq kg' 
’ "^”Am was administered to male C57BL mice and osteosarcoma incidences o f 4.3%, 
7.2%, 0%, 0% and 0%, respectively, were observed; average skeletal doses were 
calculated as 2.2 Gy, 4.8 Gy, 7.9 Gy, 11 Gy and 27.9 Gy, respectively. No osteosarcomas 
were seen in control mice. Van den Heuvel et al. (1995) reported studies in which 45, 90 
and 213 kBq kg ’ "^”Am was administered to female BALB/c mice and 103 kBq kg ’ to 
male mice. Osteosarcoma incidences o f 44%, 43% and 39%, respectively were observed 
for female mice and 8.6% for male mice. Femur doses o f 2.3 Gy, 3.6 Gy and 8.4 Gy, 
respectively were calculated for female mice and 5.8 Gy for male mice.
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Langham and Carter (1951) reported tumour incidences o f 10%, 12% and 12% after 
injecting rats with 1.2, 1.8 and 2.3 MBq kg ’ “^^’Am, respectively; the accumulated bone 
doses were reported to be 78-160 Gy. Bensted et al. (1965) observed an osteosarcoma 
incidence o f 21% in rats given 93 kBq kg ’ "^”Am. A second experiment in which 5 
fractionated injections were given, totalling 111 kBq k g ’, produced an osteosarcoma 
incidence o f 58%; these tumours were reported to occur sooner than in the single injection 
experiment. In other experiments, rats were given 260 kBq kg ’ "^”Am, resulting in an 
osteosarcoma incidence o f 34% (Taylor and Bensted, 1969). Fabrikant et al. (1972) gave 
similar levels of ^"”Am, 93 and 215 kBq kg ’, and observed tumour incidences of 12.5% 
and 13.3%, respectively. In another series o f experiments where '^’’Am was given to 7 
week old male rats, an osteosarcoma incidence o f 16% was seen; estimated bone doses 
were 10-14 Gy (Fabrikant and Smith, 1964). An osteosarcoma incidence o f 13.5% was 
reported for rats given 92.5-370 kBq kg ’ "^”Am with accumulated bone doses o f 5-50 Gy 
(Zalikin et al., 1969; Moskalev and Rudnitskaya, 1970). In experiments in which "^”Am 
nitrate or citrate was administered to rats at doses o f 0.96-493 MBq kg ’, osteosarcoma 
incidences o f 9.3% and 24.5% were observed at estimated skeletal doses o f 3.8 and 16.6 
Gy (Filippova era/., 1974).
The osteogenic effect o f Am has been studied using beagle dogs. Osteosarcoma 
incidences o f 0%, 7%, 12%, 42%, 83%, 92% and 67% were observed at administered 
activities o f 0.07, 0.2, 0.6, 1.8, 3.6, 11 and 34 kBq kg ’, respectively; a 0.7% incidence o f  
osteosarcoma was observed in control dogs (Dougherty, 1972; Lloyd et al., 1972; 1994). 
Americium-241 has also been seen to induce osteosarcomas in dogs following inhalation; 
average bone doses were calculated as being less than 20 Gy and the most common site 
for tumours was reported as being in the vertebrae (Buldakov et al., 1972; Nifatov et al.,
1972).
1.6.4.4. Uranium
Limited data are available on the induction o f osteosarcoma by isotopes o f U in mice. 
Finkel (1953) administered 3.7, 37 and 370 kBq kg ’ to CFl female mice and 
observed osteosarcoma incidences o f about 3%, 12% and 60%, respectively. In studies
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with she observed osteosarcoma incidences o f 0.9%, 3%, 5%, 8%, 13%, 24% and 
31% after administration o f 3.7, 18.5, 37, 92.5, 185, 370 and 925 kBq kg ’; no 
osteosarcomas were seen in control mice. At higher levels of^^^U, 1.8, 2.8 and 3.7 MBq 
kg ’, no osteosarcomas were observed but the average life-span o f the animals was 
reduced. The numbers o f animals used for these experiments were groups o f between 120 
and 45 for the lower doses and 15 for the three highest doses. Durbin and Wrenn (1975) 
calculated doses to the skeleton for these experiments and suggested that on the basis o f  
average dose to the skeleton and were equally effective in inducing bone 
sarcomas in mice.
1.6.4.5. Other alpha-emitting nuclides
Induction o f osteosarcomas by various Ra isotopes has been undertaken in various 
experimental animals: ^^'’Ra has been shown to induce osteosarcomas in mice (Hug et al., 
1969; Hunq)hreys et al., 1985a; 1993; 1998; Humphreys and Stones, 1991; Luz et al., 
1979; Müller et al., 1978; 1990) and rats (Hug et al., 1969); ^^ R^a in mice (Finkel et al., 
1969; Loutit et al., 1976; Taylor et al., 1983; Schoeters et al., 1991; Schoeters and 
Vanderborght, 1983; 1989) and dogs (Bruenger et al., 1989; 1991; White et al., 1994); 
and ^^ R^a in dogs (Bruenger et al., 1991).
Finkel et al. (1969) administered 1.9, 3.7, 9.3, 18.5, 27.8, 37,46, 93, 185, 370, 740, 1480, 
2960, and 4440 kBq kg ’ ^^ R^a to CFl mice and observed osteosarcoma incidences o f  
about 4%, 2%, 7%, 12%, 19%, 23%, 21%, 43%, 62%, 76%, 85%, 74%, 69% and 31%, 
respectively; an incidence o f about 1% was observed in control mice. Loutit et al. (1976) 
observed an osteosarcoma incidence o f 7.5% after the administration o f 1.9 kBq kg ’ ^^ R^a 
to male CBA/H mice; no tumours were seen at higher levels (5.6 and 18.5 kBq kg ’). The 
administration of 18.5 kBq kg ’ ^^Ra to female mice resulted in a tumour incidence o f  
46%. A further experiment was carried out investigating the effect o f mouse strain using 
male and female C3H mice; osteosarcoma incidences o f about 40% and 93%, respectively, 
were observed after administration of 18.5 kBq kg ’ ^^ R^a. In the series o f experiments 
reported by Taylor et al. (1983) groups o f 10 week old male and female C57BL/Do mice 
were given doses o f 2.1, 12.7, 38, 115, and 342 kBq kg ’ ^^ ®Ra. Osteosarcoma incidences
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o f 0%, 0%, 8%, 0% and 50%, respectively, were induced in male mice, while incidences o f  
0%, 0%, 0%, 25% and 29%, respectively, were observed in female mice. In further 
studies, 12-13 week old male and female C57BL/Do albino mice were given doses o f 2.1,
12.7, 38, 115, and 342 kBq kg ’ o f  ^ ^^ Ra which resulted in osteosarcoma incidences o f 0%, 
0%, 0%, 0% and 7%, respectively, in males and 0%, 0%, 0%, 7% and 40%, respectively, 
in female mice. One problem with both o f these studies was the small size o f the 
experimental groups used (10 and 12-16 animals, respectively); no statistical analyses were 
undertaken. Schoeters et ah (1991) and Schoeters and Vanderborght (1983; 1989) report 
experiments where 170, 350, 920 and 940 kBq kg ’ ^^ R^a was administered to C57BL/Ncb 
mice and osteosarcoma incidences o f about 7%, 9%, 21% and 14% respectively, were 
observed; an osteosarcoma incidence o f 0.9% was seen in control mice. Average skeletal 
doses 140 days before death were calculated as 24.3 Gy, 41.3 Gy, 92.2 Gy and 72.5 Gy, 
respectively.
Hug et al. (1969) administered 185, 370, 925 and 1850 kBq kg ’ ^^'’Ra to male and female 
mice and observed osteosarcoma incidences o f about 4%, 11%, 12% and 12%, 
respectively; a 1% tumour incidence was observed in control mice. Humphreys et al. 
(1985a) compared the effect o f single and protracted administration o f  ^ '^’Ra in male 
CBA/H mice at levels o f 69, 137, 275, 550, 1100 and 2200 kBq kg ’. They report 
osteosarcoma incidences o f 0%, 0%, 2.4%, 2.4%, 2.4% and 7.3%, respectively, for single 
administration and 2.5%, 2.4%, 0%, 2.6%, 5.1% and 9.8%, respectively, for protracted 
administration. In further studies, with larger numbers o f mice per group, a single 
administration o f  69, 139,280 and 550 kBq kg ’ ^^ '‘Ra was given to male CBA/H mice and 
osteosarcoma incidences o f 0.25%, 1%, 1.5% and 2.5%, respectively, were observed; a 
0.25% incidence was observed in control mice (Humphreys et al., 1993). Other 
experiments in which multiple administration o f  ^ '^’Ra was given to male CBA/H mice at 
levels o f  64, 128 and 256 kBq kg ’ to 4 week old mice and 32, 64 and 128 kBq 
kg ’ to 12 week old mice, resulted in osteosarcoma incidences o f 1%, 0% and 1.3%, 
respectively, for 4 week old mice and 0.5%, 1% and 0.5%, respectively, for 12 week old 
mice; another experiment was also reported where a single administration o f 64 kBq kg ’ 
^^"’Ra was given to 4 week old mice resulting in an osteosarcoma incidence o f 0.5% 
(Humphreys and Stones, 1991; Humphreys etal., 1998).
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Müller et al. (1978) report osteosarcoma incidences o f 2%, 3%, 8% and 7% in NMRI 
mice, following administration o f 230, 470, 930, 1850 kBq kg ’ ^^ R^a, respectively; a 1% 
incidence was observed in control mice. Further studies comparing the effect o f  
administration o f 18.5 kBq kg ’ ^^ R^a as a single dose or as a protracted administration o f  
72 doses produced osteosarcoma incidences o f 5.8% and 7%, respectively; a 3% incidence 
was seen in control mice (Müller et ah, 1990). Luz et al. (1979) administered 925 kBq 
kg ’ ^^'’Ra to 1 month old and 5-6 month old female NMRI mice and observed 
osteosarcoma incidences o f 18% and 9%, respectively. In a series o f other experiments, 
^^ '’Ra was administered to groups o f female NMRI mice at levels o f 37, 92.5, 185, 370,
444 and 1332 kBq kg ’ and combined osteosarcoma incidences o f 7%, 11.6%, 18%,
12.7%, 22.5% and 13%, respectively, were observed (Luz, 1983). Hug e ta l. (1969) 
administered 185, 370, 555, 740, 925, 1036 and 1480 kBq kg ’ ^^'’Ra to Wistar rats and 
observed osteosarcoma incidences o f 13%, 23%, 22%, 24%, 16%, 20% and 0%, 
respectively.
White et al. (1994) administered 0.79, 2.4, 13.9, 41.4, 124 and 370 kBq kg ’ ^^ R^a to 
beagle dogs and observed osteosarcoma incidences o f about 0%, 13%, 66%, 87%, 100% 
and 61%; calculated skeletal doses were 0.9, 3, 14, 32, 77 and 167 Gy. An osteosarcoma 
incidence o f 2.6% was reported for control dogs.
Experiments to examine the effect o f age on osteosarcoma were undertaken by Bruenger 
et al. (1989; 1991) who administered 41 kBq kg ’ ^^ R^a to juvenile beagle dogs (3 months 
old), young adult dogs (17-19 months old) and mature dogs (60 months old) and 
osteosarcoma incidences o f about 70%, 92%, and 56%, respectively, were observed; 
average skeletal doses were calculated as 25 Gy, 22.4 Gy and 15.4 Gy, respectively.
Other experiments (Bruenger et ah, 1991) compared the administration o f 2.31 kBq kg ’ 
^^ R^a and 1.84 kBq kg ’ ^^ R^a to beagle dogs and observed osteosarcoma incidences o f  
11% and 8%, respectively; average skeletal doses were calculated as 1.84 Gy and 2.41 Gy, 
respectively.
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1.6.4.6. Beta-emitting nuclides
A number o f workers have looked at the induction o f osteosarcomas by °^Sr, a beta 
emitter, to compare osteosarcoma induction by alpha and beta emitters. Experiments 
using mice are outlined here. Finkel and Biskis (1959) injected CFl female mice with ®^Sr 
at 70 days o f age (9 groups between 48 kBq kg ’ and 81.4 MBq kg ’). Doses were 
calculated by Mays and Lloyd (1972) as between 0-120 Gy, a decrease in bone tumour 
incidence from 91% to 73% between 66.3 and 120 Gy was observed. Loutit et al. (1973) 
administered 248, 492 and 740 kBq kg ’ ®^Sr to CBA/H mice and observed osteosarcoma 
incidences o f 5.3%, 27% and 35%, respectively. Further experiments (Loutit, 1976) 
compared the induction o f osteosarcoma following the administration o f 480 and 740 kBq 
kg ’ °^Sr to male and female CBA/H mice, resulting in osteosarcoma incidences o f 68.4% 
and 22%, respectively, for male mice and 100% and 80%, respectively, for female mice. A  
further experiment was carried out investigating the effect o f mouse strain in which male 
and female C3H mice were injected with 480 kBq kg ’ ®^Sr; osteosarcoma incidences o f  
about 40% and 100%, respectively were observed.
Loutit eta l. (1976) administered 1.9, 5.6 and 18.5 kBq kg ’ ®^Sr to male CBA/H mice and 
observed osteosarcoma incidences o f 7.5%, 0% and 0%, respectively; the administration 
o f 18.5 kBq kg ’ ”^Sr to female mice resulted in an osteosarcoma incidence o f 46%. 
Experiments in which °^Sr was administered to F, CBA x C57BL female mice at dose 
levels o f 7.4 and 37 kBq kg ’ producing osteosarcoma incidences o f 19% and 82%, 
respectively, compared with a 0% incidence in control mice were reported by van Putten 
(1961) and van Putten and de Vries (1962).
An experiment comparing the dose-response in CBA mice injected with ”^Sr was 
undertaken by Nilsson (1969; 1970; 1972), where the mice were given 7.4, 14.8, 29.6 and 
59.2 kBq kg ’. Bone tumours were reported in all groups with the highest number (292 
tumours in 120 mice) being observed in the 29.6 kBq kg ’ group, multiple tumours were 
seen in all groups except the 7.4 kBq kg ’ group. Spontaneous osteosarcoma incidence 
was low in these mice. The induction time for osteosarcoma decreased as the dose 
increased, from 485 to 268 days. Mays and Lloyd (1972).
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1.6.5. Leukaemia
Leukaemias are diseases which are characterised by an uncontrolled, abnormal and 
widespread proliferation o f leucocytic cells which infiltrate the bone marrow and other 
body tissues. This proliferation is usually accompanied by the appearance o f immature 
leucocytes, often morphologically abnormal, in peripheral blood. In other cases, there is 
an abnormal proliferation o f red cell precursors or megakaryocytes. Acute leukaemias are 
characterised by the proliferation o f immature cells known as blast cells and chronic 
leukaemias are characterised by the proliferation o f more mature cells (Stevens and Lowe, 
1995).
Leukaemic cells are similar to carcinoma cells in that they show morphological 
abnormalities and often infiltrate and destroy normal tissues. In acute leukaemias, varied 
and non-specific chromosomal abnormahties including numerical and morphological 
abnormaUties have been demonstrated (de Gruchy, 1972). However, in myeloid leukaemia 
there are specific abnormal chromosomal changes on chromosome 2 in mice (Breckon et 
aL, 1991) and the Philadelphia chromosome in humans, evident as a translocation o f the 
long arms o f chromosomes 9 and 22 (Rowley, 1973; Stevens and Lowe, 1995). Human 
leukaemias are usually fatal and account for about 4% o f all deaths from mahgnant disease.
In humans, there are five main types o f leukaemia: acute lymphocytic leukaemia (ALL) is 
mainly observed in children; chronic lymphocytic leukaemia (CLL) occurs in old age; acute 
myelogenous leukaemia (AML) is seen all ages; chronic myelogenous leukaemia (CML) 
occurs mostly in middle aged subjects; and monocytic leukaemia, both acute and chronic, 
is less common and may be observed throughout life, with a slight rise in incidence in 
middle age. In ALL, an abnormal proliferation o f T-cell lymphoblasts are observed in 
bone marrow (Kersey et ah, 1973). CLL is considered to be a monoclonal proUferation o f  
B-cell lymphocytes (Wilson and Nossal, 1971). AML is a prohferation o f haemopoietic 
stem cell prohferation, resulting in maturation defects in granulopoiesis, erythropoiesis and 
thrombopoiesis (KiUman, 1968). CML is a maturation disorder o f the haematopoietic 
stem cells involved with granulopoiesis and sometimes with thrombopoiesis. Monocytic
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leukaemia is a proliferation of monoblasts (Stevens and Lowe, 1995). Incidences o f 20- 
30%, 20-30%, 15%, 20-30% and <10% were observed for ALL, CLL, AML, CML and 
monocytic leukaemia, respectively (Lichtman and Klemperer, 1978).
Types o f leukaemia observed in mice are similar to those seen in humans and have been 
classified immunologically, by Pattengale and Taylor (1983). This classification assigns 
the leukaemias using demonstration o f cytoplasmic immunoglobulins using 
immunocytochemical staining methods.
1.6.5.1. Leukaemia in humans
Exposure to ionising radiation was suspected as causing leukaemia as early as 1911 when 
leukaemia was reported in 5 radiation workers by Jagié (1911) and anaemia in 2 X-ray 
workers in 1912 (Upton 1990). Many o f the early radiographic workers died from the 
effects o f X-rays (Seltser and Sartwell, 1965; Matanowski et al., 1975). Both Marie Curie 
and her daughter Irène Juloit-Curie died o f leukaemia, probably induced by prolonged 
exposure to radiation (Saunders and Kathren, 1983). Maitland (1931) first reported that a 
high proportion o f girls who painted the radioactive luminous material on clock faces 
developed severe anaemia and other haematological disorders. Since then high incidences 
o f leukaemia have been seen in (a) the survivors o f the atomic bomb explosions in Japan;
(b) children exposed during prenatal hfe to diagnostic radiation; (c) American radiologists 
compared with their physician colleagues; (d) persons exposed to pelvic irradiation (e) 
patients given Thorotrast and (f) patients with ankylosing spondylitis treated by 
radiotherapy. The mean latent period for induction o f leukemia by radiation is shorter than 
for the solid tumours, with mean latency to diagnosis generally averaging about 1 0  yrs 
(Ichimaru et al., 1976; Mettler and Upton, 1995).
Studies o f the A-bomb survivors have shown a 10-15 fold increase in the incidence o f  
leukaemia in exposed individuals as compared with control populations. The data indicate 
that the effects o f radiation exposure are significantly greater for ALL and CML than for 
AML. ALL and CML were also observed earlier than AML. The type o f leukaemia most 
commonly observed was CML (Ishimaru et al., 1971). Initial studies o f the A-bomb
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survivor data indicated a higher incidence o f leukaemia in Hiroshima than in Nagasaki, 
which was thought to be due in part to a difference in the neutron doses (Ishimaru et a l ,  
1971 ; 1979). Recent calculations o f radiation doses in both cities indicate that the gamma 
ray component and total dose were higher in Hiroshima and lower in Nagasaki than 
previously believed, while neutron components were lower in both cities (Loewe and 
Mendelshon, 198^- The mean interval from irradiation to death was about 12.5 years 
(Smith et al., 1977; Smith and Doll, 1982). Moriyama and Kato (1973) indicate that the 
annual frequency o f death from leukaemia had returned to about the level observed in the 
unexposed population at the end of 1972.
Seltser and Sartwell (1965) assessed the mortahty rates for all cancers in American 
radiologists compared with other specialist physicians, namely ophthalmologists and 
otolaryngologists. They concluded that a life shortening effect due to a high mortality rate 
being caused by leukaemia was evident in radiologists who practised during the period 
1920 to 1939; estimated bone marrow doses were in the range 2-6 Gy. No excess has 
been identified in those who began to practise after this time (Matanowski et al., 1975). 
The mortality rates in British male radiologists during the 60-year period from 1897 to 
1957 were assessed by Court-Brown and Doll (1958) who indicated a possible excess o f  
leukaemia in those dying before 1921.
Excess leukaemia incidence has been reported in patients who received radiotherapy for 
cervical cancer (Preston et al., 1994), peptic ulcer treatment (Griem et al., 1994) and 
treatment o f metropathia hemorrhagica (Smith and Doh, 1976). An increased incidence o f  
leukaemia has been observed in children exposed to levels of 0.01-0.02 Gy from 
radiographic pelvimetry to their mothers during pregnancy (Griem et a l ,  1967).
Leukaemia has also been reported in children treated with radiotherapy for tinea capitis 
(UNSCEAR, 1977) and X-rays to the thymic region (Pifer et al., 1968).
Therapeutic irradiation for non-malignant disease has also been associated with leukaemia. 
In Britain, ankylosing spondylitis patients were treated with spinal irradiation and an 
increased number o f deaths from leukaemia (especially AML) were observed 
(Court-Brown and Doll, 1965; I>srby e ta l., 1987); estimated mean marrow doses were
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2.2-S.2 Gy and the mean interval to death was approximately 7.4 years (Smith et a l ,  1977; 
Smith and Doll, 1982). Similar studies of non-irradiated ankylosing spondylitis patients 
showed no increased incidence o f leukaemia (Radford et al., 1977; Smith et al., 1977; 
Smith and Doll, 1982).
In Germany, increased numbers o f leukaemias were observed in ankylosing spondylitis 
patients treated with ^^'’Ra. The average skeletal doses were estimated as 1.8-2 . 8  Gy and 
bone marrow doses as 1.1-1.7 Gy, (Speiss et al., 1978; Wick and Gossner, 1983; 1989; 
Wick et a l ,  1986). In other patients treated with intrauterine radium radiotherapy for 
benign uterine bleeding, the mortality due to leukaemia was twice as high as for the 
general population; the average marrow dose was estimated to be 0.53 Gy (Inskip et al.,
1990; 1993). An increase in leukaemia incidence has also been reported following the use 
of Peteosthor, a compound containing ^^'’Ra (Rathke, 1954).
In the USA and UK, female dial painters were en^loyed between 1915 and 1930 and they 
became internally contaminated with ^^ R^a and ^^ R^a through Hcking or mouth-tipping o f  
brushes dipped in the self-luminous paint. The early reports of Ra poisoning included 
cases o f severe anaemia but no leukaemia (Maitland, 1931) and later reports indicated a 
large excess in bone cancers (Section 1.6.2.1). Polednak et al. (1978) reviewed the data 
and found an excess number o f blood dyscrasias including leukaemia. However, this 
finding was contradicted by Spiers et al. (1983) who reported no excess numbers o f  
leukaemias in the Ra dial painters in their study.
Thorotrast (^^Th0 2 ) is a colloidal substance which emits alpha-particles and was used 
firomthe late 1920s untÜthe 1950s as a contrast agent for diagnostic radiology. 
Epidemiological studies in a number o f countries, including Denmark, Germany, Japan, 
Portugal, Sweden and the USA, have shown that retention o f  ^ ^^ Th0 2  particles in the bone 
marrow has resulted in an increased risk o f leukaemia (Andersson and Storm, 1992; Faber, 
1979; Hortu e ta l ,  1978; Mori et a l ,  1986; 1989; Olsen et a l ,  1990; da Silva Horta et a l ,  
1978; Takahashi et a l ,  1965; van Kaick et a l ,  1984; 1986; 1989). An initial series o f  
3772 patients were followed for over 30 years and 44 cases o f leukaemia were identified; 
estimated bone marrow doses were 2.7 Gy (Mole, 1978).
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Recently, information has become available on the mortahty o f workers at the reactor and 
reprocessing plants at Chelyabinsk (Mayak) in Russia (Baisogolov et a l ,  1991; Buldakov 
and Guskova, 1991; Doshenko, 1991; Hohrykob and Romanov, 1994; Koshumikova et 
al., 1994; Nikipelov et al., 1990). Between 1949 and 1953, most workers received an 
annual dose o f 0.25 Gy. An analysis of 931 workers employed at the reactor plant over a 
40-year period found that 6.2% died from leukaemia and their average accumulated 
gamma dose was 3.26 Gy. A similar analysis o f staff employed in the reprocessing plant 
during the same period found that 1.4% died from leukaemia and their average 
accumulated gamma dose was 2.45 Gy.
1.6,6. Leukaemia in experimental animals
Leukaemia has been reported in experimental animals following the administration of^ ^^ ’Ra 
(Humphreys et ah, 1985a), ^^ P^u (Benstead et al., 1965; Hun^hreys et al., 1987) and ’^’Sr 
(Moskalev et a l ,  1969). Leukaemia has also been induced by external irradiation (Major 
and Mole, 1978; Major, 1979; Mole et a l ,  1983). Viruses are known to induce neoplasms 
in animals and have been imphcated in radiation-induced leukaemia (Goss, 1950; Lataryet 
and Duplan, 1962; Leiberman and Kaplan, 1959).
1.6.6.1. Leukaemia induced by external irradiation
Major and Mole (1978) used X-radiation to induce myeloid leukaemia in CBA/H mice at 
levels o f 0.75 Gy, 1.5 Gy, 3 Gy, 4.5 Gy and 6  Gy; observed incidences were 5%, 14%, 
21%, 12% and 0%, respectively. No myeloid leukaemias were observed in control mice. 
Major (1979) reported experiments on the induction o f myeloid leukaemia using 
X-radiation in male CBA/H mice. Myeloid leukaemia incidences o f about 8 %, 19%, 14%, 
10% and 2% were observed at doses o f 0.75, 1.5, 3, 4.5, and 6  Gy, respectivel)^ no 
myeloid leukaemias were seen in control mice. Mole et al. (1983) studied the effect o f a 
range o f doses from X-radiation on the production o f myeloid leukaemia in CBA/H mice. 
Incidences o f 1%, 5%, 5%, 9%, 14%, 10%, 15%, 21%,12% and 0% were observed at 
dose levels o f 0.25 Gy, 0.5 Gy, 0.75 Gy, 1 Gy, 1.5 Gy, 2 Gy, 2.5 Gy, 3 Gy, 4.5 Gy and
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6 Gy, respectively. No myeloid leukaemias were seen in control mice. Seki et a/. (1991) 
reported experiments in which C3H/He mice were irradiated using X-radiation from a 200 
kVp source at doses o f 0.47 Gy, 1.42 Gy, 2.84 Gy and 4.73 Gy and myeloid leukaemia 
incidences o f 3%, 20%, 24% and 14%, respectively, were observed. Johnson et al. (1995) 
studied the effect o f X-radiation on myeloid leukaemia induction in CBA/H mice. 
Incidences o f 4.5%, 6.4% and 6 % were observed with doses o f 1.06 Gy, 1.98 Gy and 2.64 
Gy.
1.6.6.2. Leukaemia induced by alpha-emitting nuclides
Humphreys et al. (1987) compared the effect o f single and protracted administration o f  
^^ P^u in female CBA/H mice at levels o f 1.85, 5.6 and 18.5 kBq kg ’. They reported 
myeloid leukaemia incidences o f 2 .6 %, 0 % and 0 %, respectively, after a single 
administration o f  ^ ^^ Pu and 2.2%, 4.4% and 2.3%, respectively, following multiple 
administrations of^^^Pu. Svoboda and Budenikova (1990) administered 3, 6  and 12.3 kBq 
kg ’ ^^ P^u to ICR mice and observed myeloid leukaemia incidences o f 7%, 13% and 9%, 
respectively; an incidence o f 6 % was seen in control mice. Bensted et al. (1965) reported 
a myeloid leukaemia incidence o f 4.5% following the administration o f 110 kBq kg ’ ^^ P^u 
to male F, (August x Marshall) rats. The administration o f 5 fractionated doses totaUing 
111 kBq kg ’ ^^ P^u resulted in a myeloid leukaemia incidence o f about 16%. Moskalev et 
al. (1969) reported ingestion studies in rats, in which the total intakes were 0.15, 0.86,
1.4, 13.7, 8.9 and 36.6 MBq ^^ P^u, resulting in leukaemia incidences o f 0%, 2.1%, 1.5%, 
4.4%, 3.4% and 0%, respectively; an incidence o f 1.5% was seen in control rats.
Bensted et al. (1965) administered 92.5 kBq kg ’ "^”Am to male F, (August x Marshall) 
rats and observed a myeloid leukaemia incidence o f 5.3%. Further studies (Taylor and 
Bensted, 1969) gave a myeloid leukaemia incidence o f 3% in male FI (August x Marshall) 
rats following the administration of 260 kBq kg ’ Am.
Humphreys et al. (1985a) compared the effect o f single and protracted administration o f  
^%a in female CBA/H mice at levels o f 69, 137, 275, 550, 1100 and 2200 kBq kg ’. 
Myeloid leukaemia incidences o f 0%, 0%, 4.8%, 7.3%, 2.4% and 2.4%, respectively, were
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observed after a single administration o f  ^ '^’Ra and 0%, 2.4%, 4.8%, 2.6%, 0% and 2%, 
respectively, following multiple administrations o f  ^ '^’Ra. In fiirther studies with larger 
numbers o f mice per group, myeloid leukaemia incidences o f 1.5%, 2.8%, 4.3% and 4.5%, 
were observed after a single administration o f 69, 139, 280 and 550 kBq kg ’ ^^'’Ra, 
respectively (Humphreys et al., 1993). Other experiments, in which multiple 
administrations o f  ^ '^’Ra were given to 4 and 12 week old male CBA/H mice showed 
myeloid leukaemia incidences o f 2.1%, 2.6% and 1.3% at levels o f  64, 128 and 256 kBq 
kg ’, respectively, for 4 week old mice and incidences o f 0.5%, 0.5% and 4.5% where 32, 
64 and 128 kBq kg ’, respectively, for 12 week old mice. Another experiment was also 
reported where a single administration o f 64 kBq kg ’ ^^ '’Ra was given to 4 week old 
CBA/H mice resulting in a myeloid leukaemia incidence o f 0.5% (Humphreys and Stones, 
1991; Humphreys g/ a/., 1998).
1.6.6.3. Leukaemia induction by beta-emitting nuclides
Moskalev eta l. (1969) administered 0.19, 0.37, 0.93, 1.85, 2.8, 3.7, 9.3, 18.5 MBq k g ’ 
°^Sr to rats and observed leukaemia incidences o f 1.2%, 6.1%, 4.1%, 2.5%, 8 .8 %, 10.3%, 
9% and 7%, respectively; an incidence o f 1.7% was observed in control rats. Marrow 
doses were calculated as 2.7 Gy, 5.3 Gy, 10.9 Gy, 23.6 Gy, 32 Gy, 48 Gy, 99 Gy and 186 
Gy, respectively.
Johnson et al. (1995) have studied the effect o f tritium administration on myeloid 
leukaemia induction. Incidences o f 5.9%, 6 .6 % and 8 % were observed with doses o f 0.85 
Gy, 1.86 Gy and 3.04 Gy.
1.6.7. Liver tumours
Benjamin et al. (1976) administered 74 kBq kg ’ ^^ P^u to hamsters and observed a liver 
tumour incidence o f 23%. Dagle et al. (1996) administered inhaled ^^ P^u to beagle dogs; 
estimated final body depositions were 0.1, 0.2, 1.3 and 6.7 kBq and Uver tumour 
incidences were 5%, 10%, 15% and 50%, respectively; a 5% incidence was observed in
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control dogs. Weller et al. (1995) administered inhaled to beagle dogs, estimated
initial lung deposits were 0.08, 0.7, 2.9, 13, 52 and 203 kBq and liver tumour incidences 
were 1%, 1%, 3%, 3%, 0% and 0%, respectively; an incidence o f  1% was observed in 
control dogs.
Nilsson and Broomé-Karlsson (1976) observed an increase in liver tumour incidence 
following the administration o f  ^"”Am. Incidences o f about 67%, 67% and 72% were 
observed at administered doses o f 1.5, 7.4 and 15 kBq kg ’, respectively; the incidence in 
control mice was 40%. Schoeters et al. (1991) administered 22, 58, 190, 373 and 1197 
kBq kg ’ "^”Am to male C57BL mice and observed liver tumour incidences o f  about 15%, 
13%, 0 %, 0 % and 0 %, respectively; an incidence o f  about 1 0 % was seen in control mice. 
Moskalev et al., (1973) report an increased incidence o f liver tumours following "^”Am 
administration to rats. Lloyd et al. (1995) report an increase incidence o f liver tumours in 
beagle dogs following Am administration. For malignant liver tumours an incidence o f  
about 31% was observed compared with about 3% in controls. For all liver tumours, an 
incidence o f about 53% was observed compared with about 18% in controls. If the dogs 
were grouped into low (<0.62 kBq kg ’ "^”Am) and high (>1.7 kBq kg ’ "^”Am) dose 
groups, incidences o f mahgnant hver tumours were about 28% and 33%, respectively, 
compared with about 3% in controls, and for ah hver tumours the incidences were about 
49% and 57%, respectively, compared with about 18% in controls.
1.6.8. Acute effects in bone
The greatest radiosensitivity o f the skeleton occurs during fetal development as this is a 
period o f active prohferation o f osteoblasts and chondroblasts, especiaUy during the human 
gestational stage o f 38-85 days. Relatively smaU radiation doses may cause stunting o f  
growth, changes in the size and configuration o f the head, spina bifida, abnormal limbs and 
problems with odontogenesis (Rugh, 1963). Growth retardation has been studied as a 
potential radiation effect foUowing in utero exposure o f atomic bomb survivors by Otake 
et al. (1993) and Nakashima (1994) who found a smaU positive dose response in the 
second trimester o f pregnancy but no significant dose effect in the first and third 
trimesters.
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Fractionated doses o f 10-20 Gy dehvered to the epiphyseal centres o f bone in children may 
result in permanent cessation o f bone growth and overall stunting (Rubin and Casarett,
1968). Spinal deformities have been reported in children following radiotherapy for 
Wilm’s tumour (Makipemaa et al., 1993; Rate et al., 1991; Scheibel-Jost et al., 1991; 
Thomas et al., 1983). Other deformities reported after childhood radiotherapy are 
hypoplasia o f facial bones (Heyn et al., 1986; Larson et al., 1990), leg length variation 
(Robertson et al., 1991) and hypoplasia o f the ilium after pelvic irradiation (Heaston et ah, 
1979; Smith et al., 1982). There have been reports o f abnormahties in children's teeth 
after radiotherapy, doses o f >10 Gy wih cause the arrest o f a tooth bud. Dental 
abnormahties such as arrested root development, enamel dysplasia and crown 
abnormahties may occur in up to 82% of children who survive maxihofacial radiotherapy 
(Jaffe et al., 1990; Sonis et al., 1990).
Adult bone appears to be more resistant to the effects o f radiation and the changes 
demonstrated include decreased abihty to resist infection (Regen and Wilkins, 1936;
Seldin, 1955) and increased susceptibihty to fractures, seen as spontaneous rib fractures 
fohowing post-mastectomy irradiation (Overgarrd; 1988) and pelvic fractures foUowing 
radiotherapy for uterine cancer.
In animals, cessation of growth in long bones and limb deformities have been seen 8  weeks 
after the injection o f  ^ ^^ Pu and "^”Am into 35 day old male rats (Langham and Carter,
1951). Fabrikant et al. (1972) observed growth reductions o f about 10-15% in humeri, 
tibiae and femora one year after injections o f  ^ ^^ Pu into young rats. In other studies 
skeletal abnormahties were observed several months after injection o f  ^ "”Am into 7 week 
old male rats (Fabrikant and Smith, 1964; Taylor and Bensted, 1969; Bensted and Taylor,
1969). Bone growth was reduced by 8-10 months after injection, ah long bones were 
observed to be stunted; humeri and tibiae were 1 0 % shorter and femora 15% shorter than 
in age controls. At 10 months, X-radiographs showed osteoporosis in the ends o f the long 
bones. In dogs, extensive bone damage has been observed foUowing '^"Am inhalation 
(Thomas et al., 1972). The effects in bone were simUar to those observed with ^^ P^u.
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1.6.9. Acute effects in bone marrow
In the adult human, the major sites o f bone marrow activity are the pelvis, sternum and 
vertebrae (Snyder et al., 1976). In children, up to the age o f about 20, the humerus, femur 
and other long bones are active sites o f bone marrow activity (Atkinson, 1962; Caster and 
Ahfeldt, 1932).
The first effects o f radiation on bone marrow were observed in guinea pigs exposed to 
LD5 0 levels o f total body irradiation by Heineke (1903) who later demonstrated that 
myelopoiesis was more radiosensitive than erythropoiesis (Heineke, 1906). In 1913, 
Shouse et al. demonstrated that aplasia o f the bone marrow in animals was a cause o f  
death following total-body irradiation. The blood and bone marrow changes following 
lethal accidental exposures in humans were described by Hempelmann et al. (1952). 
Casarett (1980) has shown that the cells o f the haematopoietic system in early stages o f  
differentiation (hemocytoblasts, primitive myeloblasts, erythroblasts and megakaryoblasts) 
are highly radiosensitive. Whilst differentiating cells (erythroblasts, myeloblasts and 
megakaryoblasts) were moderately radiosensitive and well-differentiated cells 
(erythrocytes, platelets and granulocytes) and post-mitotic cells in the bone marrow 
(reticular cells, macrophages and fibroblasts) were very radioresistant.
1.6.10. Acute effects in kidney
Early toxicological studies were reviewed by Hodge (1956), who noted that the toxic 
effects o f U were first examined after U was extracted tfom pitchblende, followed by the 
preparation o f uranyl nitrate, sulfate, and chloride. In 1853, Leconte (cited by Hodge, 
1956) discovered that uranium acetate could induce glycosuria in dogs. This discovery 
resulted in its widespread use as a homeopathic remedy in the treatment o f diabetes 
mellitus because o f the mistaken conclusion that the effect was an abnormahty o f  
carbohydrate metabohsm. However, extensive research soon showed that it was the result 
o f renal damage, and U compounds became the agent o f choice in the production o f  
chronic renal lesions in experimental animals. Chronic nephritis was an important and
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widespread disease at the time, and the discovery of an experimental model that appeared 
to mimic the human disease attracted much interest. The renal lesion was found to be 
unique, and was later assumed to be the only toxic effect o f U important to man, in that U 
was not thought to accumulate in bone or to constitute a radiation hazard.
The mechanism o f the renal lesions has been extensively investigated (Haley, 1982; Haley 
et al., 1982). The kidney responds to toxic levels o f U within the first 1 to 2 days after a 
single injection (Morrow et al., 1982) and the changes are progressively severe over the 
first 5 days; whether this is due to the continuous release o f further U by mobilization from 
the skeleton or the progression o f  the initial lesion is not known. The renal deposits 
formed after a single administration are excreted rapidly, either because o f reversal o f the 
phosphate-binding sites in the tubular cells or because o f the sloughing and excretion o f  
dead cells that contain U (Hodge, 1956). This acute phase o f damage can be followed by 
repair with modified epithehum consisting o f flattened, imperfectly differentiated cells that 
are remarkably resistant to the toxic effects o f further administrations o f U. Young 
animals have considerably more resistance than older animals, and there are important 
species differences in sensitivity, possible owing to differences in urinary pH (Haven and 
Hodge, 1953). The lesions in the proximal convoluted tubules result in the appearance o f  
glucose, low-molecular-weight proteins, and amino acids in the urine. These substances 
are normally reabsorbed from the tubular fluid, and their appearance in urine is due mainly 
to malabsorption by the damaged tubular cells and partly to tubular excretion, but not to 
increased glomerular permeabihty.
There is some evidence in mice and dogs that the combination o f alpha radiation and 
chemical toxicity produces a greater nephrotoxic effect than either does separately (Haven 
and Hodge, 1953).
In the studies undertaken for this thesis, the toxicity of^^^U, ^^ P^u and "^”Am in mice has 
been compared with the overall objective o f relating the incidence and distribution o f  
osteosarcoma and incidence o f leukaemia induced by these radionuclides to their 
distribution in the skeleton. Chapter 2 details the experiments undertaken and the 
methodology used. The results are presented in Chapter 3 and discussed in Chapter 4.
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Chapter 2: Materials and Methods
2.1. Animals and animal care
Male and female CBA/H mice were obtained from the MRC Radiobiology Unit, Chilton, 
Didcot, Oxon, OX 11 CRD. Groups o f five animals were housed together in polypropylene 
cages on sawdust bedding. They were first employed for this study at 12 weeks o f age, 
weighing 30 ± 3 g (x ± SD). Cages and bottles were cleaned weekly. Food (type RMI 
Expanded, Special Diet Services, Witham, Essex) and water were freely available at all 
times. Animal care and handling conformed to the Animals (Scientific Procedures) Act 
1986.
2.2. Preparation of radionuclide solutions
Stock solutions of^^^U (VI) nitrate (uranyl: ^^ U^0 2 (N0 3 )2) in 3M HNO3, ^^^u (IV) nitrate 
in 3M HNO3 and "^”Am (III) nitrate in 3M HNO3 were obtained from Amersham 
International pic, Amersham, Bucks. Aliquots o f stock solutions were evaporated to 
dryness, redissolved in 0.01 M HNO3 and an equal volume o f 70 mM tri-sodium citrate 
added to give a final pH o f about 6.5. Before administration, the solutions were filtered 
through a 25 nm MilHpore filter (Sigma-Aldrich Techware, Poole, Dorset).
2.3. Administration of radionuclide solutions for distribution and 
retention studies
A preliminary study was undertaken to estabhsh whether intraperitoneal injection o f  
radionuchde solutions could be taken to be equivalent to intravenous injection. Groups o f
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five male and five female mice were given either intraperitoneal (into the abdomen) or 
intravenous (tail-vein) injections o f 40 kBq kg'* o f either or "^**Am citrate
solutions (1.2 kBq in 0.2 ml). The mice were killed 7 days after injection and were 
dissected for separate radiochemical analysis o f liver, kidneys, adrenals, spleen, 
gastrointestinal tract, gonads, femora, humeri and the remaining carcass.
For studies on the time-course o f  radionuclide retention in tissues and individual bones, 
groups o f 96 male and 96 female mice were given intraperitoneal injections o f 40 kBq kg'* 
o f either ^^^u or "^**Am citrate solutions. Groups o f 12 male and 12 female mice 
were killed at 1, 7, 14, 28, 56, 112, 224 and 448 days after injection. At each time-point 
the animals were separated into three groups as follows: five male and five female mice for 
studies on the distribution and retention o f ^^ P^u and ^^** Am in body organs and
tissues; five male and five female mice for measurements o f the distribution o f ^^^u 
and "^**Am in the individual bones o f the skeleton; and two male and two female mice for 
autoradiographic studies o f the microdistribution of^% , ^^ P^u and "^**Am.
For measurements o f the distribution and retention o f ^^^u and ^ "** Am in body organs 
and tissues, the mice were dissected for separate radiochemical analysis o f liver, kidneys, 
adrenals, spleen, gastrointestinal tract, gonads, femora, humeri and remaining carcass. For 
the study o f the distribution o f the nuclides within the skeleton, the mice were skinned, the 
internal organs removed and the carcasses placed in a colony o f Dermestes beetles 
(Dermestes malculatus) which stripped the soft tissue from the bones. Figure 2.1 shows a 
mouse skeleton after removal from the Dermestes beetle colony. The bones were then 
separated as shown in Figure 2.2. Radiochemical analysis was undertaken separately for 
the skull, mandibles, groups o f cervical, thoracic, lumbar, sacral and caudal vertebrae, 
sternum, ribs, scapulae, humeri, radii, ulnae, pelvis, femorae, fibiae, tibiae, patellae and 
paws. For the autoradiographic studies, femora and lumbar vertebrae were removed and 
fixed in 40% (v/v) ethanol. Mandibular condyles and sections o f rib were also removed 
and fixed in Kamovsky’s fixative (Glauert, 1975) for 2-3 hours.
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Figure 2.1. Mouse skeleton after removal from the Dermestes beetle colony.
Figure 2.2. Disarticulated mouse bones ready for radiochemical anaylsis.
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2.4. Radiochemical analysis and measurements
For radiochemical analysis, tissues were reduced to a carbon-free ash by dry ashing at 
500°C in a muffle furnace, digesting the residue with 8 M HNO3 under infra-red lamps and 
re-ashing the dried-down residue. When a white ash had been obtained, samples 
containing either or ^^ P^u were dissolved in 4M HNO3 and quantitatively extracted 
into an organic solvent / scintillant mixture for liquid scintillation counting (Keough and 
Powers, 1970). The samples were counted using a Beckman scintillation counter (Model 
LS-250, Beckman, High Wycombe, Bucks.). The "^**Am samples were dissolved in 4M 
HNO3 and gamma counted using their 60 keV emissions in a Packard gamma counter 
(Minaxi 5000 Series, Canberra-Packard, Pangboume, Berks.).
2.5. Autoradiography
After fixation, the femora, lumbar vertebrae, mandibular condyles and ribs were 
dehydrated using graded alcohols and polypropylene oxide and embedded in Spurr’s resin 
(Haines, 1992). Five micron (5pm) thick central longitudinal sections were cut from the 
resin blocks containing the femora or lumbar vertebrae and one micron ( 1  pm) sections 
were cut from blocks containing the mandibular condyles or ribs. These were floated onto 
water at 60°C. Sections o f femur and lumbar vertebrae were placed on CR39 plastic slides 
for a-track autoradiography or fission track autoradiography. Sections o f mandibular 
condyle and rib were placed onto glass slides previously coated with a solution o f 1 % 
gelatin and 0.1% chrome alum for photographic emulsion autoradiography. The CR39 
autoradiographs allowed the visualisation o f the tracks in relation to bone structures {eg. 
Figure 3.9) and the photographic emulsion autoradiographs allowed more detailed 
examination o f tracks relative to the different cells o f bone and bone marrow {eg. Figure 
3J^)
The CR39 plastic is sensitive to a-particles which produce tracks of damage that are 
amplified by chemical etching and may be used to map the distribution o f a-activity in the 
tissue section (Green and Humphreys, 1990). For a-track autoradiography, the slides
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were exposed for periods o f between 1 month and 1 year. After exposure the slides were 
etched using 6.25 M NaOH solution at 60°C for between 3 and 4 hours to enable the 
a-tracks to be viewed in the plastic using a microscope (Priest et al., 1982).
Fission-track autoradiography was carried out on histological sections mounted on CR39 
slides. After preparation, the slides were sandwiched with plastic backing slides and 
assembled with adhesive tape into small packs each containing several slides. They were 
then irradiated with thermal neutrons (10*  ^- 10^ ® m'^ ) in the Herald 5 MW water-cooled 
research reactor at the Ministry o f Defence (Procurement Executive), Aldermaston, 
Berkshire. Subsequently, the slides were separated and etched in a 6.25 M NaOH solution 
at 60°C for 1 hour. The irradiation causes neutron induced fission of^^^Pu or 
resulting in fission tracks in the polycarbonate plastic (CR39) which can be revealed by 
etching with sodium hydroxide. A reaction is also caused between the surface o f the 
section and the plastic (probably due to recoil protons being knocked out o f the 
histological section by fast neutrons in the reactor) causing a latent image o f the structures 
in the section on the plastic which is also revealed by etching with sodium hydroxide. This 
process results in an image o f the bone structure on which is superimposed tracks o f  
fission fragments derived from or ^^ P^u. Since "^**Am is not thermally fissile, serial 
sections were prepared and adjacent sections used to prepare a-track autoradiographs and 
a bone image by neutron irradiation. The two images were then superimposed to show the 
relationship between the tracks and the bone sample.
Photographic emulsion autoradiography was carried out using either the stripping film or 
dipping film techniques (Rogers, 1979); both methods were carried out in a dark-room.
For the stripping film method, ARIO stripping film was peeled from its glass backing plate 
and floated onto distilled water at 25°C. When the film had uniformly expanded it was 
floated into position over the slide. The slides were allowed to dry and kept in light-proof 
boxes at 4°C for 4 weeks. For the dipping film technique, slides were dipped into a 
solution o f K5 nuclear emulsion (Ilford Ltd., London) at 37°C. The emulsion coated slides 
were dried and kept in light-proof boxes at 4°C for 4 weeks. The exposed 
autoradiographs were developed in D19 developer (Kodak, Hemel Hempstead, Herts.), 
rinsed in water, fixed in 30% sodium thiosulphate and washed in water. The sections were
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then stained by overnight immersion in pyronin g solution (0 .0 2 % pyronin g in 1 % borax) 
at 4°C. The stained autoradiographs were air dried and viewed microscopically using an 
oil-emersion lens.
2.6. Administration of radionuclide solutions for studies on the 
comparative toxicity of ^^’Pu and "^"Am
For the toxicological study, three groups o f male mice were given intraperitoneal 
injections o f each o f the three radionuclides to give estimated average skeletal doses o f  1.5 
Gy, 0.75 Gy and 0.25 Gy to 500 days after injection. Administered activities, amounts o f  
the elements and group sizes are shown in Table 2.1. The levels o f administered activity 
corresponding to the required average skeletal doses were determined from distribution 
and retention data (Section 3.1.2). The group sizes were chosen on the basis o f published 
information on osteosarcoma induction by ^^ P^u in mice o f the same strain (Humphreys et 
al., 1987) and statistical considerations on the minimum number o f mice required for 
analysis o f observed effects.
Mice were entered into experimental groups in sub-groups o f 5-10 animals over a period 
o f 18 months. To avoid chemical toxicity to the proximal convoluted tubules o f  the 
kidneys from uranium (Hodge, 1973; Yuile, 1973), citrate solution was administered 
as 9 injections over a three week period. The same procedure was adopted for animals 
given ^^ P^u and ^^ **Am citrate solutions and for controls given inactive solution. All mice 
were individually identifiable, by ear marking, within their cage group. Each animal had a 
record sheet on which all observations on health status were recorded. The animals were 
followed for their life-span as described below (Section 2.7). Additional groups o f 15 
mice were given injections o f the three radionuclides at the same levels o f activity for 
measurements o f tissue retention as described above (Sections 2.3 and 2.4).
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Table 2.1. Experimental groups in toxicity study.
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R a d i o n u c l i d e E x p e r i m e n t a l  g r o u p I n je c t io n  d o s e  
k B q  k g  '
A m o im t  o f  e l e m e n t  
a d m i n i s t e r e d  pg kg '*
N u m b e r  o f  
a n i m a l s
233u H i g h 1 9 7 5 5 2 5 0
M e d iu m 1 1 8 3 3 1 6 0
L o w 4 0 1 1 2 1 0 0
2 3 9 p u H ig h 2 5 11 5 0
M e d i u m 15 6 .6 6 0
L o w 5 2 .2 1 0 0
2^‘A m H ig h 2 9 0 .2 4 5 0
M e d i u m 1 7 0 .1 4 7 5
L o w 6 0 .0 5 6 1 0 0
C o n t r o l 0 0 1 0 0
A further group o f 30 mice were given ^^ P^u at the highest level o f activity with the 
intention o f studying bone tumour growth by in vivo serial X-ray analysis. Due to 
difficulties in appropriate maintenance o f anaesthesia for this procedure, this part o f the 
study was not undertaken but the animals were followed for their life-span and included in 
the overall analysis.
2.7. Post-mortem examination techniques used for the 
toxicological studies
All mice were checked visually each day throughout the study. When problems were 
identified, animals were checked more frequently. The animals were kept for their life­
span or until one o f the following circumstances applied:
1 ) the animal was considered to be suffering;
2 ) the animal was judged to be able to live for only one more day;
3) the animal had red feet denoting possible cardiovascular problems caused by 
congestion o f the liver;
4) the animal had pale feet denoting possible internal bleeding;
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5) respiratory distress was apparent with a "D" shaped thorax denoting pressure on the 
diaphragm;
6 ) the animal had a very distended abdomen and loss o f condition;
7) the animal showed signs o f discomfort during palpation;
8 ) the animal was displaying specific signs eg. splenomegaly, paralysis, a tumour greater 
than 1  cm in diameter, or the conditions outlined below.
Some mice developed abscesses in the abdominal region, particularly around the penis and 
testes. The causal organism was a Corynehacterium species (C. ulcerans) which is 
present in the mouths o f these mice. The abscesses were believed to be caused by fighting 
and were very slow growing. Where necessary, abscesses were lanced, cleaned and a 
small amount o f antiseptic cream applied to aid healing. From 8  months after radionuclide 
administration, the animals also received a weekly abdominal palpitation to check for the 
onset o f hepatomas. These tumours were initially detected by a "thickening" o f one or 
more lobes o f the liver. They grew over a period o f many months, some became large, 
hard and knobbly, although others remained smooth.
From 24 months after radionuclide administration, other age-related problems were 
observed. The mice commonly suffered breakage and loss o f incisor teeth; therefore all 
teeth were checked weekly from this time onwards. If loss did occur, animals were fed 
daily with a wet mash made from their regular diet which was ground to a powder and 
mixed with sufficient water to make a thick paste. In addition, teeth were clipped if lack 
o f the grinding process caused them to grow too long. Some mice became preapistic, 
evident as a permanently extruded penis. This was only a problem if the penis became sore 
or inflamed as the mouse was then reluctant to urinate; the bladder became palpable and 
the mouse was then killed. Some mice developed eye abscesses which became apparent 
when the eye started to bulge slightly in the socket. Again the mice were killed when this 
occurred. Post-mortem examination showed the abscesses to develop behind the eye in 
the socket.
Outward signs o f possible myeloid leukaemia were pale feet, nose and tail and a sudden 
loss o f condition. An enlarged spleen was also a sign o f leukaemia and the mice were
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palpated to check for the presence o f enlarged spleens during their weekly check. As soon 
as myeloid leukaemia was suspected, the animal was sacrificed immediately to enable fresh 
blood and spleen tissue to be taken for confirmation o f the leukaemia. Blood smears were 
obtained to look for increased numbers o f white blood cells and abnormal cell types. 
Myeloid leukaemia in the CBA/H mouse is characterised by the presence o f  
metamyelocytes in the blood. Myeloblasts and promyelocytes may also be present; these 
cells are normally only found in the bone marrow (Figures 3.74 and 3.75). In some cases, 
cytogenetic analysis was performed using spleen tissue from animals with suspected 
myeloid leukaemia because studies have shown a correlation between the presence o f a 
deletion or rearrangement o f chromosome 2  and myeloid leukaemia in these animals 
(Figure 3.73), (Breckon et ah, 1991). Spleen tissue was passaged into untreated animals; 
the passage was carried out by homogenising 0.1 g o f the affected spleen with 5 ml o f  
Earle’s balanced salts medium (Gibco BRL, Life Technologies Ltd, Uxbridge, Middlesex) 
and injecting 0.5 ml o f this solution intraperitoneally into 10-12 week old female mice.
The passaged animals developed myeloid leukaemia within a few months if the cells taken 
from the sacrificed mouse were malignant. Female mice were used for passaging, so that 
chromosome karyotyping could be performed to confirm if the malignant tissue originated 
from the male donor or female recipient mouse.
Osteosarcoma o f the limbs was usually detected by a stiffening o f the joints, followed by a 
swelling and sometimes paralysis. Tumours o f the spine were more difficult to detect and 
often only became apparent if the mouse showed signs o f paralysis in the hind quarters. 
Once a bone tumour was suspected the mice were monitored very carefully for signs o f  
debilitation and paralysis; when either o f these symptoms occurred the animal was 
immediately killed. A diagnostic X-ray was taken as soon as possible after death along 
with histological samples to confirm the diagnosis.
As each of the mice died or were killed they were given a post-mortem examination. A  
diagnostic X-ray was taken as soon as possible after death to detect any developing 
osteosarcomas. Samples for histology were routinely taken from the liver, lungs, kidney 
and spleen and were fixed in phosphate buffered formalin pH 1 2 -1 A  (Gurr, BDH Ltd, 
Poole, Dorset). Any other organs or tissues that appeared abnormal were also taken for
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histological examination. The remaining carcass was also fixed in phosphate buffered 
formalin. At a later time, after the X-ray had been examined, bone samples were routinely 
taken from the left femur, lumbar vertebrae and sternum. Other bones were taken if a 
tumour was suspected. The bones for histological analysis were decalcified using EDTA 
solution (Culling, 1974). To allow estimation o f the body content o f radioactivity at death 
and average skeletal doses, up to six bone sanq)les (skull, mandibles, scapulae, femora, 
fibiae/tibiae and humeri) were taken from the skeleton after fixation. Radiochemical 
analysis was performed as described previously (Section 2.4).
2.8. Histological processing and staining methods
After fixation as described above, all histology samples were dehydrated using graded 
alcohols (70%, 80%, 90% and 96% alcohol, 1 hour each, and 2 changes of absolute 
alcohol, 1 hour each), cleared using a mixture o f absolute alcohol : histosol (50:50 and 
30:70,1.5 hours each), followed by 2 changes o f histosol (Shandon Scientific Ltd, 
Runcorn, Cheshire), inpregnated with wax (2 changes, 3 and 3.5 hours) and then 
embedded in wax blocks. Five micron thick sections were cut from the wax blocks, 
floated onto a water bath at 45°C, these were then mounted on slides, dried at 37°C 
overnight. Sections for immunocytochemical staining were mounted onto slides which had 
been coated with VECTABOND reagent (Vector Laboratories, Bretton, Peterborough, 
Cambridgeshire) and also dried overnight at 37°C.
Sections were routinely stained using the Haematoxylin and Eosin stain (H&E), (Culling, 
1974). Briefly, sections were dewaxed in xylene (3 changes, 2 minutes each), and then 
rehydrated (absolute alcohol, 2 changes o f 2 minutes each; 70% alcohol, 2 minutes; 
distilled water, 2 minutes). The sections were then placed in aqueous saturated picric acid 
for 15 minutes (to remove any formalin pigment that may be present) and then washed in 
running water for 15 minutes. After rinsing in distilled water, the sections were stained 
with Ehrlich’s Haematoxylin (R.A.Lamb, London) for 30 minutes. After rinsing the slides 
in water, the amount o f cellular staining was checked microscopically and differentiated 
using a 1% acid alcohol solution (1% HCl in absolute alcohol) until the cytoplasm was 
clear and only the nuclei were stained. Following differentiation, the slides were rinsed in
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running water to "blue" the nuclei. The slides were then placed in a 1% aqueous eosin y 
solution (R.A.Lamb, London) for cytoplasmic staining. The slides were then quickly 
rinsed in water, dehydrated (70% alcohol, 1 minute; absolute alcohol, 2 changes o f 2 
minutes), cleared (xylene, 3 changes o f 2 minutes each) and coverslips mounted using 
DPX (R.A.Lamb, London).
The stained sections were examined microscopically. The tumours were classified using 
the World Health Organisation (WHO) (lARC, 1994) and European Late Effects Project 
(EULEP, 1994; 1997) classifications. Confirmation o f pathological diagnoses was 
achieved by sending selected slides to a consultant pathologist, Dr Kevin Isaacs. To 
facilitate statistical analyses o f the results, the diagnoses were entered into a database 
(Paradox 5.0, Novell Inc.). The database was also incorporated into the International 
Radiobiology Archives o f Long-Term Animal Studies (USDE, 1996).
As an additional aid in the identification o f myeloid leukaemia and malignant lymphoma, 
immunocytochemical staining using myeloperoxidase (MPO) and CD3 antibodies was 
performed on sections o f spleen tissue from mice where myeloid leukaemia or malignant 
lymphoma was suspected. The MPO antibody is used to differentiate histochemicaUy 
between myeloid leukaemia and lynphoid leukaemias. The CD3 antigen has been shown 
to be a highly specific marker for T cells and is present in the majority o f T cell neoplasms 
(Dako, 1996). Both MPO and CD3 can be used on formalin fixed paraffin sections but 
care has to be taken to ensure that the antibodies have been raised in an animal other than 
the mouse to avoid cross-reaction in mouse tissues.
For staining with MPO antibodies, sections were dewaxed in xylene and rehydrated as 
described above for H&E staining. The slides were rinsed with Tris-buffered saline (TBS) 
(Dako, High Wycombe, Bucks) and the endogenous peroxidase activity in the sections 
blocked by placing the slides in a peroxidase blocking agent (Dako, High Wycombe,
Bucks) for 10 minutes. They were then rinsed again in TBS and treated with a serum-ffee 
protein blocking agent (Dako, High Wycombe, Bucks) for 10 minutes. The slides were 
again washed in TBS buffer and treated with rabbit MPO antibody at either a 1:50 or 
1:100 dilution for 30 minutes. The slides were then rinsed in TBS buffer and treated with
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peroxidase-conjugated goat anti-rabbit immunoglobulins (Dako, High Wycombe, Bucks), 
diluted 1:100 for 30 minutes. The slides were rinsed again in TBS buffer and treated with 
a DAB chromogen substrate solution (Dako, High Wycombe, Bucks) for 10 minutes.
After rinsing in TBS buffer, the sections were counterstained using Ehrlich’s haematoxylin 
(RA Lamb, London) for 5 minutes. The sections were differentiated, dehydrated, cleared 
and coverslips mounted as described for H&E staining. Brown staining indicated the 
presence o f MPO antibody in the section (Figure 3.72). A  positive control section (ie. a 
section from a known myeloid leukaemia) was included with each staining run to check 
that specimen processing and handling were consistent. To check for non-specific 
staining, a negative control slide {ie. a slide in which the rabbit MPO antibody was not 
used) was stained at the same time as each test section.
For staining with CD3 antibodies, the sections were dewaxed and rehydrated as described 
previously for H&E staining. The slides were rinsed with TBS and the endogenous 
peroxidase activity in the sections blocked by placing the slides in a peroxidase blocking 
agent (Dako, High Wycombe, Bucks) for 10 minutes. After washing with distilled water, 
the slides were immersed in lOmM citrate buffer at pH 6.0 and covered with clingfilm (to 
allow steam to escape) and microwaved at full power (800W) for 15 minutes in a 
microwave oven (Panasonic, model NN-3454). The buffer was topped up every 5 minutes 
to prevent con^lete evaporation. After microwaving, the slides were allowed to cool to 
room tenperature (about 20 minutes) and rinsed in TBS pH 7.4. The slides were then 
covered with an EPOS Anti-CD3/HRP solution (Dako, High Wycombe, Bucks) for 60 
minutes. The slides were rinsed with TBS buffer and then placed in TBS buffer for 5 
minutes. Following this the slides were treated with a DAB chromogen substrate solution 
(Dako, High Wycombe, Bucks) for 10 minutes. The slides were rinsed in TBS buffer and 
counterstained, dehydrated, cleared and mounted as described for MPO antibody staining. 
Brown staining indicated the presence o f CD3 antibody in the section (Figure 3.83). 
Positive and negative staining controls were prepared as described for the MPO staining, 
except in this case, the step using the EPOS solution was omitted.
Chapter 2. Materials and Methods 92
2.9. Pathological criteria for nomenclature of tumours
Cells are termed neoplastic when they fail to respond normally to signals controlling cell 
growth. They proliferate, eventually forming a lump or a tissue mass called a neoplasm.
By convention, a neoplastic mass is known as a tumour. Tumours often consist o f a 
mixture o f different cell morphologies and are classified as benign or malignant based on 
observations o f the pattern o f neoplastic growth.
Benign tumours are localized to the tissue o f origin and they tend to be well-differentiated 
with cell types morphologically similar to the parent tissue. The tumours tend to be slow 
growing, have well defined margins and their growth leads to compression o f the 
surrounding tissue. They have few mitotic figures.
Malignant tumours have variable degrees o f differentiation. When the tumour cells closely 
resemble the tissue o f origin, the tumour is termed a well-differentiated malignant 
neoplasm. When the tumour cells show only a slight resemblance to the tissue o f origin, 
the neoplasm is termed a poorly differentiated malignant neoplasm. The degree o f  
differentiation o f a tumour is related to its behaviour; poorly differentiated neoplasms tend 
to be more aggressively invasive than well-differentiated neoplasms. Malignant tumours 
generally have poorly defined margins, the neoplastic cells invading and destroying 
surrounding tissues. They have many mitotic figures (Figure 3.106).
Continuous growth o f tumours is limited by their oxygen supply and increases in size are 
often accompanied by the production o f angiogenesis factors which facilitate the formation 
o f blood vessels. These vessels are rarely properly formed and provide a ready 
passageway for métastasés. This spread o f a malignant tumour from its primary site can 
occur in four ways: ( 1 ) local invasion by direct growth into adjacent tissues; (2 ) lynphatic 
spread, where tumour cells enter lymphatic vessels and move to regional lymph nodes 
where they grow as secondary tumours; (3) vascular spread, where tumour cells enter 
systemic veins draining the primary lesion and move to a different part o f the body, 
frequently forming metastatic tumours in the lung, liver, bone marrow and brain; and (4) 
transcoelomic spread where primary tumours in the abdominal cavity or thorax can spread
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directly across coelomic spaces {eg. the peritoneal or pleural cavities) by seeding cells 
which then migrate to the surface o f other organs. As with the mahgnant primary 
tumours, métastasés grow at the expense o f local tissues and usually result in tissue 
destruction.
The name given to a tumour should provide information about its cell o f origin and its 
likely behaviour either benign or malignant. The names assigned in this thesis are based on 
those used in the EULEP and WHO classifications (EULEP, 1994; 1997; lARC, 1994).
2.9.1. Nomenclature of tumours of epithelial origin
Benign neoplasms, o f both solid and surface epithelium, are termed adenomas and are 
usually prefixed by the tissue o f origin eg. renal adenoma. Some benign neoplasms o f  
surface epithelium eg. skin are known as papillomas because they form ffond-hke growths. 
This is prefixed by the cell o f origin eg. squamous cell papilloma o f the skin.
A malignant tumour o f any epithelial origin is termed a carcinoma. Tumours o f glandular 
epithelium (including the lining o f the gastrointestinal tract) are termed adenocarcinomas. 
Tumours o f other types o f epithelium are prefixed by the cell type o f origin eg. squamous 
cell carcinoma. To classify a carcinoma further, the tissue o f  origin is added eg. prostate 
adenocarcinoma.
2.9.2. Nomenclature of tumours of mesenchymal tissues
For tumours composed o f mesenchymal tissues ie. support cells or muscle cells, the 
nomenclature tends to be more consistent than that for the epithelial type. The tissue o f  
origin takes the suffix -oma if the tumour is benign and -sarcoma if it is malignant. For 
example, a benign bone tumour is termed an osteoma, and a malignant bone tumour is 
termed an osteosarcoma. A summary o f nomenclature o f other tumours o f mesenchymal 
tissues is given in Table 2.2.
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Table 2.2. Classification o f pathological nomenclature for mesenchymal tissues.
T i s s u e  o f  o r i g i n B e n i g n M a l i g n a n t
F i b r o u s F i b r o m a F i b r o s a r c o m a
B o n e O s t e o m a O s t e o s a r c o m a
C a r t i l a g e C h o n d r o m a C h o n d r o s a r c o m a
A d i p o s e L i p o m a L i p o s a r c o m a
S m o o t h  m u s c l e L e i o m y o m a L e i o m y o s a r c o m a
S k e l e t a l  m u s c l e R h a b d o m y o m a R h a b d o m y o s a r c o m a
2.9.3. Nomenclature of tumours of other tissues
Neoplasms that do not fit into either the epithelial or mesenchymal categories are named 
according to their tissue o f origin. The main categories are:
Lynqjhoma - tumours o f the lynq)hoid system which are conq>osed o f neoplastic 
lymphocytes, varying in their grade o f malignancy from slow-growing to highly aggressive.
Leukaemia - malignant tumours derived from haemopoietic elements in bone marrow, 
usually identifiable by the presence o f immature blood cells in blood eg. immature cells o f  
the granulocyte series are seen in myeloid leukaemia.
Embryonal tumours - a group o f malignant tumours seen mainly in early life, derived from 
primitive embryonal "blastic" tissue.
Glioma - tumours derived from the non-neural support tissues o f the brain, they may be 
benign or malignant and are named according to the cell o f origin.
Germ cell tumours - derived from germ cells in the gonads, occasionally arising in non- 
gonadal sites.
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Teratoma - a type o f germ cell tumour which differentiates to form elements o f all three 
embryological germ cell layers - ectoderm, endoderm and mesoderm. Teratomas may be 
benign or malignant and are usually found in the gonads.
Neuroendocrine tumours - tumours o f the neuroendocrine cells which secrete hormones or 
active amines eg. phaeochromocytoma o f the adrenal medulla.
2.10. Analysis of tumour and life-span data from studies of the 
comparative toxicity of ^^ P^u and Am
Following the death or sacrifice o f animals, all the major organs were examined as 
described in Section 2.7. The position and size o f any macroscopic tumours were noted, 
along with information on haematological disorders and details o f any tumours visible on 
the X-radiograph. Wherever possible, using this information, a cause o f death was 
assigned to each animal. Histopathological examination was carried out on all tumours 
(Section 2.9). Tumours which either directly or indirectly killed their hosts were said to 
have been "observed in a fatal context", whereas, tumours which did not kill their host and 
were observed at the post-mortem examination o f an animal which died o f an unrelated 
cause were said to have been "observed in an incidental context" (lARC, 1980; 1986). 
Records were made indicating whether the tumours were observed in an incidental or fatal 
context. Some tumour types eg. osteosarcoma and myeloid leukaemia, grow very rapidly 
and are detected shortly after onset, requiring the animal to be humanely killed. Due to the 
short period o f time between the onset o f the tumour and the tumour reaching a size where 
it is detectable, it is unlikely that the animal will die from some other cause. Tumours such 
as bronchiolo-alveolar adenomas grow slowly and are usually incidental findings at the 
post-mortem examination o f animals that have died o f other causes; such tumours are 
usually observed in an incidental context. Other tumours such as hepatocellular adenomas 
and carcinomas are seen in both fatal and incidental contexts.
The assignment o f the cause o f death and the presence o f tumours in an incidental or fatal 
context allowed the data to be analysed using statistical techniques which correct for
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longevity and death as a result o f other causes. The two methods used here ie. the 
Kaplan-Meier method and the Peto test, are fully described in the International Agency for 
Research in Cancer (lARC) Monographs on the use o f statistical methods in animal studies 
(lARC, 1980; 1986).
The analysis o f death rates resulting from fatal tumours using the Kaplan-Meier method 
were undertaken using SPSS for Windows v6.1 (SPSS UK Ltd., Chertsey, Surrey). The 
Peto analysis was performed using the methods described in the lARC Monograph (lARC, 
1980; 1986). The spreadsheets and macros for the Peto analysis were written, by the 
author, using QuatroPro (Perfect Office, v6.1, Novell Inc., Utah, USA) to undertake 
mortality analysis on those tumours found in a fatal context at post-mortem, prevalence 
analysis on those tumours found in an incidental context at post-mortem and a combined 
analysis o f mortality and prevalence incidence. Professor Georg Gerber, Vlaame Instelling 
voor Technologisch Onderzoek (VITO), Belgium, also ran the data though his suite o f  
programmes based on the lARC methods.
Brief details o f the methods used are given in the following Sections 2.10.1 and 2.10.2. A 
more detailed statistical analysis was performed using the Cox regression analysis, 
comparing life-span, dose rate and osteosarcoma and myeloid leukaemia incidence. This 
analysis was undertaken by Julia Thomas ofNRPB Epidemiology Group. The 
methodology used for this analysis is given in Section 2.12.
2.10.1. Kaplan-Meier Method
In 1958, Kaplan and Meier established a method for analysing the death rate o f a 
population using data grouped into a large number o f small time intervals (Kaplan and 
Meier, 1958; lARC, 1980; 1986). Experimental records o f age at death, or current age if 
still alive, are analysed in the following way. Suppose that on day tj there are cij deaths and 
on the previous day there were n, survivors, then the probability o f death q^ j on day tj is:-
-I
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By convention, if  any experimental subjects are censored on day tj, that is having died o f 
another cause or removed from the experiment for other reasons, then they are considered 
to have survived longer than day tj. Days when no deaths occur are ignored from the 
calculation o f the Kaplan-Meier table. Survival is a product o f survival up to day tj. Thus, 
survival on day t, l^ is described thus:-
; .  n „ _ n nj-d j
where the product o f survival is calculated over all time intervals in which a death occurs 
for days up to and including day j.
For fatal tumours, a visual display o f cumulative tumour mortality is obtained by plotting 
graphically the Kaplan-Meier estimate for a particular treatment group on each day o f the 
experiment against time. Such a graph will have flat regions along a series o f days in 
which no animals in that group died o f the tumour o f interest, with a step downwards on 
days when some animals did die as a result o f the tumour o f interest. If there are large 
effects o f different treatments on cancer death rates, then the Kaplan-Meier graph gives a 
visual display o f these differences.
2.10.2. Peto method for analysis of trend with dose
In the analysis o f a particular tumour type, observed in a fatal context, the fundamental 
principle is that if  treatment does not affect cancer death rates, then among the survivors 
on the morning o f a particular day o f the experiment all are equally likely to die o f the 
relevant cancer type before the next morning. This method, known as the Mortality 
method, relies on the comparison o f the number o f animals "observed" at death to have 
died o f a given tumour with the "expected" number calculated as if the age-specific tumour 
onset rate were the same in each experimental group including controls. A contingency 
table (Table 2.3) can be drawn up for each day o f the experiment to calculate these values.
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Table 2.3. Example o f a contingency table for the "mortality" (death rate) method for 
analysing one particular category o f "fatal" tumours. (Hypothetical data for hepatomas on 
day 650 o f a long-term experiment).
D ,  D o s e  r a t e  
( a r b i t r a r y  u n i t s )
I n i t i a l  g r o u p  
s i z e
N 0 E
0  C o n t r o l 1 0 0 8 0 1 1 .0 2 6
1 H i g h 1 0 0 6 0 0 0 . 7 6 9
2  M e d i u m 6 0 5 0 1 0 .6 4 1
3  L o w 5 0 4 4 1 0 . 5 6 4
T o t a l 3 1 0 2 3 4 3 3 . 0
where N = number o f animals still ahve at the start o f day 650.
O = observed numbers o f animals dying o f "fatal" hepatomas on day 650.
E = expected numbers o f tumours. E’s are calculated from the N ’s and O’s on this 
day only, with no reference to any previous or subsequent days, using the 
formula:
E  = —  ■ N
SiV
For each table o f the experiment a value for trend (T) and variance (V) can be calculated 
as follows:
where: T = trend statistic
V = (2i3£^). (Af-a£) 
(S£) (jV-1)
y  = number o f experimental groups 
D = dose
O = observed tumour number 
E -  expected tumour number
N = number o f animals at risk on the day o f the calculation
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E is calculated to at least 3 decimal places and T and V to at least 4 significant figures to 
ensure that the rounding errors will be negligible when many contingency tables are 
combined and all the T’s, V ’s and E’s in each treatment group, respectively, are summed.
Taken on its own, a single contingency table may give almost no useful information, but 
meaningful patterns may emerge by combination o f many tables over the course o f an 
experiment to give the total "observed" numbers in each group and their corresponding 
"expected" numbers. If the tumour incidence is unaffected by treatment, then the observed 
and expected values wiU only vary randomly from each other. The T* statistic for positive 
trend can be calculated from the grand total o f the observed and expected numbers in each 
separate contingency table. The variance, V*, can be derived from the summation o f all 
the V values for each separate contingency table. Using these values, the overall test 
statistic can be obtained as follows:-
Z = Z 1
The value o f Z can be compared to the normal distribution to see if the sum o f trends 
departs significantly from that expected by chance alone. Table 2.4 gives Z values and 
their corresponding P values.
Table 2.4. Critical values o f Z for 1-tailed test for positive trend.
z P Z P z P
0 . 0 0.5 1.55 0.06 2.46 0.007
0.25 0.4 1.64 0.05 2.52 0.006
0.52 0.3 1.75 0.04 2.58 0.005
0.67 0.25 1 . 8 8 0.03 2.65 0.004
0.84 0 . 2 1.96 0.025 2.75 0.003
1.04 0.15 2.05 0 . 0 2 2 . 8 8 0 . 0 0 2
1.28 0 . 1 2.17 0.015 3.09 0 . 0 0 1
1.34 0.09 2.33 0 . 0 1 3.29 0.0005
1.41 0.08 2.37 0.009 3.66 0 . 0 0 0 1
1.48 0.07 2.41 0.008 3.89 0.00005
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The method given above in Section 2.10.2 can be modified to analyse tumours found 
incidentally at post-mortem (known as the Prevalence method). The analysis depends on 
the principle that the treatment does not alter the cancer onset rate for the tumour o f 
interest. If this is so, then in all animals dying during a short period (--100 days) from 
causes other than the tumour o f interest, all will be equally likely to have an exanq)le o f the 
tumour o f interest discovered. The same approaches concerning the summing o f all trend 
statistics, T and V, to produce T* and V* given above, apply to this method also.
The method given above in Section 2.10.2 can be further modified to analyse all tumours 
found in both fatal and incidental contexts at post-mortem. The same argument 
concerning the summing o f all trend statistics, T and V, to produce T* and V* quoted 
above, apply to this method also.
2.11. Calculation of life-time skeletal dose for mice in the toxicity 
study of and Am
To enable an accurate measurement o f the dose received by each animal until its death, up 
to 6  bones were taken fi’om each animal (after X-ray and removal o f bones for 
histopathological examination) for radiochemical analysis as described in Section 2.4. The 
results obtained were used to estimate total skeletal retention o f radionuclides at death by 
reference to results from the study o f the distribution and retention of^^^U, ^^^u and 
"^**Am in the skeleton at times up to 448 days after administration. The bones removed 
from each animal in the toxicity study at death were the skull, mandibles, scapulae, femora, 
fibiae/tibiae and humeri. It was assumed that the distribution o f activity within the 
skeleton o f the mice in the toxicity study at death was the same as that seen in the 
distribution and retention studies at 448 days after injection (Section 3.2). The amount o f 
radioactivity remaining in the skeleton at death was estimated from each bone by 
conq)arison o f the amounts o f radioactivity present in each bone with the percentage 
distribution at 448 days; a mean value was calculated from all bones analysed. Values 
obtained for radionuclide retention at death were used together with the data on retention 
to 448 days (Section 3.2) to calculate retention in, and doses to, individual animals as
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described in Seetion 3.6.1.
Doses to the skeleton (average skeletal dose) were ealculated from estimated retention 
values for individual animals using the trapezoidal method o f integration (Watson et al., 
1981). As illustrated graphically in Figure 2.3, the number o f disintegrations between time 
points was obtained by treating each region as a trapezium such as A, B, C, D. The area 
o f A, B, C, D was then !6 AD(AB+CO). Total disintegrations were summed to 448 days.
or
CÛ
500
450
400
350
300
250
200
Death1 0 00 200 400300
Time, days
Figure 2.3. Illustration o f tissue retention o f activity and calculation o f total number o f 
disintegrations.
Doses were then calculated using the following formula:
N  . E . kDose (Gy) =
M
Chapter 2. Materials and Methods 102
where N = total number o f disintegrations, E = energy absorbed per disintegration = 
4.824 MeV, = 5.16 MeV, 2^^Am= 5.49 MeV), k =  constant (1.6021 x 10 '^  J M eV^, 
M = mass in kg.
Skeletal mass was calculated for each time point using data for wet weights o f the femora 
and humeri for time points up to 448 days (Section 3.1.2), ashed weights o f all individual 
bones and total skeleton up to 448 days (Section 3.2) and ashed weights o f selected bones 
taken at death (Section 3.6). Total skeletal wet weights at times up to 448 days were 
estimated using the ratio o f wet to ashed weight for the femora and humeri at each time- 
point. These ratios were in the range o f 7.2 to 8 . 8  with no apparent trend with time; an 
averaged value o f 7.8 was used for each time-point. In estimating total skeletal wet 
weight at death, it was assumed that the ashed weights o f the bones analysed represented 
the same proportion o f total skeletal ashed weight as at 448 days.
2.12. Statistical analysis of results using the Cox regression model
The comparison between different groups o f individuals o f the hazard o f death due to a 
cause o f interest can be carried out by modelling the survival data. A  commonly used 
model is the proportional hazards model in which the hazard for one group o f individuals 
is considered to be proportional to the hazard for another group, the magnitude o f the 
effect is determined by the attributes which make these two groups different. The 
proportional hazards model was first proposed by Cox (1972) and has therefore become 
known as the Cox regression model.
The most commonly used model for survival data is in the form:
h,(t)
K V )
where bo(t) is the hazard at time t for the baseline group and hj(t) is the hazard for the i* 
individual characterised by the variables x,|, X2 j,...,Xp|. P„ p ; , , Pp are the model 
parameters that need to be estimated and represent the magnitude o f the effect o f each 
variable on the relative hazard, or more precisely the logarithm o f the relative hazard.
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The values o f Xj to Xp could relate to variables such as the radionuclide type, the dose rate 
or the age at exposure. The ratio hj(t)/ho(t) is referred to as the relative hazard and takes 
the value 1  (ie. equal hazards) whenever the variables x,i, X2 i,...,Xpj are at the baseline level 
o f zero such that hi(t)=ho(t). Note that for variables which change over time (in this study, 
the time dependent variable is dose rate), the variable is denoted by Xjj(t) rather than Xjj and 
the baseline hazard ho(t) is interpreted as the hazard function for an individual for whom all 
the variables are zero at the time origin, say time o f initial injection, and remain at this 
same value through time.
In this study, the dose rate is calculated (Section 3.6.1) at days 0-, 1-, 7-, 14-,... up until 
death and so the model, given above for the relative hazard, uses the last recorded dose 
rate before the time at which the value o f the dose rate is needed. The time at which the 
values o f the dose rate and other variables are needed depends on the times at which a 
death occurs from the cause o f interest. Modelling the relative hazard at time t consists o f 
taking each mouse that has died from the cause o f interest and looking at all other mice 
that are at risk at the time o f each o f these deaths. The values o f the measured variables 
are then compared between the mouse currently o f interest and all the other mice at risk at 
the same time and these values are used to contribute to the estimated effect o f the 
different variables in the model. These estimates are based on contributions from all the 
mice that have died from the cause o f interest and those mice at risk at the time that these 
mice died.
During the modelling approach to the analysis o f survival data, a model is developed for 
the dependence o f the hazard function on one or more variables. In this development 
process, models with different sets o f variables are fitted, and conq)arisons made between 
them. The statistical significance o f these conq)arisons is determined from the change in a 
‘goodness o f fit’ statistic which measures how well the variables ‘explain’ the hazard o f 
death from the cause o f interest. A suitable statistic is -21nL, where L refers to the 
likelihood function and summarizes the information that the data contain about the 
unknown parameters Pj, P2 , . . . ,  Pp. Changes in -21nL are referred to a chi-squared 
distribution where the degrees o f freedom for the distribution are given by the change in 
the number o f estimated parameters between the models being compared. The comparison
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o f the change in -21nL between a model with and without a particular variable provides a 
statistical significance test for that variable.
All models were fitted using the statistical package S-PLUS (Version 3.3, Statsci Division 
o f Mathsofl Inc, Seattle, Washington).
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Chapter 3 : Results
3.1. Studies on the distribution and retention of ^^Tu and 
in male and female mice 
3.1.1. Comparison of distribution and retention after intravenous vs 
intraperitoneal injection
An initial study was performed to establish whether intraperitoneal (i.p.) injection o f 
radionuchde solutions could be taken to be equivalent to intravenous (i.v.) injection. Table 
3.1 summarises the results obtained for the tissue retention o f ^^^u and '^‘^ Am at 7 
days after either i.v. or i.p. administration to male and female mice.
For ^^ P^u and Am, differences in the retention were generally not significant and the two 
routes o f administration were equivalent. For both nuclides, the liver and skeleton were 
the principal sites o f depostion and retention, values obtained for the carcass sample being 
largely attributable to skeletal retention (Priest et al., 1985). For retention was 
significantly lower after i.p. injection than after i.v. injection. Thus the values for the 
carcass, attributable to skeletal retention, were 30-40% lower after i.p. than after i.v. 
injection. Retention in the kidneys was about 50% lower in male mice and about 30% 
lower in female mice after i.p. injection. Despite these differences, i.p. injection was used 
in subsequent studies because o f the difficulty o f tail vein injections, particularly when 
multiple administrations were required as in the toxicity study (Section 2.6).
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Table 3.1. The tissue distribution ^^^u and in male and female mice 7 days
after either intravenous or intraperitoneal injection as the citrate.
Tissue Male mice 
IV IP ttest*
Female mice 
IV IP /test
Liver 0.30 ±0.03'’ 0.16 ±0.01 ?<0.01 0.23 ±0.02 0.16 ±0.005 P<0.005
Kidney 1.02 ±0.07 0.49 ± 0.35 P<0.05 0.94 ±0.12 0.65 ±  0.08 NS
Other soft tissues' 0.40 ±0.14 0.16 ±0.02 NS“ 0.15 ±0.012 0.15 ±0.009 NS
Carcass' 10.3 ±0.71 5.99 ±0.35 P<0.002 16.0 ±0.94 11.3 ±0.47 P<0.005
Total 12.1 ±0.79 6.78 ±0.38 P<0.001 17.3 ±1.03 12.3 ±0.55 P=0.005
Liver 33.3 ±1.25 30.7 ±0.56 NS 28.0 ±2.57 22.3 ±1.51 NS
Kidney 0.41 ±0.015 0.41 ±0.014 NS 0.26 ±0.05 0.23 ±0.01 NS
Other soft tissues 1.41 ±0.11 2.08 ±0.18 P<0.02 1.77 ±0.24 1.81 ±0.19 NS
Carcass 24.2 ±1.27 24.9 ±1.42 NS 26.4 ±1.42 27.8 ±0.95 NS
Total 59.5 ±1.32 58.1 ±1.82 NS 56.4 ±3.30 52.2 ±4.34 NS
Liver 38.3 ±1.57 40.4 ±5.91 NS 30.0 ±1.01 35.9 ±2.67 NS
Kidney 1.22 ±0.04 1.48 ±0.13 NS 0.53 ±0.04 0.61 ±0.07 NS
Other soft tissues 0.89 ±0.03 2.89 ±0.1.3 P<0.0001 2.83 ±0.42 3.04 ±0.28 NS
Carcass 30.5 ±1.17 27.8 ±0.70 NS 27.9 ±0.85 23.4 ±1.45 P<0.05
Total 71.1 ±2.69 72.5 ±2.71 NS 61.0±2.16 63.0 ±2.21 NS
® w h e r e  t h e  P  v a l u e  i s  s p e c i f i e d  t h i s  i s  t h e  p r o b a b i l i t y  t h a t  a  t v a l u e  n u m e r i c a l l y  g r e a t e r  t h a n  t h a t  o b s e r v e d  c o u l d  
h a v e  o c c u r r e d  p u r e l y  b y  c h a n c e
" X d = S E , n  =  5
' o t h e r  s o f t  t i s s u e s ;  a d r e n a l s ,  g a s t r o i n t e s t i n a l  t r a c t ,  g o n a d s  a n d  s p l e e n
m e a n s  t h a t  o n  a  t w o  t a i l e d  t e s t  t h a t  t h e r e  i s  n o  d i f f e r e n c e  a t  t h e  5 %  l e v e l  o f  s i g n i f i c a n c e  
' c a r c a s s  s a m p l e ;  r e m a i n i n g  t i s s u e s  {ie. b o n e ,  m u s c l e  a n d  p e l t )
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3.1.2. Time-course of tissue retention of and in
male and female mice
Figures 3.1 and 3.2 show the whole-body retention o f ^^^u and in mice at 
times up to 448 days after i.p. injection as the citrate conçlexes. The results for ^^Tu and 
'^‘^ Am were similar, with values o f about 80% and 70%, respectively, after 1 day, falling to 
about 50% and 45%, respectively, after 28 days and about 25% and 20%, respectively, 
after 448 days. The total retention of^ ^^U was considerably lower than that for ^^^u and 
"^^ *Am falling from about 15% after 1 day to about 5% after 28 days and about 3% after 
448 days.
The results obtained for the tissue distribution of^^^u, "^^ A^m and are given in Tables 
3.2-3.7. For each nuclide the skeleton is the major site o f long-term retention. The 
skeleton was taken to be the sum o f the femora and humeri, and the remaining carcass for 
which activity is very largely in bone with little activity in associated muscle tissue (Priest 
eta /., 1985).
For ^^^u, the results for male mice (Table 3.2) show that at one day after injection, about 
50% o f injected activity was retained in the liver and about 24% in the skeleton. The level 
o f activity present in the liver decreased to about 1 2 % at 28 days after injection, further 
decreasing to about 3% at 448 days after injection. Retention in bone increased over the 
first month after injection to 37% and subsequently decreased over the 448 days to about 
21%. The other tissues analysed contained small amounts of^^^u, which also reduced 
with time. The results for female mice were similar to those for male mice (Table 3.3).
The differences in retention were generally not significant {t test, where the P value is the 
probability that a t value numerically greater than that observed could have occurred 
purely by chance). However, female mice showed significantly lower retention in the liver 
at times between 14 and 448 days after injection (P <0.003,14 days; P<0.0001, 28 days; 
P=0.005, 56 days; P <0.001,112 days; P<0.01,224 days; P<0.03,448 days). In addition, 
levels o f retention in bone were slightly higher in females than in males, with significant. 
differences at 1 and 14 days after injection, P<0.02 and P<0.03, respectively. The highest
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level o f retention in bone in females o f about 36% was observed at 14 days after injection, 
subsequently decreasing to about 25% at 448 days after injection.
The distribution o f ^ '‘^ Am in mouse tissues was similar to that of^ ^^Pu. The results for 
male mice are given in Table 3.4. The initial uptake o f ^ "^ A^m in the skeleton was less than 
for ^^^u, 13% o f injected activity compared with 24%, while uptake in the liver was 
similar. As for ^^^u, the level of^ '^^ Am activity in the liver decreased rapidly, while 
retention in bone increased over the first month and subsequently decreased. The 
maximum retention in the skeleton was seen at 28 days after injection, accounting for 30% 
o f administered "^*^ Am, subsequently decreasing to 20% at 448 days after injection. The 
results for female mice were similar to those o f male mice (Table 3.5). The differences in 
retention were generally not significant {t test). However, as for ^^ P^u, female mice 
showed significantly lower retention in the liver between 14 and 224 days after injection 
(P=0.005, 14 days; P<0.001, 28 days; P<0.05, 56 days; P<0.01, 112 days; P<0.02, 224 
days). As for ^^ P^u, the levels of^ '^ ^Am retention in bone were slightly higher in females 
than in males with significant differences at 1 and 14 days after injection, P=0.002 and 
P<0.04, respectively. The highest level o f retention, about 31% was observed at 14 days 
after injection, subsequently decreasing to about 25% at 448 days after injection.
The results for the retention of^ ^^U in male and female mice are given in Tables 3.6. and 
3.7. The total retention of^%  in male mice at one day after injection accounted for 17% 
o f administered activity, with about 10% in the skeleton and 6.5% in the kidneys.
Retention in the kidneys decreased rapidly from 6.5% at 1 day after injection to about 
0.4% at 7 days post-injection. Skeletal retention decreased progressively, accounting for 
about 7% at 14 days post-injection and about 2.5% at 448 days. The results for female 
mice were similar to those for male mice (Table 3.7). The differences in retention were 
generally not significant {t test). However, the retention of^ ^^U in bone was slightly higher 
in females than in males at times from 7 days after injection with significant differences at 
28,112 and 224 days, P<0.005, P=0.002 and P=0.02, respectively.
Figure 3.3 compares the percentage o f whole body activity of^% , ^^^u and '^*'Am 
retained in the liver and skeleton o f male mice. Initially, the skeleton accounted for about
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60%, 30% and 18% o f retained and respectively, increasing to about
97%, 85% and 8 8 %, respectively, after 56 days after injection. The corresponding values 
after 448 days were 98%, 8 6 % and 94%, respectively. Figure 3.4 conq)ares the values for 
female mice. The skeleton initially accounted for about 69%, 36% and 33% o f retained 
233u, 239py and 2'^ A^m, respectively, increasing to 97%, 90% and 91%, respectively, after 
56 days; the corresponding values after 448 days were 96%, 91% and 96%, respectively. 
The highest values for the liver were observed at 1 day after injection being about 1%,
65% and 77% in males and 2%, 60% and 63% in females for ^^^u and Am, 
respectively.
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Figure 3.2. Retention of ^^ P^u and in female mice.241
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Table 3.2. The tissue distribution of^ ^^Pu in male CBA/H mice after intraperitoneal 
injection as the citrate.
Tissue
1 7 14
% injected activity at time (d): 
28 56 112 224 448
Liver 50.9* 40.6 27.4 12.4 5.00 3.06 2.81 2.80
±2.0 ±0.5 ±0.5 ±0.2 ±0.38 ±0.10 ±0.23 ±0.16
Kidneys 0.75 0.38 0.22 0.19 0.133 0.094 0.086 0.104
±0.02 ±0.01 ±0.03 ±0.01 ±0.009 ±0.004 ±0.009 ±0.002
Adrenals 0.049 0.026 0.044 0.017 0.013 0.012 0.044 0.008
±0.018 ±0.004 ±0.019 ±0.001 ±0.002 ±0.002 ±0.033 ±0.001
Spleen 0.16 0.15 0.14 0.15 0.16 0.21 0.26 0.23
±0.03 ±0.01 ±0.01 ±0.01 ±0.02 ±0.01 ±0.03 ±0.02
GIT” 2.45 1.48 1.21 0.84 0.39 0.25 0.21 0.17
±0.16 ±0.08 ±0.08 ±0.01 ±0.01 ±0.01 ±0.02 ±0.002
Testes 0.17 0.07 0.09 0.079 0.084 0.081 0.063 0.079
±0.04 ±0.04 ±0.01 ±0.004 ±0.013 ±0.004 ±0.009 ±0.001
Femora 2.60 2.97 3.06 2.83 2.56 2.08 1.88 1.61
±0.19 ±0.09 ±0.10 ±0.12 ±0.20 ±0.11 ±0.17 ±0.09
Humeri 1.64 1.72 1.23 1.17 1.30 1.01 1.05 0.83
±0.10 ±0.16 ±0.14 ±0.10 ±0.24 ±0.12 ±0.09 ±0.10
Carcass‘d 19.8 20.2 23.1 33.0 28.8 24.9 22.1 18.6
±0.8 ±0.9 ±0.9 ±1.0 ±1.7 ±0.6 ±1.2 ±0.8
Total 78.5 67.6 56.5 50.7 38.4 31.7 28.5 24.4
±2.2 ±1.0 ±1.0 ±0.9 ±1.6 ±0.6 ±1.1 ±0.7
• X ± S E , n  =  5
' ’G I T  =  g a s t r o i n t e s t i n a l  t r a c t
'carcass sample = remaining tissue {ie. bone, muscle and pelt)
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Table 3.3. The tissue distribution o f in female CBA/H mice after intraperitoneal 
injection as the citrate.
Tissue
1 7 14
% injected activity at time (d): 
28 56 112 224 448
Liver 45.3* 36.0 18.6 7.05 2.96 2.26 1.82 2.12
±2.4 ±1.7 ±1.3 ±0.07 ±0.19 ±0.05 ±0.10 ±0.08
Kidneys 0.63 0.37 0.22 0.14 0.078 0.07 0.060 0.033
±0.04 ±0.01 ±0.01 ±0.01 ±0.003 ±0.01 ±0.004 ±0.008
Adrenals 0.047 0.019 0.013 0.012 0.014 0.009 0.006 0.005
±0.009 ±0.004 ±0.002 ±0.001 ±0.004 ±0.001 ±0.001 ±0.001
Spleen 0.14 0.17 0.17 0.15 0.148 0.216 0.223 0.206
±0.02 ±0.01 ±0.01 ±0.01 ±0.009 ±0.009 ±0.009 ±0.018
GIT” 2.10 2.34 1.48 0.67 0.36 0.30 0.217 0.145
±0.20 ±0.21 ±0.01 ±0.04 ±0.009 ±0.01 ±0.004 ±0.009
Ovaries 0.051 0.035 0.038 0.037 0.033 0.048 0.026 0.027
±0.015 ±0.003 ±0.004 ±0.003 ±0.002 ±0.004 ±0.003 ±0.004
Femora 2.79 2.55 2.61 2.39 2.29 2.61 2.06 1.65
±0.13 ±0.24 ±0.21 ±0.14 ±0.11 ±0.21 ±0.18 ±0.06
Humeri 1.49 1.55 1.24 1.20 1.03 1.37 1.13 0.81
±0.19 ±0.19 ±0.21 ±0.14 ±0.07 ±0.21 ±0.16 ±0.14
Carcass' 22.9 20.8 32.2 30.9 28.9 28.6 24.9 22.1
±0.7 ±1.3 ±2.7 ±2.4 ±1.4 ±1.6 ±1.5 ±1.6
Total 75.4 63.8 56.6 42.5 35.8 35.5 30.4 27.1
±2.5 ±2.2 ±2.8 ±2.2 ±2.5 ±1.4 ±1.4 ±1.4
• X ± S E , n  =  5
' ’G I T  =  g a s t r o i n t e s t i n a l  t r a c t
'carcass sample = remaining tissue (ie. bone, muscle and pelt)
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Table 3.4. The tissue distribution o f in male CBA/H mice after intraperitoneal
injection as the citrate.
Tissue
1 7 14
% injected activity at time (d): 
28 56 112 224 448
Liver 54.2* 31.8 24.6 13.0 3.15 1.55 1.22 0.71
±1.0 ±0.8 ±0.8 ±1.0 ±0.20 ±0.10 ±0.05 ±0.10
Kidntys 1.66 0.68 0.56 0.42 0.24 0.173 0.119 0.098
±0.38 ±0.05 ±0.04 ±0.04 ±0.03 ±0.009 ±0.009 ±0.013
Adrenals 0.05 0.04 0.06 0.016 0.013 0.012 0.009 0.008
±0.03 ±0.04 ±0.01 ±0.004 ±0.004 ±0.003 ±0.002 ±0.001
Spleen 0.15 0.10 0.08 0.098 0.105 0.113 0.120 0.093
±0.08 ±0.009 ±0.03 ±0.004 ±0.018 ±0.004 ±0.004 ±0.009
GIT” 1.37 1.90 1.15 0.99 0.51 0.32 0.17 0.17
±0.12 ±0.13 ±0.09 ±0.01 ±0.03 ±0.02 ±0.04 ±0.07
Testes 0.06 0.09 0.10 0.071 0.056 0.080 0.028 0.046
±0.01 ±0.01 ±0.02 ±0.002 ±0.009 ±0.009 ±0.008 ±0.004
Femora 1.18 1.45 1.50 1.71 1.83 1.67 1.37 1.06
±0.12 ±0.05 ±0.10 ±0.09 ±0.12 ±0.06 ±0.04 ±0.05
Humeri 0.46 0.57 0.64 0.95 0.80 0.77 0.75 0.57
±0.06 ±0.04 ±0.08 ±0.11 ±0.05 ±0.07 ±0.08 ±0.06
Carcass' 11.1 25.2 25.2 26.9 26.4 22.4 21.7 17.9
±0.6 ±0.6 ±1.4 ±1.2 ±1.5 ±1.4 ±0.6 ±1.4
Total 70.2 61.9 53.9 44.2 33.1 27.1 25.5 20.7
±1.2 ±1.0 ±1.5 ±1.4 ±1.4 ±1.4 ±0.5 ±1.8
* X ± S E , n  =  5
*’G 1 T  =  g a s t r o i n t e s t i n a l  t r a c t
'carcass sample = remaining tissue (ie. bone, muscle and pelt)
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Table 3.5. The tissue distribution o f in female CBA/H mice after intraperitoneal 
injection as the citrate.
Tissue
1 7 14
% injected activity at time (d): 
28 56 112 224 448
Liver 57.5* 37.6 17.0 5.30 2.19 1.06 0.90 0.67
±2.3 ±1.8 ±1.6 ±0.72 ±0.29 ±0.08 ±0.09 i0 .04
Kidneys 1.20 0.66 0.40 0.20 0.096 0.055 0.043 0.048
±0.02 ±0.39 ±0.02 ±0.04 ±0.009 ±0.004 ±0.002 ±0.002
Adrenals 0.03 0.03 0.005 0.009 0.01 0.005 0.009 0.006
±0.04 ±0.01 ±0.001 ±0.004 ±0.003 ±0.001 ±0.002 ±0.002
Spleen 0.12 0.10 0.10 0.089 0.067 0.058 0.089 0.075
±0.03 ±0.01 ±0.01 ±0.008 ±0.016 ±0.004 ±0.004 ±0.009
GIT” 1.92 2.85 1.51 0.87 0.44 0.25 0.15 0.093
±0.09 ±0.41 ±0.20 ±0.08 ±0.01 ±0.02 ±0.01 ±0.009
Ovaries 0.047 0.039 0.032 0.029 0.011 0.013 0.012 0.017
±0.013 ±0.004 ±0.003 ±0.002 ±0.003 ±0.003 ±0.003 ±0.002
Femora 1.66 1.68 1.84 1.85 1.77 1.28 1.39 1.36
±0.05 ±0.16 ±0.13 ±0.10 ±0.08 ±0.08 ±0.03 ±0.07
Humeri 0.84 0.88 0.84 0.94 1.02 0.84 0.91 0.70
±0.06 ±0.08 ±0.09 ±0.02 ±0.11 ±0.05 ±0.09 ±0.03
Carcass' 28.1 28.1 31.5 29.9 25.8 19.1 21.9 21.7
±1.4 ±1.4 ±2.0 ±1.0 ±1.6 ±1.3 ±0.9 ±1.3
Total 91.4 72.0 53.2 39.2 31.4 22.7 25.4 24.7
±3.8 ±2.3 ±3.4 ±1.5 ±1.4 ±1.2 ±1.1 ±1.2
“X  ±  S E ,  n  =  5
' ’G I T  =  g a s t r o i n t e s t i n a l  t r a c t
'carcass sample = remaining tissue {ie. bone, muscle and pelt)
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Table 3.6. The tissue distribution o f in male CBA/H mice after intraperitoneal 
injection as the citrate.
Tissue
1 7
% injected activity at time (d): 
14 28 56 112 224 448
Liver 0.23' 0.12 0.082 0.054 0.037 0.017 0.028 0.010
±0.009 ±0.13 ±0.004 ±0.001 ±0.004 ±0.003 ±0.003 ±0.003
Kidneys 6.53 0.40 0.24 0.162 0.057 0.024 0.019 0.019
±0.48 ±0.06 ±0.004 ±0.018 ±0.004 ±0.004 ±0.001 ±0.004
Adrenals 0.008 0.009 0.009 0.003 ND ND ND ND
±0.06 ±0.001 ±0.001 ±0.003
Spleen 0.012 0.015 0.012 0.008 0.006 ND ND ND
±0.001 ±0.001 ±0.001 ±0.003 ±0.002
GIT” 0.23 0.072 0.051 0.039 0.024 0.014 0.009 0.007
±0.04 ±0.009 ±0.004 ±0.002 ±0.004 ±0.002 ±0.001 ±0.002
Testes 0.014 0.024 0.013 ND ND ND ND ND
±0.001 ±0.003 ±0.001
Femora 0.73 0.54 0.56 0.53 0.38 0.30 0.23 0.25
±0.06 ±0.08 ±0.03 ±0.03 ±0.03 ±0.02 ±0.02 ±0.03
Humeri 0.32 0.23 0.24 0.34 0.20 0.13 0.11 0.11
±0.04 ±0.02 ±0.02 ±0.03 ±0.02 ±0.01 ±0.01 ±0.02
Carcassf 8.93 5.76 5.92 4.42 4.17 3.12 2.13 2.16
±0.57 ±0.78 ±0.35 ±0.28 ±0.31 ±0.17 ±0.26 ±0.27
Total 17.00 7.17 7.13 5.56 4.87 3.60 2.53 2.56
±1.06 ±0.71 ±0.31 ±0.25 ±0.28 ±0.15 ±0.24 ±0.24
• X ± S E , n  =  5
' ’G I T  =  g a s t r o i n t e s t i n a l  t r a c t
' c a r c a s s  s a m p l e  =  r e m a i n i n g  t i s s u e  {ie. b o n e ,  m u s c l e  a n d  p e l t )  
N D  =  n o  a c t i v i t y  d e t e c t e d  i n  t h e s e  s a m p l e s
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Table 3.7. The tissue distribution in female CBA/H mice after intraperitoneal 
injection as the citrate.
Tissue
1 7
% injected activity at time (d): 
14 28 56 112 224 448
Liver 0.26* 0.109 0.096 0.060 0.027 0.027 0.028 0.012
±0.02 ^0.009 ±0.004 i0.002 ±0.001 ±0.002 ±0.002 ±0.001
K id n ^ 4.17 0.46 0.42 0.18 0.08 0.12 0.11 0.09
±1.17 ±0.03 ±0.09 ±0.009 ±0.02 ±0.06 ±0.04 ±0.04
Adrenals 0.02 0.008 0.011 0.011 ND ND ND ND
±0.003 ±0.002 ±0.002 ±0.001
Spleen 0.001 0.004 0.013 0.017 ND ND ND ND
±0.001 ±0.001 ±0.004 ±0.001
GIT” 0.09 0.078 0.064 0.049 0.028 0.015 0.007 0.008
±0.02 ±0.004 ±0.002 ±0.001 ±0.002 ±0.001 ±0.003 ±0.001
Ovaries 0.003 0.004 0.015 0.014 ND ND ND ND
±0.001 ±0.001 ±0.004 ±0.001
Femora 0.94 0.68 0.89 0.56 0.42 0.43 0.36 0.28
±0.08 ±0.03 ±0.04 ±0.03 ±0.04 ±0.03 ±0.04 ±0.02
Humeri 0.43 0.34 0.51 0.27 0.20 0.24 0.145 0.109
±0.05 ±0.05 ±0.02 ±0.01 ±0.02 ±0.02 ±0.005 ±0.005
Carcass' 8.66 5.79 6.10 5.94 4.51 4.19 3.08 2.49
±0.90 ±0.13 ±0.27 ±0.19 ±0.38 ±0.20 ±0.21 ±0.11
Total 14.57 7.47 8.12 7.10 5.27 5.01 3.73 2.99
±1.42 ±0.13 ±0.26 ±0.17 ±0.34 ±0.19 ±0.20 ±0.11
• X ± S E , n  =  5
*’G I T  =  g a s t r o i n t e s t i n a l  t r a c t
' c a r c a s s  s a m p l e  =  r e m a i n i n g  t i s s u e  {ie. b o n e ,  m u s c l e  a n d  p e l t )  
N D  =  n o  a c t i v i t y  d e t e c t e d  i n  t h e s e  s a m p l e s
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Figure 3.3. Total body activity retained by liver and skeleton in male mice.
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Figure 3.4. Total body activity retained by liver and skeleton in female mice.
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3.2. Studies on the distribution and retention of ^^ P^u and 
Am in the individual bones of the mouse skeleton
Figures 3.5 and 3.6 show the total skeletal retention o f ^^^u and in mice at 
times up to 448 days after i.p. injection as the citrate complexes, obtained by summing 
values for retention in individual bones. The values obtained in this way were similar to 
those estimated in Section 3.1.2 by summing values for femora, humeri and remaining 
carcass, providing support for the assunq)tion that retention o f each radionuclide in the 
carcass was largely attributable to retention in bone.
For ^^^u, the results for male mice show that 1 day after injection about 29% o f injected 
activity was retained in the skeleton. Skeletal retention increased to a maximum o f about 
33% o f injected activity at 28 days after injection. After 28 days, retention gradually 
reduced with time to about 20% o f injected activity after 448 days. Results for females, 
while appearing slightly higher than those for males, were not significantly different {t 
test).
The uptake and retention o f ^ '‘'Am in the skeleton was similar to that seen for ^^^u 
although the maximum retention in the skeleton, at 28 days after injection, accounted for 
about 24% o f administered "^^ 'Am compared with about 33% of^^^u. Retention after 448 
days accounted for about 20% o f injected activity for both nuclides (Figure 3.5). As 
observed for ^^ P^u, retention in female mice appeared to be slightly higher than that seen in 
male mice; differences were significant at 1 and 14 days after injection, P=0.002 and 
P<0.05, respectively test).
Total skeletal retention of^ ^^U in male mice was greatest at one day after injection, about 
12% o f injected activity, reducing to about 5% at 7 days and about 4% at 448 days. 
Results for females were significantly lower than those for males at 1 day after injection 
(P<0.05, t test) but were significantly greater at 28, 56 and 112 days after injection 
(P<0.001, P<0.03 and P<0.02, respectively). At 224 and 448 days after injection, results 
for males and females were not significantly different.
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Figure 3.6. Skeletal retention of U, Pu and Am in female mice.
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The results obtained for the retention of^^^u, and in individual bones o f the 
skeleton expressed as a percentage o f the total skeletal retention at times up to 448 days 
are given in Tables 3.8-3.13.
The skull accounted for the greatest proportion o f retained ^^^u, about 12-14% o f the 
total retention at 1 day after administration to males and females. Bones accounting for 
about 5-13% o f total skeletal retention in males and females at 1 day after injection were 
the humeri, fibiae / tibiae, ribs, pelvis, femora and vertebral groups. Smaller proportions 
were retained in smaller bones. Differences between males and females were generally not 
significant {t test) but female mice showed slightly higher uptakes in the sacral and caudal 
vertebrae at 1 day after injection (P<0.005 and P<0.05, respectively); significantly lower 
retentions in the thoracic vertebrae, pelvis and femora at 28 days after injection (P<0.05, 
?<0.05 and ?<0.05, respectively) and a significantly higher retention in the sternum at 448 
days after injection (P<0.05). The distribution of^ ^^Pu between individual bones o f the 
skeleton changed with time with increases in the proportion retained in, for example, the 
skull and caudal vertebrae and decreases in the thoracic and lumbar vertebrae, pelvis and 
femora.
The pattern o f distribution o f ^ '’^ Am in the skeleton was the same as that for ^^ P^u. The 
skull accounted for about 20% o f total skeletal retention at 1 day after administration to 
males and females. Bones accounting for about 5-10% o f total skeletal retention in males 
and females at 1 day after injection were the fibiae /  tibiae, ribs, pelvis, femora and 
vertebral groups. Smaller proportions were retained in smaller bones. Differences 
between males and females were generally not significant {t test) but at 14 days after 
injection female mice showed significantly higher retentions in the skull, mandibles, 
cervical and sacral vertebrae, scapulae, pelvis, femora and fibiae/tibiae (P<0.001, P<0.001, 
P<0.002, P<0.001, P<0.001, P<0.001, P<0.002 and P<0.002, respectively). At 28 days 
after injection, females showed significantly higher retentions in the ribs and clavicles 
(P=0.01 and P=0.01, respectively); at 56 days after injection, females showed significantly 
higher retentions in the radii and fibiae/tibiae (P<0.05 and P<0.05, respectively); at 112 
days females showed significantly higher retentions in the mandibles, sacral vertebrae, 
scapulae and fibiae/tibiae (P<0.005, P<0.002, P<0.005 and P<0.005, respectively); at 224
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days females showed a significantly lower retention in the caudal vertebrae (P<0.005) and 
a significantly higher retention in the fibiae/tibiae (P<0.05). The distribution o f 
between individual bones in the skeleton changed with time but the changes appeared 
smaller than for ^^ P^u.
The pattern o f distribution of^%  in the skeleton was similar to that for ^^^u and "^*^ Am. 
The skull accounted for 16-17% o f total skeletal retention at 1 day after administration to 
males and females. Bones accounting for about 5-12% o f total skeletal retention in males 
and females at one day after injection were the humeri, fibiae/tibiae, ribs, pelvis, femora 
and vertebral groups. Differences between males and females were generally not 
significant (/ test) except that male mice showed a significantly higher uptake in all bones 
except the thoracic and lumbar vertebrae and patellae at 1 day after injection (P=0.02 for 
the total skeleton). At 7 days after injection, females showed significantly higher 
retentions in the lumbar and sacral vertebrae and pelvis (P<0.05, P<0.01 and P<0.05, 
respectively); at 14 days after injection, females showed a significantly higher retention in 
the thoracic vertebrae (P<0.05); at 28 days after injection, females showed significantly 
higher retentions in the mandibles, thoracic, lumbar and sacral vertebrae, scapulae, humeri 
and radii (P<0.002, P<0.005, P<0.03, P<0.003, P<0.002, P<0.01 and P<0.05, 
respectively); at 56 days after injection, females showed significantly higher retentions in 
the mandibles, thoracic, lumbar and caudal vertebrae (P<0.03, P<0.005, P<0.003 and 
P<0.02, respectively); at 112 days after injection, females showed significantly higher 
retentions in the cervical, lumbar, thoracic and sacral vertebrae and pelvis (P<0.05,
P<0.04, P<0.02, P<0.003 and P<0.03, respectively); at 224 days after injection, females 
showed significantly higher retentions in the skull, mandibles cervical, thoracic, lumbar, 
sacral and caudal vertebrae, humeri and pelvis (P<0.001, P<0.005, P<0.01, P<0.005, 
P<0.002, P=0.002, P<0.02, P<0.03 and P<0.02, respectively) and at 448 days after 
injection, females showed significantly higher retentions in the mandibles, cervical, thoracic 
and sacral vertebrae and ribs (P<0.03, P<0.03, P<0.002, P<0.01 and P<0.05, 
respectively). The distribution of^%  between individual bones o f the skeleton changed 
with time but the changes appear smaller than for ^^ P^u.
The results in Tables 3.8-3.13 take no account o f differing bone masses; for example, the
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skull bones are much heavier than some o f the smaller bones. To make allowance for this, 
the same results are expressed as % injected activity per g’  ^o f bone ash in Tables 3.14- 
3.19. Comparison o f the results in the two sets o f Tables shows that while the skull 
accounted for a larger proportion o f the total retention o f each radionuclide in the 
skeleton, the concentration o f nuclides in the skull was less than for a number o f other 
bones. The general pattern o f distribution o f the three radionuclides was similar with 
higher concentrations being seen in the thoracic, lumbar and sacral vertebrae and sternum 
and low concentrations in the paw bones, radii, ulnae and clavicles. For ^ ^^ Pu and Am, 
the highest overall concentrations were observed at 7 days after injection in males and 14 
days in females. For the highest concentrations were measured at 1 day after 
injection in both males and females.
In male and female mice given ^^^u, the concentrations o f ^ ^^u in the main body o f the 
vertebrae at 7 days and 14 days after administration were about four times greater than 
that in the bones with the lowest concentrations and about twice the average skeletal 
concentrations. The differences in concentration were reduced by 448 days after injection, 
with vertebral concentrations being about twice the lowest concentrations and 50% greater 
than average concentrations.
In male and female mice given "^^ A^m, the concentrations o f ^ "^ A^m in the main body o f the 
vertebrae at 7 and 14 days after injection were about twice the lowest concentrations and 
about 50-60% greater than the average skeletal concentrations. The overall differences in 
concentration were similar at 448 days after injection, with vertebral concentrations about 
50% greater than average concentrations.
In male and female mice given the concentrations o f in the main body o f the 
vertebrae at 1 day after injection were about 3-4 times the lowest concentrations and about 
twice average skeletal concentrations. The differences in concentration were reduced by 
448 days after injection, with vertebral concentrations about twice lowest concentrations 
and about 50% greater than the average skeletal concentrations.
Figures 3.7 and 3.8 show changes in the inhomogeneity o f concentrations o f ^^^u
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and Am within the skeleton o f male and female mice with time after injection. The 
inhomogeneity ftmction (IF) (Priest et aL, 1985; Stather, 1974) was calculated for each 
nuclide at each time point as:
IF =
where W„ is the proportion o f the mass o f the skeleton represented by bone or bone group 
n, Cn is the concentration o f the nuclide in bone or bone group n relative to the average 
skeletal concentration.
Initial inhomogeneity was greatest for ^^ P^u as indicated above in direct comparisons o f 
concentrations in different bones. For male mice, inhomogeneity at 1 day after injection 
was in the order ^^ P^u > > "^‘‘Am with values o f about 0.62, 0.48 and 0.35,
respectively. Subsequently, the greatest change in inhomogeneity was observed for ^^Tu, 
falling to 0.36 after 448 days compared with 0.33 for and 0.3 for "^^‘Am.
For ^^ P^u and the results for female mice were not significantly different from those 
for male mice {t test). For "^^‘Am, the inhomogeneity values for female mice were initially 
higher than those calculated for male mice (reducing from 0.45 to 0.33); significant 
differences were seen at 1, 28 56, 224 and 448 days (P<0.01, P<0.003, P<0.001, P<0.005 
and P>0.05, respectively, t test).
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Table 3.8. The distribution of^ ^^Pu between the individual bones o f male CBA/H mice 
after injection as the citrate.
Bone
1 7
% total skeletal retention at time (days): 
14 28 56
X ± SE, n = 5 
112 224 448
Skull 14.36 14.72 14.86 14.98 14.95 15.77 17.99 19.58
±0.25 ±0.17 ±0.17 ±0.20 ±0.10 ±0.14 ±0.17 ±0.39
Mandibles 2.76 2.75 2.91 2.82 2.65 2.91 3.43 3.71
±0.10 ±0.05 ±0.07 ±0.08 ±0.03 ±0.06 ±0.07 ±0.04
Cervical Vertebrae 4.68 5.02 5.03 4.92 4.84 5.04 5.01 4.83
±0.15 ±0.10 ±0.47 ±0.14 ±0.22 ±0.17 ±0.15 ±0.12
Thoracic Vertebrae 10.60 9.84 8.97 10.10 10.27 9.04 8.08 7.00
±0.54 ±0.58 ±0.56 ±0.53 ±0.19 ±0.54 ±0.40 ±0.28
Lumbar Vertebrae 13.48 12.79 12.75 12.71 12.76 11.14 9.80 8.12
±0.33 ±0.53 ±0.35 ±0.27 ±0.30 ±0.64 ±0.21 ±0.28
Sacral Vertebrae 5.20 6.18 6.56 5.60 5.76 5.63 5.86 5.23
±0.62 ±0.46 ±0.44 ±0.82 ±0.28 ±0.61 ±0.24 ±0.16
Caudal Vertebrae 5.94 6.59 6.91 6.87 5.82 8.09 9.24 10.19
±0.41 ±0.54 ±0.63 ±0.54 ±0.44 ±0.27 ±0.24 ±0.24
Sternum 1.88 1.91 1.87 1.77 1.82 1.71 1.81 1.29
±0.04 ±0.01 ±0.08 ±0.04 ±0.02 ±0.009 ±0.14 ±0.05
Ribs 7.54 7.43 6.90 6.87 7.03 6.68 6.71 6.76
±0.24 ±0.07 ±0.22 ±0.12 ±0.13 ±0.11 ±0.22 ±0.20
Scapulae 2.92 2.89 2.92 2.76 2.93 2.88 3.04 3.15
±0.06 ±0.02 ±0.05 ±0.06 ±0.03 ±0.04 ±0.03 ±0.06
Clavicles 0.48 0.51 0.50 0.47 0.51 0.50 0.53 0.54
±0.01 ±0.03 ±0.08 ±0.03 ±0.01 ±0.004 . ±0.01 ±0.01
Humeri 4.53 4.48 4.64 4.45 4.66 4.65 4.56 4.26
±0.13 ±0.05 ±0.11 ±0.06 ±0.07 ±0.08 ±0.08 ±0.15
Radii 0.68 0.63 0.74 0.73 0.70 0.76 0.85 0.92
±0.02 ±0.04 ±0.01 ±0.02 ±0.01 ±0.02 ±0.008 ±0.01
Ulnae 0.99 1.01 1.09 1.01 1.13 1.18 1.30 1.36
±0.02 ±0.009 ±0.17 ±0.03 ±0.01 ±0.01 ±0.02 ±0.01
Pelvis 7.62 7.47 7.40 7.40 7.08 6.71 6.15 5.80
±0.24 ±0.08 ±0.13 ±0.14 ±0.14 ±0.10 ±0.18 ±0.07
Femora 8.23 8.09 8.08 8.31 8.07 8.09 7.78 7.47
±0.41 ±0.08 ±0.13 ±0.04 ±0.28 ±0.08 ±0.12 ±0.25
Fibiae /  Tibiae 5.20 4.98 5.32 5.32 5.25 5.46 5.06 5.57
±0.08 ±0.29 ±0.09 ±0.05 ±0.03 ±0.15 ±0.10 ±0.21
Patellae 0.19 0.21 0.21 0.22 0.25 0.30 0.28 0.29
±0.02 ±0.005 ±0.009 ±0.009 ±0.007 ±0.01 ±0.001 ±0.02
Paws 2.25 2.19 1.97 2.32 2.44 2.80 2.47 3.29
±0.15 ±0.08 ±0.17 ±0.09 ±0.13 ±0.13 ±0.07 ±0.36
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Table 3.9. The distribution of^^^u between the individual bones o f female CBA/H mice 
after intraperitoneal injection as the citrate.
Bone
1 7
% total skeletal retention at time (days): 
14 28 56
X ± SE, n = 5 
112 224 448
SkuU 12.46 14.77 15.44 15.14 15.45 15.49 16.98 18.24
±0.79 ±0.38 ±0.35 ±0.27 ±0.18 ±0.12 ±0.25 ±0.34
Mandibles 2.51 3.07 3.44 3.09 3.06 2.82 3.25 3.86
±0.09 ±0.09 ±0.31 ±0.08 ±0.11 ±0.08 ±0.06 ±0.06
Cervical Vertebrae 4.65 4.64 6.22 4.87 4.79 5.38 5.18 5.33
±0.16 ±0.18 ±0.98 ±0.07 ±0.12 ±0.09 ±0.20 ±0.06
Thoracic Vertebrae 9.36 10.28 8.56 8.77 10.16 9.16 8.22 7.55
±0.12 ±0.29 ±0.21 ±0.23 ±0.33 ±0.62 ±0.18 ±0.24
Lumbar Vertebrae 13.40 13.78 12.30 12.22 12.50 11.80 9.90 8.11
±0.16 ±0.34 ±0.22 ±0.20 ±0.31 ±0.24 ±0.14 ±0.21
Sacral Vertebrae 7.80 5.52 7.13 7.25 5.48 5.92 6.74 5.31
±0.09 ±0.45 ±0.23 ±0.12 ±0.50 ±0.50 ±0.15 ±0.22
Caudal Vertebrae 7.26 6.67 7.09 8.35 7.66 7.73 9.63 10.67
±0.22 ±0.31 ±0.54 ±0.34 ±0.26 ±0.46 ±0.09 ±0.37
Sternum 2.08 1.87 1.63 1.80 1.72 1.68 1.34 1.52
±0.13 ±0.03 ±0.12 ±0.05 ±0.04 ±0.01 ±0.17 ±0.03
Ribs 7.94 7.25 7.45 7.34 6.85 6.57 6.72 7.26
±0.42 ±0.24 ±0.18 ±0.16 ±0.12 ±0.05 ±0.16 ±0.23
Scapulae 2.89 2.63 2.94 2.90 2.95 2.80 2.92 3.05
±0.12 ±0.26 ±0.07 ±0.02 ±0.04 ±0.05 ±0.06 ±0.06
Clavicles 0.49 0.38 0.48 0.43 0.48 0.48 0.46 0.51
±0.03 ±0.06 ±0.02 ±0.05 ±0.03 ±0.02 ±0.01 ±0.02
Humeri 4.57 4.45 4.28 4.23 4.51 4.40 4.14 4.14
±0.09 ±0.07 ±0.08 ±0.07 ±0.06 ±0.07 ±0.08 ±0.07
Radii 0.64 0.70 0.71 0.70 0.76 0.69 0.84 0.91
±0.006 ±0.02 ±0.01 ±0.01 ±0.01 ±0.02 ±0.02 ±0.02
Ulnae 1.02 1.07 1.07 1.10 1.14 1.16 1.21 1.34
±0.04 ±0.02 ±0.02 ±0.03 ±0.01 ±0.01 ±0.04 ±0.02
Pelvis 7.11 6.93 6.64 6.41 6.32 6.19 5.79 5.11
±0.07 ±0.39 ±0.10 ±0.16 ±0.09 ±0.05 ±0.13 ±0.06
Femora 7.84 7.84 7.74 7.28 7.63 7.99 7.25 7.01
±0.12 ±0.17 ±0.26 ±0.17 ±0.03 ±0.12 ±0.03 ±0.06
Fibiae/Tibiae 5.28 5.27 5.01 5.03 4.90 5.13 4.94 5.00
±0.07 ±0.08 ±0.08 ±0.07 ±0.16 ±0.06 ±0.08 ±0.12
Patellae 0.21 0.17 0.10 0.26 0.23 0.23 0.26 0.23
±0.03 ±0.03 ±0.06 ±0.01 ±0.05 ±0.06 ±0.03 ±0.04
Paws 2.18 2.33 2.36 2.42 3.01 3.47 3.46 4.25
±0.21 ±0.15 ±0.16 ±0.14 ±0.22 ±0.16 ±0.11 ±0.33
Chapter 3. Results: Individual bone distribution studies 126
Table 3.10. The distribution o f between the individual bones o f male CBA/H mice 
after intraperitoneal injection as the citrate.
Bone
1 7
% total skeletal retention at time (days); 
14 28 56
X ±  SE, n = 5 
112 224 448
Skull 20.02 20.27 19.77 21.25 19.01 19.16 19.33 21.17
±0.35 ±0.25 ±0.20 ±0.35 ±0.34 ±0.27 ±0.21 ±0.50
Mandibles 5.70 5.76 5.54 6.31 4.89 4.09 4.20 4.66
±0.32 ±0.17 ±0.11 ±0.13 ±0.20 ±0.08 ±0.06 ±0.07
Cervical Vertebrae 4.16 4.14 4.13 4.37 4.17 4.25 3.98 4.34
±0.06 ±0.08 ±0.06 ±0.07 ±0.13 ±0.10 ±0.28 ±0.004
Thoracic Vertebrae 6.79 6.78 6.37 6.89 7.59 7.56 6.26 5.89
±0.18 ±0.09 ±0.13 ±0.08 ±0.59 ±0.09 ±0.13 ±0.03
Lumbar Vertebrae 8.74 8.53 8.40 8.81 8.85 9.04 7.49 6.42
±0.43 ±0.10 ±0.04 ±0.11 ±0.21 ±0.11 ±0.04 ±0.02
Sacral Vertebrae 4.75 4.93 4.90 5.12 4.88 4.10 4.61 4.05
±0.06 ±0.09 ±0.06 ±0.09 ±0.17 ±0.15 ±0.06 ±0.09
Caudal Vertebrae 8.81 10.46 11.18 10.06 10.99 11.12 12.71 12.60
±0.36 ±0.34 ±0.51 ±0.18 ±0.34 ±0.34 ±0.37 ±0.28
Sternum 1.52 1.53 1.31 1.17 1.38 1.39 1.21 1.28
±0.07 ±0.03 ±0.06 ±0.16 ±0.03 ±0.06 ±0.12 ±0.03
Ribs 7.47 6.31 6.51 4.95 6.55 6.50 7.29 6.74
±0.44 ±0.60 ±0.17 ±0.55 ±0.17 ±0.17 ±0.37 ±0.34
Scapulae 3.02 3.01 2.92 3.04 2.99 2.91 3.01 3.23
±0.07 ±0.03 ±0.04 ±0.04 ±0.07 ±0.05 ±0.11 ‘ ±0.07
Clavicles 0.47 0.30 0.36 0.13 0.39 0.44 0.49 0.57
±0.04 ±0.08 ±0.05 ±0.09 ±0.06 ±0.03 ±0.10 ±0.09
Humeri 3.48 3.51 3.44 3.51 3.52 3.43 3.32 3.48
±0.05 ±0.08 ±0.03 ±0.07 ±0.04 ±0.08 ±0.07 ±0.05
Radii 0.84 0.84 0.87 0.87 0.84 0.89 1.03 0.89
±0.03 ±0.02 ±0.02 ±0.02 ±0.02 ±0.03 ±0.08 ±0.11
Ulnae 1.03 1.24 1.15 1.23 1.19 1.21 1.32 1.23
±0.12 ±0.03 ±0.02 ±0.03 ±0.04 ±0.03 ±0.11 ±0.18
Pelvis 5.70 5.87 5.64 5.99 5.77 5.65 5.20 5.34
±0.11 ±0.09 ±0.13 ±0.03 ±0.05 ±0.10 ±0.04 ±0.21
Femora i 5.90 6.31 6.34 6.44 6.55 6.40 6.08 5.77
±0.13 ±0.11 ±0.09 ±0.08 ±0.11 ±0.07 ±0.06 ±0.22
Fibiae / Tibiae 4.72 5.08 4.95 4.90 5.00 4.89 4.72 5.21
±0.09 ±0.08 ±0.09 ±0.07 ±0.04 ±0.07 ±0.19 ±0.25
Patellae 0.25 0.08 0.16 0.06 0.17 0.23 0.22 0.26
±0.04 ±0.04 ±0.04 ±0.04 ±0.05 ±0.03 ±0.06 ±0.11
Paws 4.14 4.74 4.84 4.43 5.76 6.36 5.84 6.13
±0.28 ±0.51 ±0.33 ±0.33 ±0.29 ±0.17 ±0.19 ±0.63
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Table 3.11. The distribution o f between the individual bones o f female CBA/H mice
after intraperitoneal injection as the citrate.
Bone
1 7
% total skeletal retention at time (days): 
14 28 56
X ±  SE, n = 5 
112 224 448
Skull 20.15 20.08 21.84 20.07 18.87 19.80 20.69 20.93
±0.47 ±0.26 ±1.43 ±0.08 ±0.22 ±0.18 ±0.96 ±0.57
Mandibles 6.09 5.69 6.74 5.86 4.88 4.54 4.84 4.57
±0.12 ±0.12 ±0.61 ±0.07 ±0.06 ±0.11 ±0.17 ±0.08
Cervical Vertebrae 4.21 4.91 4.60 4.15 5.14 4.19 4.77 4.27
±0.11 ±0.38 ±0.36 ±0.07 ±0.67 ±0.12 ±0.17 ±0.13
Thoracic Vertebrae 7.05 7.17 6.91 7.26 7.56 6.86 7.00 6.42
±0.20 ±0.22 ±0.08 ±0.27 ±0.55 ±0.21 ±0.14 ±0.32
Lumbar Vertebrae 9.52 8.78 8.23 9.11 8.45 8.46 7.61 6.70
±0.41 ±0.37 ±0.76 ±0.27 ±0.26 ±0.15 ±0.49 ±1.15
Sacral Vertebrae 5.11 5.22 5.87 4.61 4.67 5.13 5.02 4.19
±0.24 ±0.09 ±0.58 ±0.32 ±0.23 ±0.05 ±0.17 ±0.13
Caudal Vertebrae 7.17 8.21 7.55 8.63 9.46 10.09 9.94 10.76
±0.33 ±0.62 ±0.83 ±0.22 ±0.42 ±0.54 ±0.62 ±0.80
Sternum 1.50 1.46 1.45 1.47 1.49 1.22 1.39 1.34
±0.05 ±0.12 ±0.14 ±0.03 ±0.04 ±0.19 ±0.08 ±0.08
Ribs 7.03 8.08 8.34 7.07 7.00 7.00 6.80 7.58
±0.79 ±0.32 ±0.33 ±0.16 ±0.10 ±0.10 ±0.64 ±0.38
Scapulae 2.98 3.23 3.61 3.05 3.03 3.13 2.91 3.30
±0.15 ±0.05 ±0.26 ±0.04 ±0.07 ±0.03 ±0.26 ±0.06
Clavicles 0.30 0.44 0.37 0.45 0.45 0.46 0.41 0.48
±0.10 ±0.02 ±0.04 ±0.02 ±0.03 ±0.08 ±0.02 ±0.06
Humeri 3.98 3.55 3.47 3.56 3.51 3.60 3.67 3.37
±0.29 ±0.05 ±0.27 ±0.06 ±0.03 ±0.05 ±0.18 ±0.05
Radii 0.79 0.84 0.84 0.89 0.91 0.91 0.94 0.93
±0.02 ±0.03 ±0.13 ±0.01 ±0.03 ±0.03 ±0.03 ±0.03
Ulnae 1.14 1.13 1.17 1.21 1.27 1.24 1.29 1.38
±0.04 ±0.02 ±0.17 ±0.02 ±0.04 ±0.02 ±0.06 ±0.03
Pelvis 6.05 6.00 6.65 5.50 5.32 5.46 5.60 4.99
±0.25 ±0.11 ±0.61 ±0.04 ±0.09 ±0.11 ±0.19 ±0.12
Femora 6.37 6.28 7.01 6.19 6.16 6.36 6.37 5.58
±0.30 ±0.07 ±0.74 ±0.07 ±0.09 ±0.17 ±0.23 ±0.12
Fibiae/Tibiae 5.05 5.16 5.80 4.98 5.60 5.35 5.37 4.90
±0.19 ±0.06 ±0.57 ±0.10 ±0.15 ±0.08 ±0.20 ±0.24
Patellae 0.08 0.47 0.28 0.22 0.22 0.23 0.19 0.26
±0.01 ±0.15 ±0.11 ±0.03 ±0.04 ±0.06 ±0.03 ±0.05
Paws 3.54 3.93 3.45 4.71 6.52 5.06 4.77 5.66
±0.37 ±0.08 ±0.55 ±0.11 ±0.25 ±0.45 ±0.86 ±0.18
Chapter 3. Results: Individual bone distribution studies 128
Table 3.12. The distribution between the individual bones o f male CBA/H mice
after intraperitoneal injection as the citrate.
Bone
1 7
% total skeletal retention at time (days): 
14 28 56
X ± SE, n = 5 
112 224 448
SkuU 16.45 16.99 17.07 18.28 16.87 18.48 17.93 18.60
±0.12 ±0.45 ±0.42 ±0.35 ±0.34 ±0.24 ±0.97 ±0.42
Mandibles 4.93 5.78 6.44 6.13 6.36 5.08 5.99 6.36
±0.17 ±0.17 ±0.21 ±0.16 ±0.33 ±0.19 ±0.14 ±0.15
Cervical Vertebrae 3.94 3.78 4.00 4.15 3.33 3.90 3.80 3.36
±0.10 ±0.12 ±0.19 ±0.56 ±0.83 ±0.15 ±0.16 ±0.09
Thoracic Vertebrae 7.11 7.56 7.20 6.51 6.16 5.53 4.85 3.81
±0.22 ±0.27 ±0.25 ±0.34 ±0.21 ±0.11 ±0.14 ±0.15
Lumbar Vertebrae 9.85 9.23 9.74 8.82 7.76 6.92 6.70 5.39
±0.20 ±0.55 ±0.16 ±0.38 ±0.30 ±0.23 ±0.06 ±0.15
Sacral Vertebrae 5.13 2.94 3.41 3.64 3.86 3.92 3.57 3.22
±0.09 ±0.47 ±0.32 ±0.37 ±0.54 ±0.09 ±0.34 ±0.15
Caudal Vertebrae 8.21 8.11 9.35 10.61 13.17 12.70 12.47 16.51
±0.47 ±0.13 ±0.93 ±0.90 ±0.42 ±0.49 ±0.16 ±1.31
Sternum 1.39 1.46 1.32 1.05 0.84 1.00 0.90 0.80
±0.06 ±0.04 ±0.03 ±0.06 ±0.14 ±0.04 ±0.04 ±0.06
Ribs 7.02 8.30 7.86 7.00 6.53 6.40 5.56 4.40
±0.24 ±0.28 ±0.14 ±0.14 ±0.22 ±0.27 ±0.21 ±0.27
Scapulae 3.15 3.19 3.21 2.65 3.04 3.25 3.32 3.16
±0.15 ±0.04 ±0.15 ±0.22 ±0.16 ±0.14 ±0.08 ±0.11
Clavicles 0.49 0.45 0.53 0.41 0.38 0.54 0.43 0.53
±0.01 ±0.05 ±0.04 ±0.07 ±0.05 ±0.02 ±0.10 ±0.08
Humeri 4.83 4.60 4.43 4.23 4.60 4.53 4.83 4.67
±0.06 ±0.16 ±0.11 ±0.15 . ±0.13 ±0.11 ±0.18 ±0.17
Radii 0.76 0.79 0.72 0.77 0.78 1.13 1.00 1.30
±0.02 0.02 ±0.02 ±0.05 ±0.10 ±0.05 ±0.07 ±0.04
Ulnae 0.95 1.00 1.01 0.97 1.08 1.35 1.35 1.57
±0.02 ±0.05 ±0.03 ±0.06 ±0.05 ±0.06 ±0.06 ±0.07
Pelvis 7.48 7.12 7.12 6.98 6.12 5.87 6.33 5.68
±0.04 ±0.25 ±0.13 ±0.24 ±0.18 ±0.18 ±0.26 ±0.49
Femora 8.94 8.92 8.94 6.43 9.51 9.85 10.78 11.05
±0.37 ±0.19 ±0.32 ±0.46 ±0.37 ±0.20 ±0.67 ±0.48
Fibiae / Tibiae 6.88 6.64 6.39 6.52 6.47 6.98 7.40 7.14
±0.14 ±0.17 ±0.16 ±0.24 ±0.26 ±0.20 ±0.18 ±0.34
Patellae 0.17 0.10 0.11 0.16 0.14 0.35 0.28 0.41
±0.05 ±0.04 ±0.02 ±0.03 ±0.009 ±0.03 ±0.08 ±0.03
Paws 1.66 1.54 1.44 1.60 1.98 20.8 2.40 2.43
±0.08 ±0.13 ±0.15 ±0.13 ±0.11 ±0.11 ±0.06 ±0.18
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Table 3.13. The distribution between the individual bones o f female CBA/H mice 
after intraperitoneal injection as the citrate.
Bone
1 7
% total skeletal retention at time (days): 
14 28 56
X ± SE, n = 5 
112 224 448
SkuU 17.10 16.74 17.26 17.44 17.51 18.44 18.30 18.99
±0.38 ±0.32 ±1.25 ±0.47 ±0.58 ±0.59 ±0.39 ±0.31
Mandibles 5.34 6.10 6.64 6.86 6.86 6.23 6.69 7.12
±0.06 ±0.14 ±0.39 ±0.22 ±0.30 ±0.13 ±0.22 ±0.19
Cervical Vertebrae 3.89 3.28 3.90 3.84 4.23 4.55 4.21 3.95
±0.04 ±0.22 ±0.19 ±0.19 ±0.14 ±0.38 ±0.14 ±0.13
Thoracic Vertebrae 8.14 7.45 8.30 7.89 8.04 6.29 5.64 5.07
±0.58 ±0.36 ±0.96 ±0.28 ±0.51 ±0.37 ±0.16 ±0.25
Lumbar Vertebrae 11.96 11.22 10.48 9.83 10.35 8.10 6.92 5.62
±0.83 ±0.33 ±0.59 ±0.14 ±0.46 ±0.18 ±0.23 ±0.13
Sacral Vertebrae 4.71 5.33 4.83 4.16 4.05 5.55 4.98 4.47
±0.59 ±0.58 ±0.72 ±0.19 ±0.31 ±0.19 ±0.18 ±0.40
Caudal Vertebrae 7.18 7.81 8.43 9.11 8.99 10.65 12.81 13.54
±0.43 ±0.18 ±1.03 ±0.43 ±0.39 ±0.64 ±0.69 ±0.96
Sternum 1.45 1.42 1.40 0.87 0.90 0.67 0.81 0.71
±0.04 ±0.04 ±0.08 ±0.14 ±0.0 ±0.15 ±0.04 ±0.05
Ribs 7.48 7.08 7.18 6.64 5.99 5.97 4.99 4.84
±0.07 ±0.24 ±0.22 ±0.28 ±0.15 ±0.23 ±0.15 ±0.23
Scapulae 3.02 3.09 3.22 3.10 2.87 2.83 2.72 2.69
±0.09 ±0.10 ±0.15 ±0.07 ±0.09 ±0.11 ±0.09 ±0.06
Clavicles 0.31 0.40 0.43 0.47 0.37 0.42 0.53 0.55
±0.05 ±0.05 ±0.13 ±0.06 ±0.07 ±0.06 ±0.04 ±0.04
Humeri 4.66 4.59 4.56 4.26 4.34 4.50 4.61 4.59
±0.15 ±0.21 ±0.57 ±0.33 ±0.14 ±0.15 ±0.08 ±0.08
Radii 0.71 0.62 0.73 0.86 0.78 1.02 1.07 1.13
±0.03 ±0.03 ±0.15 ±0.10 ±0.07 ±0.04 ±0.05 ±0.04
Ulnae 0.86 0.83 0.98 0.89 1.04 1.21 1.22 1.34
±0.02 ±0.02 ±0.06 ±0.09 ±0.06 ±0.03 ±0.03 ±0.05
Pelvis 6.76 7.50 7.28 6.61 6.16 6.62 6.13 5.53
±0.36 ±0.12 ±0.31 ±0.08 ±0.21 ±0.14 ±0.15 ±0.24
Femora 7.77 8.85 9.08 8.38 9.41 9.53 9.63 10.07
±0.54 ±0.28 ±0.56 ±0.22 ±0.34 ±0.30 ±0.13 ±0.24
Fibiae / Tibiae 7.20 6.34 6.59 5.67 5.94 6.34 6.11 6.74
±0.62 ±0.43 ±0.23 ±0.08 ±0.27 ±0.05 ±0.06 ±0.17
Patellae 0.17 0.12 0.40 0.18 0.33 0.25 0.20 0.31
±0.03 ±0.08 ±0.15 ±0.02 ±0.18 ±0.04 ±0.03 ±0.08
Paws 1.67 1.19 1.40 1.68 1.83 1.91 2.19 2.42
±0.09 ±0.04 ±0.10 ±0.12 ±0.13 ±0.19 ±0.09 ±0.13
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Table 3.14. The concentration o f in the individual bones o f male CBA/H mice after 
intraperitoneal injection as the citrate.
Bone
1 7
% injected activity g'' ash at time (days) : 
14 28 56
X ± SE, n = 5 
112 224 448
Skull 26.65 37.58 28.11 32.64 27.35 24.54 36.06 22.79
±0.80 ±5.60 ±1.36 ±4.87 ±4.83 ±0.36 ±2.63 ±4.18
Mandibles 13.26 23.54 17.40 18.50 15.15 12.09 12.79 13.83
±0.46 ±4.59 ±1.94 ±4.11 ±3.15 ±0.20 ±1.61 ±3.30
Cervical Vertebrae 70.91 81.07 68.30 76.59 73.22 63.93 69.63 37.31
±2.15 ±8.02 ±6.94 ±7.74 ±7.82 ±2.73 ±10.69 ±7.00
Thoracic Vertebrae 86.00 100.20 80.30 88.69 82.02 70.24 72.09 38.78
±4.26 ±8.70 ±4.27 ±10.42 ±6.75 ±4.28 ±6.93 ±5.41
Lumbar Vertebrae 91.22 95.12 84.28 85.34 84.05 70.06 63.26 34.37
±2.57 ±12.69 ±4.95 ±10.77 ±6.69 ±1.50 ±4.88 ±4.82
Sacral Vertebrae 73.97 92.91 91.84 80.00 78.06 76.48 64.68 38.39
±9.31 ±10.44 ±2.72 ±9.80 ±10.61 ±7.71 ±5.48 ±4.55
Caudal Vertebrae 19.69 22.77 22.47 22.30 19.46 20.58 21.90 16.71
±1.52 ±2.96 ±1.23 ±1.72 ±1.79 ±0.66 ±1.51 ±0.73
Sternum 76.02 86.35 78.76 73.89 75.91 72.93 45.86 27.36
±1.37 ±7.23 ±7.12 ±17.02 ±3.57 ±1.68 ±6.13 ±2.03
Ribs 56.15 59.83 53.56 55.80 48.69 38.83 40.67 25.54
±3.09 ±5.21 ±3.02 ±3.95 ±4.69 ±1.66 ±4.32 ±5.72
Scapulae 56.92 59.27 59.44 61.07 59.44 54.69 59.37 31.96
±1.88 ±4.00 ±3.95 ±8.35 ±5.69 ±4.82 ±8.52 ±6.86
Clavicles 61.76 , 45.19 60.30 60.00 50.82 55.38 31.54 21.99
±6.53 ±7.82 ±14.02 ±6.06 ±9.26 ±4.86 ±4.41 ±2.60
Humeri 53.03 62.95 56.11 58.41 56.07 44.36 60.07 32.20
±2.52 ±8.09 ±3.13 ±7.45 ±7.64 ±1.81 ±5.36 ±4.02
Radii 33.28 24.98 28.75 28.07 28.78 27.57 29.43 17.32
±4.99 ±2.32 ±1.75 ±2.95 ±3.98 ±4.31 ±4.49 ±0.87
Ulnae 30.44 33.22 29.35 38.57 33.85 30.86 41.05 21.04
±4.01 ±0.86 ±0.65 ±8.92 ±6.36 ±5.10 ±6.91 ±2.25
Pelvis 55.65 65.03 53.46 55.29 51.66 41.01 43.97 29.22
±1.56 ±5.65 ±2.12 ±3.73 ±5.27 ±0.82 ±2.36 ±4.04
Femora 44.46 59.66 49.64 50.00 48.21 37.03 47.77 27.93
±1.05 ±7.45 ±3.35 ±5.55 ±6.82 ±0.39 ±3.55 ±4.33
Fibiae/ Tibiae 33.38 41.25 34.86 37.48 33.14 29.03 34.61 21.36
±1.84 ±6.16 ±1.01 ±4.92 ±3.66 ±0.62 ±2.94 ±2.03
Patellae 23.92 26.16 39.42 36.54 36.71 37.45 27.51 20.52
±5.93 ±3.58 ±8.20 ±2.60 ±2.42 ±3.93 ±4.82 ±3.93
Paws 12.41 14.36 13.07 15.21 13.18 14.29 17.50 14.72
±1.28 ±1.29 ±0.57 ±1.93 ±1.01 ±0.21 ±1.67 ±0.96
Total skeleton 39.57
±1.07
47.73
±5.17
42.63
±3.45
41.47
±0.85
39.03
±4.18
38.30
±3.04
33.90
±0.35
23.39
±2.77
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Table 3.15. The concentration of^^^u in the individual bones o f female CBA/H mice after 
intraperitoneal injection as the citrate.
Bone
1 7
% injected activity g ' ash at time (days) ; 
14 28 56
X ± SE, n = 5 
112 224 448
Skull 27.19 27.52 31.71 28.75 32.72 27.96 23.34 19.00
±1.92 ±2.60 ±2.73 ±1.33 ±3.28 ±2.53 ±2.34 ±0.54
Mandibles 13.79 17.29 20.71 14.55 15.82 12.37 11.03 10.07
±1.01 ±4.78 ±2.23 ±0.62 ±1.36 ±1.04 ±1.13 ±0.22
Cervical Vertebrae 65.19 65.20 96.69 71.08 81.47 66.40 47.41 36.39
±5.10 ±6.94 ±11.62 42.87 ±6.10 ±7.91 ±6.73 ±1.28
Thoracic Vertdwae 88.47 94.89 89.36 92.42 100.98 79.93 52.54 36.69
±8.34 ±14.82 ±18.49 ±3.73 ±10.16 ±7.50 ±6.14 ±1.12
Lumbar Vertebrae 93.42 108.80 101.52 92.49 97.24 77.86 48.73 32.12
±8.63 ±14.62 ±12.17 ±4.46 49.89 ±8.48 ±5.23 ±1.36
Sacral Vertebrae 83.02 102.67 110.44 93.65 103.09 73.79 59.93 38.83
±8.89 ±15.65 ±14.04 ±5.81 ±14.64 ±8.04 ±6.34 ±2.93
Caudal Vertebrae 22.67 25.41 28.46 28.08 26.91 25.07 21.73 19.02
±2.60 ±3.42 ±3.63 ±1.07 ±4.25 ±2.52 ±2.40 ±0.72
Sternum 79.23 79.79 83.08 79.59 84.99 72.71 44.94 36.96
±8.04 ±10.56 ±10.72 ±4.75 ±9.66 46.66 ±2.31 ±2.46
Ribs 59.47 63.22 64.65 61.87 63.64 48.77 32.91 26.76
M.58 ±13.09 ±8.44 42.20 ±6.29 ±4.84 ±3.75 ±1.16
Scapulae 59.97 65.12 81.45 70.26 73.34 65.77 44.82 36.21
±6.63 ±10.37 ±6.63 ±5.04 ±6.61 ±6.66 ±6.47 ±2.79
Clavicles 39.06 61.16 72.62 67.35 73.86 63.90 45.60 27.43
±6.27 ±9.49 ±5.99 ±3.54 44.31 ±5.28 ±6.96 ±3.45
Humeri 52.00 65.35 61.23 51.93 60.83 51.38 34.62 26.41
±6.08 ±15.41 ±5.34 ±1.96 ±5.30 ±5.36 ±3.53 ±1.47
Radii 19.89 34.22 37.85 32.89 36.23 38.29 26.65 23.96
±4.81 ±4.89 ±3.44 ±2.43 ±2.67 ±5.01 ±4.79 ±3.40
Ulnae 29.59 33.74 39.47 34.77 37.80 43.67 28.64 18.35
±3.07 ±3.11 ±2.34 ±1.14 ±1.80 ±7.41 ±5.08 ±1.76
Pelvis 51.99 61.25 61.56 50.73 55.84 47.87 31.50 22.10
±5.66 ±9.69 ±4.87 ±2.49 ±5.00 ±3.99 ±3.20 ±0.76
Femora 43.63 60.11 52.29 43.12 54.45 45.34 28.76 21.31
±3.99 ±14.44 ±4.51 42.25 ±5.83 ±4.36 ±3.08 ±0.80
Fibiae/ Tibiae 34.58 40.67 40.79 34.35 38.32 34.01 23.93 18.26
±2.87 ±6.98 ±3.03 ±1.72 ±426 ±3.64 42.75 ±0.98
Patellae 24.19 25.68 17.46 37.80 36.78 30.11 32.27 25.47
±3.95 ±4.78 ±10.70 ±1.71 ±8.26 ±9.90 ±5.89 ±5.10
Paws 14.37 16.24 19.37 16.65 19.84 19.39 17.03 15.81
±0.79 ±2.88 ±1.20 ±1.19 ±1.43 ±1.70 ±2.08 ±0.88
Total skeleton 40.93
±3.47
45.42
±6.91
48.00
±3.87
42.63
±1.72
46.27
±4.78
39.62
±3.81
29.17
±3.22
22.25
±0.66
Chapter 3. Results: Individual bone distribution studies 132
Table 3.16. The concentration of in the individual bones o f male CBA/H mice after 
intraperitoneal injection as the citrate.
Bone
1 7
% injected activity g ' ash at time (days) : 
14 28 56
X ±  SE, n = 5 
112 224 448
Skull 24.40 29.48 30.39 28.82 27.52 25.10 24.54 22.22
±2.11 ±1.41 ±0.76 ±1.05 ±1.25 ±0.57 ±0.62 ±1.15
Mandibles 18.36 22.20 23.23 21.16 17.21 15.50 14.35 12.45
±2.19 ±1.11 ±0.81 ±0.55 ±0.98 ±0.66 ±0.31 ±0.59
Cervical Vertebrae 35.01 46.33 45.23 41.85 43.14 41.97 38.12 33.28
±2.57 ±3.59 ±0.88 ±2.09 ±2.06 ±2.09 ±1.58 ±3.12
Thoracic Vertebrae 41.98 52.03 49.90 48.48 47.73 46.13 40.90 34.70
±3.76 ±4.39 ±1.01 ±2.48 ±2.82 ±1.73 ±1.69 ±2.66
Lumbar Vertebrae 40.10 49.38 48.87 47.04 45.06 44.06 37.36 28.80
±3.90 ±3.01 ±1.15 ±1.88 ±2.38 ±1.75 ±1.10 ±2.59
Sacral Vertebrae 42.11 54.86 50.10 49.01 46.61 44.82 41.58 34.31
±4.92 ±4.48 ±1.97 ±0.80 ±2.60 ±2.49 ±1.56 ±3.38
Caudal Vertebrae 18.30 25.80 26.34 25.88 24.01 23.68 24.46 20.56
±1.62 ±1.83 ±1.46 ±1.55 ±0.94 ±0.98 ±0.87 ±1.05
Sternum 48.51 58.09 53.84 52.06 51.48 46.31 45.62 40.84
±2.79 ±2.21 ±4.51 ±0.56 ±2.54 ±7.74 ±3.15 ±5.43
Ribs 36.03 43.91' 40.73 40.54 35.72 35.13 29.68 25.02
±2.18 ±2.95 ±1.00 ±2.06 ±1.99 ±1.73 ±0.64 ±2.13
Scapulae 38.94 48.61 44.95 43.62 42.28 35.27 32.96 27.72
±2.86 ±6.41 ±3.59 ±1.35 ±1.97 ±0.99 ±828 ±9.02
Clavicles 38.13 28.81 44.80 40.45 36.83 35.75 27.28 17.84
±5.44 ±6.72 ±8.66 ±5.59 ±5.25 ±6.08 ±3.62 ±1.50
Humeri 25.22 31.47 36.20 29.67 28.66 28.41 24.04 23.39
±2.07 ±2.83 ±7.54 ±0.55 ±1.17 ±0.85 ±1.08 ±1.63
Radii 21.00 31.88 32.50 24.62 23.62 23.32 23.24 19.11
±2.05 ±6.37 ±5.59 ±1.49 ±1.49 ±2.15 ±0.33 ±2.60
Ulnae 21.19 29.28 24.76 23.87 23.19 22.28 22.07 21.21
±2.95 ±3.91 ±1.75 ±1.07 ±1.66 ±2.63 ±1.51 ±1.13
Pelvis 27.77 34.20 33.75 32.01 31.26 29.36 25.57 24.28
±2.50 ±2.07 ±1.24 ±1.40 ±1.44 ±0.76 ifl.87 ±2.34
Femora 21.90 27.78 27.25 27.20 27.15 25.42 22.78 19.25
±1.87 ±1.69 ±1.43 ±1.00 ±0.66 ±1.15 ±0.83 ±0.97
Fibiae / Tibiae 19.92 25.29 23.91 23.87 23.83 21.52 19.74 18.96
±1.69 ±1.47 ±0.87 ±1.06 ±1.37 ±1.01 ±0.60 ±0.86
Patellae 23.48 27.78 21.72 20.09 19.71 19.70 18.45 12.85
±0.94 ±3.67 ±3.69 ±5.77 ±5.00 ±5.46 ±5.45 ±6.36
Paws 16.17 23.42 28.14 26.94 25.38 23.62 23.01 22.70
±1.34 ±2.15 ±1.34 ±1.15 ±1.09 ±2.90 ±1.52 ±1.62
Total skeleton 26.22
±2.21
32.33
±1.93
31.44
±0.96
31.04
±1.25
30.62
±1.64
28.29
±0.90
26.54
±0.74
22.18
±1.70
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Table 3.17. The concentration in the individual bones o f female CBA/H mice
after intraperitoneal injection as the citrate.
Bone
1 7
% injected activity g ' ash at time (days) : 
14 28 56
X ±  SE, n = 5 
112 224 448
SkuU 29.65 31.56 39.15 31.61 31.05 30.18 28.41 24.93
±2.03 ±2.93 ±2.29 ±1.37 ±2.37 ±1.53 ±0.97 ±1.59
Mandibles 20.97 24.51 29.88 22.47 18.69 17.92 16.12 13.50
±1.28 ±2.88 ±2.05 ±1.12 ±1.02 ±1.35 ±0.48 ±1.34
Cervical Vertebrae 49.64 58.57 74.06 59.66 52.06 48.99 48.93 38.78
±3.33 ±5.14 ±5.71 ±4.87 ±2.32 ±3.75 ±3.28 ±2.97
Thoracic Vertebrae 60.98 77.38 71.98 61.89 57.84 57.83 56.01 48.70
±2.70 ±5.35 ±16.96 ±4.92 ±5.14 ±2.73 ±2.93 ±8.54
Lumbar Vertdjrae 54.73 65.56 66.19 53.58 53.56 55.42 47.44 38.69
±3.18 ±3.41 ±15.78 ±3.23 ±2.51 ±4.92 i4.18 ±3.58
Sacral Vertebrae 61.53 64.69 79.57 67.04 53.63 52.82 51.43 43.72
±3.95 ±4.59 ±8.27 ±5.81 ±1.69 ±2.94 ±2.46 ±4.36
Caudal Vertebrae 22.09 23.22 43.34 28.55 27.35 24.24 24.22 23.17
±2.68 ±2.62 ±9.29 ±2.83 ±1.51 ±1.29 ±0.57 ±2.38
Sternum 53.97 55.07 66.09 61.59 60.39 54.14 53.80 47.42
±4.24 ±2.76 ±8.41 ±4.43 ±4.32 ±3.17 ±1.67 ±3.66
Ribs 44.52 50.80 71.14 46.72 45.73 45.47 37.29 33.47
±7.14 i2.54 ±6.93 ±2.02 ±4.32 ±2.10 ±3.00 ±3.18
Scapulae 66.95 69.49 88.48 72.13 65.65 58.71 50.80 46.91
±8.77 ±7.48 ±8.74 ±6.40 ±5.55 ±4.11 ±4.07 ±2.50
Clavicles 19.80 33.97 50.83 52.04 51.81 46.19 42.44 29.41
±9.76 ±3.36 ±4.68 ±6.91 ±6.73 ±6.94 ±4.22 ±1.58
Humeri 37.03 40.83 50.22 39.86 34.93 34.67 33.63 30.17
±2.83 ±3.30 ±5.61 ±3.13 ±2.25 ±1.94 ±2.72 ±5.40
Radii 43.75 45.23 49.22 45.46 43.45 38.70 35.29 32.17
±2.01 ±6.62 ±6.26 ±3.43 ±3.60 ±3.75 ±6.86 ±19.4
Ulnae 35.53 38.26 46.34 39.42 39.06 35.19 32.41 30.50
±4.92 ±5.77 ±4.08 ±3.60 ±1.84 ±1.43 ±2.60 42.15
Pelvis 37.93 45.29 51.41 38.77 36.54 35.77 33.05 30.86
±2.57 ±4.96 ±^.89 ±3.17 ±1.52 ±1.65 ±1.34 44.35
Femora 29.25 31.13 38.33 31.10 30.90 29.60 26.71 21.96
±1.52 ±2.93 ±3.51 42.17 ±2.33 ±1.27 40.89 42.76
Fibiae/Tibiae 28.47 3 2 2 4 39.30 31.91 31.51 28.70 28.19 24.93
±1.56 ±3.49 ±4.35 ±2.08 ±2.28 ±1.59 ±0.97 44.39
Patellae 13.29 20.24 29.40 29.20 26.63 15.57 14.09 10.62
±1.73 ±5.24 ±8.30 ±7.48 44.65 ±3.38 ±6.67 ±5.93
Paws 21.61 23.12 35.95 32.50 32.00 30.53 28.98 25.53
±1.56 ±2.17 ±3.66 ±2.69 44.20 ±1.46 ±1.00 ±2.19
Total skeleton 34.23
±2.18
36.82
±3.65
45.59
±3.82
37.06
±2.69
34.85
±1.75
34.85
±1.72
30.40
±1.62
28.46
±2.90
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Table 3.18. The concentration o f in the individual bones o f male CBA/H mice after 
intraperitoneal injection as the citrate.
Bone
1 7
% injected activity g ' ash at time (days) : 
14 28 56
X ±  SE, n = 5 
112 224 448
SkuU 12.93 5.69 5.42 5.35 4.89 4.02 3.63 3.37
±1.73 ±0.31 ±0.51 ±0.42 ±0.35 ±026 ±0.13 ±0.38
Mandibles 10.34 5.40 5.03 4.39 4.08 3.93 3.58 3.22
±1.22 ±0.73 ±0.27 ±0.24 ±0.33 ±0.10 ±0.29 ±0.16
Cervical Vratebrae 30.16 9.30 10.62 9.18 8.04 7.74 7.23 5.31
±5.33 ±0.81 ±0.73 ±0.75 ±0.69 ±1.01 ±1.07 ±0.43
Thoracic Vertebrae 32.38 11.57 10.35 8.75 8.22 7.78 5.85 4.20
44.53 ±0.79 ±1.00 ±0.75 ±0.56 ±0.57 ±0.34 ±0.14
Lumbar Vertebrae 33.78 1126 11.41 9.41 9.12 7.62 5.68 4.26
±4.97 ±0.89 ±1.26 ±1.39 ±1.08 ±0.79 ±0.47 ±0.24
Sacral Vertebrae 34.42 10.01 9.41 8.46 7.99 6.81 6.30 4.98
±5.24 ±0.93 ±0.59 ±1.13 ±0.55 ±0.91 ±0.55 ±0.16
Caudal Vertebrae 11.37 4.66 4.77 4.71 5.80 5.02 5.05 4.01
±1.68 ±0.37 4:0.66 ±0.46 ±0.40 ±0.31 ±0.86 ±0.33
Sternum 28.03 13.10 10.87 8.68 7.83 5.76 5.34 5.00
±4.35 ±0.80 ±1.22 ±0.68 ±0.59 # .5 2 ±1.08 ±0.49
Ribs 26.06 11.12 9.91 8.22 6.62 6.12 4.32 3.00
±3.93 ±0.72 ±0.88 ±0.56 ±1.61 ±0.60 ±0.31 ±0.15
Scapulae 32.71 9.98 13.08 10.25 8.36 8.33 8.27 6.99
±5.37 ±0.55 ±1.51 ±1.06 ±1.02 ±0.74 ±125 ±0.69
Clavicles 23.02 6.39 10.06 7.62 7.52 7.46 7.15 6.12
±4.22 ±1.65 ±1.60 ±1.73 ±0.98 ±1.94 ±1.37 ±0.82
Humeri 24.07 9.05 9.51 8.50 6.79 6.71 5.42 4.95
±3.26 ±0.42 ±0.80 ±1.00 ±0.90 ±0.56 ±0.39 ±0.52
Radii 22.16 5.38 11.60 8.44 7.36 6.51 6.05 5.19
±4.06 ±0.59 ±1.79 ±0.84 ±0.69 ±1.49 ±1.49 ±0.99
Ulnae 15.83 4.13 10.88 6.75 5.58 5.04 4.25 3.33
42.35 ±0.31 ±1.85 ±0.96 ±1.92 ±1.10 ±0.93 ±0.64
Pelvis 26.53 8.84 8.87 7.44 7.31 5.89 5.01 4.40
±3.46 ±0.75 ±1.07 ±0.80 ±0.68 dO.57 ±0.68 ±0.24
Femora 21.88 8.50 8.65 8.07 7.33 6.98 6.72 6.35
±2.53 ±0.54 ±0.84 ±0.84 ±0.78 ±0.82 ±0.61 ±0.45
Fibiae/Tibiae 20.06 727 7.39 6.84 5.86 5.39 5.30 4.78
±3.00 ±0.48 ±0.61 ±0.68 ±0.32 ±0.39 ±0.33 ±0.33
Patellae 9.24 7.87 6.66 5.32 4.52 2.51 2.40 1.34
±2.43 ±0.90 ±0.86 ±1.51 ±1.74 ±1.17 ±1.00 ±0.57
Paws 428 1.64 2.44 1.80 1.77 1.42 1.34 1.23
±0.50 ±0.20 ±0.24 ±0.20 ±0.11 ±0.09 ±0.31 ±0.34
Total skeleton 18.31
42.52
7.03
±0.40
6.76 
‘ ±0.71
6.73
±0.48
5.46
±0.56
5.17
±0.36
4.64
±0.36
4.17
±0.29
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Table 3.19. The concentration of^ %  in the individual bones o f female CBA/H mice after 
intraperitoneal injection as the citrate.
Bone
1 7
% injected activity g ' ash at time (days) : 
14 28 56
X ±  SE, n = 5 
112 224 448
Skull 8.22 7.15 6.83 6.33 6.21 5.60 4.91 4.22
±0.85 ±0.80 ±1.30 ±0.41 ±0.70 ±0.39 ±0.18 ±0.20
Mandibles 6.42 6.35 6.20 5.95 5.90 5.07 4.70 4.08
±0.82 ±0.57 ±0.41 ±0.88 ±0.40 ±0.32 ±0.29 ±0.27
Cervical Vertd)iae 14.17 12.56 11.21 11.04 10.65 9.64 9.23 8.30
±1.39 ±1.51 ±1.10 ±1.56 ±0.69 ±0.48 ±1.97 ±0.58
Thoracic Vertebrae 18.79 15.71 14.72 14.35 11.71 10.20 10.16 6.84
±1.36 ±2.29 ±1.76 ±1.67 ±0.50 ±0.87 ±0.48 ±0.38
Lumbar Vertebrae 20.96 17.62 14.65 13.24 12.38 9.88 8.41 6.23
±2.17 ±2.14 ±1.81 ±0.58 ±1.04 ±0.42 ±0.61 ±0.47
Sacral Vertebrae 18.99 16.63 14.50 14.62 12.22 11.24 8.71 8.48
±2.57 ±1.65 ±3.39 ±1.49 ±0.55 ±0.49 ±0.54 ±0.59
Caudal Vertebrae 6.89 6.71 6.22 6.16 5.98 5.83 5.73 4.61
±0.89 ±0.56 ±0.72 ±1.47 ±0.36 ±0.96 ±0.62 ±0.19
Sternum 17.44 15.36 12.79 8.41 7.35 7.09 6.77 4.81
±0.94 ±1.46 ±1.38 ±1.61 ±1.87 ±0.51 ±0.44 ±0.27
Ribs 15.70 13.05 12.99 10.12 9.62 7.24 6.48 4.82
±1.45 ±1.48 ±2.61 ±0.53 ±1.21 ±0.33 ±0.48 ±0.10
Scapulae 17.80 15.27 15.22 14.64 13.34 9.63 9.47 9.13
±2.67 ±2.15 ±1.59 ±1.74 ±0.69 ±0.78 ±0.33 ±2.04
Clavicles 13.93 13.25 12.58 12.23 11.31 10.75 9.61 7.58
±2.41 ±2.28 ±1.94 ±2.52 ±1.97 ±1.66 ±1.08 ±1.38
Humeri 13.97 12.37 10.38 10.38 9.59 9.10 7.86 7.62
±1.33 ±1.45 ±0.91 ±1.62 ±0.58 ±0.49 ±0.48 ±0.55
Radii 14.16 11.78 9.69 9.27 8.98 820 7.06 6.55
±1.10 ±0.62 ±2.03 ±0.78 ±1.43 ±2.10 ±1.48 ±1.17
Ulnae 10.03 7.43 7.21 7.02 6.53 6.23 6.04 4.81
±1.85 ±2.21 ±1.44 ±0.87 ±0.69 ±0.96 ±1.22 ±0.40
Pelvis 13.33 12.80 11.22 9.91 9.68 7.91 7.14 6.44
±1.16 ±1.30 ±1.46 ±0.48 40.40 ±0.48 ±0.34 ±0.11
Femora 11.75 11.04 10.24 9.92 8.94 8.91 7.95 7.12
±1.54 ±1.10 ±1.03 ±1.12 40.29 ±0.47 ±0.42 ±0.51
Fibiae/Tibiae 11.81 9.46 8.78 8.61 7.31 7.01 5.96 5.95
±1.03 ±1.26 ±1.26 ±0.96 ±0.41 ±0.38 ±0.23 ±0.43
Patellae 8.39 6.20 5.99 5.18 4.77 4.18 3.21 2.49
. ±1.65 ±1.67 ±0.68 ±1.13 ±0.62 ±1.44 ±2.53 iO.85
Paws 2.83 2.71 2.61 2.12 1.89 1.59 1.58 1.68
±0.30 ±0.20 ±0.40 ±0.13 ±0.14 ±0.21 ±0.08 ±0.35
Total skeleton 10.80
±0.96
9.38
±1.08
8.52
±1.15
8.50
±0.84
7.56
±0.37
6.66
±0.56
6.14
±0.15
5.44
±0.33
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Figure 3.7. Change in inhomogeneity values with time after i.p. injection of ^^ ^Pu and 
"^^‘Am citrate in male mice.
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Figure 3.8. Change in inhomogeneity values with time after i.p. injection of ^^^Pu and
^^^Am citrate in female mice.
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3.3. Autoradiographic studies of the distribution of ^^ P^u and 
Am in mouse bone
The micro-distribution o f and in the femurs o f mice has been studied
using CR39 plastic detectors and fission track autoradiographs prepared at 1,28 and 224 
days after administration. The CR39 autoradiographs were used to obtain on overall 
picture o f the distribution of the radionuclides. Fission track autoradiographs allowed the 
relationship o f the tracks to bone structures to be established quantitatively. Photographic 
emulsion autoradiographs were prepared from sections o f rib and mandibular condyle at 
the same time-points to allow examination o f the location o f the alpha-emitters relative to 
different ceU types.
The initial deposition of^^^Pu was predominantly on cortical and trabecular endosteal bone 
surfaces and to a lesser extent on periosteal surfaces (Figures 3.9 and 3.10). There also 
appeared to be a low concentration o f activity throughout the bone marrow. By 224 days, 
some burial o f surface deposits of ^ ^^u had occurred, particularly in cortical bone, seen as 
lines o f activity within the bone (Figures 3.11 and 3.12); other areas showed a more 
diffuse pattern o f activity. Bone growth led to the formation o f a region o f new 
metaphyseal bone with low concentrations of^^^Pu. At later times, increasing amounts o f  
^^ P^u accumulated in the bone marrow.
Americium-241 initially deposited fairly evenly on all bone surfaces including those o f  
vascular canals in the cortical bone (Figures 3.13 and 3.14). At later times, some burial 
occurred in the form o f lines o f activity, particularly in cortical bone (Figures 3.15 and 
3.16); low concentrations of^ ^ '^Am were seen in regions o f new metaphyseal bone. Some 
accumulation o f  ^ '*^ Am in the marrow was also observed but less than that seen for ^^ P^u.
Initially, was deposited on both periosteal and endosteal (cortical and trabecular) bone 
surfaces but the distribution was uneven and concentrations o f activity were seen in some 
areas (Figures 3.17 and 3.18). There was also evidence for diffuse distribution of 
radioactivity in bone mineral. At later times, 28 and 224 days, the autoradiographs
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showed some uneven lines o f buried deposits o f and small amounts o f diffuse activity 
were seen throughout the bone mineral (Figures 3.19 and 3.20); little activity was seen in 
the marrow.
Figures 3.21 and 3.22 show fission track autoradiographs from mouse femurs 1 and 224 
days after injection o f  ^ ^^u; Figures 3.23 and 3.24 show similar autoradiographs from 
mice that received Autoradiographs prepared in this way show two distinct types o f  
tracks, point tracks and line tracks. Point tracks are those for which the fission fragment 
travels at a right angle to the tissue section surface and so leaves a small circular hole on 
the surface o f the plastic slide. Line tracks travel through the plastic slide at an angle 
producing a distinctive teardrop-shaped track. The atom from which the fragment 
originated was assumed to be approximately one track length back from the rounded end 
of the track.
To determine the distribution of the nuclides within bone, random areas o f sections were 
selected and the number o f tracks in each section counted using a MOP image analysis 
system (Kontron Messgeraet, Munich, Germany). Between 5,000 and 6,000 tracks were 
counted on each slide, their origins mapped and associated with the different regions of 
bone. It was assumed that bone surfaces were 10pm thick. Table 3.20 shows the numbers 
of tracks associated with different regions o f bone ie. periosteal surfaces, cortical 
endosteal surfaces, trabecular endosteal surfaces, cortical volume, trabecular volume, 
vascular canals and bone marrow. For "^*^ Am, which is not fissionable, a similar procedure 
was employed using adjacent CR39 slides showing alpha tracks and bone image, both 
slides being viewed together.
One day after injection of  ^ ^^ Pu citrate, about 60% of observed tracks were assigned to 
cortical and trabecular endosteal surfaces with 4-5 times more activity on trabecular 
surfaces than on cortical surfaces. A small proportion o f activity (2.5%) was associated 
with the periosteal surfaces. Some tracks (about 14%) were assigned to the bone marrow 
due to diffuse distribution throughout the region. At 28 days, the proportion o f activity 
associated with the cortical and trabecular endosteal surfaces had reduced to about 17%; 
activity in bone volume and marrow had increased.
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Initially, at one day after injection citrate, about 70% o f tracks were attributable
to bone surface deposition but association with endosteal surfaces was lower for Am 
than for ^^^u (28% o f total tracks cf. 60%), deposition on periosteal surfaces was greater 
for '^‘‘Am than for ^^ P^u (18% cf. 2.5%) and ^^ *Am showed substantial association with 
surfaces o f vascular canals (24%), not observed for ^^^u. There was also a difference 
between "^*^ Am and ^^ P^u in their distribution on endosteal surfaces, with 40% trabecular 
and 60% cortical for '^‘^ Am compared with 80% trabecular and 2 0 % cortical for ^^ P^u.
The initial deposition of^ "*^ Am in bone marrow was less than for ^^^u (6 % cf. 16%). 
Distributions at 28 days and 224 days after injection showed a progressive reduction in the 
association o f  ^ '*^ Am with bone surfaces, although values for trabecular endosteal surfaces 
remained constant, and increases in levels o f activity assigned to bone volume and bone 
marrow were observed.
One day after injection o f citrate, about 45% of total activity was assigned to bone 
surfaces, 8 % to bone marrow and the remainder to bone volume. The activity was 
associated with trabecular endosteal surfaces was about twice that recorded for cortical 
endosteal surfaces. There was a progressive transfer o f activity to bone volume, which 
accounted for about 90% of the total at 28 days after injection and about 99% after 224 
days. Retention in the marrow fell Ifom 8 % at 1 day to 0.5% at 224 days.
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Figure 3.9. CR39 autoradiograph of mouse femur 1 day after injection of ^ ^^ Pu citrate 
showing an even deposition predominantly on endosteal bone surfaces (e) with some 
accumulation on periosteal bone surfaces (p).
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Figure 3.10. Photographic emulsion autoradiograph of mouse rib 1 day after injection of
^^^Pu citrate showing an even distribution of activity on the endosteal bone surface (e).
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Figure 3.11. CR39 autoradiograph of mouse femur 224 days after injection of ^ ^^ Pu citrate 
showing burial of activity, particularly in cortical bone, an accumulation of activity in the 
bone marrow (m) and a region of new metaphyseal bone with low concentrations of ^ ^^ Pu.
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Figure 3.12. Photograpliic emulsion autoradiograph o f mouse rib 224 days after injection
of 239pu citrate showing buried activity in cortical bone (b) and an accumulation o f activity
in the bone marrow (m).
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Figure 3.13. CR39 autoradiograph of mouse femur 1 day after injection of citrate 
showing an even distribution on all bone surfaces (e&p) including those of vascular canals 
(vc) within the cortical bone.
' .1
l i t  ~ ' r -
'V®».
p ' f'-
4.
Figure 3.14. Photograpliic emulsion autoradiograph of mouse rib 1 day after injection of
Am citrate showing an even distribution o f activity on periosteal (p) and endosteal (e)
bone surfaces.
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Figure 3.15. CR39 autoradiograph of mouse femur 224 days after injection of ^ "‘'Am 
citrate showing burial particularly in cortical bone, a region of new metaphyseal bone with 
low concentrations of ^ '^ ‘Am and some accumulation of activity in the bone marrow.
. I j t r  ' -
- .
Figure 3.16. Photographic emulsion autoradiograph of mouse rib 224 days after injection
of ^ "“Ani citrate showing burial of activity in cortical bone (b) and deposition o f activity on
the surface of new bone (s).
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Figure 3.17. CR39 autoradiograph of mouse femur 1 day after injection of citrate 
showing uneven distribution of activity, on bone surfaces and some diffuse activity 
throughout the bone.
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Figure 3.18. Photographic emulsion autoradiograph of mouse rib 1 day after injection of
citrate showing the uneven distribution o f activity on bone surfaces (s).
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Figure 3.19. CR39 autoradiograph of mouse femur 224 days after injection of citrate 
showing uneven lines of buried activity and small amounts of diffuse activity tlu oughout 
the bone mineral.
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Figure 3.20. Photographic emulsion autoradiograph of mouse rib 224 days after injection
of citrate showing an uneven line of buried activity (ba) in the bone mineral.
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Figure 3.21. Fission track autoradiograph of mouse femur 1 day after injection of ^ ^^ Pu 
citrate showing an even deposition predominantly on endosteal bone surfaces (e) with 
some deposition on periosteal bone surfaces (p).
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Figure 3.22. Fission track autoradiograph femur 224 days after injection of ^ ^^ Pu citrate 
showing burial of activity in cortical bone and an accumulation of activity in the bone 
marrow (m).
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Figure 3.23. Fission track autoradiograph of mouse femur 1 day after injection of 
citrate showing distribution o f activity on endosteal (e) and periosteal (p) bone surfaces.
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Figure 3.24. Fission track autoradiograph of mouse femur 224 days after injection of
citrate showing an uneven line of buried activity (ba) and small amounts of diffuse activity
thioughout the bone mineral.
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Table 3.20. Distribution o f fission tracks (% total tracks per region) in femur 
autoradiographs.
Region “ 'Pu
1  day 28 days 224 days
Cortical endosteal surface 1 0 . 2 4.3 1.5
Cortical volume 8.7 16.6 13.6
Trabecular endosteal surface 48.8 12.5 4.2
Trabecular volume 15.9 27.5 23.3
Periosteal surface 2.5 2 . 6 2.9
Bone marrow 13.9 36.5 54.5
""'Am
1 day 28 days 224 days
Cortical endosteal surface 17.3 7.6 1.7
Cortical volume 18.4 20.7 16.9
Trabecular endosteal surface 10.7 11.9 13.1
Trabecular volume 5.4 11.9 28.9
Periosteal surface 18.0 13.5 9.8
Bone marrow 5.8 22.4 24.4
Vascular canals 24.4 1 2 , 0 5.2
233u
1  day 28 days 224 days
Cortical endosteal surface 10.4 0.9 0.3
Cortical volume 15.7 57.2 78.5
Trabecular endosteal surface 24.7 5.4 0.3
Trabecular volume 32.1 31.6 2 0 . 1
Periosteal surface 8 . 8 2.4 0.3
Bone marrow 8.3 2.5 0.5
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3.4. Studies of the comparative toxicity of """U, ""’Pu and ""'Am in 
CBA/H mice
Mice were entered into experimental groups as described in Section 2.6. Measurements o f 
tissue retention from mice injected at the same time (Section 2.6) indicated that mice in 
two experimental groups, high dose ^^ P^u and medium dose ‘^^ ’Am, had received less 
radioactivity than was anticipated (by about 1 0 -2 0 %) and repeat groups were included in 
the experiments. However, when statistical analysis was undertaken (Section 3.7) there 
was no apparent difference in the average bone doses received by these groups and 
therefore these groups o f mice were combined with those injected previously. Also 
included with the high dose ^^^u group were the group o f 30 mice which had been 
included in the study with the intention o f studying bone tumour growth by serial X-ray 
analysis which was not possible due to difficulties in the appropriate maintenance o f  
anaesthesia for this procedure (Section 2.6). The revised numbers in the experimental 
groups are given in Table 3.21.
Table 3.21. Experimental groups in toxicity study.
R a d i o n u c l i d e E x p e r i m e n t a l  g r o u p I n j e c t i o n  d o s e  k B q  k g  ' N u m b e r  o f  a n i m a l s
233U H i g h 1 9 7 5 0
M e d i u m 1 1 8 6 0
L o w 4 0 1 0 0
239p u H i g h 2 5 1 3 0
M e d i u m 1 5 6 0
L o w 5 1 0 0
H i g h 2 9 5 0
M e d i u m 1 7 1 5 0
L o w 6 1 0 0
C o n t r o l 0 1 0 0
All mice found dead or humanely killed due to iU health were given a full post-mortem 
examination as described in Section 2.7. This examination included radiography o f the
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carcass to check for bone tumours.
Wherever possible a cause o f death was assigned to each mouse following the post­
mortem examination. The incidence o f all tumours and apparent pathological lesions was 
noted and histopathological examination was carried out as described in Section 2.8. In 
some cases this was not possible. Nine mice died shortly after injection o f the 
radionuclides. One animal in the control group was sent for virological / bacteriological 
screening to identify the causative agent o f abscesses (Section 2.7).
The major assigned cause o f death was liver tumours (hepatocellular adenoma and 
carcinoma) which occurred in about 55% o f mice. Other causes o f death were: lung 
tumours (bronchiolo-alveolar adenoma and carcinoma) seen in about 8 % o f mice; bone 
tumours (osteosarcoma, haemangiosarcoma, osteoma, odontoma and haemangioma) seen 
in about 7% of mice; and haemopoietic diseases (myeloid leukaemia, malignant lymphoma 
and histiocytic sarcoma) seen in about 11% of mice. Another major reason for sacrificing 
the animals was the presence o f abscesses, which were debilitating or caused discomfort, 
which occurred in about 10% of mice. Virological / bacteriological screening o f one o f the 
control mice showed that the causative organism was Corynebacterium ulcerans which is 
present in the mouths o f these mice. Death o f the remaining mice (about 7%) was due to a 
variety o f diseases (Section 3.4.2).
The incidences o f tumours and pathological lesions observed are given in Section 3.4.1. 
Survival times and death from the different causes were evaluated by the Kaplan-Meier 
procedure (Section 2.10.1) and the results are given in Section 3.4.2. Analysis o f the 
incidences o f the most frequently observed tumours and pathological lesions was 
performed using the Peto analysis (Section 2.10.2) and the results o f this analysis are given 
in Section 3.4.3.
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3.4.1. Incidence of tumours and pathological lesions
Tumour types and pathological lesions found at post-mortem were scored on a per animal 
basis as recommended by the International Agency for Research on Cancer (I ARC) 
Committee on the appraisal o f long-term and short-term animal carcinogenesis studies 
(IARC, 1980). For exanqjle, a liver with multiple tumours would be scored singly for each 
tumour type eg. if a liver had 3 adenomas and 1 carcinoma then it would be scored once 
for hepatocellular adenoma and once for hepatocellular carcinoma. Similarly, a 
hepatocellular carcinoma with metastatic secondaries in the lung would be scored as a 
single incidence o f disease.
The incidences o f all benign and malignant tumours are reported in Sections 3.4.1.1- 
3.4.1 . 8  and the incidences o f pathological lesions in Section 3.4.1.9. Histological 
descriptions o f these tumours and lesions together with data on multiple incidences in 
specific organs / tissues and information on métastasés to other organs / tissues are given 
in Section 3.5.
The incidence o f all tumour types were recorded and these are listed in Tables 3.22-2.25 
for control mice and experimental groups.
3.4.1.1. Osteosarcoma
As can be seen from Tables 3.22-3.25, a total o f 46 animals were observed with 
osteosarcoma. Control mice had a incidence o f about 2%. Low, medium and high dose 
groups showed incidences o f about 2 % in aU groups for about 2 %, 1 1 % and 15% for 
^ ^ u  and 0%, 3% and 21% for '^**Am. These incidences are plotted graphically in Figure 
3.25, the data indicate an increase in osteosarcoma incidence with increasing dose for ^^ P^u 
and Am but not for
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Table 3.22. Tumour incidence observed in CBA/H control mice.
Group
Number of animals entered into study 
Number of animals analysed
Control
100
88
Osteosarcoma 2
Osteoma 1
Odontoma 1
Cementifying fibroma 1
Haemangiosarcoma - skeletal 2
Haemangioma - skeletal 0
Myeloid leukaemia 0
Malignant lynqjhoma 1
Histiocytic sarcoma 4
Lymphoid hyperplasia 0
Extramedullary haemopoiesis 0
Mastocytoma 0
Hqjatocellular adenoma 47
Hepatocellular carcinoma 38
Hepatoblastoma 0
Cholangioma 0
Cholangiocellular carcinoma 0
Bronchiolo-alveolar adenoma 17
Bronchiolo-alveolar carcinoma 13
Renal tubular cell adenoma 2
Renal tubular cell carcinoma 1
Adrenal phaeochromocytoma 1
Adrenal cortical adenoma 0
Pancreatic islet cell adenoma 0
Pancreatic islet cell carcinoma 3
Haemangioma - sofi tissue 0
Haemangiosarcoma - soft tissue 1
Harderian gland adenocarcinoma 0
Rhabdomyosarcoma 0
Malignant Schwannoma 0
Meningeal sarcoma 0
Malignant thymoma 0
Malignant mesothelioma 0
Prostate adenocarcinoma 1
Seminal vesicle adenocarcinoma 0
Salivary gland carcinoma 0
Sertoli cell carcinoma 0
Adenomatous polyp - gastrointestinal tract 0
Leiomyoma - gastrointestinal tract 0
Squamous cell papilloma - tongue 0
Trichoqrithelioma - skin 0
Amelanotic melanoma - skin 0
Melanoma - skin 0
Squamous cell carcinoma - skin 0
Fibrosarcoma - skin 0
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Table 3.23. Tumour incidence observed in CBA/H mice after the administration of^%  
citrate.
Group
Nuniber of animals entered into study 
Number o f animals analysed
Low
100
91
Medium
60
54
High
50
48
Osteosarcoma 2 1 1
Osteoma 1 0 0
Odontoma 0 0 0
Cemoitifying fibroma 0 0 0
Haemangiosarcoma - skeletal 2 0 0
Haemangioma - skeletal 0 0 0
Myeloid leukaemia 4 2 2
Malignant lynphoma 2 0 2
Histiocytic sarcoma 4 . 1 1
Lynphoid hyperplasia 0 0 0
Extramedullary haemopoiesis 0 0 0
Mastocytoma 0 0 0
Hepatocellular adenoma 35 19 18
Hepatocellular carcinoma 52 29 26
Hepatoblastoma 0 1 0
Cholangioma 1 0 0
Cholangiocellular carcinoma 0 0 0
Bronchiolo-alveolar adenoma 17 6 7
Bronchiolo-alveolar carcinoma 25 12 8
Renal tubular cell adenoma 1 0 1
Renal tubular cell carcinoma 4 6 7
Adrenal phaeochromocytoma 0 0 0
Adrenal cortical adenoma 0 0 0
Pancreatic islet cell adenoma 0 0 0
Pancreatic islet cell carcinoma 2 3 1
Haemangioma - soft tissue 0 0 0
Haemangiosarcoma - soft tissue 1 1 2
Harderian ^and adenocarcinoma 0 0 1
Rhabdomyosarcoma 0 0 0
Malignant Schwannoma 0 0 0
Meningeal sarcoma 0 0 0
Malignant tiiymoma 0 0 1
Malignant mesothelioma 0 0 1
Prostate adoiocarcinoma 2 0 2
Seminal v«icle adenocarcinoma 2 0 0
Salivary ^ and carcinoma 0 0 0
Sertoli cell carcinoma 0 0 0
Adenomatous polyp - gastrointestinal tract 0 0 1
Leiomyoma - gastrointestinal tract 0 0 0
Squamous cell papilloma - tongue 0 0 0
Trichoepitiielioma - skin 0 0 0
Amelanotic melanoma - skin 0 0 1
Melanoma - skin 0 0 1
Squamous cell carcinoma - skin 0 0 0
Fibrosarcoma - skin 0 1 0
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Table 3.24. Tumour incidence observed in CBA/H mice after the administration of^^^u 
citrate.
Group
Number of animals entered into study 
Number of animals analysed
Low
100
97
Medium
60
55
H i^
150
124
Osteosarcoma 2 6 18
Osteoma 0 0 1
Odontoma 0 1 0
Cementifying fibroma 0 0 0
Haemangosarcoma - skeletal 0 0 3
Haemangioma - skeletal 0 0 1
Myeloid leukaemia 4 3 11
Malignant lynphoma 5 5 4
Histiocytic sarcoma 1 1 3
Lynphoid hyperplasia 5 0 2
Extramedullary haemopoiesis 2 0 20
Mastocytoma 0 0 0
Hepatocellular adenoma 62 39 76
Hepatocellular carcinoma 55 43 72
Hepatoblastoma 0 0 0
Cholangoma 0 0 0
Cholangiocellular carcinoma 1 0 0
Bronchiolo-alveolar adenoma 24 12 27
Bronchiolo-alveolar carcinoma 18 7 12
Renal tubular cell adenoma 1 0 0
Renal tubular cell carcinoma 4 2 4
Adrenal phaeochromocytoma 1 0 0
Adrenal cortical adenoma 0 1 1
Pancreatic islet cell adenoma 0 0 1
Pancreatic islet cell carcinoma 4 2 2
Haemangioma - soft tissue 0 0 0
Haemangiosarcoma - soft tissue 0 0 0
Harderian ^and adenocarcinoma 0 0 0
Rhabdomyosarcoma 0 1 0
Malignant Schwannoma 1 1 0
Meningeal sarcoma 0 0 1
Malignant thymoma 0 0 0
Malignant mesothelioma 0 0 0
Prostate adenocarcinoma. 1 0 0
Seminal vesicle adenocarcinoma 0 0 0
Salivaiy gland carcinoma 0 0 0
Sertoli cell carcinoma 0 0 1
Adenomatous polyp - gastrointestinal tract 0 0 0
Leiomyoma - gastrointestinal tract 0 1 0
Squamous cell papilloma - tongue 1 0 0
Trichopithelioma - skin 0 0 0
Amelanotic melanoma - skin 0 0 0
Melanoma - skin 0 0 0
Squamous cell carcinoma - skin 0 0 0
Fibrosarconfâ - skin 0 0 0
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Table 3.25. Tumour incidence observed in CBA/H mice after the administration of^ '^ ^Am 
citrate.
Group Low Medium High
Number of animals entered into study 100 150 50
Number of animals analysed 93 143 48
Osteosarcoma 0 4 10
Osteoma 0 1 0
Odontoma 1 1 0
Cementilying fibroma 0 0 0
Haemangiosarcoma • skeletal 0 3 0
Haemangioma - skeletal 0 0 0
Myeloid leukaemia 4 12 5
Malignant lynphoma 5 4 0 .
Histiocytic sarcoma 1 9 0
Lynphoid hyperplasia 0 0 0
Extramedullaiy haemopoiesis 0 0 0
Mastocytoma 0 2 0
Hpatocellular adenoma 60 63 17
Hepatocellular carcinoma 45 90 36
Hepatoblastoma 0 0 0
Cholangioma 0 0 0
Cholangiocellular carcinoma 0 0 0
Bronchiolo-alveolar adenoma 22 27 8
Bronchiolo-alveolar carcinoma 22 26 4
Renal tubular cell adenoma 0 3 0
Renal tubular cell carcinoma 0 5 3
Adrenal phaeochromocytoma 0 0 0
Adrenal cortical adenoma 0 0 0
Pancreatic islet cell adenoma 0 0 0
Pancreatic islet cell carcinoma 5 6 0
Haemangioma - soft tissue 1 0 0
Haanangiosarcoma - soft tissue 1 2 0
Harderian gland adenocarcinoma 0 0 1
Rhabdomyosarcoma 0 0 0
Malignant Schwannoma 2 0 0
Meningeal sarcoma • 0 1 0
Malignant thymoma 0 2 0
Malignant mesothelioma 1 0 0
Prostate adaiocarcinoma 1 0 0
Seminal vesicle adenocarcinoma 0 1 1
Salivary gland carcinoma 1 0 0
Sertoli cell carcinoma 0 0 0
Adenomatous polyp - gastrointestinal tract 0 0 0
Leiomyoma - gastrointestinal tract 0 0 0
Squamous cell papilloma - tongue 0 0 0
Trichoepithelioma - skin 1 0 0
Amelanotic melanoma - skin 0 0 0
Melanoma - skin 0 • 0 0
Squamous cell carcinoma - skin 0 1 0
Fibrosarcoma - skin 0 1 0
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Figure 3.25. Incidence of osteosarcoma in control mice compared with mice injected with 
citrate, citrate and Am citrate.
3.4.1.2. Other bone tumours
A low incidence of other bone tumours were observed: haemangioma, haemangiosarcoma, 
osteoma, odontoma and cementifying fibroma. For haemangioma, a single case was 
recorded in the high dose ^^ ^Pu group. Ten haemangiosarcomas were seen, 2 in the 
control and low dose groups and 3 in the high dose ^^ P^u and the medium dose ^^ ^Am 
groups. Four osteomas were seen, one in each of the control, low dose high dose 
^^ ^Pu and medium dose Am groups. Four odontomas were seen, one in each of the 
control, medium dose ^^ ^Pu, low and medium dose "^^ A^m groups. One cementifying 
fibroma was seen in the control group.
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3.4.1.3. Myeloid leukaemia
A total of 47 animals were identified with myeloid leukaemia. No myeloid leukaemias 
were observed in controls. Low, medium and high dose groups showed incidences of 
about 4% in all groups for about 4%, 6% and 9%, respectively, for ^^ ^Pu and about 
4% 8% and 10%, respectively, for "^^ 'Am. These incidences are plotted graphically in 
Figure 3.26, the data indicate an increase in myeloid leukaemia incidence with increasing 
dose for ^^ ^Pu and '^^ ^Am but not for
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Figure 3.26. Incidence of myeloid leukaemia in control mice compared with mice injected 
with citrate, ^^ ^Pu citrate and "^^ A^m citrate.
3.4.1.4. Other haemopoietic disorders
Malignant lymphoma and histiocytic sarcoma were the most common haemopoietic 
disorders other than myeloid leukaemia observed in the studies, with total incidences of 28 
and 25, respectively. Low incidences of other haemopoietic disorders were observed: 
lymphoid hyperplasia, extramedullary haemopoiesis and mastocytoma (Tables 3.22-3.25).
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Extramedullary haemopoiesis was observed only in mice given injections of ^ ^^ Pu. For all 
other haemopoietic disorders there was no apparent trend with dose or between the 
controls and experimental groups.
3.4.1.5. Hepatocellular adenoma and carcinoma
Liver tumours were the most common observation with 436 mice having hepatocellular 
adenoma and 486 mice having hepatocellular carcinoma. For hepatocellular adenoma, an 
incidence of about 53% was seen in control mice. Low, medium and high dose groups 
showed incidences of about 39%, 35% and 38%, respectively, for 64%, 71% and 
61%, respectively for ^^ ^Pu, and about 65%, 44% and 35%, respectively, for “^^ 'Am. For 
hepatocellular carcinoma, an incidence of about 43% was seen in control mice. Low, 
medium and high dose groups showed incidences of about 57%, 54% and 54%, 
respectively for about 60%, 78% and 58%, respectively, for ^^ ^Pu; and about 48%, 
63% and 75%, respectively, for ^ '^Am. These incidences are plotted graphically in Figure 
3.27. These data suggest greater incidences of hepatocellular carcinoma in experimental 
groups than in controls.
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Figure 3.27. Incidence of hepatocellular carcinoma in control mice compared with mice 
injected with citrate, ^^ ^Pu citrate and "^^ A^m citrate.
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3.4.1.6. Bronchiolo-alveolar adenoma and carcinoma
Lung tumours were the second most common tumour observed with 167 mice having 
bronchiolo-alveolar adenoma and 147 mice having bronchiolo-alveolar carcinoma. 
Incidences o f bronchiolo-alveolar adenoma in all groups were broadly similar and appeared 
similar to controls. For bronchiolo-alveolar carcinoma, the results suggest an increased 
incidence in animals given compared with controls. For ^^^u and greater
incidences o f bronchiolo-alveolar carcinoma were observed in the low dose groups.
3.4.1.7. Renal tubular cell adenoma and carcinoma
Eight mice were diagnosed with renal tubular cell adenoma and 36 mice with renal tubular 
cell carcinoma. For renal tubular cell adenoma, the observed incidences in the 
experimental groups did not differ significantly from the control group. For renal tubular 
cell carcinoma an incidence o f about 1% was seen in control mice. Low, medium and high 
dose groups showed incidences o f about 4%, 11% and 15%, respectively for about 
and 3%, respectively, for ^^^u; and 0%, 3% and 6 %, respectively, for These
incidences are plotted graphically in Figure 3.28, illustrating the increasing tumour 
incidences with increasing dose.
3.4.1.8. Other benign and malignant tumours
Small incidences o f a variety o f other benign tumours were observed (Tables 3.22-3.35). 
The tumours included the following: cholangioma, adrenal phaeochromocytoma, 
adrenal cortical adenoma, pancreatic islet cell adenoma, soft-tissue haemangioma, 
adenomatous polyp (in the gastrointestinal tract), leiomyoma, squamous cell papilloma, 
trichoepithelioma, amelanotic melanoma and melanoma. Small incidences o f a variety o f 
other malignant tumours were also observed (Tables 3.22-3.35). These included the 
following tumours: hepatoblastoma, cholangiocellular carcinoma, pancreatic islet ceU 
carcinoma, soft-tissue haemangiosarcoma, Harderian gland adenocarcinoma.
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Figure 3.28. Incidence of renal tubular cell carcinoma in control mice compared with mice 
injected with citrate, ^^ ^Pu citrate and '^ '^Am citrate.
rhabdomyosarcoma, malignant schwannoma, meningeal sarcoma, malignant thymoma, 
malignant mesothelioma, prostate adenocarcinoma, seminal vesicle adenocarcinoma, 
sahvary gland carcinoma, sertoli cell carcinoma, squamous cell carcinoma and 
fibrosarcoma. For aU tumours, there arc no apparent differences in incidences between the 
controls and experimental groups.
3.4.1.9. Pathological lesions
Various pathological lesions were observed in the mice and are reported in Tables 3.26-
3.29. These varied from gross lesions such as dentition abnormalities, abscesses and 
seminitis which were evident at the post-mortem examination to lesions such as 
hyperostosis and non-tumorous lesions which were only observed after microscopic 
examination.
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Dentition abnormalities, apparent as broken or overgrown incisors, were observed as the 
mice aged. On examination of the X-radiographs (Section 3.5) it was evident that some of 
the incisors were broken off at the gums and in others the teeth had fallen out. Once 
dentition abnormahties had been noted the mice were maintained on a diet of wet mash 
(Section 2.7). As can be seen from Tables 3.26-3.29, a total of 259 animals were 
observed with dentition abnormahties. Control mice had an incidence of about 16%.
Low, medium and high dose groups showed incidences of about 29%, 28% and 34%, 
respectively for about 19%, 12% and 21%, respectively for ^^ ^Pu and about 44%, 
35% and 67%, respectively for "^^ *Am. These incidences are plotted graphically in Figure
3.29. The data suggest an increase in dentition abnormahties in experimental groups 
exposed to and '^^ ^Am.
A low incidence of duet hyperplasia and biliary cysts was recorded in experimental groups 
with none in controls. For all other lesions, there was no evidence of greater incidences in 
experimental groups that in controls.
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Figure 3.29. Incidence of dentition abnormahties in control mice compared with mice 
injected with citrate, ^^ ^Pu citrate and Am citrate
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Table 3.26. Pathological lesions observed in control CBA/H mice.
Group
Number of animals altered into study 
Number of animals analysed
Control
100
88
Dentition abnormalities 16
Preapistic 24
Seminitis 13
Eye abscess 10
Other abscess 5
Hyperostosis 57
Prolapsed intervertébral discs 28
Focal myelofibrosis of bone 0
Cartilage degoieration in bone 0
Focal fibrous osteodystrophy of bone 0
Atrial thrombus 3
Valvular endocarditis 0
Cystic kidneys 5
Renal tubular hyperplasia 1
Bladder cystitis 0
Intussusception of gastrointestinal tract 1
Nematodes in gastrointestinal tract 0
Serosal keratinised cysts in gastrointestinal tract 0
Bronchio-pulmOTiary oedema 0
Bronchio-pulmonary pneumonia 0
Bronchiolo-alveolar hyperplasia/metaplasia 0
Bile duct hyperplasia 0
Biliary cysts 0
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Table 3.27. Pathological lesions observed in CBA/H mice after the administration o f 
citrate.
Group Low Medium High
Number of animals entered into study 100 60 50
Number of animals analysed 91 54 48
Dentition abnormalities 29 17 17
Preapistic 35 20 20
Seminitis 29 13 10
Eye abscess 9 9 5
Other abscess 2 0 4
Hyperostosis 64 35 34
Prolapsed intervertébral discs 28 21 19
Focal myelofibrosis of bone 0 0 0
Cartilage degeneration in bone 0 2 2
Focal fibrous osteodystrophy of bone 0 0 0
Atrial thrombus 4 5 3
Valvular endocarditis 0 0 0
Cystic kidneys 6 1 5
Renal tubular hyperplasia 2 0 0
Bladder cystitis 0 0 0
Intussusception of gastrointestinal tract 1 0 0
Nematodes in gastrointestinal tract 1 1 1
Serosal keratinised cysts in gastrointestinal tract 3 2 1
Bronchio-pulmonary oedema 0 0 0
Bronchiopulmmary pneumonia 0 0 0
Bronchiolo-alveolar hyperplasia/metaplasia 0 0 1
Bile duct hyperplasia 0 0 0
Biliary cysts 2 3 1
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Table 3.28. Pathological lesions observed in CBA/H mice after the administration o f 
citrate.
Group Low Medium High
Number of animals entered into stu<fy 100 60 130
Number o f animals analysed 97 55 124
Dentiticm abnormalities 19 7 27
Preapistic 33 23 35
Seminitis 19 4 38
Eye abscess 13 5 14
Odier abscess 4 1 1
Hypoostosis 49 33 88
Prolapsed intervertébral discs 27 24 22
Focal myelofibrosis of bone 1 0 0
Cartilage degeneration in bone 2 0 3
Focal fibrous osteodystrophy of bone 0 0 1
Atrial fiuombus 2 2 3
Valvular endocarditis 0 0 0
Cystic kidneys 3 0 6
Reual tubular hyperplasia 0 0 0
Bladder cystitis 0 0 0
Intussuscqrtion o f gastrointestinal tract 0 0 1
Nematodes in gastrointestinal tract 0 1 1
Serosal keratinised cysts in gastrointestinal tract 0 0 0
Bronchio-pulmonary oedema 0 0 1
Bronchiopulmonary pneumonia 1 1, 0
Bronchiolo-alveolar hyperplasia/metaplasia 0 0 4
Bile duct hyperplasia 0 4 2
Biliary cysts 1 0 3
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Table 3,29. Pathological lesions observed in CBA/H mice after the administration o f 
“^^ A^m citrate.
Group
Number of animals entered into study 
Number of animals analysed
Low
100
93
Medium
150
143
H i^
50
48
Dentition abnormalities 43 51 33
Preapistic 41 40 20
Semirutis 17 . 53 8
Eye abscess 10 16 1
Other abscess 0 7 1
Hyperostosis 55 90 34
Prolapsed intervertébral discs 41 43 19
Focal myelofibrosis o f bone 0 0 0
Cartilage degeneration in bone 0 0 0
Focal fibrous osteodystrophy of bone 1 0 0
Atrial thrombus 2 11 3
Valvular endocarditis 0 1 0
Cystic kidneys 5 12 7
Renal tubular hyperplasia 0 0 1
Bladder cystitis 0 0 1
Intussusception of gastrointestinal tract 0 1 4
Nematodes in gastrointestinal tract 3 2 4
Serosal keratinised c j ^  in gastrointestinal tract 3 2 1
Bronchio^ulmonaiy oedema 0 0 0
Bronchio-pulmonary pneumoitia 0 3 0
Bronchiolo-alveolar hyperplasia/metaplasia 5 0 1
Bile duct hyperplasia 4 4 1
Biliary cysts 5 2 0
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3.4.2. Analysis of survival data using the Kaplan-Meier method
Wherever possible a cause o f death was assigned to each mouse at the post-mortem 
examination (see Section 2.7). A total o f 900 mice were used in these studies. Nine mice 
which died following radionuclide injection and the animal which was sent for virological / 
bacteriological screening were excluded from the Kaplan-Meier analysis. A total o f 49 
mice were not assigned causes o f death; these animals were included in the Kaplan-Meier 
analysis o f survival but excluded from the analysis o f different tumours.
Times o f survival and death from different causes in each group were evaluated by the 
Kaplan-Meier procedure (Kaplan and Meier, 1958; lARC, 1980; 1986) using SPSS for 
Windows as described in Section 2.10. The cut-off time used was 1200 days ie., slightly 
beyond the time when the longest surviving animal from all groups had died. The data 
shown in the Tables and Figures has been corrected for competing risks. The principal 
diseases analysed were osteosarcoma, myeloid leukaemia, hepatocellular adenoma and 
hepatocellular carcinoma. In addition, all bone tumours (osteosarcoma, osteoma, 
odontoma, haemangiosarcoma and haemangioma), all haemopoietic diseases (myeloid 
leukaemia, malignant lymphoma and histiocytic sarcoma), all liver tumours (hepatocellular 
adenoma and carcinoma) and all lung tumours (bronchiolo-alveolar adenoma and 
carcinoma) were pooled for analysis. Tables 3.30-3.32 list the Kaplan-Meier product limit 
estimates for mean survival times for all causes o f death as well as the percentages o f 
animals dying from these causes and the number o f animals involved in the low, medium 
and high groups for each nuclide compared with the control group.
For fatal tumours, a visual display o f the Kaplan-Meier estimates o f cumulative tumour 
mortality can be obtained by plotting the probability o f remaining alive if all intercurrent 
deaths are not included and the tumour type o f interest is the sole remaining cause o f 
death. These graphs have flat regions along a series o f days in which no animals in that 
particular treatment group died o f a tumour type o f interest, with a step downwards on 
days when animals did die o f such tumours. Kaplan-Meier plots for survival, 
osteosarcoma, myeloid leukaemia and hepatocellular carcinoma are shown in Figures 3.30- 
3.32, 3.33-3.35, 3.36-3.38 and 3.39-3.41, respectively.
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Table 3.30. Kaplan-Meier estimates® o f survival and percentage o f mice dying from a 
disease for the groups o f mice treated with
Group Control Low Medium H i^
No of animals entered 100 100 60 50
No of animals wiüi histopaûiolo^cal diagnoses 88 91 54 48
Survival Mean survival time 6 3 7 * 2 3 ” 7 1 1 * 1 6 6 9 9 * 2 6 6 5 4 * 2 4
Median survival time 6 5 4 * 3 4 7 0 2 * 2 6 693* 2 7 659* 2 5
Osteosarcoma Mean survival time 1067*13 1051*10 1033*14 995 *  13
% incidence 2.3 2.2 1.9 2.1
All bone tumours Mean survival time 1037*20 1034*16 1033 *  14 995 * 1 3
% incidence 6.8 4.4 1.9 2.1
Myeloid leukaemia Mean survival time - 1032*13 1022*17 9 8 2 * 1 8
% incidence 0 4.4 3.7 4.2
All haemopoietic tumours Mean survival time 1039*20 975*23 1022*17 928*31
% incidence 5.7 10.1 3.7 10.6
Hepatocellular adenoma Mean survival time 912*31 951 * 2 2 957*27 907* 3 3
% incidence 22.7 15.4 14.8 14.6
Hepatocellular carcinoma Mean survival time 863*32 842* 2 2 8 6 7 * 3 0 8 2 0 * 3 4
% incidence 31.8 42.9 37.0 33.3
All liver tumours Mean survival time 761 * 3 0 799* 2 0 844*35 7 64 * 3 3
% incidence 54.5 58.2 51.9 47.9
All lung tumours Mean survival time 1000*27 974 * 2 2 961* 2 9 9 7 1 * 3 0
% incidaice ' 10.2 12.1 16.7 6.3
® K a p l a n - M e i e r  e s t i m a t e s  w e r e  c a l c u l a t e d  w i t h  a  c u t - o l f  o f  1 2 0 0  d a y s  
X ±  S E
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Table 3.31. Kaplan-Meier estimates® o f survival and percentage o f mice dying from a 
disease for the groups o f mice treated with ^^^u.
Group Control Low Medium H i^
No of animals 100 100 60 130
No of animals witii histopaAoIogcal diagnoses 88 97 55 124
Survival Mean survival time 637* 2 3 717*18 6 7 8 * 2 3 63 2 * 1 5
Median survival time 654 *  34 729*23 7 0 9 * 2 3 651 *  12
Osteosarcoma Mean survival time 1067 *  13 1035*9 947*21 8 9 4 * 2 8
% incidence 2.3 2.1 10.9 14.5
All bone tumours Mean survival time 1037 *  20 1034*9 947*21 8 7 7 * 2 6
% incidence 6.8 2.1 10.9 16.9
Myeloid leukaemia Mean survival time - 1021 *  12 968*15 9 3 6 * 1 9
% incidence 0 4.1 5.5 8.9
All haemopoietic tumours Mean survival time 1039 *  20 9 85*18 9 0 0 * 2 6 9 5 9 * 2 8
% incidence 5.7 10.3 16.4 13.7
Hepatocellular adenoma Mean survival time 912*31 957*28 9 4 6 * 2 2 953*21
% incidence 22.7 16.5 7.3 15.3
Hepatocellular carcinoma Mean survival time 863*32 849*22 794 * 2 5 8 2 9 * 2 7
% incidence 31.8 42.3 47.3 32.3
All liver tumours Mean survival time 7 6 1 * 3 0 814*26 774 * 2 5 764 *  25
% incidence 54.5 58.8 54.5 47.6
All lung tumours Mean survival time 1000*27 9 7 0 * 2 0 9 7 1 * 1 6 1035*28
% incidaice 10.2 13.4 3.6 2.4
® K a p l a n - M e i e r  e s t i m a t e s  w e r e  c a l c u l a t e d  w i t h  a  c u t - o f f  o f  1 2 0 0  d a y s  
” X ±  S E
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Table 3.32. Kaplan-Meier estimates® o f survival and percentage o f mice dying from a 
disease for the groups o f mice treated with '^‘‘Am.
Group Crmtrol Low Medium Hi^i
No of animals 100 100 150 50
No of animals with histopathological diagnoses 88 93 143 48
Survival Mean survival time 637*23 703 *  22 670 *  14 70 7 * 2 8
Median survival time 6 5 4 * 3 4 7 5 8 * 2 6 683 *  13 7 2 6 * 4 3
Osteosarcoma Mean survival time 1067*13 - 985*11 8 4 1 * 2 4
% incidence 2.3 0 2.8 20.8
All bwie tumours Mean survival time 1037 *  20 - 981*11 9 4 1 * 2 4
% incidence 6.8 0 3.5 20.8
Myeloid leukaemia Mean survival time - 1006*11 946*15 9 6 3 * 2 6
% incidence 0 4.3 8.4 10.4
All haemopoietic tumours Mean survival time 1039*20 9 7 6 * 1 6 914 * 1 8 9 4 2 * 3 0
% incidence 5.7 10.8 14.0 14.0
Hepatocellular adenoma Mean survival time 912*31 897 * 2 4 1034*41 974* 2 3
% incidence 22.7 25.8 10.5 8.3
Hepatocellular carcinoma Mean survival time 863*32 872*22 798 *  17 8 2 5 * 2 7
% incidence 31.8 35.5 42.7 50.0
All liver tumours Mean survival time 7 6 1 * 3 0 790*23 768 *  16 8 0 3 * 2 6
% incidence 54.5 61.3 53.1 58.3
All lung tumours Mean survival time 1000*27 9 7 4 * 1 4 939 * 1 5 9 9 7 * 1 8
% incidence 10.2 9.7 9.1 4.2
* K a p l a n - M e i e r  e s t i m a t e s  w e r e  c a l c u l a t e d  w i t h  a  c u t - o f f  o f  1 2 0 0  d a y s  
” x ± S E
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3.4.2.1. Life-span
All mice were included in the calculation o f average life-span except animals which died 
during the injection period. Mean and median life-span for the control group were less 
than the values observed for many o f the experimental groups (Tables 3.30-3.32). As 
illustrated by the Kaplan-Meier plots for survival (Figures 3.30-3.32), a larger number o f 
the mice in the control group than in the experimental groups were killed during the 400- 
600 day time-period. This is attributable to early inexperience in the handling o f mice 
developing liver tumours and subsequent changes in the criteria for sacrificing animals. 
Because controls were included in the study shortly in advance o f other groups, this 
change is seen as reduced survival times in the control group. For subsequent periods the 
survival curves were similar and the longest survivals in the control group were greater 
than in most experimental groups. There were no statistical differences between the mean 
survival times o f the medium and high dose experimental groups for all three radionuclides 
compared with the mean survival time for the control group. However, statistical 
differences {t test) were apparent when the low dose groups were compared with the 
control group (P<0.01-0.02).
3.4.2.2. Osteosarcoma
Comparison o f mean survival times o f animals in experimental groups and controls, 
considering death from osteosarcoma (Tables 3.30-3.32) showed significant decreases for 
the high dose group (P<0.001) and medium and high dose ^^Tu and "^^ *Am groups 
(P<0.001). Survival times for other experimental groups were not significantly different 
from controls. Figures 3.33-3.35 con^are survival probabilities for death from 
osteosarcoma for control and experimental groups, showing the time-course o f 
osteosarcoma development between 380 and 1100 days. For ^^^u and "^^ A^m, the earliest 
osteosarcomas occurred in the high dose groups at around 380 and 460 days, respectively, 
compared with 685 days in controls.
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Figure 3.30. Kaplan-Meier plot for survival of mice injected with U compared to control mice
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Figure 3.31. Kaplan-Meier plot for survival of mice injected with ^^ ‘^ Pu compared to control mice.
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Figure 3.32. Kaplan-Meier plot for survival of mice injected with Am compared to control mice
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Figure 3.33. Kaplan-Meier plot for death from osteosarcoma for mice injected with compared 
to control mice.
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Figure 3.34. Kaplan-Meier plot for death from osteosarcoma for mice injected with ^^ P^u 
compared to control mice.
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Figure 3.35. Kaplan-Meier plot for death from osteosarcoma for mice injected with Am
compared to control mice.
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3.4.2.3. All bone tumours
Comparison o f mean survival times o f animals in experimental groups and controls, 
considering death from all bone tumours (Tables 3.30-3.32), showed significant decreases 
for the medium and high dose ^^^u groups (P<0.005 and P<0.001, respectively) and 
medium and high dose '^’^ Am groups (P<0.001 and P<0.005, respectively). Survival times 
for other experimental groups were not significantly different from controls.
3.4.2.4. Myeloid Leukaemia
Myeloid leukaemia was not observed in the control mice; a mean survival time o f 1200 
days was assumed to apply. Con^arison o f mean survival times o f animals in experimental 
groups and the assumed mean survival time for the controls, considering death from 
myeloid leukaemia (Tables 3.30-3.32), showed significant decreases for all experimental 
groups. Figures 3.36-3.38 compare survival probabilities for death from myeloid 
leukaemia for control and experimental groups, showing the time-course o f leukaemia 
development between 250 and 1000 days.
3.4.2.5. All haemopoietic disorders
Comparison o f mean survival times o f animals in experimental groups and controls, 
considering death from all haemopoietic disorders (Tables 3.30-3.32), showed significant 
decreases for the low and high dose groups (P<0.05 and P<0.002, respectively), for 
the low, medium and high dose ^^^u groups (P<0.05, P<0.001 and P<0.05, respectively) 
and for the low, medium and high dose groups (P<0.02, P<0.001 and P<0.01, 
respectively). The mean survival time for the medium dose group was not 
significantly different from controls.
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Figure 3.36. Kaplan-Meier plot for death from myeloid leukaemia for mice injected with 
compared to control mice.
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Figure 3.37. Kaplan-Meier plot for death from myeloid leukaemia for mice injected with ^^ P^u 
compared to control mice.
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Figure 3.38. Kaplan-Meier plot for death from myeloid leukaemia for mice injected with "^^‘Am
compared to control mice.
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3.4.2.6. Liver tumours
Conparison o f the mean survival times o f animals in experimental groups and controls, 
considering death from hepatocellular adenoma, hepatocellular carcinoma and all liver 
tumours (Tables 3.30-3.32), showed no significant differences except for hepatocellular 
adenoma in the medium dose '^’^ Am group (P<0.05). Figures 3.39-3.41 compare survival 
probabilities for death from hepatocellular carcinoma for control and experimental groups, 
showing the time-course o f tumour development between about 250 and 1100 days.
3.4.2.7. All Ixmg tumours
Comparison o f the mean survival times o f animals in experimental groups and controls, 
considering death from all lung tumours (Tables 3.30-3.32), showed no significant 
differences except for the medium dose "^*^ Am group (P<0.05).
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Figure 3.39. Kaplan-Meier plot for death from hepatocellular carcinoma for mice injected with 
compared to control mice.
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Figure 3.40. Kaplan-Meier plot for death from hepatocellular carcinoma for mice injected with 
^^ P^u compared to control mice.
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Figure 3.41. Kaplan-Meier plot for death from hepatocellular carcinoma for mice injected with
compared to control mice.
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3.4.3. Analysis of tumour incidence data using the Peto test
The Peto test (Section 2.10.2) was originally developed to analyse the results o f 
carcinogenicity tests and con^ares data for tumours at different dose levels o f a 
confound with corresponding control data. Tumours recorded at the post-mortem 
examination (Section 2.7) were assigned to a category indicating whether they were 
observed in a fatal or incidental context (Section 2.10). Tumours such as osteosarcoma or 
myeloid leukaemia grow very rapidly and are detected shortly after onset, requiring the 
animal to be humanely killed. These tumours are almost always regarded as fatal. Due to 
the short period o f time between the onset o f the tumour and its growth to a size where it 
is detectable, it is unlikely that the animal will die o f some other cause. Tumours such as 
pulmonary adenomas grow slowly and are usually incidental findings at the post-mortem 
examination o f animals that have died o f other causes; these are referred to as incidental 
tumours. Other tumours such as hepatocellular adenomas and carcinomas are seen both in 
fatal and incidental contexts.
The Peto test was performed to compare the tumour incidences in the low, medium and 
high dose groups for each radionuclide with the control group. The test was performed in 
3 ways, (a) analysis o f tumour mortality data (Section 2.10.2.1), (b) analysis o f tumour 
prevalence data (Section 2.10.2.2) using the incidental tumour data and pathological lesion 
data and (c) analysis o f mortality and prevalence data (Section 2.10.2.3) for tumours 
which were observed in categories (a) and (b). For tumours, the following were analysed: 
osteosarcoma and myeloid leukaemia using the tumour mortality method and malignant 
lymphoma, histiocytic sarcoma, hepatocellular adenoma, hepatocellular carcinoma, 
bronchiolo-alveolar adenoma, bronchiolo-alveolar carcinoma and renal tubular carcinoma 
using the tumour mortality, tumour prevalence, and tumour mortality and prevalence 
methods. For pathological lesions, the following were analysed: dentition abnormalities, 
endosteal hyperostosis and prolapsed intervertébral discs using the prevalence method.
The results are given in Table 3.33.
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Table 3.33. Results from Peto test for trend: tumour mortality; tumour prevalence; 
tumour mortality and prevalence.
Tumour / lesion type “«Pu '^"Am
z P* z P* z P*
Mortality method
Osteosarcoma -0.164 p<0.5 4.195 p<0.00005 4.171 pO.OOOOS
Myeloid leukaemia 1225 p<0.15 2.325 p<0.015 3.152 pcO.OOl
Malignant lymphoma -1.113 p<0.15 0.151 p<0.07 -0.889 p<0.2
Histiocytic sarcoma -1.455 p<0.08 -0.951 p<0.2 -1.086 p<0.04
Hepatocellular adenoma -0.733 p<0.25 -0.618 p<0.3 -2.442 p<0.008
Hepatocellular carcinoma -0.334 ?<0.4 -0.651 P<0.3 1.336 P<0.09
Bronchiolo-alveolar adenoma 0.854 ?<0.2 -0.627 P<0.25 -1.543 P<0.04
Bronchiolo-alveolar carcinoma 0.573 ?<0.3 -2.175 PO.015 -0.064 P<0.3
Renal carcinoma 2.054 P<0.02 1.257 P<0.15 1.543 P<0.07
Prevalence method
Malignant lymphoma -0.195 p<0.5 1.496 p<0.08 0.804 p<0.25
Histiocytic sarcoma 1.065 p<0.15 - - 1.183 p<0.15
Hepatocellular adenoma -0.735 p<0.25 1.541 p<0.07 0.075 p<0.5
Hepatocellular carcinoma 1.288 p<0.1 2.273 p<0.015 2.284 p<0.015
Bronchiolo-alveolar adenoma -1.281 p<0.1 0.829 p<0.25 •0.340 p<0.4
Bronchiolo-alveolar carcinoma -0.368 p<0.4 -0.921 p<0.2 -0.922 p<0.2
Renal carcinoma 2.980 p<0.002 0.805 p<0.25 1.667 p<0.05
Dentition abnormalities 2.326 p<0.015 2.292 pO.OlS 4.175 p<0.00005
Endosteal hyperostosis 0.225 p<0.5 1.669 p<0.05 0.529 p<0.3
Prolapsed intervertébral discs 1.104 p<0.15 -0.077 p<0.25 -0.269 p<0.4
Mortality and prevalence method
Malignant lynphoma -0.991 p<0.2 0.534 p<0.3 -0.469 p<0.4
Histiocytic sarcoma -1.113 p<0.15 -0.951 p<0.2 -0.407 p<0.4
Hepatocellular adenoma -1.031 p<0.2 -0.989 p<q.2 -1.391 p<0.09
Hepatocellular carcinoma 0.395 p<0.4 0.849 p<0.2 2.418 p<0.008
Bronchiolo-alveolar adenoma -0.814 p<0.25 0.617 p<0.3 -0.869 p<0.2
Bronchiolo-alveolar carcinoma -0.0069 p<0.5 -2.066 p<0.02 -0.718 p<0.25
Renal carcinoma 3.563 p<0.0005 1.694 p<0.05 2.041 p<0.025
p  =  I  t a i l e d  t e s t  f o r  p o s i t i v e  t r e n d
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3.4.3.1. Osteosarcoma
All osteosarcomas were classed as fatal tumours. Analysing the tumour incidence data 
using the mortality method showed that the number o f osteosarcomas observed in the 
dose groups were not significantly different from the numbers seen in controls while the 
numbers o f osteosarcomas seen in the ^^ P^u and "^^ A^m dose groups were significantly 
greater than those seen in controls (P<0.00005).
3.4.3.2. Myeloid leukaemia
All myeloid leukaemias were classed as fatal tumours. Analysing the tumour incidence 
data using the mortality method showed that the numbers o f mice observed with myeloid 
leukaemia in the experimental groups were not significantly different from the 
numbers seen in controls while the numbers o f mice with myeloid leukaemia in the ^^ P^u 
and '^*‘Am experimental groups were significantly greater than those seen in controls 
(P<0.015 andP<0.001, respectively).
3.4.3.3. Malignant lymphoma
The tumour incidence data were analysed using all three methods. The results fi*om all 
methods showed that the numbers o f malignant lymphomas observed in the experimental 
groups were not significantly different from those seen in the control group.
3.4.3.4. Histiocytic sarcoma
The tumour incidence data were analysed using all three methods. For the and ^^ P^u 
dose groups, the results from all methods showed that the numbers o f histiocytic sarcomas 
were not significantly different from those seen in controls. For the "^**Am dose groups, 
the mortality analysis showed that the number o f histocytic sarcomas seen in these groups 
were significantly greater from those seen in controls (P<0.04). However, analysis using 
the other two methods showed that the incidence o f histiocytic sarcomas in the '^^ 'Am
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experimental groups were not significantly different than those seen in controls.
3.4.3.5. Hepatocellular adenoma
The tumour incidence data were analysed using all three methods. For the and ^^^u
experimental groups, the results from all methods showed that the numbers o f 
hepatocellular adenomas observed were not significantly different from those seen in 
controls. For the dose groups, the mortality analysis showed that the numbers o f  
hepatocellular adenomas observed were statistically greater than those seen in controls 
(P<0.008). However, analysis using the other methods showed that the incidence o f  
tumours seen in the '^’’Am dose groups were not significantly different from those seen in 
controls.
3.4.3.6. Hepatocellular carcinoma
The tumour incidence data were analysed using aU 3 methods. Analysis using the 
mortality method showed that the numbers o f hepatocellular carcinomas observed in all 
experimental groups were not significantly different from those seen in the control group. 
Analysis using the prevalence method showed that the numbers o f hepatocellular 
carcinomas observed in the dose groups were not significantly different from those 
seen in controls while the numbers o f tumours observed in the ^^^u and '^‘‘Am dose 
groups were significantly greater than those seen in controls (P<0.015). Combined 
analysis for tumour mortality and prevalence showed that the numbers o f hepatocellular 
carcinomas observed in the and ^^^u dose groups were not significantly different 
from those seen in controls. The numbers o f hepatocellular carcinomas observed in the 
Am dose groups were significantly greater than those seen in the control group 
(P<0.008).
3.4.3.7. Bronchiolo-alveolar adenoma
The tumour incidence data were analysed using all three methods. For the and ^^^u
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dose groups, the results from all methods showed that the numbers o f bronchiolo-alveolar 
adenomas observed were not significantly different from those in controls. For the "^*^ Am 
dose groups, the mortality analysis showed that the numbers o f bronchiolo-alveolar 
adenomas observed were statistically greater than those seen in controls (P<0.04). 
However, analysis using the other methods showed that the incidence o f tumours in the 
Am dose groups were not significantly different from those in controls.
3.5.3.8. Bronchiolo-alveolar carcinoma
The tumour incidence data were analysed using all three methods. For the and "^*^ Am 
dose eroups, the results from all methods showed that the numbers o f bronchiolo-alveolar 
carcinomas observed were not significantly different from those seen in controls. For the 
^^^u experimental groups, the mortality and mortality and prevalence methods showed 
that the numbers o f bronchiolo-alveolar carcinomas seen were significantly greater than 
those seen in controls (P<0.015 and P<0.02, respectively) but the results from the 
prevalence method showed no significant difference from controls.
3.4.3.9. Renal tubular carcinoma
The tumour incidence data were analysed using all three methods. Analysis using the 
mortality method showed that the number o f renal tubular carcinomas observed in the 
^^ P^u and^ '^ ^Am experimental groups were not significantly different from those seen in 
controls. The numbers o f renal tubular carcinomas observed in the experimental
groups were significantly greater than those seen in controls (P<0.02). Analysis using the 
prevalence method showed that the numbers o f renal tubular carcinomas observed in the 
^T u dose groups were not significantly different from those seen in controls while the 
numbers observed in the and Am dose groups were significantly greater than those 
seen in controls (P<0.002 and P<0.05, respectively). Combined analysis for tumour 
mortality and prevalence showed that the numbers observed in the ^^^u and "^‘‘Am
experimental groups were significantly greater than those seen in the control mice group 
('P<0.0005. P<0,05 and P<0.025. resnectivelvT
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3.4.3.10. Dentition abnormalities
Analysis o f the numbers o f mice with dentition abnormalities using the prevalence analysis 
showed that the numbers observed in the ^^^u and '^^ A^m dose groups were 
significantly greater than those seen in controls (P<0.015, P<0.015 and P<0.00005, 
respectively).
3.4.3.11. Endosteal hyperostosis
Analysis using the prevalence method showed that the numbers o f mice observed with 
endosteal hyperostosis in the and "^*^ Am dose groups were not significantly different 
from those seen in controls while the numbers in the ^^ P^u experimental groups were 
significant (P<0.05).
3.4.3.12. Prolapsed intervertébral discs
Analysis using the prevalence method showed that the numbers o f mice observed with 
prolapsed intervertébral discs in the experimental groups were not significantly different 
from those seen in controls.
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3.5. Histological descriptions of tumours and pathological lesions 
observed in the studies of the comparative toxicity of ^^ P^u and
The tumours and main pathological lesions observed in this study are described in the 
following sections. Total incidences o f tumours and pathological lesions are given here 
(the individual incidences in experimental groups are given in Section 3.4.1) together with 
numbers o f métastasés observed and metastatic sites. Photographic examples o f 
haemopoietic disorders, bone tumours and lesions and the other frequently observed 
tumour types (liver, lung and kidney) are included.
3.5.1. Bone and skeletal tumours
Lesions in bone were first detected by careful examination (xlO magnification) o f dorsal 
and lateral radiographs taken at the post-mortem examination. Diagnoses were confirmed 
by histological examination o f the suspect bone regions.
3.5.1.1. Osteosarcoma
Fifty osteosarcomas were observed in 46 animals. Macroscopically, the tumours appeared 
as firm greyish-white tissue, sometimes with a yellowish to pinkish tinge. However, larger 
tumours had regions o f necrosis and haemorrhage. Table 3.34 shows the osteosarcoma 
sites in groups treated with ^^ P^u and For and '^‘‘Am, a greater
proportion o f tumours were in the axial skeleton rather than the appendicular skeleton, 
whereas for ^^^u the tumours were divided about equally between the axial and 
appendicular skeleton. Four mice in the high dose^^^u group and one mouse in the high 
dose and “^^‘Am groups had 2 tumours. Métastasés were seen in 6 cases, 1 mouse 
having 3 métastasés. Métastasés were seen in the ribs, lung, spleen and liver (3, 3, 1 and 1 
cases, respectively).
Chapter 3. Results: Toxicological studies - Histopathology 184
Table 3.34. Osteosarcoma sites in mice injected with and
O s t e o s a r c o m a  s i t e
2 3 3 |j
R a d i o n u c l i d e
2 3 9 p u
S k u l l 1
M a n d i b l e s 1 2
C e r v i c a l  v e r t e b r a e 1
T h o r a c i c  v e r t e b r a e 2 3
L u m b a r  v e r t e b r a e 2 7 7
C a u d a l  v e r t e b r a e 4 1
S t e r n u m 2
H u m e r u s 4
U l n a 1
F e m u r 1 0 2
Examples o f skeletal radiographs and histological sections o f osteosarcoma are shown in 
Figures 3.42-3.49. These examples illustrate the division o f osteosarcomas into 
predominantly bone-forming (Figures 3.42 and 3.44) and predominantly non-bone-forming 
tumours (Figures 3.46 and 3.48). Bone-producing tumours tended to be seen in the head 
and vertebrae where they had longer to become established. Non-bone-forming tumours 
tended to be seen in the axial skeleton, where they grew quickly and were picked up whilst 
still a cellular mass, before bone had been laid down.
Histologically, the bone tumours tended to be heterogeneous and showed a mixed pattern 
o f cellular differentiation although one form o f cell type predominated in some cases. 
Figure 3.43 shows an example o f a tumour with a large amount o f osteoid present. The 
tumour had a smooth edge with only a few layers o f  active neoplastic cells on the surface. 
Figure 3.45 shows an exanq)le o f an aggressively invasive tumour in the thoracic vertebrae 
which has destroyed normal bone and marrow. However, in other tumours osteoid 
formation was minimal and the tumours consisted o f a cellular mass. Figures 3.47 and 
3.49 show examples o f typical tumours consisting o f spindle to ovoid, basophilic cells 
amidst trabeculae o f newly formed osteoid. These tumours contained pleomorphic and 
anaplastic cells, with large nuclei, atypical mitoses and multinucleated giant cells.
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A few métastasés were seen in these studies; the primary tumours were usually spotted and 
the animals sacrificed before métastasés could occur. Figures 3.50-3.53 show exan^les of  
métastasés seen in the kidney, liver, lung and rib muscle.
3.5.1.2. Other bone and skeletal tumours
A number o f other bone and skeletal tumours were diagnosed but no statistical difference 
was observed between groups o f experimental animals and controls.
One case o f cementifying fibroma was seen; this tumour is a benign tumour o f the 
mandible and is classified by EULEP as an ossifying fibroma (EULEP, 1994) and by WHO 
(IRAC, 1994) as a cementifying fibroma. Figure 3.54 shows the histological appearance 
o f the tumour with trabeculae o f lamellar bone surrounded by fibrous tissue.
Odontomas are benign tumours o f the dental tissues o f the mandible; four cases were 
observed. Figure 3.55 shows the radiographic appearance o f an odontoma. As illustrated 
in Figure 3.56 the tumours may produce a disorderly pattern o f dental tissue or may, more 
commonly, produce masses o f misshapen teeth, each o f which have enamel, dentine, 
cementum and pulp arranged as in a normal tooth (Figure 3.57).
Osteomas are benign slow-growing compact bone tumours; 4 cases were observed. As 
illustrated by Figure 3.58 they appear on radiographs as dense tumours with a sharply- 
defined perimeter and are often seen at ends o f bones. Figure 3.59 shows the histological 
appearance o f the tumours which consist o f mature compact bone (with enq)ty osteocyte 
lacunae) blending in with the underlying compact bone. They show characteristic smooth 
outlines, lined either with a single uniform layer o f flattened inactive osteoblasts, a layer o f  
active osteoblasts or if the tumour is actively growing, multiple layers o f osteoblasts.
One case o f haemangioma was observed. Haemangiomas are benign neoplasms o f  
endothelial cells. Macroscopically, the tumour appeared as a raised, soft spongy red mass 
and, microscopically, it consisted of large irregular vascular channels lined by a single layer 
o f endothelial cells.
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Ten cases o f haemangiosarcoma were seen. Haemangiosarcomas are malignant neoplasms 
o f endothelial cells. Figure 3.60 shows the appearance o f a radiograph o f a typical 
haemangiosarcoma. It can be seen that the tumour has a similar appearance to a non­
bone-forming osteosarcoma. Macroscopically, the tumours appeared as raised red-purple, 
soft, spongy well-demarcated masses, seen in the legs and vertebrae. The cut surface had 
a honey-comb like appearance showing haemorrhagic areas. Figure 3.61 shows the 
histological appearance o f the tumour which consisted o f vascular spaces filled with blood. 
The vascular spaces were separated by varying amounts o f connective tissue and were 
lined with spindle-shaped cells with have hyperchromatic, round to oval nuclei. There was 
considerable cellular pleomorphism and mitoses were commonly seen.
Rhabdomyosarcoma is a malignant tumour o f skeletal muscle. One case was observed in 
the pelvic region; métastasés were seen in the ribs, diaphragm and lymph nodes. Grossly, 
the rhabdomyosarcoma appeared as a firm, fleshy white to pinkish-grey nodule. Figure 
3.62 shows the histological appearance o f the tumour which consisted o f pleomorphic 
rhabdomyoblasts, immature spindle cells, and multinucleated rounded or polygonal cells. 
The cells were arranged in interlacing bundles and sheets in various directions; numerous 
atypical mitotic figures were seen. Figure 3.63 shows an example o f a metastasis in the 
kidney.
3.5.1.3. Bone lesions
Dentition abnormalities, apparent as broken or overgrown incisors, were observed at post­
mortem examination in 259 animals. The incidences in all experimental groups were 
significantly higher than in the control group. On examination o f the X-radiographs it 
could be seen that in some mice the teeth had broken off at the gums and in other mice the 
teeth had fallen out. Table 3.35 gives the incidences o f these abnormalities in the different 
groups. It can be seen from the Table that there was an increased incidence o f teeth loss in 
the experimental groups (about 1 1 %, 17% and 2 0 %, in the low, medium and high 
dose groups, respectively) and in the experimental groups (about 30%, 16%, and 
35% in the low, medium and high dose groups, respectively).
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Abnormal bone growth, or hyperostoses, were observed in 743 animals but with no 
significant difference between the experimental groups and controls. Hyperostoses were 
seen on the endosteal surfaces o f long bones and vertebrae and as exostoses on the 
periosteal surfaces o f the elbows. Microscopically, the lesions were first noticed as a 
thickening o f trabeculae in the metaphysis or the accumulation o f osteoid seams adjacent 
to endosteal surfaces. Examples are given in Figures 3.65 and 3.67 and normal bone is 
shown for conq)arison in Figures 3.64 and 3.66. In more severe lesions wide, irregular 
trabeculae became dispersed throughout the marrow cavities (see Figure 3.67). Figure 
3.68 shows the radiological appearance o f a normal elbow and Figure 3.69 shows the 
appearance o f an exostosis which can either occur as a cartilaginous or calcified exostosis.
Table 3.35. Incidence of dentition abnormalities in mice injected with ^^^u and
Group Number of mice 
examined
Number of mice with 
abnormalities
Type of dentition abnormality 
Teeth broken off One incisor missing Two incisors missing
Control 99 16 15 1 0
a iu Low 99 29 18 11 0
Medium 60 17 7 10 0
High 50 17 7 10 0
Low 100 19 18 1 0
Medium 60 7 7 0 0
High 128 27 23 4 0
^'Am Low 98 43 13 27 3
Medium 147 51 28 22 1
High 49 32 15 1.1 6
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Figure 3.42. X-ray of skull showing osteosarcoma.
Figure 3.43. Histological appearance of osteosarcoma. H&E x25.
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Figure 3.44. X-ray of thoracic vertebrae showing osteosarcoma.
Figure 3.45. Histological appearance of osteosarcoma. H&E x25.
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Figure 3.46. X-ray of osteosarcoma in radius/ulna.
%
Figure 3.47. Histological appearance of osteosarcoma. H&ExlOO.
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Figure 3.48. X-ray of osteosarcoma in femur.
%ure 3.49. Histological appearance of osteosarcoma. H&ExlOO.
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Figure 3.50. Osteosarcoma metastasis (a) in kidney (b). H&E xlOO.
Figure 3.51. Osteosarcoma metastasis (a) in liver (b). H&E xlOO.
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Figure 3.52. Osteosarcoma metastasis (a) in lung (b). H&E xlOO.
Figure 3.53. Osteosarcoma metastasis in rib. H&E xlOO.
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Figure 3.54. Cementifying fibroma in jaw. H&E x40.
Figure 3.55. X-ray of head showing odontoma of mandible.
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Figure 3/56. Odontoma of mandible showing disorderly pattern of dental tissue. 
H&E xlOO.
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Figure 3.57. Odontoma of mandible showing misshapen teeth with enamel, dentine, 
cementium and pulp arranged as m a normal tooth. H&E xl 00.
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Figure 3.58. X-ray of leg showing osteoma ia tibia.
Figure 3.59. Histological appearance of osteoma H&E x25.
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Figure 3.60. X-ray of leg showing haemangiosarcoma of tibia.
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Figure 3.61. Histological appearance of haemangiosarcoma. H&E x40.
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Figure 3.62. Rhabdomyosarcoma o f pelvis. H&E x250.
Figure 3.63. Rliabdomyosarcoma metastasis (a) in kidney (b). H&E xlOO.
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Figure 3.64. Normal vertebra. H&E x40.
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Figure 3.65. Lumbar vertebra showing endosteal hyperostosis. H&E x40.
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Figure 3.66. Normal femur. H&ExlOO.
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Figure 3.67. Femur showing marked endosteal hyperostosis. H&E x25.
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Figure 3.68. X-ray showing normal elbow.
Figure 3.69. X-ray of elbow showing calcified exostosis.
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3.5.2. Haemopoietic disorders
In the mouse, the most common sign that a haemopoietic disorder might be present is the 
presence o f an enlarged spleen. As described in Section 2.7, the presence o f enlarged 
spleens was usually picked up during the weekly examination. Mice were sacrificed for 
histological examination o f splenic tissue and blood smears, cytogenetic analysis and 
passaging o f spleen tissue as aids to diagnosis. Occasionally, mice were found dead with 
enlarged spleens; in these cases, only histological examination o f the spleen could be 
carried out.
The diagnoses o f myeloid leukaemia and malignant lymphoma used in this thesis were 
based on morphological criteria, demonstration o f cytoplasmic immunoglobulins using 
immunocytochemical staining methods (Section 2.8) and data from blood smears and 
karyotyping o f cells from spleen cultures when available (Section 2.7).
3.5.2.1. Myeloid leukaemia
Myeloid leukaemia was not seen in the control mice; a total o f 47 mice in the experimental 
groups injected with radionuclides were observed with myeloid leukaemia. As indicated 
above the most obvious lesion was the enlarged spleen but enlarged lymph nodes and 
infiltrations of the liver and kidneys, apparent as pale areas in these organs, were also 
observed. Nineteen o f the cases involved other sites in addition to the spleen. Two, 3, 4,
5 and 7 sites were involved in 7, 8 , 2 , 1  and 1 mice, respectively. Organs, other than the 
spleen which were involved were liver (14), lymph nodes (10), kidney (8 ), lung (4), small 
intestine (2 ), sternum (2 ), lumbar vertebrae (2 ) and femur ( 1 ).
Figures 3.70 and 3.71 show the appearance o f myeloid leukaemia in the spleen. In mice, 
the neoplastic cells resemble immature granulocytes and are termed premyelocytes, 
promyelocytes and metamyelocytes; a single developmental stage is usually seen, in this 
case metamylocytes evident by their characteristic ringed nuclei. Figure 3.72 shows 
positive staining for myeloperoxidase (evident as brown pigmentation) using the
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immunocytochemical staining method (Section 2.8). Figure 3.73 shows a typical 
karyotype obtained from spleen cell cultures from leukaemic animals (Section 2.7), 
showing a shortened chromosome 2  allele, as well as other chromosomal abnormalities not 
indicative o f myeloid leukaemia. Figures 3.74 and 3.75 show examples o f promyelocytes 
and metamyelocytes which were seen in blood smears prepared from leukaemic animals.
Organs other than the spleen showed accumulation o f leukaemic cells in about 40% o f  
myeloid leukaemia cases in these studies. Figure 3.76 shows an example of 
metamyelocytes in a blood vessel in liver and infiltration into the surrounding tissue.
Figure 3.77 shows an example o f leukostasis o f the hepatic sinusoids where 
metamyelocytes may be clearly seen. Figures 3.78-3.80 show examples o f infiltrations into 
bone marrow, lymph nodes and kidney and Figure 3 .81 shows an example o f the positive 
staining for myeloperoxidase o f leukaemic cell infiltration into the kidney.
3.5.2.2. Malignant lymphoma
Thirty mice were observed with malignant lymphoma but no significant difference was 
observed between groups o f experimental animals and controls. As indicated previously, 
the most obvious lesion was the enlarged spleen but infiltrations o f other organs such liver, 
lung, lymph nodes, kidney and Peyer’s patches, apparent as white nodules, were also 
observed. Twenty-two o f the cases involved other sites in addition to the spleen. Two, 3, 
4, 5 and 6  sites were involved in 3, 5, 10, 3 and 5 mice, respectively. Organs, other than 
the spleen, which were involved were lymph nodes (13), kidney (13), lung ( 1 0 ), liver ( 1 0 ), 
small intestine (5), lumbar vertebrae (3), sternum (2), ribs (1), pancreas (1), diaphragm (1), 
gastrointestinal tract ( 1 ) and adrenal ( 1 ).
Figure 3.82 shows the appearance o f malignant lymphoma in the spleen. The rounded 
basophilic neoplastic cells seen infiltrating the spleen were shown to be o f T cell origin by 
positive staining o f the CD3 antigen, evident as brown pigmentation (Figure 3.83).
Organs other than the spleen showed infiltration o f lymphoma cells in about 70% o f cases 
of malignant lynq)homa. Figure 3.84 shows malignant lymphoma cells in a vessel in a 
lymph node and infiltration of the lyn^homa cells into the surrounding tissue. Figure 3.85
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shows an example o f lymphoma cell infiltration into the kidney.
3.5.2.3. Histiocytic sarcoma
Histiocytic sarcomas were observed in 25 mice but no statistical difference was observed 
between groups o f experimental animals and controls. Histiocytic sarcoma was seen as an 
enlarged mottled spleen and in some cases involved other organs which appeared enlarged, 
paler than normal and had a nodular appearance. Eleven o f the 25 cases involved other 
sites in addition to the spleen. Two, 3, 4, 5, and 6  organs were involved in 2, 4, 1 ,2  and 2 
mice, respectively. Organs, other than the spleen, which were involved were liver (7), 
kidney (4), lymph nodes (6 ), femur (3), thymus (2), lumbar vertebrae (2), lung (2), 
gastrointestinal tract (2 ), pancreas ( 1 ), adrenal ( 1 ) and sternum ( 1 ).
Figure 3.86 shows the characteristic appearance o f histiocytic sarcoma in the spleen with 
infiltration o f rounded histiocytic cells with basophilic nuclei and eosinophilic cytoplasm; 
multinucleated cells similar to fbreign-body or Langhans’s cells were also present. 
Remnants o f the original parenchymal tissue were also seen between foci o f histiocytic 
cells. Organs other than the spleen were involved in about 40% o f cases o f histiocytic 
sarcoma. Figure 3.87 shows an example o f infiltration o f the liver by histiocytic sarcoma 
cells.
3.5.2.4. Other haemopoietic disorders
A number o f other haemopoietic disorders were diagnosed but no statistical difference was 
observed between groups o f experimental animals and controls.
Extramedullary haemopoiesis was seen in mice which had been exposed to ^^ P^u. A total 
o f 2 2  mice were observed with the condition; these were mostly in the high dose group. 
Figure 3.88 shows an exan^le o f extramedullary haemopoiesis in the spleen, with the red 
pulp containing erythrocytic, granulocytic or megakaryocytic cell lines. As shown in ; 
Figure 3.89, immunocytochemical staining for myeloperoxidase showed a negative
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reaction.
Seven cases o f lymphoid hyperplasia were observed in the high and low dose groups. 
Figure 3.90 gives an example, showing a characteristic increase in the number and size o f  
the lymphoid follicles in the spleen. As shown in Figure 3.91, immunocytochemical 
staining for the CD3 antigen showed a negative reaction.
Three cases o f malignant thymoma were observed within the thymus showing varying 
proportions o f neoplastic lymphocytes and neoplastic epithelial reticular cells arranged in 
sheets or nests (Figure 3.92). All 3 cases showed métastasés; organs involved were the 
diaphragm, liver, lung, ribs and sternum. Figure 3.93 shows an example o f metastasis in 
the diaphragm.
Figures 3.94 and 3.95 show the appearance o f mastocytoma present in 2 mice consisting 
o f cuboidal and rhomboidal mast cells with rounded or slightly oval nuclei and variable 
sized granules in the cytoplasm.
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Figure 3.70. Myeloid leukaemia in spleen showing sub-capsular proliferation of
metamyelocytes. H&E x250.
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Figure 3.71. Higher magnification of myeloid leukaemia in spleen showing the 
characteristic ringed nucleus of metamyeloctes and dividing cells. H&E x600.
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Figure 3.72. Myeloid leukaemia of spleen showing positive staining (brown pigmentation) 
with immunocytochemical staining for myeloperoxidase. MPO x400.
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Figure 3.73 Karyotype from spleen culture cells from mouse with myeloid leukaemia 
showing chi'omosome 2 with deleted region (other cluomosomal abnormalities are also 
present)
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Figure 3.74. B lo o d  smear showing promyelocyte. Giemsa x400.
Figure 3.75. B lood  smear showing metamyelocyte. Giemsa x400.
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Figure 3.76. Liver showing metamyelocytes in blood vessel and infiltration by myeloid 
leukaemic cells into surrounding tissue. H&E x250.
#m
^0,
#
% ^
4'T T .I* m; - f  ' .  *  i  f
»
i
Figure 3.77. Liver showing infiltration of sinusoids by myeloid leukaemic cells. 
H&E x250.
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Figure 3,78. Bone marrow showing infiltration by myeloid leukaemia. H&E x400.
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Figure 3.79. Lymph node showing infiltration by myeloid leukaemia. H&E x400.
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Figure 3.80. Kidney showing infiltration by myeloid leukaemic cells. H&E x400.
m
Figure 3.81. Kidney with infiltration by myeloid leukaemic cells showing positive staining 
(brown pigmentation) with immunocytochemical staining for myeloperoxidase.
MPO x400.
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Figure 3.82. Malignant lymphoma of spleen. H&E x250.
Figure 3.83. Malignant lymphoma of spleen showing positive staining for CD3 antigen 
(brown pigmentation) with immunocytochemical staining. CD3 x400.
Chapter 3. Results: Toxicological studies - Histopathology 213
r
Figure 3.84. Lymph node showing malignant lymphoma cells in vessel. H&E x400.
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Figure 3.85. Kidney (a) showing malignant lymphoma infiltration (b). H&E x250.
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Figure 3.86. Histiocytic sarcoma in spleen. H&E x250.
Figure 3.87. Histiocytic sarcoma (a) in liver (b). H&E x250.
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Figure 3.88. Spleen showing extramedullary haemopoiesis. H&E x250.
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Figure 3.89. Spleen with extramedullary haemopoiesis showing negative staining for 
myeloperoxidase (lacking brown pigmentation). MPO x250.
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Figure 3.90. Spleen showing lymphoid hyperplasia. H&E x400.
m
Figure 3.91. Spleen with lymphoid hyperplasia showing negative staining for CD3 antigen 
(lacking brown pigmentation). CD3 x250.
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Figure 3.92. Malignant thymoma of thymus. H&E x250.
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Figure 3.93. Malignant thymoma metastasis (a) in diaphragm (b). H&E x250.
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Figure 3.94. Mastocytoma of marrow in lumbar vertebrae. H&E x250.
m
Figure 3.95. Higher magnification of mastocytoma. H&E x400.
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3.5.3. Liver tumours
Large numbers o f mice had liver tumours present and many had multiple tumours. For the 
purposes o f tumour incidence (Section 3.4.1) and Peto analysis (Section 3.4.3) the tumour 
types were only counted once per mouse despite the fact that several tumours may have 
been present. Table 3.36 gives details o f the number o f mice in each group with multiple 
tumours. Comparing total numbers showing a liver tumour (either hepatocellular adenoma 
or carcinoma), dose groups showed incidences o f about 87-90%, ^^^u dose groups 
showed incidences o f 93-98% and '^‘^ Am dose groups showed incidences o f 93-96% 
compared with an incidence o f 75% in controls. Comparing numbers o f mice with 
multiple tumours then dose groups showed incidences o f about 61-64%, ^^^u dose 
groups showed incidences o f 71-94% and "^**Am dose groups showed incidences o f 74- 
84% compared with an incidence o f about 52% in controls. Thus, these results suggest a 
greater incidence o f multiple tumours in ^^^u and "^''Am groups than in groups or 
controls. In the mice with larger numbers o f tumours, carcinoma predominated.
Table 3.36. Incidence o f liver tumours in experimental groups.
Experimental group No of mice analysed No of mice with liver 
tumour
Total number of tumours observed in liver
1 2 3 4 5 6 7
Control 88 66 32 14 11 8 1 0 0
233u Low 91 81 29 30 12 7 3 0 0
Medium 54 47 18 9 12 5 1 0 0
H # 48 43 17 13 5 5 1 2 0
Low 97 90 26 26 24 8 2 2 2
Medium 55 54 3 11 20 15 5 0 0
High 124 117 20 32 27 21 14 3 0
^'Am Low 93 89 14 29 21 16 9 0 0
Medium 143 133 28 43 32 14 12 3 1
H i^ 48 46 12 15 10 6 1 1 1
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3.5.3.1. Hepatocellular adenoma
Hepatocellular adenomas were seen in 436 animals. Macroscopically, they were well- 
defined rounded tumours which appeared paler than normal liver tissue. Histologically, 
they consisted o f closely packed cells with similar morphology to normal liver cells. Their 
cytoplasm either appeared to be more eosinophilic, more basophilic or more vacuolated 
than that o f normal liver cells. Con^ression o f the surrounding tissue by larger tumours 
was seen. The tumours had well-defined borders and there was no invasion o f adjacent 
tissue and the lesions rarely had mitotic figures present.
Figure 3.96 shows the histological appearance o f an eosinophilic adenoma which consisted 
of cells larger than normal hepatocytes; their cytoplasm was more eosinophilic and had a 
granular appearance when compared to adjacent hepatocytes. Figure 3.97 shows a typical 
basophilic adenoma which consisted of cells smaller than normal hepatocytes with a more 
basophilic cytoplasm. Figure 3.98 shows an example o f a vacuolated cell adenoma which 
consisted o f hepatocytes containing varyingly sized vacuoles. The nuclei o f the affected 
cells were either absent or flattened against the cytoplasmic membrane. Figure 3.99 shows 
a clear-cell adenoma which consisted o f cells with a clear or lacy cytoplasm suggestive o f  
glycogen storage. The nuclei o f these cells were not flattened against the cell membrane as 
in the vacuolated adenoma, but were located in the centre o f the cells surrounded by clear 
cytoplasm. Mixed cell tumours were also observed and contained, in varying proportions, 
two or more o f any of the cell types described above.
3.5.3.2. Hepatocellular carcinoma
Hepatocellular carcinomas were seen in 486 animals; métastasés were seen in 8 6  cases, 6  
mice having 2 métastasés. Métastasés were most commonly seen in the lungs (84 cases) 
and were also seen in the kidneys, sternum, lumbar vertebrae, thoracic vertebrae, 
diaphragm and rib (2, 2 ,1 , 1, and 1 cases, respectively). Grossly, the tumours were well 
circumscribed and appeared either grey-white in colouration or dark red if haemorrhage 
and necrosis were present.
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There were two main histological types o f tumour: trabecular and solid. Each type could 
be well, moderately well or poorly differentiated. Well-differentiated hepatocellular 
carcinomas had a well preserved trabecular structure similar to that seen in hepatocellular 
adenomas. Moderately well-differentiated hepatocellular carcinomas were composed o f  
larger cells which varied more in size and shape. Poorly differentiated tumours showed 
marked cell atypia and polymorphism, and mitotic figures could often be found. 
Haemorrhages, thrombosis and areas o f necrosis were frequently seen and Figure 3.100 
shows an exan^le o f a tumour where a large area o f necrosis was present.
Trabecular tumours consisted o f cylindrical cords which were clearly seen when the 
sinusoids were dilated. The trabeculae consisted o f a variety o f cells, some closely 
resembling normal hepatocytes and others which were very small cells with small dark 
nuclei. When trabeculae were sectioned transversely, the cords displayed an acinar-like 
structure with a small lumen in the centre, as illustrated by Figure 3.101. Cysts or pseudo­
glands o f various sizes were also present and were lined with one or two slightly flattened 
cells which appeared to be in continuity with the trabeculae.
Solid carcinomas were characterized by a great variability in cell and nuclear size. Large 
cells with hyperchromatic nuclei and cells smaller than normal hepatocytes were seen as 
well as infrequent mitotic figures, haemorrhages and necrotic areas. As shown in Figure 
3.102 the border with the surrounding tissue was usually sharp, disrupted occasionally by 
small groups o f tumour cells which penetrated into the adjacent tissue. Métastasés were 
seen in about 20% o f cases and Figures 3.103-3.106 show exanples o f métastasés in the 
lungs observed in these studies.
3.5.3.3. Other liver tumours
One case o f cholangioma of the liver was observed. Microscopically, the cholangioma 
was a well circumscribed lesion which consisted o f proliferating bile ducts lined by cells 
similar to normal bile duct epithelium.
One case of cholangiocellular carcinoma of the liver was observed. Microscopically, the 
tumour appeared papillary in structure with spindle to polygonal shaped neoplastic cells
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containing large nuclei with prominent nucleoli and basophilic cytoplasm The tumour 
cells formed acini separated by collagen and showed invasive growth the surrounding 
hepatic tissue.
One case o f hepatoblastoma was observed. Macroscopically, the tumour appeared as a 
well circumscribed dark red nodule consisting o f lobulated growths o f tumour tissue 
separated by vascular cavities filled with blood. Microscopically, the tumour consisted o f  
poorly differentiated, basophilic cells arranged iu sheets or rosettes, with many vascular 
channels present.
3.5.4. Lung tumours
3.5.4.1. Bronchiolo-alveolar adenoma
j
Lung tumours were the second most common type o f tumour and bronchiolo-alveolar 
adenoma was seen in 167 mice. Macroscopically, bronchiolo-alveolar adenomas appeared 
as discrete l-3mm white nodules situated in the alveolar parenchyma. Histologically, two 
types were seen, either solid tumours or papillary tumours. Figure 3.107 shows an 
example o f the solid type more commonly seen in these studies. They were seen to consist 
of well-differentiated cuboidal or polygonal cells with hyperchromatic nuclei and 
prominent nucleoli, arranged in cords or nests, forming discrete foci that minimally 
compressed the surrounding tissue (Figure 3.108); mitotic figures were occasionally seen.
3.5.4.2. Bronchiolo-alveolar carcinoma
Bronchiolo-alveolar carcinoma was seen in 147 mice; métastasés were seen in 15 cases, 8  
animals having one metastasis, 3 having 2 métastasés, 3 having 3 métastasés and one 
having 4 métastasés. Métastasés were seen in the ribs (9), sternum (5), diaphragm (4), 
kidney (3), LN (2), spleen (1), heart (1), thoracic vertebrae (1) and thymus (1).
Macroscopically, pulmonary carcinomas in mice appeared as white 3-10mm nodules in the 
alveolar parenchyma. Histologically, three patterns were recognized: solid, papillary, and 
mixed. Figure 1.109 shows the papillary type o f tumour which was most frequently
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observed in these studies and has infiltrative growths which destroyed the normal alveolar 
architecture. The tumour cells were round to columnar in shape with large round to oval 
nuclei and varying amounts o f cytoplasm; a few mitotic figures were present. Figure 3.110 
shows an exan^le o f the solid type o f tumour which consisted o f rounded cells arranged in 
nests or cords forming contact masses which con^ressed and invaded surrounding lung 
tissue. Mixed tumours with both solid and papillary growth patterns were also identified; 
mitotic figures were observed.
3.5.5. Kidney tumours
3.5.5.1. Renal tubular adenoma
Renal cell adenomas are benign tumours o f renal tubular cells and 8  cases were observed 
in these studies. Macroscopically, the lesions were visible as yellow/white well- 
demarcated nodules in the kidney cortex. Microscopically, the tumours consisted o f well- 
differentiated or poorly-differentiated polygonal or round cells that were larger than 
normal tubular epithelial cells and formed solid, cystic or papillary patterns. The tumour 
cells were either more basophilic, more eosinophilic than normal cells or consisted o f clear 
cells. Figures 3.111 and 3.112 show examples o f a well-differentiated and poorly- 
differentiated renal tubular adenomas.
3.5.5.2. Renal tubular carcinoma
Renal cell carcinomas are malignant tumours o f renal tubular cells and 36 cases o f renal 
tubular carcinoma were observed in these studies, 17 o f these cases were in 
experimental groups. Macroscopically, the tumours appeared as well-demarcated 
yellow/orange nodules in the renal cortex. Microscopically, the tumour cells consisted o f  
well-differentiated or poorly-differentiated pleomorphic basophilic or eosinophilic cells 
arranged in irregular tubular structures with occasional mitotic figures present; invasion o f  
the surrounding tissue could occasionally be seen. Figure 3.113 shows an exan^le o f a 
poorly-differentiated renal carcinoma. Well-differentiated tumours may be o f two types: 
solid as shown in Figure 3.114 or papillary as shown in Figure 3.115.
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Figure 3.96. Liver showing eosinophillic hepatocellular adenoma (a). H&E x250.
Figure 3.97. Liver showing basopliMc hepatocellular adenoma (a). H&E x250.
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Figure 3.98. Liver showing vacuolated cell hepatocellular adenoma (a). H&E x250.
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Figure 3.99. Clear cell hepatocellular adenoma. H&E x250.
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Figure 3.100. HepatoceUular carcinoma (a) and area of necrosis (b). H&E x250.
Figure 3.101. Well-differentiated trabecular hepatocellular carcinoma, showing pseudo- 
glandular appearance. H&E x250
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Fig 3.102. Well-differentiated solid hepatocellular carcinoma. H&ExlOO.
Figure 3.103. Hepatocellular carcinoma métastasés in the lungs. H&E xlOO.
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Figure 3.104. Hepatocellular carcinoma metastasis in lung blood vessel. H&E x250.
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Figure 3.105. Hepatocellular carcinoma metastasis in lung airway. H&E xlOO.
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Figure 3.106. Hepatocellular carcinoma metastasis in lung showing mitotic figure. 
H&E x250.
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Figure 3.107. Broncliiolo-alveolar adenoma (a) of lung (b). H&E xlOO.
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Figure 3.108. Bronchiolo-alveolar adenoma showing compression of surrounding tissues. 
H&E x250.
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Figure 3.109. Bronchiolo-alveolar carcinoma showing papillary pattern of tumour. 
H&E x250.
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i
Figure 3.110. Bronchiolo-alveolar carcinoma showiug solid pattern of tumour. 
H&E x250.
Figure 3.111. Well-differentiated renal adenoma (a) of kidney (b). H&E xlOO.
Chapter 3. Results: Toxicological studies - Histopathology 232
Figure 3.112. Poorly differentiated renal adenoma (a) of kidney. H&E xlOO.
1 % f a
Figure 3.113. Undifferentiated renal carcinoma (a) of kidney. H&E xlOO.
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Figure 3.114. Well-difFerentiated renal carcinoma of kidney showing solid pattern of 
tumoLir (a). H&E x 100.
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Figure 3.115. Well-differentiated renal carcmoma of kidney showing papillary pattern of 
tumour (a). H&E xlOO.
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3.5.6. Other benign tumours
In addition to the benign tumours described in the preceding sections, 10 other benign 
tumours were seen and are described here. No statistical differences were observed 
between incidences in the experimental groups and controls.
Two cases o f adrenal cortical adenoma were observed as sub-capsular, well-demarcated 
tumours conpressing the surrounding tissue. Histologically, they consisted o f densely 
packed basophilic cells with round to oval nuclei and scant cytoplasm arranged in cords or 
nests.
Two cases o f adrenal phaeochromocytoma were observed. Adrenal phaeochromocytomas 
are tumours o f the adrenal medulla. Microscopically, the cells resembled normal medullary 
cells with dark nuclei and were arranged in nests separated by vascular sinusoids.
One case o f amelanotic melanoma was seen. Macroscopically the tumour formed a nodule 
in the dermis. Microscopically, the tumour appeared benign and consisted o f well- 
differentiated round or polygonal melanocytes; no pigmentation was seen in this tumour.
One case o f haemangioma was seen in a renal lymph node. MacroscopicaUy, the tumour 
appeared as a soft, red spongy mass separated by fibrous tissue into varying sized nodules. 
Microscopically, the tumour consisted o f blood vessels and irregularly shaped lacunae 
lined by a single layer o f well-differentiated, flattened endothelial cells. The vascular 
spaces were separated by bands o f collagenous tissue.
One animal was found with an adenomatous polyp in its smaU intestine. Histologically, the 
adenoma was an outgrowth o f the mucosa composed o f glandular structures which were 
lined by cuboidal or columnar epithelium containing numerous goblet cells; a few mitotic 
figures were seen in the basal parts o f the tumour.
One case o f leiomyoma was observed in the smooth muscle o f the small intestine. 
Histologically, the tumour consisted o f spindle cells with oval nuclei arranged in interlacing 
bundles.
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One case o f melanoma was seen and was visible macroscopically as a black tumour in the 
skin. Microscopically, the tumour was benign and consisted o f round or irregularly 
polygonal melanocytes containing black melanin granules.
One case o f pancreatic islet cell adenoma was observed. Pancreatic islet-cell adenoma is a 
benign tumour arising from the Islets o f Langerhans and was visible grossly as a discrete, 
pinkish-white nodule. Microscopically, the tumour consisted o f pol>fredral, oval to spindle 
shaped cells with round centrally located nuclei and granular cytoplasm which were 
arranged in rows or nests along sinusoidal thin-walled vessels with few mitotic figures 
present.
One squamous cell papilloma was observed on the tongue as an outgrowth from the skin 
surface in the form of a wart 5mm in diameter. Microscopically, the papilloma consisted 
o f folds o f tissue containing a central connective tissue core covered by stratified 
squamous epithelium.
One case o f trichoepithelioma, a benign skin tumour o f the hair follicles was seen. 
Histologically, the follicle-like structures o f the tumours contained predominantly round to 
oval cyst-like structures filled with comified material, arranged in whorling patterns.
3.5.7. Other malignant tumours
In addition to the malignant tumours described in the preceding sections, 12 other 
malignant tumours were seen and are described here. No statistical differences were 
observed between incidences in the experimental groups and controls.
Three cases o f fibrosarcoma, a malignant tumour o f connective tissue, were seen. 
Macroscopically, they were white, firm nodular tumours, about 5cm in diameter found in 
the connective tissue underneath the skin. Microscopically, the tumours consisted o f  
closely packed spindle-shaped fibroblasts surrounded by collagen fibres with many mitotic 
figures present.
Haemangiosarcomas are malignant tumours o f the endothelium of the blood vessels and 8
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cases were observed; 3 mice had two tumours. Tumours were seen in the liver (5), lymph 
nodes (2), spleen (2), kidney (1) and heart (1). MacroscopicaUy, the tumour appeared 
red, reddish-brown or black, soft spongy, cystic masses. The cut surface o f the tumours 
appeared honey-combed with different sized spaces fdled with blood. MicroscopicaUy, the 
tumours consisted o f atypical endothelial ceUs, forming vascular spaces lined by one or 
more layers o f highly polymorphic endothelial ceUs as weU as soUd ceUular masses. The 
vascular spaces were separated by varying amounts o f connective tissue. The neoplastic 
cells were spindle-shaped with hyperchromatic, round to oval nuclei; mitotic figures were 
common.
Two cases o f Harderian gland adenocarcinomas were identified; both mice also had 
métastasés in the lungs. MicroscopicaUy, the tumours were papiUary in structure, with 
ceUs resembling those o f the normal gland and invasion into the glandular stroma and 
surrounding tissue was apparent.
Two maUgnant mesotheUomas, located in the heart, were observed in these studies; 
métastasés were seen at 4 sites; kidney, rib, saUvary gland and sternum. HistologicaUy, the 
tumours were spindle ceUs tumour found in the endocardium.
Four cases o f maUgnant Schwannomas, derived from the Schwann ceUs o f the peripheral 
nerves or spinal gangUa, were seen. HistologicaUy, the tumour consisted o f paraUel rows 
o f densely packed spindle-shaped ceUs with elongated pleomorphic nuclei with many 
mitotic figures present.
Two cases o f meningeal sarcomas were observed developing in the meninges o f the brain; 
one animal also had a metastasis m the lungs. MicroscopicaUy, the tumours consisted o f  
spindle shaped ceUs, with indistinct cytoplasmic borders; mitotic figures were common.
Twenty-eight cases o f pancreatic islet ceU carcinoma were observed, with 15 showing 
metastasis at one site; 6  showing métastasés at 2 sites and 1 showing métastasés at 3 sites. 
Métastasés were most commonly found in the Uver (20) but they were also seen in lung 
(4); kidney (2 cases); fibia/tibia, sternum, testes and heart (1 case each). MacroscopicaUy, 
the tumours appeared as large white encapsulated masses in the pancreas which, were
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shown microscopically, to consist o f oval to spindle-shaped cells with enlarged pale nuclei, 
with many mitotic figures present.
Seven cases o f prostate adenocarcinoma were observed. Macroscopically, the tumours 
appeared as dark red, firm, masses which consisted histologically o f cuboidal and columnar 
epithelial cells with large and vesicular nuclei divided into lobular structures by fibrous 
connective tissue; mitotic figures were common and some invasion o f adjacent tissues was 
observed.
One case o f salivary gland carcinoma was seen which consisted histologically o f large, 
polygonal neoplastic cells with well-defined borders and granular eosinophilic cytoplasm.
Four cases o f seminal vesicle adenocarcinoma were observed and appeared grossly as 
large, firm, white-pink masses. Histologically, the tumour consisted o f pleomorphic 
columnar epithelial cells with a basophilic cytoplasm arranged in a papillary structure; 
occasional mitotic figures were seen.
One case o f Sertoli cell carcinoma o f the testes was seen and appeared grossly as a firm, 
white, lobulated mass. Microscopically, the tumour consisted o f fusiform cells with 
eosinophilic cytoplasm arranged in tubular structures. Adjacent neoplastic tubules were 
circumscribed and separated from one another by bands o f collagenous connective tissue.
One case o f squamous cell carcinoma o f the skin was observed as a dermal nodule with an 
ulcerated surface. Microscopically, the tumours consisted o f well-differentiated stratum 
comeum-like cells, containing comified material resembling keratinizing stratified 
epithelium; local invasion o f the dermis was seen.
Chapters. Results: Dosimetry 238
3.6. Skeletal dose from and in the comparative
toxicity study
Average skeletal doses to individual mice throughout life were calculated for use in a 
detailed statistical analysis o f tumour incidence and life-span as a function o f skeletal dose 
(Section 3.7) to death for each animal in the comparative toxicity study of^^^U, ^^ P^u and 
'^‘‘Am.
3.6.1. Calculation of average skeletal dose to death.
Retention o f ^^ P^u or "^^ A^m in the skeleton o f individual animals at death was 
determined by removing up to 6  bone groups (skull, mandibles, scapulae, femora, 
fibiae/tibiae and humeri) as described in Section 2.11 and performing radiochemical 
analysis on these bones as described in Section 2.4. It was assumed that the distribution of  
activity within the skeleton o f the mice at death was the same as that seen at 448 days in 
the studies on the distribution and retention o f the radionuclides in the individual bones o f  
the mouse skeleton reported in Section 3.2.
A mean value for skeletal retention at death was calculated from the individual results from 
each group o f bones. Figures 3.116-3.119 show the values obtained for total skeletal 
retention in each animal in the comparative toxicity study showing the overall loss o f each 
radionuclide from the skeleton with time. These data together with the data presented in 
Sections 3.1.2 and 3.2 for skeletal retention o f ^^ P^u and "^^‘Am at times up to 448 
days were used to fit equations for each nuclide o f the form:
% retained activity at time t =
a + p^+yr
where for a = -0.1016 P = 0.1914 y= 0.0003
^ ^ u  a = 0.0044 p = 0.0332 y = 0.00002
24iAm a = 0.0227 p = 0.0379 y = 0.00003
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Retention for individual mice at time-points o f interest throughout their lives (1 ,7 ,1 4 , 56, 
112,224 and 448 days) were then calculated using scaling factors relating expected 
skeletal retention at the time o f  death and skeletal retention calculated from measurements 
o f bones taken at death (sacrifice).
For each mouse, the cumulative average skeletal dose was then calculated using the 
trapezoidal method o f integration described in Section 2.11, using the estimated retention 
values for each time-point. Skeletal bone mass at each time point was estimated as 
described in Section 2.11. Figures 3.120-3.122 show the individual average skeletal dose 
to death calculated for each animal in the conq)arative toxicity study. Figure 3.123 
combines these data showing the increase o f dose with time was very similar for the low 
dose groups for the 3 radionuclides and for the medium and high dose and "^^ 'Am 
groups. Medium and high ^^^u dose groups were shown to have lower doses than 
corresponding and "^^ A^m groups.
In addition to the calculations o f life-time cumulative average skeletal dose, the average 
dose rates (mGy day *) were also calculated for the various time periods up to death. 
Figures 3.124-3.126 show the median daily dose rates for the low, medium and high dose 
groups for each radionuclide. The dose rate was assumed to be constant within the time 
periods and to change only on days 1, 7, 14, 28, 56, 112, 224 and 448. For all groups, 
there is an initial increase in the daily dose rate during the first 7 days, after which the dose 
rate remains fairly constant, falling sightly over the course of the experiment.
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Fig 3.116. Skeletal retention o f at death in all dose groups combined.
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Fig 3.117. Skeletal retention of at death in all dose groups combined.
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Fig 3.118. Skeletal retention of Am at death in all dose groups combined.
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Fig 3.119. Comparison of skeletal retention of and at death.241
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Fig 3.121. Cumulative average skeletal bone dose in mice injected with ^^^Pu
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Figure 3.125. Median dose rate for medium dose groups o f ^^^Pu and "^^‘Am241
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Figure 3.126. Median dose rate for high dose groups of ^^ P^u and 241
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3.6.2. Average skeletal dose in mice with osteosarcoma
As reported in Section 3.4, a total o f 46 mice were observed with osteosarcoma, o f which 
4, 26 and 14 were observed in the and '^‘‘Am dose groups, respectively. The
average skeletal dose to death for all animals in the con^arative toxicity studies were 
calculated as described in Section 3.6.1. Tables 3.37-3.39 show the individual skeletal 
doses to death for each animal with osteosarcoma and their survival time. The data are 
shown graphically in Figure 3.127. Table 3.40 gives the median average skeletal dose and 
the median survival time for each radionuclide and the individual dose groups.
Table 3.37. Average skeletal dose and time to death from osteosarcoma for mice injected 
with
D o s e  g r o u p T i m e  ( d a y s ) A v e r a g e  s k e l e t a l  d o s e  ( G y )
L o w 4 6 3 0 . 1 7 5
1 0 5 8 0 . 5 0 0
M e d i u m 8 7 3 1 . 2 3 2
H i g h 5 7 5 1 . 7 1 2
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Table 3.38. Average skeletal dose and time to death from osteosarcoma for mice injected 
with
D o s e  g r o u p T i m e  ( d a y s ) A v e r a g e  s k e l e t a l  d o s e  ( G y )
L o w 4 8 4 0 . 1 7 5
7 0 3 0 . 2 7 5
M e d i u m 5 7 8 0 . 6 6
6 3 0 0 . 5 7 1
7 4 8 0 . 5 7 2
7 7 2 0 . 9 4 3
7 8 1 0 . 8 3 8
9 9 5 1 . 0 0 0
H i g h 3 8 0 0 . 9 0 1
4 6 1 0 . 9 5 6
6 5 2 1 . 2 9 7
7 0 1 1 . 3 2 8
7 0 1 1 . 5 3 8
7 2 9 1 . 4 8 0
7 3 4 1 . 6 5 7
7 4 4 1 . 4 7 2
7 9 7 1 .7 4 1
8 4 0 1 . 8 3 4
8 6 5 1 . 6 9 6
8 6 9 1 .9 7 1
8 7 6 1 . 7 8 4
8 7 9 1 . 6 5 0
8 8 5 1 . 2 9 5
8 9 0 1 . 7 0 7
9 5 3 1 . 9 2 6
1 0 8 6 2 . 0 0 1
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Table 3.39. Average skeletal dose and time to death from osteosarcoma for mice injected 
with^ '^ A^m.
D o s e  g r o u p  T i m e  ( d a y s )  A v e r a g e  s k e l e t a l  d o s e  ( G y )
M e d i u m
H i g h
6 9 2 1 .0 0 3
8 0 5 1 . 1 8 4
8 8 5 1 .2 0 5
1 0 0 2 1 . 4 5 9
4 6 3 1 .0 1 3
6 7 5 1 .5 8 3
7 9 2 1 . 8 8 2
8 6 7 2 . 2 4 6
8 9 0 2 . 0 7 4
9 2 5 2 . 5 7 6
9 2 6 2 . 6 6 6
9 4 8 2 . 5 7 9
1 0 2 3 2 . 5 5 5
1 0 2 3 2 . 5 9 6
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Figure 3.127. Average skeletal dose to death from osteosarcoma in mice injected with 
233u, and
Table 3.40. Median average skeletal doses and median ages at death from osteosarcoma 
for mice injected with and '^^ A^m.
Dose group Median survival time (days) Median average skeletal dose 
(Gy)
Control 696 0
233u Low 761 0.258
Medium 873 1.024
High 575 1.426
239pu Low 594 0.261
Medium 760 0.475
High 819 1.282
Low - -
Medium 845 1.195
High 908 2.401
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3.6.3. Calculation of average bone dose at osteosarcoma sites
For bones in which osteosarcoma originated, life-span doses were calculated separately. 
For each bone, the cumulative dose was calculated using the trapezoidal method o f  
integration described in Section 2.11, using estimates o f the percentage o f total skeletal 
activity in the bone at the various time points prior to death (1 ,7 , 14, 28, 56,112, 224 and 
448 days) from the studies reported in Section 3.2. The distribution o f activity between 
individual bones at death was taken to be the same as that seen at 448 days. Individual 
bone mass was estimated from the ash weights o f the various bones by the method 
described in Section 2.11. As reported in the previous Section, 46 mice were observed 
with osteosarcoma, o f which 4 mice in the ^^^u high dose group and 1 mouse in the 
and 2"^ A^m high dose groups had two tumours.
Tables 3.41-3.43 show the individual bone doses to death for each osteosarcoma site and 
the survival time o f the animal. The data are shown graphically in Figure 3.128. Table 
3.44 shows the median bone dose and the median time until death for all radionuclides. It 
can be seen from the Tables and Figure that the bone doses for the bones with 
osteosarcoma appear to be higher in the '^’^ Am dose groups than those observed in the 
corresponding dose groups.
Table 3.41. Average bone dose and time to death from osteosarcoma for mice injected 
with
D o s e  g r o u p T u m o u r  s i t e T i m e  ( d a y s ) B o n e  d o s e  ( G y )
L o w U l n a 4 6 3 0 . 1 5 0
S t e r n u m 1 0 5 8 0 . 5 3 4
M e d i u m L u m b a r  V e r t e b r a e 8 7 3 1 .4 0 1
H i g h ’•‘L u m b a r  V e r t e b r a e 5 7 5 2 . 0 2 7
’•‘S t e r n u m 5 7 5 0 . 2 8 2
*  m o u s e  w i th  m u lt ip le  tu m o u r s
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Table 3.42. Average bone dose and time to death from osteosarcoma for mice injected 
with^^^u.
D o s e  g r o u p T u m o u r  s i t e T i m e  ( d a y s ) B o n e  d o s e  ( G y )
L o w M a n d i b l e 4 8 4 0 . 0 7 5
L u m b a r  V e r t e b r a e 7 0 3 0 . 4 6 7
M e d i u m F e m u r 5 7 8 0 . 6 7 9
F e m u r 6 3 0 0 . 6 1 2
L u m b a r  V e r t e b r a e 7 4 8 0 . 8 4 0
T h o r a c i c  V e r t e b r a e 7 7 2 1 . 5 9 9
F e m u r 7 8 1 1 .0 0 5
L u m b a r  V e r t e b r a e 9 9 5 1 . 8 8 2
H i g h L u m b a r  V e r t e b r a e 3 8 0 1 . 6 9 9
* F e m u r 4 6 1 1 .0 8 1
♦ C a u d a l  V e r t e b r a e 4 6 1 0 . 6 2 0
F e m u r 6 5 2 1 .4 3 5
C e r v i c a l  V e r t e b r a e 7 0 1 1 .8 4 1
L u m b a r  V e r t e b r a e 7 0 1 2 . 6 8 2
H u m e r u s 7 2 9 1 . 9 0 6
F e m u r 7 3 4 1 .6 7 5
♦ F e m u r 7 4 4 1 . 5 5 2
♦ C a u d a l  V e r t e b r a e 7 4 4 0 . 9 4 0
C a u d a l  V e r t e b r a e 7 9 7 1 . 2 7 8
♦ S k u l l 8 4 0 1 . 4 6 9
♦ H u m e r u s 8 4 0 2 . 2 9 5
L u m b a r  V e r t e b r a e 8 6 5 2 . 6 8 8
F e m u r 8 6 9 2 . 2 6 7
T h o r a c i c  V e r t e b r a e 8 7 6 3 . 2 3 5
C a u d a l  V e r t e b r a e 8 7 9 1 . 2 2 3
L u m b a r  V e r t e b r a e 8 8 5 2 . 1 9 7
H u m e r u s 8 9 0 2 . 2 1 2
♦ F e m u r 9 5 3 2 . 2 5 6
♦ H u m e r u s 9 5 3 2 . 6 7 4
F e m u r 1 0 8 6 2 . 1 0 5
* m o u s e  w i th  m u lt ip le  tu m o u r s
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Table 3.43. Average bone dose and time to death from osteosarcoma for mice injected 
with '^‘‘Am.
D o s e  g r o u p T u m o u r  s i t e T i m e  ( d a y s ) B o n e  d o s e  ( G y )
M e d i u m M a n d i b l e 6 9 2 0 . 5 3 2
T h o r a c i c  V e r t e b r a e 8 0 5 1 . 4 8 5
L u m b a r  V e r t e b r a e 8 8 5 1 .8 4 5
L u m b a r  V e r t e b r a e 1 0 0 2 1 . 8 6 8
H i g h L u m b a r  V e r t e b r a e 4 6 3 1 .4 2 5
F e m u r 6 7 5 1 . 3 3 9
L u m b a r  V e r t e b r a e 7 9 2 2 . 3 2 7
L u m b a r  V e r t e b r a e 8 6 7 2 . 9 4 0
M a n d i b l e 8 9 0 1 . 1 5 8
T h o r a c i c  V e r t e b r a e 9 2 5 3 . 3 2 2
C a u d a l  V e r t e b r a e 9 2 6 2 . 2 2 3
♦ F e m u r 9 4 8 2 . 0 4 3
♦ L u m b a r  V e r t e b r a e 9 4 8 3 . 1 3 4
L u m b a r  V e r t e b r a e 1 0 2 3 3 . 3 7 4
T h o r a c i c  V e r t e b r a e 1 0 2 3 3 . 9 7 7
* mouse with multiple tumours
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Figure 3.128. Average bone dose at osteosarcoma sites for mice injected with ^ ^ u  
and "^^‘Am.
Table 3.44. Median average bone doses for osteosarcoma sites and median ages at death 
for mice injected with and '^^ A^m.
Dose group Median survival time (days) Median average bone dose (Gy)
233U
239Pu
241 Am
Low
Medium
High
Low
Medium
High
Low
Medium
High
7 6 1
8 7 3
5 7 5
5 9 4
7 6 0
8 1 9
8 4 5
9 0 8
0 . 3 4 2
1 .4 0 1
1 .1 5 5
0 . 2 7 1
0 . 9 2 3
1 . 9 0 6
1 .6 6 5
2 . 3 2 7
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3.6.4. Average skeletal dose in mice with myeloid leukaemia
As reported in Section 3.4 a total o f 47 mice were observed with myeloid leukaemia, of 
which 8 , 18 and 2 1  were seen in groups o f  mice injected with and '^‘^ Am,
respectively. The average skeletal dose to death for individual animals in the con^arative 
toxicity studies were calculated as described in Section 3.6.1. Tables 3.45-3.47 show the 
individual skeletal doses to death for each animal with myeloid leukaemia and their 
survival times. The data are shown graphically in Figure 3.129. Table 3.48 gives the 
median average skeletal dose and median survival time for each radionuclide and the 
individual dose groups.
Table 3.45. Average skeletal dose and time to death from myeloid leukaemia for mice 
injected with
D o s e  g r o u p T i m e  ( d a y s ) A v e r a g e  s k e l e t a l  d o s e  ( G y )
L o w 5 9 2 0 . 2 7 6
6 3 4 0 . 1 9 4
6 3 7 0 . 2 3 9
6 7 5 0 . 2 8 2
M e d i u m 7 1 8 1 .1 5 5
8 2 3 0 . 8 9 3
H i g h 4 3 6 1 .4 2
6 0 4 1 .4 3 2
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Table 3.46. Average skeletal dose and time to death from myeloid leukaemia for mice 
injected with
D o s e  g r o u p T i m e  ( d a y s ) A v e r a g e  s k e l e t a l  d o s e  ( G y )
L o w 5 2 5 0 . 2 4 1
7 1 8 0 . 2 1 6
7 9 8 0 . 2 8
9 7 4 0 . 3 9 9
M e d i u m 5 7 6 0 . 3 2 2
6 6 1 0 . 4 7 5
7 1 6 0 . 6 2 5
H i g h 3 4 1 0 . 7 7 1
4 8 3 1 . 0 2 2
5 9 2 1 . 2 1 4
5 9 8 1 . 2 6 4
6 1 6 1 .3 1
6 2 8 1 . 2 0 6
6 4 5 1 . 4 4 2
6 6 9 1 . 2 8 2
7 0 0 1 .8 2 1
7 2 1 1 . 7 1 4
8 1 0 1 .7 4
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Table 3.47. Average skeletal dose and time to death from myeloid leukaemia for mice 
injected with
D o s e  g r o u p T i m e  ( d a y s ) A v e r a g e  s k e l e t a l  d o s e  ( G y )
L o w 6 9 7 0 . 2 8 5
8 0 1 0 . 3 3 6
8 8 3 0 . 3 2 9
9 9 7 0 . 5 1 3
M e d i u m 2 5 4 0 . 3 6 9
3 0 8 0 . 4 2 6
4 2 8 0 . 5 3 9
4 3 8 0 . 7 4 1
4 4 3 0 . 7 0 9
4 7 1 0 . 5 4 6
5 2 0 0 . 6 6 3
5 8 5 0 . 5 9
5 9 1 1 . 0 5 8
7 4 9 1 . 1 1 7
8 6 4 1 . 2 4 2
9 1 8 1 . 3 4 8
H i g h 3 4 5 1 . 0 5 9
4 5 0 1 . 3 4 7
5 0 7 . 1 .1 8 2
5 3 2 1 . 2 2 7
5 9 0 1 . 4 3 2
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Figure 3.129. Average skeletal dose to death for mice with myeloid leukaemia injected 
with ^^ P^u and
Table 3.48. Median average skeletal doses and median ages at death from myeloid 
leukaemia for mice injected with ^^ P^u and "^^ *Am.
Dose group Median survival time (days) Median average skeletal dose 
( G y )
2 3 3 u Low 6 3 6 0 . 2 5 8
Medium 771 1 . 0 2 4
High 5 2 0 1.426
Low 7 5 8 0 . 2 6 1
Medium 661 0.475
High 6 2 8 1 . 2 8 2
Low 8 4 2 & 3 3 3
Medium 496 0 . 6 8 6
High 507 1.227
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3.7. Statistical comparison of osteosarcoma and myeloid leukaemia 
incidence with skeletal dose and life-span using the Cox regression 
model
Methods o f statistical analysis such as the Kaplan-Meier estimate o f the probability o f  
survival (Section 3.4.2) and the Peto test used for analysis o f tumour incidence (Section 
3.4.3) can be used to analyse date from toxicological studies. However, when the number 
o f variables under analysis is large and/or the data become more complex, the effectiveness 
o f these methods can be limited and a statistical modelling approach such as the Cox 
regression model is used.
For the studies reported in this thesis, a modelling approach based on the Cox regression 
method (Section 2.12) was used to find the best fitting but simplest model to explain the 
hazard of death from myeloid leukaemia or osteosarcoma and the following variables were 
considered:
age at exposure 
dose rate 
radionuclide type
It is appropriate to use dose rate rather than the total cumulative dose to death as the 
measure o f exposure in this analysis. This is because dose from the radionuclides is 
delivered throughout the lifetime of the animals. If cumulative dose is used, it would be 
related in a complicated way to the response itself, ie. the survival time. Nevertheless, 
cumulative dose was used in survival analysis o f the data to compare the statistical 
significance of the resulting estimates with models based on using dose rate. The form of  
the Cox regression with dose rate as a time-dependent variable means that the last 
recorded dose rate before the time o f interest (death) is used. Models were also fitted to 
investigate the effect o f the dose rate during the time period 1 to 7 days as this was the 
time at which the dose rate peaked following injection into the body (Section 3.6.1).
Table 3.49 gives the median values for the cumulative average skeletal bone dose in Gy 
and the average skeletal bone dose rates in mOy day'  ^ at 448 days after initial injection in
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the various experimental groups; 448 days was the last date, other than at death, on which 
an estimate was made to determine the cumulative dose and dose rate. A few mice had 
already died by this time and so the number o f mice still alive is also given.
Table 3.49. Number o f mice alive, dose rate and cumulative dose at 448 days after initial 
injection with either ^^^u or "^**Am.
Radionuclide and 
exposure level
Number alive at 
448 days (%)
Median cumulative 
average skeletal 
bone dose (Gy)
Median average 
skeletal bone dose 
rate (mGy day )^
233u low 93 (93%) 0 . 2 0.3
medium 54 (90%) 0.7 1 . 2
high 44 (8 8 %) 1.3 2.3
low 90 (90%) 0 . 2 0.3
medium 52 (87%) 0.4 0 . 8
high 109 (84%) 1 . 0 2 . 0
^^'Am low 79 (79%) 0 . 2 0.4
medium 129 (8 6 %) 0 . 6 1.3
high 46 (92%) 1 . 2 2.3
3.7.1. Analysis of myeloid leukaemia incidence
3.7.1.1. Best fitting model
The best fitting but simplest model to explain the relative hazard o f death from myeloid 
leukaemia was:
h,{t)
K (f)
=  exp(P[age + Pj</ojerafe(0)
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where p, = 0.032,
and p2  = 0.604, irrespective o f radionuclide type.
Table 3.50 shows the significance o f each of the variables in the above model. Although 
the effect o f age at exposure only had a significance level o f around 9%, it was decided to 
retain this variable in the model. This was to allow for the allocation o f mice o f different 
ages to the exposure groups.
Table 3.50. Statistical significance o f variables in the best fitting model for myeloid 
leukaemia.
E f f e c t C h a n g e  i n  - 2 1 n L C h a n g e  i n  d e g r e e s  o f p - v a l u e
f r e e d o m  ( d . f )
A g e  a d j u s t e d  f o r  d o s e  r a t e 2 .9 1 1 0 . 0 8 8
D o s e  r a t e  a d j u s t e d  f o r  a g e 1 1 .3 2 1 0 . 0 0 0 8
Statistics to check the model gave no indication that individual observations were having 
an undue influence on the parameters pj and P2  or the model fitting in general and there 
were no unusual observations that were poorly fitted by the model.
The effect of dose rate was highly significant (P=0.0008) and an increase in the dose rate 
by ImGy day'  ^ corresponded to an increase in the hazard o f death from myeloid leukaemia 
by a factor o f 1.8 (95% confidence interval o f 1.3 to 2.6). The effect o f dose rate is 
illustrated Figure 3.130.
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Figure 3.130. Fitted line and 95% confidence limits for the effect of dose rate on the 
relative hazard of death from myeloid leukaemia (for all radionuclides combined).
3.7.1.2. Including a separate effect of dose rate for each 
radionuclide
There was no evidence that the effect of dose rate differed for the three radionuclides 
(change in -21nL = 1.14 on 2 d.f, P=0.56). Specifically, there was no significant difference 
between ^^^u and in the effect of dose rate (change in -21nL = 0.24 on 1 d.f, 
P=0.63) and the effect o f is consistent with no increase with increasing dose rate 
(change in -21nL = 1.40 on 1 d.f, P=0.24).
Although there was no evidence that the effect o f dose rate differed for the three 
radionuclides, it is informative to estimate the magnitude o f the effect separately for each 
of the radionuclides. The effect of increasing the dose rate by 1 mGy day** is shown in 
Table 3.51 along with 95% confidence intervals for each o f these estimates.
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Table 3.51. Estimated effect o f each radionuclide on the relative hazard o f death from 
myeloid leukaemia per unit increase in dose rate.
RadionucHde Increase in relative hazard of death 
from myeloid leukaemia for an 
increase in dose rate of ImGy day’^
95% confidence interval
Plutonium 1.8 (1.1, 2.8)
Americium 2.0 (1.4,2.9)
Uranium 1.5 (0.8, 2.7)
Figure 3.131 further shows the effect o f dose rate for each of the three radionuclides. To 
reduce the number o f curves on the graph, the 95% confidence limits have been omitted.
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Figure 3.131. Fitted curves for the three radionuclides showing the effect o f dose rate on 
the relative hazard o f death from myeloid leukaemia.
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3.7.1.3. Including a quadratic effect of dose rate
There was no evidence of a non-linear effect of dose rate on the log (relative hazard) as 
indicated by the addition of a quadratic term for dose rate in the best fitting model (change 
in -21nL = 0.08 on 1 d.f, P=0.78). Where the relative hazard is modelled as the 
exponential o f terms related to dose rate (Section 2.12).
3.7.1.4. Including an effect for the dose rate at days 1 to 7
The best fitting model described in Section 3.7.1 used the last calculated dose rates for 
each mouse dying o f myeloid leukaemia, usually 448 days. A term representing the dose 
rate during days 1 to 7, which was when the dose rate generally peaked, was included in 
the model. The last known dose rate was still found to be much more informative than the 
dose rate at days 1-7. There was some evidence, though not strong, that the dose rate at 
days 1 to 7 further improved the fit o f the best fitting model described in Section 3.7.1. 
However, the effect of dose rate at days 1 to 7 was highly correlated with the effect o f the 
last known dose rate, making the inteipretation o f models rather more problematic. The 
predictions from the models were very similar and it was decided that the best fitting 
model described in Section 3.7.1 should still be used for the purposes o f interpretation and 
description o f the effect o f dose rate.
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3.7.2. Analysis of osteosarcoma incidence
3.7.2.I. Best fitting model
The best fitting but simplest model to explain the relative hazard o f death from 
osteosarcoma was:
h.if)
= exp + P^doserate(t))
where pi = -0 .0 0 0 2 ,
Pz = 0.139 for 
p2  = 1.423 for ^^^u, 
and P2 = 0.815 for Am.
The best fitting model for osteosarcoma differed from that for myeloid leukaemia in that a 
single parameter for the three radionuclides was not sufficient to describe the effect o f  
dose rate. Consequently, a dose rate term (t) was included in the model to allow for 
different effects o f dose rate for each o f ^^Tu and "^^ *Am.
Table 3.52 shows the significance o f each o f the variables in the above model. Age at 
exposure was retained in the model to allow for the allocation o f mice o f  different ages to 
the exposure groups.
Table 3.52. Statistical significance o f variables in the best fitting model for osteosarcoma.
Effect Change in -21nL Change in degrees 
of freedom (d.f)
p-value
Age adjusted for dose rate and 
rad.dose rate
0.00 1 0.99
Dose rate adjusted for age 28.23 1 <0.0001
Rad.dose rate adjusted for age 
and dose rate
14.94 2 0.0006
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Statistics to check the model gave no indication that individual observations were having 
an undue influence on the parameters pj and p2  or the model fitting in general and there 
were no unusual observations that were poorly fitted by the model.
The effect o f dose rate was highly significant (P<0.0001) but a single parameter to 
describe the dose rate effect for the three radionuclides was not sufficient as indicated by 
the significance o f including the dose rate term into the model (P=0.0006). Specifically, 
the effect o f dose rate was significantly different between ^ ^ u  and '^‘'Am (change in -21nL 
= 8.94 on 1 d.f, P=0.003) and the estimates show that the effect o f dose rate was greater 
for ^^ P^u than it is for '^‘’Am. The effect of^^U is statistically consistent with no effect o f  
dose rate (change in -21nL = 0.07 on 1 d.f, P=0.79).
The effect o f increasing the dose rate by 1 mGy day"' is shown in Table 3.53 along with 
95% confidence intervals for each o f these estimates.
Table 3.53. Estimated effect o f each radionuclide on the relative hazard o f death from 
osteosarcoma per unit increase in dose rate.
R a d i o n u c l i d e I n c r e a s e  i n  r e l a t i v e  h a z a r d  o f  d e a t h  f r o m  
o s t e o s a r c o m a  f o r  a n  i n c r e a s e  i n  d o s e  r a t e  
o f  I m G y  d a y '*
9 5 %  c o n f i d e n c e  i n t e r v a l
P l u t o n i u m 4 . 2 ( 2 . 7 , 6 . 5 )
A m e r i c i u m 2 .3 ( 1 . 4 , 3 . 4 )
U r a n i u m 1 .1 ( 0 . 4 , 3 . 1 )
Figure 3.132 further shows the effect o f dose rate for each of the three radionuclides. To 
reduce the number o f curves on the graph, the 95% confidence limits have been omitted.
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Figure 3.132. Fitted curves for the three radionuchdes showing the effect o f dose rate on 
the relative hazard o f death from osteosarcoma.
3.7.2.2. Including a quadratic effect of dose rate
There was some evidence o f a non-linear effect o f dose rate as indicated by including a 
quadratic effect o f dose rate in the best fitting model described in the previous section 
(change in -21nL = 2.46 on 1 d.f, P=0.12). The significance of this quadratic effect o f dose 
rate was adjusted for all terms present in the best fitting model, ie. age and dose rate.
There was no evidence that this non-linear effect differed between the three radionuchdes. 
Adding a quadratic effect of dose rate (the same for all three radionuchdes) to the best 
fitting model, the resulting model and parameter estimates are:
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= exp (P^age + ^.^.^oserateit) ^^doserate{if)
where pj = 0.0006,
Pz= 1.233 fbr^^U,
P2  = 2.508 fbr^^u,
P2  = 2.012 for Am, 
and P2 = -0.415.
Table 3.54 shows the significance o f each o f the variables in the above model.
Table 3.54. Statistical significance o f variables in the best fitting model with adjustment 
for a quadratic effect o f dose rate.
Effect Change in -21nL Change in degrees of 
freedom (d.f)
p-value
Age adjusted for radiation dose 
rate and dose rate^
0.00 1 0.98
Dose rate^ adjusted for age and 
rad.dose rate
2.46 1 0.12
Radiation dose rate adjusted for 
age and dose rate and dose rate^
12.42 2 0.002
Inclusion o f a quadratic term for dose rate resulted in a reduction in the significance o f the 
dose rate term, although the evidence for this difference between the radionuchdes in the 
linear effect o f dose rate is stih strong. The linear effect o f dose rate was sthl significantly 
different between ^^^u and Am (change in -21nL = 5.42 on 1 d.f, P=0.02) and the 
estimates show that the effect o f dose rate was greater for ^^ P^u than for "^^ 'Am. The effect 
for was statisticahy consistent with no effect o f dose rate (change in -21nL = 0.45 on 1 
d.f, P=0.50). Figure 3.133 shows the effect o f dose rate for each o f the three 
radionuchdes based on the above model which includes a quadratic term for dose rate. 
(Figure 3.133 has been produced on the same scale as Figure 3.132 for ease o f  
comparison).
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Figure 3.133. Fitted curves for the three radionuclides o f the effect o f dose rate on the 
relative hazard o f death from osteosarcoma (with adjustment for a quadratic effect o f dose 
rate).
3.7.2.3. Including an effect for the dose rate at days 1 to 7
The best fitting model described in Section 3.7.2.1 used the last calculated dose rates for 
each mouse dying of osteosarcoma, usually 448 days. A term representing the dose rate 
during days 1 to 7, which was when the dose rate generally peaked, was included in the 
model. The last known dose rate was still found to be much more informative than the 
dose rate at days 1 to 7. The dose rate at days 1 to 7 further improved the fit o f the best 
fitting model described in Section 3.7.2.1 (change in -21nL = 6.10 on 1 d.f, P=0.01). 
However, the effect o f dose rate at days 1 to 7 was highly correlated with the effect o f the 
last known dose rate making the interpretation o f models rather problematic. The 
predictions from the best fitting model and a model including a term for dose rate at days 1
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to 7 were fairly similar although the predictions for uranium, based on the latter model, 
were less stable and difficult to interpret. It was decided that the best fitting model 
described in Section 3.7.2.1 should still be used for the purposes of interpretation and 
description of the effect o f  dose rate.
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Chapter 4: Discussion
4.1. Experimental animals
The CBA/H mice used in these experiments were obtained from the Medical Research 
Council (MRC) Radiobiology Unit, Harwell, Didcot, Oxon. The CBA mouse was 
developed by Strong in 1920 from a cross o f a Bagg albino female and a DBA male. The 
CBA/H strain kept at the MRC was originally derived in 1954 from the CBA/Ca strain 
kept by Carter since 1947 (Testing, 1979; Lyon et a/., 1996). Mole commented that the 
CBA/H strain was originally kept because o f its longevity (mean age at death o f 27 months 
for males and 29 months for females) and low incidences o f fatal diseases before 2 years o f  
age (Mole, 1958).
The CBA/H mouse has about a 1% incidence o f osteosarcomas and about a 0.07% 
incidence o f myeloid leiikaemia, 1  case o f myeloid leukaemia having been observed in 
>1400 mice (Humphreys et al., 1993). The mouse has a high incidence o f Hver tumours 
but the tumours do not start to appear until the mice have reached about 450 days o f age; 
Major (1979) reports an incidence o f about 70% in male mice and also reports incidences 
o f about 23% for lung tumours and about 1% for kidney tumours.
The strain has been extensively used both at the MRC and elsewhere in sub-colonies 
derived from the original colony; for example, in the Atomic Energy Board o f Canada 
facility in Chalk River, Ontario (Johnson et al., 1995), ENEA-Casaccia, Rome (di Majo et 
al., 1996), and ECN, Petten (Huiscamp et ah, 1991; Meijne, 1996; Meijne et al., 1991; 
1996; 1998).
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The CBA strain o f mouse was chosen for these studies because o f its low spontaneous 
incidences o f osteosarcoma and myeloid leukaemia and because it has shown a unique 
sensitivity among mouse strains to the induction o f osteosarcoma and myeloid leukaemia 
by radiation. Osteosarcoma has been induced by radionuclides such as ®^Sr (Loutit et al., 
1973), ^^ "^ Ra and ^^ R^a (Loutit et al., 1976; Humphreys et al., 1985a; 1993; 1998) and 
^^ P^u (Loutit et a l ,  1976; Humphreys et a l ,  1987). Myeloid leukaemias have been 
induced following X-irradiation (Major and Mole, 1978; Major, 1979; Mole et a l ,  1983) 
and administration o f  ^ '^‘Ra (Humphreys et a l ,  1985a; 1993; 1998) and ^^ P^u (Humphreys 
e ta l ,  1987).
The present studies o f the biokinetics of^^^U, ^^ P^u and '^‘‘Am were carried out in both 
male and female mice as it was hoped to examine the toxicological effects o f  these 
radionuchdes in both sexes. At the time the comparative toxicity studies were undertaken 
it was not possible to obtain female mice as these were required for MRC studies and 
therefore only male mice were used.
4.2. Biokinetics of and
Long-term retention o f Pu, Am and U is confined largely to the skeleton in ah mammahan 
species studied (ICRP, 1979; 1986; 1989; Durbin, 1973; Crawley a l ,  1976; Durbin et 
a l ,  1969; Vaughan et a l ,  1973). The dose from ^^^u, '^‘‘Am and to target ceUs for 
the induction o f osteosarcoma and acute myeloid leukaemia will depend on their gross 
retention in the skeleton, the distribution between different parts o f the skeleton and 
distribution within bone. Importantly, as discussed below, the radionuchdes differ in their 
initial pattern o f distribution on bone surfaces and in aspects o f their subsequent burial and 
the proportion transferred to marrow.
The hver is also an important site o f deposition for ^^ P^u and '^‘^ Am (Durbin, 1973; 
Humphreys et a l ,  1976; Lindenbaum et a l ,  1968; Uhberg et a l ,  1962). However, the 
elements are quite rapidly transferred from the hver o f rats and mice such that, as shown in
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Figures 3.3 and 3.4 (page 117), the skeleton accounts for more than 85% o f the body 
content after about 56 days. The situation is different in humans in that retention in the 
hver is considerably longer with an estimated half-time o f about 20 years (ICRP, 1986). 
Results consistent with longer retention half-times in the hver have also been obtained for 
hamsters and dogs (Crawley et ah, 1976; Lloyd et ah, 1978). For the overaU tissue 
retention is considerably lower than for ^^ P^u and due largely to rapid initial urinary 
excretion (Neuman et al., 1948a; 1953; Neuman and Neuman, 1948; Durbin and Wrenn, 
1975; Stevens et ah, 1980). The only significant site o f accumulation of^^^U other than 
the skeleton is the kidneys; the toxicity o f natural U is due to its chemical damage to the 
kidneys (Hursh and Spoor, 1973; Neuman, 1951). In humans, chemicahy toxic effects 
have been seen at average renal concentrations o f 2-3pg U per g o f  renal tissue (Bernard 
and Struxness, 1957).
Pu and Am ions are bound to the iron-transport protein, transferrin, in circulating blood, 
probably as Pu (IV) and Am (III) (Boocock and PoppleweU, 1965; Stover et al., 1968; 
Turner and Taylor, 1968a). A proportion o f each element wih also be present in low 
molecular weight form, probably as the citrate complexes, and it is likely that this 
proportion wih be greater for Am than Pu because the binding o f Am to transferrin is 
weaker than that o f Pu (Turner and Taylor, 1968a, Bruenger et al., 1969; Cooper and 
Go wing, 1981). Uptake o f both elements into the hver involves transfer from transferrin 
to the iron-storage protein, ferritin, in hepatocytes (Turner and Taylor, 1968a;b; Bruenger 
et al., 1969a;b). The association o f Pu and Am with the longer-term storage protein, 
haemosiderin, in hver reticuloendothehal cehs has also been demonstrated (Bruenger et al., 
1969a; b; Boocock et al., 1970). The reasons for species differences in the hepatic 
retention o f Pu and Am are not understood but may relate to differences in transfer to 
haemosiderin, or differences in uptake into lysosomes and transfer to bile (Bruenger et al., 
1971).
In bone, the binding o f Pu and Am to plasma transferrin wih lead to their dehvery to 
reticulocytes the main destination o f iron transport, for the synthesis o f haem. However, 
as shown in Figures 3.9, 3.10, 3.13 and 3.14 (pages 140 and 142), the initial distribution o f  
^^ P^u and Am in bone is largely inconsistent with association with cells in the marrow
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although some diffuse distribution o f  ^ ^^ Pu in the marrow is apparent. The main site o f  
deposition, as established in previous studies, is the bone surfaces (Jee and Arnold, 1961; 
Vaughan et al., 1973), indicating the presence o f molecules with a higher binding affinity 
for Pu and Am than transferrin. It has been suggested that the binding molecules are 
glycoproteins or proteoglycans, constituents o f the osteoid layer o f unminerahsed new 
bone on growing surfaces (Chipperfield and Taylor, 1968; 1970; 1972; Williams and 
Peacocke, 1965). However, this suggestion is not consistent with the presence of^^^u 
and "^^ A^m on all types o f bone surface, including resting and resorbing areas, and the 
observation that ^^ P^u on growing surfaces is largely concentrated on the surface o f the 
mineralised bone (Priest, 1981). Other studies have implicated phosphoproteins, 
demonstrating the ability o f molecules in mineralising rat dentine to bind lanthanum 
(Cooksan et al., 1979); binding to phospholipids has also been suggested (Bulman, 1980). 
Uptake o f radium from transferrin and incorporation into ferritin in osteoblasts has also 
been demonstrated (Spanner et al., 1992). Uptake into osteoblasts may also occur for 
^^ P^u and '^‘‘Am with important implications for their potential to induce osteosarcoma.
Differences are apparent in the initial pattern o f distribution of  ^ ^^ Pu and ^^ *'Am in the 
skeleton. As shown in Figures 3.9, 3.10, 3.13 and 3.14 (pages 140 and 142), ^^ P^u 
deposits preferentially on endosteal surfaces while Am deposits more evenly on 
endosteal and periosteal surfaces and within vascular canals. These differences may reflect 
quantitative rather than quahtative differences in their binding to transferrin and Ugands in 
bone. Binding to periosteal surfaces and the walls o f vascular canals involves passage 
through the endothelium o f blood vessels and may therefore favour "^^ A^m in comparison 
with ^^ P^u because o f weaker binding to plasma transferrin retained within the vessels.
The sinusoidal nature o f marrow does not present the same barrier to endosteal deposition.
Uranium is present in blood as the hexavalent uranyl ion, (U 0 2 )^ ,^ binding to transferrin 
with a proportion circulating as U(VI) bicarbonate (Stevens et al., 1980; Gindler, 1973). 
The rapid early urinary excretion o f the major proportion o f U reaching the circulation is 
indicative o f weak protein binding. In the skeleton, uranyl ions replace Ca^  ^on the surface 
of the hydroxyapatite crystals o f mineral bone (Priest et al., 1982; Stevens et al., 1980). 
The size o f the (U0 2 )^  ^ions are thought to prevent inclusion in the internal domain o f  the
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crystal lattice and it then remains on the crystal surfaces, subject to ion exchange reactions. 
As shown in Figures 3.17 and 3.18 (page 144), the initial pattern o f distribution of^ %  in 
mouse bone is uneven. This observation is consistent with previous findings (Priest et al., 
1982) and is thought to be due to preferential binding to growing surfaces by 
coprecipitation with Ca^  ^during bone formation. While the highest concentrations 
were associated with bone surfaces, a proportion o f the activity in bone appeared to be 
diffusely distributed throughout the bone mineral.
A comparison o f the long-term retention of^^^Pu, "^‘'Am and in the skeleton o f rats 
has been reported by Sontag (1983; 1984). The animals used were over a year old at the 
time o f injection. As in the present study using mice, skeletal retention of^^^Pu and Am 
in the rats was several times greater than that of^^^U (2-4 times greater in rats; 5-6 times 
greater in mice). However, in contrast to the results for mice, a difference in retention 
between male and female rats was shown for Am and although not for ^^ P^u. At 
one week after injection, the skeleton accounted for 17% and 29% o f administered '^‘‘Am 
in female and male rats, respectively, with corresponding values o f 8 % and 15% for 
the skeleton retained about 40% of administered ^^ P^u in females and male animals. These 
differences between females and males for Am and were maintained over the 
duration o f the study o f more than one year (Sontag, 1984). In comparison, skeletal 
retention in our mice showed no differences between females and males with values at 7 
days after injection o f about 25-28% o f administered activity for ^^ P^u and "^^‘Am and 
about 7% for The observed differences may be a reflection o f different skeletal 
growth rates between old rats and young adult mice ( 1 2  weeks old) and between female 
and male rats. Comparison with the results obtained by Sontag (1983; 1984) for female 
rats with data from short-term studies using younger rats (Priest et al., 1982; Crawley et 
al., 1976; Lynch et al., 1988) show greater skeletal retention in the younger growing 
animals for ^^^u, ^ '^Am and Sontag (1984) showed that while the skeletal weight 
was proportional to body weight in old female and male rats, the skeletal weight o f  the 
female rats remained constant, whereas the skeletal and body weight o f  male rats increased 
progressively. That the difference between females and males applied to "^"Am and 
but not ^^ P^u suggests that skeletal uptake o f  ^ ^^ Pu was relatively insensitive to the greater 
skeletal turnover and growth in males. This may reflect a greater affinity o f binding
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ligands in bone for than for and
Differences between Am and in their distribution between individual bones o f
the skeleton in mice are consistent with results reported by Sontag (1983; 1984) for 
distribution in rats. Thus, the general pattern o f distribution of the nuclides was similar in 
both species, with greater concentrations in the main body o f the spine, limb girdles and 
ribs and lower concentrations in the paw bones, head bones and caudal vertebrae. The 
inhomogeneity o f distribution was in the order Pu > U > Am in both species but with 
somewhat greater values in mice than in rats. For example, for ^^ P^u inhomogeneity 
changed from 0.6 to 0.4 (Figures 3.7 and 3.8, page 136) in mice over 448 days while the 
corresponding change in rats was from 0.45 to 0.3. Data for the distribution for ^^ P^u and 
"^^‘Am in the human skeleton, from four cases o f long-term occupational exposure, have 
been compared with data for baboons and monkeys by Lynch et al. (1988). As in rodents, 
the greatest concentrations were in the thoracic and lumbar vertebrae and inhomogeneity 
was greater for ^^ P^u than for "^^‘Am. It would appear that factors affecting distribution 
between different bones are the proportion o f trabecular bone, and consequently the 
relative surface area for deposition, and differences in blood supply (Kathren et al., 1987; 
Humphreys et al., 1977).
The high values obtained for the initial uptake o f  ^ ^^ Pu and "^^‘Am in the mouse liver o f  
about 40-45% o f injected activity are consistent with previous results for ^^ P^u in mice 
(Humphreys et al., 1976). Comparison o f  ^ ^^ Pu distribution in a number o f strains o f mice 
showed that uptake in the liver was particularly high in CBA/H mice, and that skeletal 
retention was correspondingly lower due to direct competition for circulating ^^ P^u.
The burial o f surface deposits o f  ^ ^^ Pu, '^^ A^m and in areas o f bone growth (Figures 
3.11, 3.12, 3.15, 3.16, 3.19 and 3.20, pages 141, 143 and 145) is consistent with previous 
findings (Jee, 1972; Neuman and Neuman, 1948; Priest et al., 1982; Vaughan et al., 1973; 
Priest et al., 1983). This process results in a reduction in radiation dose to sensitive cells 
on or near bone surfaces and in the bone marrow because o f the short range o f  alpha- 
particles in bone o f less than 30pm. The current ICRP dosimetric model for isotopes o f  
Pu and Am (ICRP, 1989; 1993) takes account o f burial o f activity in bone although it does
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not take account o f the differences in the initial distribution of the two elements on 
different bone surfaces (Section 1.5.4). For autoradiographs (Figures 3.17-3.20, 
pages 144 and 145) showed that a proportion o f the activity in bone was diffusely 
distributed throughout bone mineral from one day after injection. At later times, burial o f  
surface deposits was observed but with no indication o f a trend towards uniform 
distribution, contrary to the assumptions made in the current ICRP model (ICRP, 1995a).
Transfer from bone to marrow is recognised as an important aspect o f the behaviour o f  
isotopes o f Pu and is included in the ICRP model (ICRP, 1989; 1993). Retention in the 
marrow is thought to be due to uptake in macrophages (Jee, 1972; Vaughan et al., 1973). 
The autoradiographs show that transfer of^ ^^ A^m was less than that of^^^Pu and 
accumulation of^ %  in the marrow was negligible (Figures 3.11, 3.15 and 3.19, pages 
141, 143 and 145). Each o f these observations is consistent with the behaviour o f  the 
nuchdes in rats (Priest et al., 1985). While the ICRP actinide model (ICRP, 1989; 1993) 
includes accumulation in the marrow, the same parameters are applied to isotopes o f  Pu 
and Am and no account is taken o f quantitative differences. The alkaline earth model 
(ICRP, 1993) adopted for isotopes of U (ICRP, 1995a) does not consider retention in the 
bone marrow, consistent with the negligible accumulation of^^U in marrow observed in 
these studies.
Preliminary quantitative estimates o f the distribution o f  ^ ’^Pu, '^‘‘Am and in bone were 
made in these studies (Table 3.20, page 148) and this work is being continued at the 
Paterson Institute for Cancer Research, Christie Hospital, Manchester (Cartlidge et al., 
1998). Estimates o f cumulative dose to 224 days after radionuclide administration have 
been made considering:
1 ) the region 0 - 1 0 pm from the cortical and trabecular endosteal surfaces, thought to 
contain the target cells for osteosarcoma induction (ICRP, 1989),
2) aU red bone marrow, considered by ICRP (1989) to present a random distribution o f  
target cells for leukaemia induction, and
3) the central 100pm regions o f red marrow which may contain the highest concentration 
o f leukaemogenic target cells (Lord, 1990).
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Considering administered activities giving equal average bone doses, doses delivered to 
the three regions o f interest were in each case in the order dose to the
central marrow from was negligible.
4.3. Comparative toxicity of and
This study was undertaken using male mice; female mice were unavailable. It has been 
reported (Müller et al., 1978; Taylor et al., 1983) that female mice are more susceptible 
than males to osteosarcoma induction and that males are possibly more susceptible to 
myeloid leukaemia induction (Major, 1979).
Groups o f mice (50-100) were given three activity levels o f each o f (36-211 kBq 
kg"'), ^^Tu (5-27 kBq kg' )^ and ^^ A^m (6-33 kBq kg' )^. The administered activities were 
intended to deliver equal average skeletal doses o f the three radionuclides to 448 days, 
calculated on the basis o f the earlier distribution studies o f 0.1 Gy, 0.3 Gy and 0.6 Gy. In 
practice, mean average skeletal doses to death were estimated as 0.28±0.07 (±SD), 
0.97±0.28 Gy and 1.71±0.45 Gy for the groups, 0.26±0.07 Gy, 0.65±0.26 Gy and
1.38±0.34 Gy for the ^^ P^u groups and 0.29±0.11 Gy, 0.92±0.26 Gy and 1.81±0.56 Gy for 
the "^^ 'Am groups. These values and plotted values for individual animals (Figure 3.123, 
page 243) show that doses from the three radionuchdes in corresponding groups were 
similar except for the somewhat lower doses received by medium and high dose ^^^u 
groups.
In some reports o f tumour induction by radionuchdes in animals, doses were not 
calculated to death but rather to some time before death to distinguish between dose 
resulting in initiation o f the mahgnancy and "wasted dose" dehvered during tumour 
progression. For example the "radiation-independent time" has been assumed to last 12 
months for beagle dogs (Bruenger et a l ,  1991; Thurman et al., 1971) and 140 days for 
mice (Mays et al., 1989). Clearly such assumptions involve arbitrary decisions as to when 
tumour initiation may have taken place, likely to be different for different tumour types. In 
some cases, radiation may have a role in tumour progression as weU as initiation. In the
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regression analysis undertaken in these studies, tumour incidence was analysed in terms o f  
dose rate received by individual animals.
A deficiency in the experimental design was that control mice were introduced into the 
study earlier than those in experimental groups. A better design would have involved 
randomly assigning mice to control and experimental groups. Criteria for sacrificing mice 
found to have tumours (specifically hver adenoma) changed during the course o f the study 
and as a result, a larger number o f mice in the control group than in the experimental 
groups were kihed during the 400-600 day period. This is reflected in the Kaplan-Meier 
plots for survival (Figures 3.30-3.32, page 171). Nevertheless, average survival times 
were similar in control and experimental groups and consistent with reported survival 
times for CBA/H mice (Humphreys eta l., 1985a; 1987; 1989; 1993; 1998; Major, 1979; 
di Majo et al., 1996; Myers et al., 1991; Smith et al., 1973).
4.4. Osteosarcoma
A total o f 50 osteosarcomas were recorded in 46 mice. Two osteosarcomas were 
identified in control mice {ie. 2% incidence); Humphreys etal. (1985a; 1987; 1993) 
reported one case o f osteosarcoma in about 600 unirradiated CBA/H mice. Total numbers 
o f osteosarcomas in mice exposed to ^^ P^u and '^^ ‘Am were 5, 30 and 15, 
respectively, with incidences in the three dose groups o f 2 % in each case for 2 %,
11% and 15% for ^^ P^u and 0%, 3% and 21% for "^^ A^m. Cox regression analysis o f  
osteosarcoma incidence as a fimction o f dose rate showed that:
1 ) considering ah radiation-induced tumours together, there was a highly significant 
increase in risk with increasing dose rate,
2 ) ^^ P^u was more effective than "^*^ Am in inducing osteosarcoma; for example, an increase 
in dose rate o f 1 mGy d'^  increased the relative hazard o f osteosarcoma by a factor o f 4.2 
{2.1-6.5) for ^ ^ u  and 2.3 (1.4-3.4) for ""‘Am,
3) the effect o f was lower than that o f "^ P^u and ""‘Am and was statisticahy consistent 
with no effect o f dose rate.
Thus, the effectiveness o f induction o f osteosarcoma by the three radionuchdes in terms o f
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equal average skeletal dose can be summarised as: "^ P^u>""‘Am>"^^U=controls. There was 
a suggestion from the results that "^ P^u was not only more effective than ""‘Am in the 
induction o f  osteosarcoma but that "^^u induced tumours occurred earlier than those 
induced by ""‘Am. In addition, a difference was apparent in the sites o f osteosarcoma in 
the skeleton after exposure to "^ P^u and ""‘Am. For "^ P^u, osteosarcoma was observed in 
almost equal proportions in the axial and appendicular regions o f the skeleton, principally 
in the vertebrae and femora. For ""‘Am, most tumours occurred in the vertebrae.
The observed incidences o f osteosarcoma in male CBA/H mice after exposure to "^ P^u o f  
2% at 5 kBq kg ‘, 11% at 15 kBq kg ‘ and 15% at 25 kBq kg ‘ are consistent with 
reported incidences in females o f the same strain o f 7.5% at 6  kBq kg*‘ and 30% at 19 kBq 
kg*‘ (Humphreys et al., 1987) and the observation that females are more sensitive than 
males to osteosarcoma induction by a factor o f 3-4 for "^ P^u and 4-6 for ""^ Ra (Loutit et 
al., 1976). Similar incidences have been reported for male ICR mice exposed to "^ P^u o f  
2% at 3 kBq kg ‘, 3% at 6  kBq kg ‘ and 10% at 12 kBq kg ‘ (Svoboda and Budenflcova, 
1990). Finkel and Biskis (1962) also observed similar incidences o f  osteosarcoma in 
female CFl mice exposed to "^ P^u o f 4% at 6  kBq kg ‘, 8 % at 13 kBq kg ‘ and 10% at 26 
kBq kg ‘ suggesting that this strain is less sensitive to osteosarcoma induction or that 
male/female differences are less apparent. Taylor et al. (1983) administered "^ P^u to male 
C57BL/DO mice and observed an incidence o f 27% at 32 kBq kg*', and zero incidences at 
lower activity levels o f 3.5 and 10.6 kBq kg '.
The observed incidences o f osteosarcoma in male CBA/H mice exposed to ""‘Am o f zero 
at 6  kBq kg ', 3% at 17 kBq kg ' and 21% at 29 kBq kg ' are consistent with reported 
incidences in the same strain o f 2% at 1.5 kBq kg ', 2% at 7 kBq kg ', 4% at 15 kBq kg ' 
and 45% at 300 kBq kg ' (Nilsson and Broomé-Karlsson, 1976). Lower incidences were 
observed in male C57BL/Do mice (Taylor et al., 1983) and male C57BL mice (Schoeters 
and Vanderborght, 1983; 1989).
Finkel (1953) studied the induction o f osteosarcoma in female CFl mice by radionuchdes 
including and observed incidences o f 0.9% at 3.7 kBq kg ', 3% at 18.5 kBq kg ', 5% 
at 37 kBq kg ', 8 % at 92.5 kBq kg ', 13% at 185 kBq kg ', 24% at 371 kBq kg ' and 31%
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at 925 kBq kg '. Thus, female CFl mice appear to be more sensitive to induction of 
osteosarcoma by than male CBA/H mice in which observed incidences were 2% for 
each group after administration o f 40, 118 and 197 kBq kg*‘.
Sex differences in the induction o f osteosarcoma are probably a reflection o f differences in 
bone turnover with greater rates o f turnover in females. Taylor et a l  (1983) showed that 
removal o f the gonads resulted in similar incidences in male and female mice after "^ P^u 
exposure. Nilsson and Rormbach (1973) demonstrated that long-acting oestrogens 
administered subcutaneously to mice increased the incidence of osteosarcoma induction by 
°^Sr. Tumour incidence was not increased in control animals. The increased effectiveness 
of administered radionuclides resulting fi*om oestrogen induced increases in bone turnover 
is probably attributable to continued redeposition o f activity on bone surfaces near to 
target cells.
The observed difference in osteosarcoma induction by "^ P^u and ""‘Am in these studies 
using CBA/H mice appeared to be smaller than reported previously. Bensted et al. (1965) 
reported that 17 out o f 22 male rats given 108 kBq kg ‘ developed osteosarcoma 
compared with 4 out o f 19 given 92 kBq kg ‘ ""‘Am. Using small groups o f animals (10- 
20), Taylor et al. (1983) showed a significantly greater incidence o f osteosarcoma in male 
and female C57BFDo black mice given 105 kBq k g ‘ and 32 kBq k g ‘ of""Tu than in 
comparable groups given 102 kBq k g ‘ and 30-34 kBq k g ‘ of ""‘Am. Similar studies using 
C57BL/DO albino mice showed greater osteosarcoma incidence with ""^ Pu than ""‘Am in 
female mice but no difference in male mice. Taylor et al. (1983) concluded that ""^ Pu was 
about three times more effective than ""‘Am in terms o f equal average skeletal doses.
They also showed that both ""^ Pu and ""‘Am were substantially more effective than ""^ Ra, 
consistent with the lower incidence o f osteosarcoma observed after exposure to "^ "U in 
these studies. Radium, as an alkaline earth element behaves similarly to Ca and is 
incorporated into bone mineral in place of Ca leading to more rapid burial after initial 
deposition on bone surfaces than is observed with elements such as Pu and Am. Uranium 
shows similarities to the behaviour of the alkaline earth elements and its behaviour in bone 
is modelled by ICRP by a modification o f the model for these elements (ICRP, 1995).
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The greater effectiveness o f than in the induction o f osteosarcoma for equal 
average skeletal doses is consistent with the difference between the nuclides in the 
proportion of dose delivered to endosteal bone surfaces (see above). Thus, ^^Pu delivers 
a greater proportion of its dose to endosteal surfaces, particularly trabecular endosteal 
surfaces. The observed difference between ^^Tu and Am in the distribution of 
osteosarcomas in different skeletal sites is probably also a reflection o f differences in their 
distribution within bone. As illustrated in Table 3.34 (page 184), ^^ P^u and "^^ 'Am induced 
quite similar numbers o f osteosarcomas in the axial skeleton, mainly the vertebrae, but 
^^ P^u appeared more effective in inducing tumours in the appendicular skeleton. It is 
possible that in the long bones o f the appendicular skeleton, with their smaller proportion 
of trabecular bone, a greater proportion of alpha-emissions from Am are "wasted" on 
surfaces, particularly periosteal surfaces, with low potential for osteosarcoma induction. It 
may be that because of its preferential association with trabecular endosteal surfaces, ^^ P^u 
is more effective than '^‘^ Am and this difference is more noticeable in the long bones.
4.5. Myeloid leukaemia
A total o f 47 leukaemias were recorded, none in controls, 8  in total in exposed 
groups, 18 for ^^Pu and 21 for "^”Am. Humphreys et al. (1993) reported one case o f  
leukaemia in over 1400 control CBA/H mice. Incidences were 4% in each group,
4%, 6 % and 9% in ^^ P^u groups and 4%, 8 % and 10% in '^^ 'Am groups. Kaplan-Meier 
plots illustrate that in general leukaemia occurred somewhat earlier than osteosarcomas. 
Cox regression analysis of myeloid leukaemia incidence as a function o f dose rate showed 
that:
1 ) considering aU leukaemias, there was a highly significant increase in risk with increasing 
dose rate,
2 ) there was no significant difference in effect between ^^Pu and "^^‘Am,
3) the effect o f was lower than that of^^^Pu and Am and statistically consistent with 
no effect o f dose rate.
Thus, the effectiveness o f induction of myeloid leukaemia by the three radionuclides in 
terms o f equal average skeletal doses can be summarised as: ^^ P^u=^ ’^Am>^^^U=controls.
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Major and Mole (1978) reported the induction o f myeloid leukaemia in CBA/H mice by 
X-irradiation, showing a peak incidence at about 2 Gy o f about 20% in male mice; no 
leukaemias were seen in controls. Di Majo et al. (1986) reported a similar dose-response 
for CBA/Cne mice exposed to X-rays. The induction o f smaU but significant numbers o f  
myeloid leukaemias in CBA/H mice by ^^Pu and ^^ "^ Ra has also been demonstrated 
(Humphreys et a l ,  1985a; 1987; 1993; 1998); an incidence o f 5% was recorded for 
exposure at 5 kBq kg'\ Svoboda et al. (1982) have presented less clear data using ICR 
mice with a spontaneous incidence o f about 2 0 %; they claimed that ^^ P^u increased risk 
and shortened onset. Myeloid leukaemia has also been diagnosed in small numbers in rats 
given ^^Pu (Bensted et a l ,  1965).
Comparison of the incidence of myeloid leukaemia in CBA/H mice exposed to ^^Pu and 
'^’^ Am o f up to 10% and the incidence o f 20% after 2 Gy X-irradiation (Major and Mole, 
1978) suggests a low RBE for the effect o f alpha irradiation from these nuclides since the 
average bone doses in animals developing myeloid leukaemia were in the range of 0 .2 - 2  
Gy. However, this comparison ignores differences in the time-course o f dose delivery and 
the localisation o f alpha dose within bone relative to target cells.
The assumption made by ICRP for the purposes o f estimating doses and risks o f leukaemia 
is that target cells are uniformly distributed throughout red bone marrow (ICRP, 1979; 
1989). However, marrow fractionation studies have shown that in the femoral shaft o f the 
mouse, the more primitive, pluripotential haemopoietic stem cells, believed to be the target 
cells for myeloid leukaemia are concentrated towards the central or axial region o f the 
bone marrow, close to the central venous sinus (Lord, 1990). Preliminary estimates o f the 
proportions o f alpha dose from ^^ P^u and “^^ 'Am dehvered to different marrow regions 
do not correlate completely with observed incidences o f myeloid leukaemia. Thus, the low  
effectiveness o f is consistent with the low dose to marrow, the dose to the axial 
region being negligible. For ^^ P^u and '^**Am, accumulation in marrow macrophages at 
later times after administration leads to dose to the axial region but greater accumulation 
of^^Pu is not reflected by greater incidence o f myeloid leukaemia.
H u m a n  e x p o s u r e  t o  R a  i s o to p e s  h a d  b e e n  s h o w n  to  r e s u l t  in  o s te o s a r c o m a  b u t  n o t
'  J
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leukaemia (Sections 1.6.3 and 1.6.5.1) and it has been suggested that target cells are not 
sufficiently close to the bone surfaces to be irradiated. Thorotrast patients have developed 
leukaemia (Section 1.6.5.1); the colloidal ^^ T^h oxide is distributed throughout marrow. 
However, Wick et a/. (1986) have reported marrow neoplasms in ankylosing spondylitis 
patients exposed to It is possible that irradiation of target cells in the marrow is 
from its daughter ^^ °Rn diffusing from the bone marrow rather than directly from ^^ "^ Ra 
decay. It seems likely that ^^ P^u and Am have the potential to cause myeloid leukaemia 
in humans due to their transfer to marrow macrophages during bone remodelling.
4.6. Other tumours
As expected with the CBA/H mouse, high incidences of liver tumours, both adenoma and 
carcinoma, were observed in experimental and control groups (Section 3.4.1.5). Although 
the incidences o f carcinoma in experimental groups appeared greater than in controls {eg. 
Figure 3.27, page 158), a significant increase was only recorded for "^^ A^m groups, with 
75% incidence in the high dose group compared with 43% in controls.
Nilsson and Broomé-Karlsson (1976) report an increased incidence o f liver hepatomas 
after the administration o f 1.48, 7.4 and 14.8 kBq kg’* of '^ *^Am to CBA male ntice, with 
incidences o f 67%, 67% and 72%, respectively, compared to 56% in controls. An 
increase in the incidence o f liver tumours in dogs has also been reported following the 
administration o f  ^ ®^Pu0 2  (Weller et al., 1995), ^^ P^u and "^**Am (Lloyd et al., 1994 a;b).
An increased number of renal carcinomas was evident in the experimental groups when 
compared to the control group ( 1 %), particularly for with incidences o f up to about 
15% at the highest dose. Kidney tumours resulting from exposure to U  isotopes have not 
been reported by other authors but damage to the proximal convoluted tubules and other 
signs o f chemical toxicity have been reported following administration o f large amounts o f  
U  (Haley, 1982; Haley et al., 1982; Morrow et al., 1982). It is possible that the renal 
carcinomas in this study were induced as a result o f the chemical toxicity o f U  rather than 
its radiotoxicity. Renal carcinoma has not been a recognised feature of radiation exposure
Chapter 4. Discussion 284
in animals or man (UNSCEAR, 1997; BEIR 1980; 1988).
4.7. Dentition abnormalities
Dentition abnormalities, apparent as broken or overgrown incisors, were observed as mice 
aged. Incidences in experimental groups were greater than in controls (16%), particularly 
for 2"*Am (35-67%).
Humphreys et al. (1985b) reported dentition abnormalities following the administration o f  
^^ "*Ra that were consistent with the findings in these studies. Thus, the abnormalities were 
more frequent in the upper incisors than in the lower incisors. Mandibular incisors 
opposite short upper incisors were often overgrown. The molars appeared normal with no 
visible periodontal disease. Disturbances o f dentition have also been reported in the dog 
following X-irradiation o f the jaws and the administration o f bone-seeking isotopes (Jee 
and Arnold, 1960; Taylor et al., 1978). Taylor and Bensted (1969) gave 260 kBq kg'* 
"^**Am to rats resulting in varying degrees o f damage ranging from loosening o f the incisors 
with breakage o f the tooth to complete loss o f the upper incisors with marked overgrowth 
o f the lower incisors and severe damage to the molar dentition.
In the mouse and rat, unlike humans, there is only one generation o f teeth. Normal mouse 
dentition consists o f an incisor and three molars in each quadrant. Rodents obtain their 
food by a gnawing action which causes considerable wearing down o f the incisors, which 
must therefore be renewed by a process o f continuous eruption (Pearson and Phelps,
1981). New tooth substance is continually produced in the odontogenic organ, or tooth 
progenitor region, situated proximally, deep in the bony socket. These cells are supported 
by a complex system o f connective tissues and nutrient vessels. It is this tooth progenitor 
region which is most radiosensitive; irradiation o f the cells in this region will later manifest 
itself as tooth damage. Hansen and English (1957) and Adkins (1967) have described the 
sequence o f events at the histological level which produce changes in the incisors which 
could be described as early as 5 days after irradiation. Following a large dose o f radiation, 
destruction o f apical endothelioblasts causes vascular thrombosis and subsequent loss o f
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blood supply to the distal part o f the tooth. Dentine formation ceases and osteodentin is 
formed. Thus, a broken or missing tooth may result from a weakness in the defective 
tooth substance. After extreme damage it is possible that the entire odontogenic organ 
could be destroyed, thus preventing the production o f any new tooth substance.
4.8. Conclusions
These studies have provided information on the distribution and retention of^^^U, ^^ P^u 
and '^”Am in the skeleton o f the CBA/H mouse and on their relative toxicity, principally in 
terms o f induction o f osteosarcoma and myeloid leukaemia.
The relative effectiveness o f the three radionuclides in the induction o f osteosarcoma is 
explainable in terms o f dose delivered to or near to endosteal bone surfaces. It is unlikely 
that the data obtained in these studies will allow more detailed comment on cells at risk in 
the vicinity o f bone surfaces. Further work on the microdosimetry o f the radionuclides is 
in progress at the Paterson Institute for Cancer Research, Christie Hospital, Manchester.
The relative effectiveness o f the nuclides in the induction o f myeloid leukaemia is not 
completely consistent with dose delivery to red marrow. As discussed, considering equal 
average bone doses, the proportion o f dose delivered to marrow was in the order;
^^ P^u>^ '*'Am>^ ^^ U, whether dose was averaged over all marrow or the axial region was 
considered separately. The difference between ^^Tu and ^^ *Am reflects the greater 
observed accumulation o f  ^ ^^ Pu in the marrow, presumably due to the transfer from 
osteoclasts to macrophages as resorption occurs. Greater marrow doses from ^^ P^u are 
not reflected in greater incidences o f myeloid leukaemia; there was no statistical 
differences between the effect o f  ^ ^^u and "^**Am. Further work is in progress at the 
Paterson Institute for Cancer Research, Christie Hospital, Manchester to refine estimates 
o f dose to different marrow regions in an attempt to resolve this apparent discrepancy.
In current ICRP models (ICRP, 1993; 1995a) for the calculation o f doses and risks to 
humans, the behaviour of^^^u and "^**Am is treated similarly and estimates o f doses to
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bone surfaces and to red bone marrow are similar for the two nuclides. It is concluded 
that the observed differences between ^^ P^u and "^"Am in their effectiveness in the 
induction of osteosarcoma are not sufficiently great to warrant changes to the actinide 
models but should be included in considerations o f uncertainties in dose and risk estimates. 
The model for gives much lower doses to bone surfaces and red bone marrow, 
consistent with the results obtained in these studies.
287
REFERENCES
Adkins KF, (1967) The effect o f 1200 R o f  X-irradiation on dentinogenesis in the 
mandibular teeth o f  rats. Archs. Oral Biol. 12 1569-1576.
Andersson M and Storm H. (1992) Cancer incidence among Danish thorotrast-exposed 
patients. J. Natl. Cancer Inst. 84 1318-1325.
ANL. (1977) Argonne National Laboratory, Center for Human Biology Exposure. Data 
fo r  radium patients. ANL-77-65, Part II. Argonne National Laboratory, Illinois.
Arlen M, Higinbotham NI and Huvos AG. (1971) Radiation-induced sarcoma o f  bone. 
Cancer 28 1087-1099.
Arnold JS. (1951) Metabolism o f  bone as studied by radioautographic distribution o f  
calcium, plutonium and radium. Am. J. Physiol. 67 559-762.
Arnold JS and Jee WSS. (1957) Bone growth and osteoclastic activity as indicated by 
radioautographic distribution o f  plutonium. Amer. J. Anat. 101 367-418.
Arnold JS and Jee WSS. (1959) Autoradiography in the localization and radiation 
dosage of^^^Ra and ^^ P^u in the bones o f  dogs. Lab. Invest. 8 194-204.
Arnold JS and Jee WSS. (1962) Pattern o f  long-term skeletal remodelling revealed by 
radioautographic distribution of^^^Pu in dogs. Health Physics 8 705-707.
Atkinson HR. (1962) Bone marrow distribution as a factor in estimating radiation to 
the blood forming-organ. A survey o f  present knowledge. J. Coll. Radiol. Austr. 6 
149-154.
Aub JC, Evans RD, Hempelmann LH and Maitland HS. (1952) The late effects o f  
internally deposited radioactive materials in man. Medicine 31 221-329.
References 288
Baisogolov G, Bolotnikova MD, Galstian lA, Gus’kova AK, Koshumikova NA, Lyzlov 
AF, Nikipelov BV, Pestemikova VS and Shil’nikova NS. (1991) Malignant neoplasms o f  
hematopoietic and lymphatic systems in the personnel o f  the first plant o f  atomic 
industry. Vopr. Onkol. 37 553-559.
Barwick KW, Huvos AG and Smith J. (1980) Primary osteogenic sarcoma o f  the 
vertebral column. Cancer 46 595-604.
Bauer GCH. (1964) Kinetics o f  bone diseases, pp 489-507 in Bone dynamics. Ed HM 
Frost. Little Brown and Co, Boston.
Baverstock K and Cardis E. (1996) The WHO activities on thyroid cancer. pp715-726 
in The Radiological Consequences o f the Chernobyl Accident. Eds A Karaglou, G 
Desmet, GN Kelly and HG Menzel. CEC Publication EURl 6544EN, ECSC-EC-EAEC, 
Brussels-Luzembourg.
Baverstock K and Papworth D. (1989) The UK radium luminiser survey, pp 72-76 in 
Risks from Radium and Thorotrast. Eds. DM Taylor, CW Mays, GB Gerber and RG 
Thomas. BIR report 21. British Institute of Radiology, London.
BEIR (1980) The effect on populations o f  exposure to low levels o f  ionising radiation. 
(BEIR III). National Research Council, Committee on the Biological Effects o f Ionizing 
Radiations. National Academy of Sciences, Washington, DC.
BEIR (1988) Health effects o f  radon and other internally depositied alpha-emitters. 
(BEIR IV). National Research Council, Committee on the Biological Effects o f Ionizing 
Radiations. National Academy of Sciences, Washington, DC.
Behling UH and Hilderbrand JE. (1986) Radiation and health effects: a report on the 
TMI-2 accident and related health studies. GPU, Nuclear Corporation Middleton,
PAl 70057, USA.
Belyaev Yu. A. (1962) In book "Plutoni 239" Ed. M Medgiz cited by Buldakov et al., 
1970.
Benjamin SA, Brooks AL and McClellan RO. (1976) Biological effectiveness of^^^Pu, 
and ^^ Sr citrate in producing chromosome damage, bone-related tumours, liver 
tumours and life shortening in the Chinese hamster, pp 143-152 in Biological and 
Environmental Effects o f Low Level Radiation, Vol II, International Atomic Energy 
Agency, Vienna.
Bensted JPM, Taylor DM and SowbyFD. (1965). The carcinogenic effects o f  
americium-241 and plutonium-239 in the rat. Brit. J. Radiol. 38 920-925.
References 289
Bensted JPM and Taylor DM. (1969) A comparison o f  the carcinogenic effects o f  the 
bone seeking nuclides "^^ A^m and ^ ^^ Pu. pp 211-214 in Symposium Ossium, London, 
England 1969. Eds. AM Jelliffe & B Strickland. Livingstone, Edinburgh-London.
Bernard S and Struxness EG. (1957) A study o f  the distribution and excretion o f  
uranium in man. Oak Ridge National Laboratory Report 2304. Oak Ridge, Tenn.
Betts RH and Leigh RM. (1950) Ionic species o f  tetravalent uranium in perchloric and 
sulphuric acids. Canad. J. Res. B. 28 514-525.
BirchaU A, Baüey MR and James AC. (1991) LUDEP: A lung dose evaluation program. 
Radiat. Prot. Dosim. 38 167-174.
Bishop JM. (1987) The molecular genetics o f  cancer. Science 235 305.
Bleaney B. (1969) The radiation dose-rates near bone surfaces in rabbits after 
intravenous or intramuscular injection o f  plutonium-239. Br. J. Radiol. 42 51-56.
Bleaney B and Vaughan J. (1971) Distribution of^^^Pu in the bone marrow and on the 
endosteal surface o f  the femur o f  adult rabbits following injection of^^^Pu(N0^4. Brit. J 
Radiol. 44 67-73.
BlumT. (1924) Osteomyelitis o f  the mandible and maxilla. J. Amer. Dent. Assoc. 11 
802-805.
Boocock G and Popplewell DS. (1965) Distribution o f  plutonium in human blood serum 
proteins. Nature 208 282-283.
Boocock G and Popplewell DS. (1966) In vitro distribution o f americium in human 
blood serum proteins. Nature 210 1283-1284.
Boocock G and Popplewell DS. (1968) Distribution o f  some actinides in blood serum 
proteins, pp 45-55 in Diagnosis and Treatment o f Deposited Radionuclides. (Eds. HA 
Komberg and WD Norwood). Amsterdam: Excerpta Med. Found.
Boocock G, Danpure CJ, Popplewell DS and Taylor DM. (1970) The subcellular 
distribution o f  plutonium in rat liver. Radiation Research 42 381-396.
Bradbury S. (1975) Hewer's textbook o f histology for medical students. London: 
Heinemann.
Breckon G, Silver AJR and Cox R. (1991) Murine radiation myeloid leukaemogenesis: A 
possible role fo r  radiation-sensitive sites on chromosome 2. Genes Chromsom. Cancer 3 
367-375.
References 290
Breitenstein BD Jr. and Palmer HE. (1989) Lifetime follow-up o f  the 1976 americium 
accident victim. Rad. Prot. Dosim. 26 317-322.
Brostrom LA, Aparisi T, Ingimarsson S, Lagergreb C, Nilsonne U, Strander H and 
Soederberg G. (1980) Can historical controls be used in current clinical trials in 
osteosarcoma. Métastasés and survival in a historical and concurrent group. Int. J 
Radiat. Oncol. Biol. Phys. 6  1711-1721.
Brooks AL, Mewhinney JA, Redman HC, Guilmette RA and McClellan RO. (1981) 
Distribution and retention of^^^Pu, and cytogenetic damage in cynomologous monkeys 
after inhalation of^^^Pu(NOs)4. pp 294-297 in Inhalation Toxicology Annual Report 
1980-1981. Lovelace Biomedical and Environmental Research Foundation, Albuquerque, 
New Mexico. LMF-91, National Technical Information Service, Springfield, Virginia.
Brooks AL, Benjamin SA, Hahn FF, Brownstein DG, Griffith WC and McClellan RO. 
(1983) The induction o f  liver tumours by ^^ P^u citrate or ^ ^^ Pu oxide particles in the 
Chinese hamster. Radiat. Res. 96 135-151.
Brown H, Moretti ES, Rosenthal MW and Lindenbaum A. (1970) Cited by Vaughan et 
a l,  1973.
Bruenger FW. (1969) Dialogue in Delayed Effects o f  Bone-Seeking Radionuclides, pp 
122-123 Eds CW Mays WSS Jee and RD Lloyd, Univ. o f Utah Press, Salt Lake City.
Bruenger FW, Stevens W and Stover BJ. (1969a) Americium-241 in the blood in vivo 
and in vitro observations. Radiation Research 37 349-360.
Bruenger FW, Stover BJ and Stevens W. (1969b) On the binding of^ '^ ^Am in the canine 
liver, pp 139-161 in Research in Radiobiology. University of UTAH Report, COO-119- 
240.
Bruenger FW, Stover BJ, Stevens W and Atherton DR. (1969c) Exchange o f  Pu(lV) 
between transferrin andferritin in vitro. Health Physics 16 339-340.
Bruenger FW, Stover BJ and Stevens W. (1971) ^^ P^u (IV): its subcellular distribution 
and association with ferritin in the canine liver. Health Physics 21 679-687.
Bruenger FW, Smith JM, Atherton DR, Miller SC, Jee WSS and Stevens W. (1984) 
Radiation dose rate to the proximal humerus o f  growing beagles injected with 
plutonium-229. Radiat. Res. 97 302-317.
Bruenger FW, Lloyd RD and Egger MJ. (1989) The effects of age at time o f exposure on 
the distribution and toxicity o f radium-226 in the beagle dog. pp 81-85 in Risks from 
Radium and Thorotrast. Eds. DM Taylor, CW Mays, GB Gerber and RG Thomas. BIR 
Report 21, British Institute o f Radiology, London.
References 291
Bruenger FW, Miller SC and Lloyd RD. (1991) A comparison o f  the natural survival o f  
beagle dogs injected intravenously with low levels of^^^Pu, ^^ R^a, ^^ R^a, ^^ T^h or ^ S^r. 
Radiat. Res. 126 328-337.
Bryant FJ and Loutit JF. (1961) Human bone metabolism deduced from strontium 
assays. AERE-R3718.
Buldakov LA and Guskova A. (1991) Effects o f  chronic exposure to radiation. J 
Physician 5 34-39.
Buldakov LA, Lyubchanskii ER, Moskalec YI and Nifatov AP. (1970) Problems o f  
plutonium toxicity. Atom Publications Moscow, 1969. (Translation and production 
prepared for US Atomic Energy Commission). LF-tr-41, UC-48.
Buldakov LA, Kalmykova ZI, Nifator AP, Doshchenko VN, Tseveleva lA, Mushkacheva 
GS, Kudasheva NP, Pestemikov VM, Matveer VI, Suria AG and Karpova VN. (1972) 
Metabolism and biological effects o f  inhaled ^ "^ A^m and ^ ^^ Pu in dogs. Health Physics 22 
873-874.
Bulman RA. (1980) Some aspects o f  the bioinorganic chemistry o f  the actinides. Coord. 
Chem. Rev. 31221-250.
Busted LK, Clarke WJ, George LA, Horstman VG, McClellan RO, Persing RL, Seigneur 
LJ and Terry JL. (1962) Preliminary observations on metabolism and toxicity o f  
plutonium in miniature swine. Health Physics 8  615-620.
Camplin WC. (1992) Radioactivity in surface and costal waters o f  the British Isles,
1990. Aquatic environment monitoring report. No 29. Directorate o f Fisheries Research, 
MAFF, Lowestoft.
Camplin WC. (1993) Radioactivity in surface and costal waters o f  the British Isles,
1991. Aquatic environment monitoring report. No 30. Directorate o f Fisheries Research, 
MAFF, Lowestoft.
Carbough EH, Decker WA and Swint MJ. (1989) Medical and health physics 
management o f  a plutonium wound. Rad. Prot. Dosim. 26 345-349.
Cardis E and Okeanov AE. (1996) What is feasible and desirable in the epidemiologic 
follow-up o f  Chernobyl, pp 835-850 in The Radiological Consequences o f the Chernobyl 
Accident. Eds A Karaglou, G Desmet, GN Kelly and HG Menzel. CEC Publication 
EURl 6544EN, ECSC-EC-EAEC, Brussels-Luzembourg.
Carritt J, Fryxell R, Kleinschmidt J, Kleinschmidt R, Langham W, San Pietro A,
SchafferrR and Schnap B. (1947) The distribution and excretion o f  plutonium 
administered intravenously to the rat. J. Biol. Chem. 171 273-283.
References 292
Cartlidge AL. (1997) Radiation dosimetry o f  the alpha-emitting radionuclides Pu, and 
and Transfer report. Institute o f Cancer Studies, Manchester University.
Cartlidge AL, Lord BI, Ellender M, Haines JW and Harrison JD. (1998) Microdosimetry 
to leukaemogenic target cells fo r  bone-incorporated alpha-emitting radionuclides. (In 
press)
Casarett GW. (1980) Radiation histopathology Vols 1 & 2. CRC Press
Chemelevsky D, Speiss H, Mays C and Keller AM. (1990) The reverse protraction factor  
in the induction o f  bone sarcomas in radium-224patients. Radiat. Res. 124 Suppl. 1, 
S69-79.
Chipperfield AR and Taylor DM. (1968) Binding o f  plutonium and americium to bone 
glycoproteins. Nature 219 609-610.
Chipperfield AR and Taylor DM. (1970) The binding o f  plutonium and americium to 
bone glycoproteins. European Journal o f Biochemistry 17581-585.
Chipperfield AR and Taylor DM. (1972) The binding o f  thorium (IV), plutonium (IV), 
americium (III) and curiumflll) to the constituents o f  bovine cortical bone in vitro.
Radiat. Res. 51 15-30.
Choppin G, Rydberg J and Liljenzin JO. (1995a) Chp. 5: Radionuclides in nature, pp 
94-122 in Radiochemistry and Nuclear Chemistry. 2nd Edn. Oxford: Butterworth- 
Heinemann Ltd.
Choppin G, Rydberg J and Liljenzin JO. (1995b) Chp. 16: The transuranium elements. 
pp 414-437 in Radiochemistry and Nuclear Chemistry. 2nd Edn. Oxford: Butterworth- 
Heinemann Ltd.
Clarke RH. (1989) Current radiation risk estimate and implications fo r  the health 
consequences o f  Windscale, TMI and Chernobyl incidents, pp 102-118 in Medical 
response to effects of ionising radiation. Eds WA Crosbie and JH Gittus. London: Elsevier 
Applied Science.
Cooksan DJ, Levine B, Williams RJP, JonteU M, Linde A, de Bernard B and Zanetti M. 
(1979) MNR studies o f  a dentine phosphoprotein. Calcified Tissue International 
(Supplement) 27 A 8 .
Cooper JR and Gowing HS. (1981) The binding o f  americium and curium to human 
serum proteins. Int. J. Radiat. Biol. 40 569-572.
Cotton FA and Wilkinson G. (1980) Advanced inorganic chemistry. 4th Edn. New  
York: John Wiley and Sons.
References 293
Court-Brown WM and Doll R. (1958) Expectation o f  life and mortality from cancer 
among British Radiologists. Br. Med. J. 2 1327-1332.
Court-Brown WM and Doll R. (1965) Mortality from  cancer and other causes after 
radiotherapy fo r  ankylosing spondylitis. Brit. Med. Jour. 2 1327-1332.
Cox DR. {\912) Regression models and life-tables. J. R. Stat. Soc. B 34 187-220.
Crawley FEH, Humphreys ER and Stather JW. (1976) A comparison of239-plutonium  
in soft tissues and skeleton o f  mice, rats and hamsters. Health Physics 30 493-496.
Crick MJ and Linsley GS. (1984) An assessment o f  the radiological impact o f  the 
Windscale reactor fire  October 1957. Int. J. Radiat. Biol. 46 479-506.
Cristy M and Eckerman KF. (1987) Specific absorbed fractions o f  energy at various 
ages from internal proton sources. ORNL/TM-8381A/1-7, Oak Ridge National 
Laboratory, Oak Ridge, USA.
Culling CFA. (1974) Handbook o f  histopathological and histochemical techniques. 3rd 
Edn. Butterworths, London.
Dagle GE, Cannon WC, Stevens DL and McShane JF. (1983) Comparative distribution 
o f  inhaled ^ ^^ Pu and ^ ^^ Pu nitrates in beagles. Health Phys. 44 275-277.
Dagle GE, Weller RE, Filipy RE, Watson CR and Buschbom RL. (1996) The distribution 
and effects o f  inhaled ^ ^^Pu(NO  ^4 depostited in the liver o f  dogs. Health Phys. 71 198- 
205.
Dahlin DC. (1967) Bone tumours. 2nd edition. CC Thomas & Co. Springfield, Illinois.
Dako (1996) Handbookoflmmunocytochemical staining methods. EdSJNaish. Dako, 
Carpinteria, California.
Darby S, DoH R and GUI S. (1987) Long-term mortality after a single treatment course 
with X-rays in patients treated fo r  anklyosing spondylitis. Br J Cancer 55 179-190.
da Sliva Horta J, da Sliva Horta ME, da Motta LC and Tavers MH. (1978) Malignancies 
in Portuguese thorotrast patients. Health Phys. 35 137-151.
de Gruchy GC. (1972) Clinical haematology in medical practice. 3rd edition, Blackwells 
Scientific Publications, Oxford.
di Majo V, Coppola M, Rebessi S, Bassani B, Alati T, Saran A, Bangrazi C and Covelli V. 
(1986) Dose-response relationship o f  radiation-induced harderian gland tumours and 
myeloid leukaemia in the CBA/Cne mouse. JNCI 76 955-963.
References 294
di Majo V, Coppola M, Rebessi S, Saran A, Pazzaglia S, Pariset L and Covelli V. (1996) 
The influence o f  sex on life shortening and tumour induction in the CBA/Cne mouse 
exposed to X-rays or fission neutrons. Radiat. Res. 146 81-87.
Doerfel H and Oliveira CAN. (1989) In vivo measurement of^ '^ ^Am organ burdens: 
techniques and results o f  measurements after an incident in an industrial research 
institute. Rad. Prot. Dosim. 26 189-193.
Doshenko V. (1991) Causes o f  mortality after considerable occupational chronic total 
gamma irradiation. J. Med. Radiol. 8  40.
Dougherty TF. (1972) Injection tables. pl4-105 in Research in Radiobiology, University 
of Utah, Annual Report. Salt Lake City, Utah. USDOE Report COO-119-246.
Dunnill MS, Anderson JA and Whitehead R. (1967) Quantitative histological studies on 
age changes in bone. J. Pathol. Bact. 94 275-291.
Duport P and Horvath F. (1989) Practical aspects o f  monitoring and dosimetry o f  long- 
lived dust in uranium mines and mills - Determination o f  the annual limit on intake fo r  
uranium and uranium/thorium ore dust. Rad. Prot. Dosim. 26 43-48
Durbin PW. (1962) Distribution o f  the transuranic elements in mammals. Health Physics 
8  665-671.
Durbin PW. (1972) Plutonium: A new look at old data, in Radiobiology o f Plutonium. 
Eds. BJ Stover and WSS Jee. The JW Press, Salt Lake City.
Durbin PW. (1973) Metabolism and biological effects o f  the transplutonium elements. 
pp 739-896 in Uranium, plutonium, transplutonic elements. Eds. HC Hodge, JB Stannard 
and JB Hursh. Springer-Verlag, New York.
Durbin PW, Jeung N  & Williams MH. (1972) Distribution, retention and excretion o f  
"^^ A^m in adult female rats and monkeys, cited by Durbin in chp 17 in Uranium, Plutonium, 
Transplutonic Elements.
Durbin PW and Wrenn ME. (1975) Metabolism and effects o f  uranium in animals, pp 
68-129 in the Conference on Occupational Health Experience with Uranium. ERDA 93. 
US Energy Research and Development Administration, Arlington, Virginia, USA.
Eidson AF. (1994) The effect o f  solubility on inhaled uranium compound clearance: a 
review. Health Phys. 67 1-14.
Eisenbud M. (1987) Environmental radioactivity. New York: Academic Press.
EULEP. (1994) Pathology o f  neoplasia and preneoplasia in rodents. EULEP Colour 
Atlas. Vol 1. Eds P Bannasch and W Gossner. Schattauer, Stuttgart, Germany.
References 295
EULEP. (1997) Pathology o f  neoplasia and preneoplasia in rodents. EULEP Colour 
Atlas. Vol 2. Eds P Bannasch and W Gossner. Schattauer, Stuttgart, Germany.
Evans RD. (1966) The effect o f  skeletally deposited alpha-ray emitters in man. Br. J. 
Radiol. 39 881-895.
Evans RD, Keane AT and Shanahan MM. (1972) Radiation effects in man o f  long-term 
skeletal alpha irradiation. In Radiobiology of Plutonium. Eds BJ Stover and WSS Jee, 
JW Press, University o f Utah, Salt Lake City.
Eve IS. (1966) A review o f  the physiology o f  the gastrointestinal tract in relation to 
radiation doses from radioactive materials. Health Phys. 12 131-161.
Faber M. (1979) Twenty-eight years o f  continuous follow-up ofpatients injected with 
thorotrast fo r  cerebral angiography. Environ. Res. 18 37-43.
Fabrikant JI and Smith CLD. (1964) Radiographic changes following the administration 
o f  bone-seeking radionuclides. Brit.J.Radiol. 37 53-62.
Fabrikant JI, Hsu THS, Knudson DH and Smith CLD. (1972) Effect o f  LET on radiation 
carcinogenesis: comparison o f  single and fractionated doses off^^Pu, '^ "^ A^m, ^^ P and 
X-rays on the production o f  osteosarcomas in rats, pp 322-346 in Radionuclide 
Carcinogenesis. AEC Symposium 29. US Atomic Energy Commission, CONF-720505.
Fawcett DW. (1986) A Textbook o f  Histology. Philadelphia: WB Saunders & Co.
Fearon ER and Vogelstein B. (1990) A genetic model fo r  colorectal tumorigenesis. Cell 
61 759-767.
Festmg MFW. (1979) Inbred strains in biomedical research. Macmillan, London.
Filippova LI, Nifatov AP and Buldakov LA. (1974) Late effects in rats after 
intraperitoneal injection off'^^Am. Radiobiology 14 875-878.
Finkel MP. (1953) Relative biological effectiveness o f  radium and other alpha emitters 
in the CFN ol female mice. Proc. Exp. Biol. Med. 83 494-498.
Finkel MP and Biskis BO. (1959) The induction o f  malignant bone tumours in mice by 
radioisotopes. Acta Un. Int. Cancer 15 99-106.
Finkel MP and Biskis BO. (1962) Toxicity o f  plutonium in mice. Health Physics 8 
565-579.
Finkel MP and Biskis BO. (1968) Experimental induction o f  osteosarcomas. Prog. Exp. 
Tumour Res. 100 72-111.
References 296
Finkel MP, Biskis BO and Jinkins PB. (1969) Toxicity off^^Ra in mice, pp 369-391 in 
Radiation Induced Cancer, International Atomic Energy Agency, Vienna.
FouldsL. (1975) Neoplastic development. Vol 2, Academic Press, New York.
Foreman H, Trujillo TT, Johnson O and Finnegan C. (1955) Ca EDTA and excretion o f  
plutonium. Proc. Soc. Exp. Biol. (NY) 89 339-342.
Fried JF, Graul EH, Schubert J and Westfall WM. (1959) Superior chelating agents fo r  
the treatment o f  plutonium poisoning. Atompraxis 5 1-5.
Frost HM. (1961) Human osteoblastic activity - Part II. Measurement o f  the biological 
half-life o f  bones with the aid o f  tetracyclines. Henry Ford Hosp. Med. Bull. 9 87-96.
Frost HM (1963) Measurement o f  human bone formation by means o f  tetracyline 
labelling. Can. J. Biochem. Physiol. 41 31-42
Frost HM. (1964) Dynamics o f  bone remodelling, pp 315-333 in Bone dynamics. Ed 
HM Frost. Little Brown & Co, Boston, USA.
Frost HM. (1969) Tetracycline based histological analysis o f  bone remodelling. Calcif. 
Tissue Res. 3 211-237.
Frost HM. (1980) Skeletal physiology and bone remodelling, pp 208-241 in 
Fundamental and Clinical Bone Physiology. Ed. MR Urist. Philadelphia: JB Lippincott & 
Co.
GindlerJE. (1973) Physical and chemical properties o f  uranium, pp 69-164 in 
Uranium, plutonium, transplutonic elements. Eds. HC Hodge, JB Stannard and JB Hursh, 
New York: Springer-Verlag.
Glauert AM. (1975) Fixation, dehydration and embedding o f  histological specimens. 
North-Holland Publishing Company, Amsterdam.
Gross L. (1950) Oncogenic viruses. Proc. Soc. Exp. Biol. Med. 73 246
Gray. {\995) Gray’s Anatomy. 38th Edition, Churchill Livingstone, Edinburgh.
Grebenschikova VI and Davydov YuP. (1961) Investigation o f  the state o f  Pu(IV) in 
dilute nitric acid. Radiokhimiya 3 155-164.
Green D and Humphreys JA. (1990) The detection o f  radioactive trace elements in bone 
sections by autoradiography, pp 27-40 in Trace Metals and Flouride in Bones and Teeth, 
Eds ND Priest and FL Van De Vyver, CRC Press, Boca Raton, Florida.
References 297
Greenwood NN and Eamshaw A. (1994) Chp. SI: The actinide elements, pp 1450-1486 
in The Chemistry o f the Elements. Oxford: Pergamon Press.
Griem ML, Meier P and Dobben GD. (1967) Analysis o f  the morbidity and mortality o f  
children irradiated in fe ta l life. Radiol 88 347-349.
Griem ML, Kleinerman R and Boice JD. (1994) Cancerfollowing radiotherapy fo r  peptic 
ulcer. J. Natl. Cancer Inst. 86 842-849.
Guglielmotti MB, Ubois AM, de Rey BM and Cabrini RL. (1984) Effects o f  uranyl 
nitrate on bone formation. Experimentia 40 474-476
Haines JW (1992) A technique fo r  embedding undecalcified bone samples fo r  detecting 
alpha-emitters using vacuum impregnation with Spurr's resin. Biotech. Histochem. 67 
45-49.
Haley DP. (1982) Morphologic changes in uranyl nitrate-induced acute renal failure in 
saline and water drinking rats. Lab. Invest. 46 196-208.
Haley DP, Bulger RE and Dobyan DC. (1982) The long-term effects o f  uranyl nitrate on 
the structure and function o f  the rat kidney. Virchows Arch. (Cell Pathol.) 41 181-192.
Ham AW and Cormack DH. (1979) Histology. 8th edition, JB Lippincott Company, 
Philadelphia.
Hamilton JG. (1947) The metabolism o f  the fission products and the heaviest elements. 
Radiology 49 325-343.
Hamilton JG. (1948) The metabolic properties o f  the fission products and actinide 
elements. Rev. Mod. Phys. 20 718-728.
Hamilton JG and Scott KG. (1953) Effect o f  calcium salt o f  versene upon metabolism o f  
plutonium in the rat. Proc. Soc. Exp. Biol. (NY) 83 301-305.
Hammond CR. (1993) The Elements. Chp. 4 in CRC Handbook of Chemistry and 
Physics. 74th Edn. Eds. DR Lide and HPR Frederikse. Boca Raton: CRC Press.
Hansen LS and English JA. (1975) Histologic changes in the incisor teeth o f  rats serially 
sacrificed after receiving 1,500 R o f 200 KVX-ray irradiation. J. Dent. Res. 36 417-431.
Hammarstrom L and Nilsson A. (1970) Radiopathology o f  americium-241. II. Uptake 
in the developing teeth o f  rats. Acta. Radiol. Ther. Phys. Biol. 9 609-617.
Harrison JD. (1991) The gastrointestinal absorption o f  the actinide elements. Sci. Total 
Environ. 100 43-60.
References 298
Harrison JD. (1995) Ingested radionuclides, pp 253-288 in Radiation and Gut. Eds CS 
Potten and JH Hendry, Elsevier Science, Amsterdam.
Hart IR, Goode NT and Wilson RE. (1989) Molecular aspects o f  the metastatic cascade. 
Biochim. Biophys. Acta. 989 65-84.
Hartsock RJ, Smith EB and Petty CS. (1965) Normal variations with aging o f  the 
amount o f  hematopoietic tissue in bone marrow from the anteroiliac crest, a study made 
from 177 cases o f  sudden death examined by necropsy. Am. J Clin. Pathol. 43 326-331.
Hashimoto EG and Jee WSS. (1976) Cells at riskfrom bone-seeking radionuclides, pp 
643-656 in A review of health effects o f radium and plutonium. Ed. WSS Jee. The JW 
Press, Salt Lake City, Utah.
Hasterhk RJ, Finkel AJ and Miller CE. (1964) The cancer hazards o f  industrial and 
accidental exposure to radioactive isotopes. Ann. NY Acad. Sci. 114 832-837.
Hatch CM, Beyea J, Nieves JW and Susser M. (1993) Cancer near the Three Mile 
Island nuclear plant: radiation emissions, pp 428-430 in Childhood Cancer and Nuclear 
Installations. Eds. V Beral, E Roman and M Bobrow. BMJ, London.
Haven FL and Hodge HC. (1953) Toxicity following the parenteral administration o f  
certain soluble uranium compounds, pp 281-308 in The Pharmacology and Toxicology o f  
Uranium Compounds. McGraw-Hill, New York.
Heaston L, Libshitz H and Cahn R. (1979) Skeletal effects o f  megavoltage irradiation in 
survivors o f  Wilms’ tumour. Am. J. Reontgenol. 133 398-395.
Heineke H. (1903) Munchien Med. Wehnschr. 50 2090 cited by CL Saunders and RL 
Kathren pp 125-143 in Ionising radiation: Tumorgenic and tumoricidal effects. 
Springer-Verlag, New York. 1973.
Heineke H. (1906) cited by Upton AC. (1990) Radiobiology and radiation protection: 
The past century and prospects fo r  the future, pp 199-231 in Radiation Protection Today 
- The NCRP at Sixty years. NCRP Proceedings No 11. National Council on Radiation 
Protection and Measurements, Bethesda, Maryland, USA.
Heim S and Mitehnan F. (1989) Primary chromosome abnormalities in human 
neoplasia. Adv. Cancer Res. 52 2.
Hempelmann LH, Lisco H and Hoffinan JG. (1952) The acute radiation syndrome. A 
study o f  9 cases and a review o f  the problem. Ann. Intern. Med. 36 279.
Herring GM, Vaughan JM and Williamson M. (1962) Preliminary report on the site o f  
localisation and possible binding sites fo r  yttrium, americium and plutonium in cortical 
bone. Health Physics 8  717-724.
References 299
Heyn R, Ragab A and Raney RB. (1986) Late effects o f  therapy in orbital 
rhabdomyosarcoma in children. A report from the Intergroup Rhabdomyosarcoma 
Study. Cancer 57 1738-1743.
Hodge HC. (1956) Mechanism o f  uranium poisoning. Arch. Indust. Heath 2 43-47.
Hodge HC. (1973) A history o f  uranium poisoning, pp 5-68 in Uranium, plutonium, 
transplutonic elements: Handbook o f experimental pharmacology 36. Eds. HC Hodge, JN 
Stannard and JB Hursh. Berlin: Springer-Verlag.
Hoekstra HR and Katz JJ. (1954) The chemistry o f  uranium. In The Actinide Elements. 
Eds. GT Seaborg and JJ Katz. New York: McGraw-HiU.
Hohryakob V and Romanov S. (1994) Lung cancer in radiochemical industry workers. 
Sci. Total Environ. 142 25-28.
Horta J, da Silva M, Horta ME, da Motta LV and Tavares MH. (1978) Malignancies in 
Portuguese thorotrast patients. Health Phys. 35 137-151.
Howells GR and Green D. (1981) The temporal and spatial distribution of^^^Pu within 
bone, pp 57-71 in Bone and bone-seeking radionuclides: physiology, dosimetry and 
effects. Ed. V.Volf. EULEP Symposium, EUR 7168EN, Harwood.
Hug O, Gossner W, Müller WA, Luz A and Hindringer B. (1969) Production o f  
osteosarcomas in mice and rats by incorporation o f  radium-224, pp 393-409 in 
Radiation Induced Cancer, International Atomic Energy Agency, Vienna.
Hughes JS, Shaw KB and O’Riordan MC. (1989) Radiation exposure o f  the UK  
population - 1988 review. NRPB-R227. London: HMSO.
Hughes JS and O’Riordan MC. (1993) Radiation exposure o f  the UK population -1993  
review. NRPB-R263. London: HMSO.
Huiskamp R, Davids JAG and Mole RH. (1991) Acute myeloid leukaemia induction in 
CBA/H mice by irradiation with fission neutrons as a function o f  exposure rate, pp 258 
m Radiation Research. A Twentieth-Century Perspective. Eds. JD Chapman, WL Dewey 
and GF Whitemore. Vol 1. Academic Press, London.
Humphreys ER, Metalli P, Seidel A, Szot Z and Vanderborght O. (1976) The 
distribution of^^^Pu in several strains o f mice - a collaborative experiment. Int. J o f App. 
Radiat. and Isotop. 27 507-513.
Humphreys ER, Fisher G and Thome MC. (1977) The measurement o f  blood low in 
mouse femur and its correlation with ^^ P^u deposition. Calcif. Tiss. Res. 23 141-145.
Humphreys ER, Loutit JF, Major IR and Stones VA. (1985a) The induction by ^^ R^a o f  
myeloid leukaemia and osteosarcoma in male CBA mice. Int. J. Radiat. Biol. 47 239-247.
Humphreys ER, Robins MW and Stones VA. (1985b) Age related and ^ '^^Ra-induced 
pathology in the teeth o f  CBA mice. Archs. oral B io l 30 55-64.
References  ^ 300
Humphreys ER, Loutit JF and Stones VA. (1987) The induction by ^^ P^u o f  myeloid 
leukaemia and osteosarcoma in female CBA mice. Int. J. Radiat. Biol. 51 331-339.
Humphreys ER, Isaacs KR, Raine TA, Saunders J, Stones VA and Wood DL. (1993) 
Myeloid leukaemia and osteosarcoma in CBA/H mice given Inj. J. Radiat. Biol. 64 
231-235.
Humphreys ER and Stones VA. (1991) Update o f  late effects o f  alpha-particle emitters 
in CBA/H mice. EUELP Newsletter 62 22-23.
Humphreys ER, Isaacs KR, Humphreys VA, Raine T and Wood DL. (1998) Influence o f  
dose protraction on the induction o f  myeloid leukaemia in CBA/H mice given ^^ "^ Ra. Int.
J. Radiat. Biol, (in press).
Hunt GJ, Leonard DRP and Lovett MB. (1986) Transfer o f  environmental plutonium 
and americium across the human gut. Sci. Total. Environ. 53 89-109.
Hunt GJ, Leonard DRP and Lovett MB. (1989) Transfer o f  environmental plutonium 
and americium across the human gut. Radiol. Prot. Bull. 106 7-11.
Hunt GJ, Leonard DRP and Lovett MB. (1990) Transfer o f  environmental plutonium 
and americium across the human gut: A second study. Sci. Total Environ. 90 273-282.
Hursh JB and Spoor NL. (1973) Data on man. pp 197-240 in Uranium, plutonium, 
transplutonic elements: Handbook o f experimental pharmacology 36. Eds. HC Hodge, JN 
Stannard and JB Hursh. Berlin: Springer-Verlag.
Huvos A and Woodard H. (1988) Postradiation sarcomas o f  bone. Health Phys. 55 
631-636.
IAEA. (1986) International Atomic Energy Agency. Summary report on the post­
accident review meeting on the Chernobyl accident. Safety Series 75-INS AG-1, IAEA, 
Vienna.
lARC. (1980) Long and short term screening assays fo r  carcinogenesis: A critical 
apprasial. lARC Monograph, Suppl 2. International Agency for Research on Cancer, 
Lyon, France.
lARC. (1986) Statistical methods in cancer research: Volume III - The design and 
analysis o f  long-term animal experiments. lARC Scientific Publications 79. International 
Agency for Research on Cancer, Lyon, France.
lARC. (1994) World Health Organisation / International Agency for Research on Cancer / 
International Life Sciences Institute. Pathology o f  tumours in laboratory animals. Volume
II. Tumours o f  the mouse. 2nd Edition. Eds VS Turusov and U Mohr, lARC Scientific 
Publications 111. International Agency for Research on Cancer, Lyon, France.
References 301
ICRP. (1966) International Commission on Radiological Protection. Recommendations 
o f  the International Commission on Radiological Protection. ICRP Publication 9, 
Pergammon Press, Oxford.
ICRP. (1968) International Commission on Radiological Protection. A review o f  the 
sensitivity o f  the tissues in bone. ICRP Publication 11. Pergammon Press, Oxford.
ICRP. (1973) International Commission on Radiological Protection. Alkaline earth 
metabolism in adult man. ICRP Publication 20. Pergamon Press, Oxford.
ICRP. (1977) International Commission on Radiological Protection. Recommendations 
o f  the International Commission on Radiological Protection. ICRP publication 26. 
Pergammon Press, Oxford.
ICRP. (1979) International Commission on Radiological Protection. Limits fo r  intakes o f  
radionuclides by workers. ICRP Publication 30, Part 1. Annals of the ICRP 2 (3/4). 
Oxford: Pergamon Press.
ICRP. (1980) International Commission on Radiological Protection. Limits fo r  intakes o f  
radionuclides by workers. ICRP Publication 30, Part 2. Annals of the ICRP 4 (3/4). 
Oxford: Pergamon Press.
ICRP. (1986) International Commission on Radiological Protection. The metabolism o f  
plutonium and related elements. ICRP Publication 48. Oxford: Pergamon Press.
ICRP. (1989) International Commission on Radiological Protection. Age-dependent 
doses to members o f  the public from intake o f  radionuclides: Part 1. ICRP Publication 
56. Oxford: Pergamon Press.
ICRP. (1991) International Commission on Radiological Protection. 1990 
Recommendations o f  the International Commission on Radiological Protection. ICRP 
Publication 60. Annals o f the ICRP 21 (1-3). Oxford: Pergamon Press.
ICRP. (1993) International Commission on Radiological Protection. Age-dependent 
doses to members o f  the public from intake o f  radionuclides: Part 2, Ingestion dose 
coefficients. ICRP Publication 67. Annals o f the ICRP 23 (3/4). Oxford: Pergamon Press.
ICRP. (1994) International Commission on Radiological Protection. Human respiratory 
tract model fo r  radiological protection. ICRP Publication 6 6 . Annals o f the ICRP 24 (1-
3). Oxford: Pergamon Press.
ICRP. (1995a) International Commission on Radiological Protection. Age-dependent 
doses to members o f  the public from intake o f  radionuclides: Part 3, Ingestion dose 
coefficients. ICRP Publication 69. Annals o f the ICRP 23 (3/4). Oxford: Pergamon Press.
References 302
ICRP. (1995b) International Commission on Radiological Protection. Reference M an - 
The Skeleton. ICRP Publication 70. Annals o f the ICRP 25 (2) Oxford: Pergamon Press.
ICRP. (1995c) International Commission on Radiological Protection. Age-dependent 
doses to members o f  the publicfrom intake o f  radionuclides: Part 4, Inhalation dose 
coefficients. ICRP Publication 71. Annals o f the ICRP 25 (3/4). Oxford: Pergamon Press.
Ichimaru M, Ishimaru J and Belsky JL. (1976) Incidence o f  leukameia in A-bomb 
survivors by dose, years after exposure, age and type o f  leukaemia, 1950-1971. RERF 
Technical Report 10-76, Hiroshima, Radiation Effects Research Foundation, 1976.
Ichimaru M, Tomonaga M and Amenomori T. (1991) Atomic bombings and leukaemia. 
Radiat. Res. 32 Suppl 2 14-19.
Inskip P, Kleinerman R and Stovall M. (1993) Leukaemia, lymphoma and multiple 
myeloma following pelvic irradiation fo r  benign disease. Radiat. Res. 135 108-124.
Inskip P, Monson R, Wagoner J. (1990) Cancer mortality following radium treatment 
fo r  uterine bleeding. Radiat. Res. 123 331-344.
Inskip P, Kleinerman R and Stovall M. (1993) Leukaemia, lymphoma and multiple 
myeloma following pelvic radiotherapy fo r  benign disease. Radiat. Res. 135 108-124.
Ishimaru T, Hoshino T, Ichimaro M, Okada H, Tomiyaso T, Tsuchimoto T, Tsuchimoto T 
and Yamamoto T. (1971) Leukaemia in atomic bomb survivors, Hiroshima and 
Nagasaki. Radiat. Res. 45 216-233.
Ishimaru T, Otake M and Ichimaru M. (1979) Dose-relationship o f  neutrons and gamma 
rays to leukaemia incidence among atomic bomb survivors in Hiroshima and Nagasaki 
by type o f leukaemia. Radiat. Res. 77 377-394.
Jaffe N, Toth B and Hoar R. (1990) Dental and maxillofacial abnormalities in long­
term survivors o f  childhood cancer: Effects o f  treatment with chemotherapy and 
radiation to the head and neck. Pediatrics 3 816-823.
Jagié. (1911) cited by Upton AC. (1990) Radiobiology and radiation protection: The 
past century and prospects fo r  the future, pp 199-231 in Radiation Protection Today - 
The NCRP at Sixty years. NCRP Proceedings No 11. National Council on Radiation 
Protection and Measurements, Bethesda, Maryland, USA.
Jarvis NS, BirchaU A, James AC, Bailey MR and Dorrian M-D. (1993) LUDEP 1.0. 
Personal Computer Program fo r  Calculating Internal Doses Using the New ICRP 
Respiratory Tract Model. National Radiological Protection Board, Chilton, NRPB- 
SR264.
Jarvis NS and BirchaU A. (1994) LUDEP 1.0, A Personal Computer Program to 
Implement the New ICRP Respiratory Tract Model. Radiat. Prot. Dosim. 53 191-193.
Jee WSS. (1972) Distribution and toxicity o f  plutonium-239 in bone. Health Physics 2 
583-595.
References 303
Jee WSS and Arnold JS. (1960) Radioisotopes in the teeth o f  dogs. 1. The distribution 
o f  plutonium, radium, radiothorium, mesothorium and strontium, and the sequence o f  
histopathologic changes in teeth containing plutonium. Arch. Oral Biol. 2 215-238.
Jee WSS and Arnold JS. (1961) The toxicity o f  plutonium deposited in skeletal tissues o f  
beagles. 1. The relation o f  the distribution o f  plutonium to the sequence o f  
histopathological bone changes. Laboratory Investigation 7 797-825.
Jee WSS, Stover BJ, Taylor GN and Christensen WR. (1962) The skeletal toxicity o f  
^^ P^u in adult beagles. Health Physics 8  599-607.
Jee WSS, Park HZ and Burggraaf R. (1969a) Estimates o f  residence time off^^Pu in 
trabecular bones o f  beagles, pp 188-198 in Research in Radiobiology Report, University 
of Utah, Annual Report. Salt Lake City, Utah. USDOE Report COO-119-240.
Jee WSS, Bartley MH, DockumNL, Yee J and Kenner GH. (1969b) Vascular changes 
in bones following bone-seeking radionuclides, pp 437-454 in Delayed effects of 
bone-seeking radionuclides. Eds. CW Mays, WSS Jee and RD Lloyd. Univ. o f Utah Press, 
Utah.
Jee WSS, Atherton DR, Bruenger F, Dougherty JH, Lloyd RD, Mays CW, Nabors CJ, 
Stevens W, Stover BJ, Taylor GN and Woodbury LA. (1976) Current status o f  UTAH 
long-term ^^ P^u studies, pp 79-93 in Biological and Environmental Effects o f Low Level 
Radiation, Vol II, International Atomic Energy Agency, Vienna.
Johnson LC. (1964) Morphologic analysis. Chp. 29 pp 543-654 in Bone Dynamics. Ed. 
HM Frost. Boston: Little, Brown and Co.
Johnson JR, Myers DK, Jackson JS, Dunford DW, Gragtmans NJ, Wyatt HM, Jones AR 
and Percy DH. (1995) Relative biological effectiveness o f  tritium fo r  induction o f  
myeloid leukaemia in CBA/H mice. Radiat. Res. 144 82-89.
Kalproth MH. (1789) Cited by Greenwood NN and Eamshaw A. (1994) Chp. 31: The 
actinide elements, pp 1450-1486 in The Chemistry o f the Elements. Oxford: Pergamon 
Press.
Kaplan EL and Meier P. (1958) Nonparametric estimation from incomplete observations. 
J. Am. Stat. Assoc. 53 457-481.
Kathren RL, Mclnroy JF and Swint MJ. (1987) Actinide distribution in the human 
skeleton. Health Phys. 52 179-192.
Katz JJ and Rabinowitz E. (1951) The Chemistry o f  Uranium. New York: McGraw-HiU.
Katz JJ and Seaborg GT. (1957) The Chemistry o f  the Actinide Elements. London: 
Methuen and Co. Ltd.
References 304
Kazakov S, Demidctdk, Astakhova (1992) Thyroid cancer after Chernobyl. Nature 359 
21.
Kendall GM, Muirhead CR, MacGibbon BH, O’Hagan JA, Conquest AJ, GoodhiU AA, 
Butland BK, Fell TP, Jackson DA, Wedd MA, Haylock RGB, Thomas JM and Silk TJ. 
(1992) First analysis o f  the National Registry fo r  Radiation Workers: Occupational 
exposure to ionising radiation and mortality. NRPB-R251, Chilton, London, HMSO.
Keough RF and Powers GJ. (1970) Determination o f  plutonium in biological materials 
by extraction and liquid scintillation counting. Analytical Chemistry 42 419-421.
Kerley ER. (1965) The microscopic determination o f  age in human bone. Am. J. Phys. 
Anthrop. 23 149-164.
Kersey JH, Sabad A, Gajl-Peczalska K, HaUgren HM, Yunis EJ and Nesbit ME. (1973) 
Acute lymphoblastic leukaemic cells with T (Thymus-derived) lymphocyte markers. 
Science 182 1355-1356.
Knudson AG. (1986) Genetics o f  human cancer. Ann. Rev. Genet. 20 231.
Koshumikova N, Buldakov L and Bysolo golov G. (1994) Mortality from malignant 
tumours in haematopoietic and lymphatic tissues among personnel o f  the first nuclear 
plant in the USSR. Sci. Total Environ. 142 19-23.
Kragstmp J, Melsen F and Mosekilde L. (1982) Reduced wall thickness o f  completed 
remodelling sites in iliac trabecular bone following anticonvulsant therapy. Metab. 
Bone Dis. Relat. Res. 4 181-185.
Kraus KA and Nelson F. (1950) Hydrolytic behaviour o f  metal ions. I. The acid 
constants o f  uranium (IV) and plutonium (IV). J. Amer. Chem. Soc. 72 3901-3906.
LaBauve RJ, Brooks AL, McClellan RO and Meade RJ. (1980) Cytogenetic and other 
biological effects of^^^Pu02 inhaled by the rhesus monkey. Radiat. Res. 82 310-335.
Langham WF. (1956) Determination o f  internally deposited radioactive isotopes from  
excretion analyses. Am. Indust. Hyg. Ass. J. 17 305.
Langham W and Carter RE. (1951) The relative physiological and toxicological 
properties o f  americium and plutonium. Los Alamos Scientific Laboratory, Univ. o f  
California USA. Report LA-1309.
Larson D, KroU S and Jaffe N. (1990) Long-term effects o f  radiotherapy in childhood 
and adolescence. Am. J. Surg. 160 348-351.
Laskin W, Silvermann T and Enzinger F. (1988) Postradiation soft tissue sarcomas: An 
analysis o f S3 cases. Cancer 62 2330-2340.
References 305
Lataijet R and Duplan JF. (1962) Experiment and discussion on leukaemogenesis by 
cell-free extracts o f radiation-induced leukaemia in mice. Int. J. Radiat. Biol. 5 339-344.
Latimer WM. (1952) Oxidation Potentials. 2nd Edn. New York: Prentice-Hall.
Leconte (1853) cited by Hodge HC. (1956) Mechanism o f  uranium poisoning. Arch. 
Indust. Heath 2 43-47.
Lederer CM., Hollander JM and Perlman I. (1967) Table o f  Isotopes. 6th Edn. New 
York: J.Wiley and Sons.
Leggett RW. (1985) A model fo r  the retention, translocation and excretion o f  systemic 
plutonium. Health Phys. 49 1115-1137.
Leggett RW. (1992) A generic age-specific biokinetic model fo r  calcium-like elements. 
Radiat. Prot. Dosim. 41 183-198.
Leggett RW and Eckerman KF. (1984) A model fo r  the age-dependent skeletal retention 
o f plutonium, pp 454-457 in Radiation Risk Protection. Eds. A Kaul, R Neider, J Pensko, 
F-E Stieve and H Brunner. Vol 1. Jühch: Fachverband fur Strahlenschutz.
Leggett RW, Eckerman KF and Williams LR. (1982) Strontium-90 in bone: A case study 
in age-dependent dosimetric modelling. Health Phys. 43 307-322.
Leggett RW and Harrison JD. (1995) Fractional absorption o f ingested uranium in 
humans. Health Phys. 6 8  484-498.
Leiberman M and Kaplan HS. (1959) Radiation induced myeloid leukaemias in mice. 
Science 130 387.
Lichtman MA and Klemperer MR. (1978) Clinical Oncology. Univ. o f Rochester, 
Rochester, NY.
Lindenbaum A, Rosenthal MW, Russell JJ, Moretti ES and Smyth MA. (1969)
Metabolic and therapeutic studies o f  plutonium. V. pp 186- 190 m Argonne National 
Laboratory report ANL 7635.
Lindenbaum A, Lund CJ, Smoler M and Rosenthal MW. (1968) Preparation, 
characterization and distribution in mouse tissues o f  graded polymeric and monomeric 
plutonium. Radiochemical and autoradiographic studies, pp 56-64 in Diagnosis and 
treatment o f deposited radionuclides. Eds. HA Komberg and WD Norwood. Exerpta 
Medical Foundation, Monograph on Nuclear Medicine No 2.
Little K. (1973) Bone behaviour. Academic Press, London.
Lloyd RD, Jee WSS, Atherton DR, Taylor GN and Mays CW. (1972) Americium-241 in 
beagles: biological effects and skeletal distribution, pp 141-148 in Radiobiology o f  
plutonium. Eds. BJ Stover and WSS Jee. The JW Press, Univ.of Utah, Salt Lake City.
References 306
Lloyd RD, McFarland SS, Atherton DR and Mays CW. (1978) Plutonium retention, 
excretion and distribution in juvenile beagles soon after injection. Radiat. Res. 75 633- 
641.
Lloyd RD, Taylor GN, Angus W, Miller SC and Boecker BB. (1994a) Skeletal 
malignancies among beagles injected with Health Phys. 6 6  172-177.
Lloyd RD, Taylor GN, Angus W, Miller SC, Bruenger FW and Jee WSS. (1994b) 
Distribution o f  skeletal malignancies in beagles injected with ^^ P^u citrate. Health Phys. 
6 6  407-413.
Lloyd RD, Taylor GN, Angus W and Miller SC. (1995) Soft-tissue tumours in beagles 
injected with citrate. Health Phys. 6 8  225-233.
Loewe WS and Mendelshon E. (1981) Revised dose estimates at Hiroshioma and 
Nagasaki. Health Physics 41 663-666.
Looney WB, Hasterlik RJ and Brues AM. (1955) A clinical investigation o f  the chronic 
effects o f  radium salt administered therapeutically. Am. J. Roentgenol Radium Ther. 
NucLMed. 73 1006-1037.
Lord BI. (1990) The architecture o f  bone marrow cell populations. Int. J. CeU Cloning 
8  317-331.
Loutit JF. (1976) Vasoformative non-osteogenic (angio) sarcomas o f  bone marrow 
stroma due to strontium-90. Int. J. Radiat. Biol. 30 359-383.
Loutit JF, Bland MR, Carr TEF, Sansom JM and Smith C. (1973) Tumours in bone and 
bone-marrow in CBA mice by °^Sr and ^ ^^ Ra. pp 395-408 in Bone - Certain Aspects o f  
Neoplasia. Colston Papers 24. Eds. CHG Price and FAM Ross. Butterworth, London.
Loutit JF, Samson J and Carr TEF. (1976) The pathology o f  tumours induced in Harwell 
mice by plutonium-239 and radium-226, pp 505-519 in Proceedings o f a Symposium: 
The health effects o f plutonium and radium. The JW Press, University o f Utah, Utah.
Luz A, MüUer WA, Gossner W and Hug O. (1979) Osteosarcoma induced by short-liver 
bone-seeking a-emitters in mice: the role o f  age. Environ. Res. 18 115-119.
Lyon ME, Rastan S and Brown SDM. (1996) Genetic variants and strains o f  the 
laboratory mouse. Vol 2. Oxford University Press, Oxford.
Lynch TP, Kathren RL and Mclnroy JF. (1988) Macrodistribution o f  plutonium and 
americium in four human skeletons. J. Radiol. Prot. 8  67-76.
References 307
Mahlum DD and Sikov MR. (1975) Metabolism o f  americium-241 citrate in rats 
relative to age. pp 81-83 in Battelle Pacific Northwest Laboratory. Annual Report for 
1974. Part 1. Biomedical sciences. BNWL-1950.
Major IR. (1979) Induction o f  myeloid leukaemia by whole-body single exposure o f  
CBA male mice to X-rays. Br. J. Cancer 40 903-913.
Major IR and Mole RH. (1978) Myeloid leukaemia in X-ray irradiated CBA/H mice. 
Nature 272 455-456.
Makipemaa A, Heikkila J and Merikanto J. (1993) Spinal deformity induced by 
radiotherapy fo r  solid tumours in childhood: A long-term follow-up study. Eur. J.
Pediat. 152 197-200.
Markley JF, Rosenthal MW and Lindenbaum A. (1964) The distribution and removal o f  
monomeric and polymeric plutonium in rats and mice. Int. J. Radiat. Biol. 8  271-278.
Marks SC and Popofif SN. (1988) Bone cell biology: the regulation o f  development, 
structure andfunction in the skeleton. Amer. J. Anat. 183 1-44.
Marshall JH. (1969). The retention o f  radionuclides in bone, pp 7-27 in The delayed 
effects of bone seeking radionucfides. Eds. CW Mays, WSS Jee and RD Lloyd. University 
o f Utah Press, Salt Lake City, Utah.
Martland HS. (1931). The occurrence o f  malignancy in radioactive persons. Am. J. 
Cancer 15 2435-2516.
Matanowski GN, Seltser R and Sartwell PE. (1975) The current mortality rates o f  
radiologists and other physician specialists: Specific causes o f  death. Am. J. Epidem.
101 199-210.
Matthews JL. (1980) Bone structure and ultrastructure, pp 4-44 in Fundamental and 
clinical bone physiology. Ed. MR Urist. JB Lippincott Co, Philadelphia.
Mays CW. (1978) Risk to bone from present ^^ "^ Ra therapy. In Biological Effects o f  
Radium-224: Benefit and Risk of Therapeutic Applications, Nijoff Medical Division, The 
Hague.
Mays CW and Lloyd RD. (1972) Bone sarcoma risk from ^^ Sr. pp 352-375 in Biomedical 
Imphcations o f  Radio strontium Exposure. Eds. M Goldman and LK Bustad. US Atomic 
Energy Commission, Office o f Information Services Report CONF-710201, Oak Ridge, 
Tennasse, USA.
Mays CW, Lloyd RD, Taylor GN, Shabestari LR, Angus W, Atherton DR and GÜlett NA. 
(1989) Fission fragment RBE fo r  bone sarcoma induction. Radiat. Res. 119 432-442.
References 308
McCoUister Evarts C and Rubin P. (1978) Clinical Oncology. Univ. o f Rochester,
Amer. Cancer Soc. Rochester NY 203.
Mclnroy JF, Kathren RL and Swint MJ. (1989) Distribution o f  plutonium and 
americium in whole bodies donated to the United States Transuranium Registry. Rad. 
Prot. Dosim. 26 151-158.
McKay LR, Brooks AC, McClellan RO. (1972). Retention, distribution, dose and 
cytogenetic effects o f  241 Am citrate in the Chinese hamster. Health Phys. 22 633-640.
Meijne EIM. (1996) Radiosensitivity o f  the murine haemopoietic stem cell compartment: 
The effects o f  1 MeVfission neutrons and 300 kVX-rays. PhD Thesis, Erasmus 
University, Rotterdam, Holland.
Meijne EIM, van der Winden-van Groenewegen AJM, Ploemacher RE, Vos O, Davids 
JAG and Huiskamp R. (1991) The effects o f  X-irradiation on haemopoietic stem cell 
compartments inthe mouse. Exp. Haematol. 19 617-623.
Meijne EIM, Ploemacher RE and Husikamp R. (1998) The sensitivity o f  murine 
hemopoietic stem sell populations fo r  1 MeVfission neutrons. Radiat. Res (in press).
Melson F and Mosekilde L. (1988) Tetracycline double-labelling o f  iliac trabecular 
bone in 41 normal adults. Calcif. Tiss. Res. 26 99-102.
MétivierH. (1988) Transuranium elements. Chp 66 pp 715-731 in Handbook on 
Toxicity o f Inorganic Compounds. Eds. HG Seiler, H Sigel and A Sigel New York: 
Marcel Dekker Inc.
Mettler FA and Upton AC. (1995) Medical effects o f  ionising radiation. 2nd edition. 
WB Saunders Co, Philadelphia.
Miller SC, Bruenger FW and Williams FW. (1989) Influence o f  age at exposure on 
concentrations of^^^Pu in beagle gonads. Health Phys. 56 485-491.
Mole RH. (1958) The development o f  leukaemia in irradiated animals. Brit. Med. Bull. 
14 174-177.
Mole RH. (1978) The radiobiological significance o f  the studies with ^^ "^ Ra and 
Thorotrast. Health Phys. 35 167-174.
Mole RH and Major IR. (1983) Myeloid leukaemia frequency after protracted exposure 
to ionising radiation: Experimental confirmation o f  the fla t dose-response found in 
ankylosing spondylitis after a single treatment course with X-rays. Leuk. Res. 7 295.
Mole RH, Papworth DG and Corp MJ. (1983) The dose-response fo r  X-ray induction o f  
myeloid leukaemia in male CBA/H mice. Br. J. Cancer 47 285-291.
References ' 309
Mori T, Kumatori T and Kato Y. (1986) Present status o f  the medical study on 
thorotrast administered patients in Japan Strahlentherapie 80 Suppl. 123-134.
Mori T, Kumatori T, Hatakeyma S, Irie H, Mori W, Fukatomi K, Baba K, Maruyama T, 
Veda A, Iwata S, Tamai T and Akita Y. (1989) Current status o f  the Japanese follow-up 
study o f  the throrotrast patients and its relationships to the statistical ananlysis o f  the 
autopsy series, pp 119-124 in Risks from Radium and Thorotrast, Eds. DM Taylor, CW 
Mays, GB Gerber and RC Thomas, British Institute o f Radiology, London.
Moiiyama IM and Kato H. (1973) Mortality experience o f  the A-bomb survivors, 1970- 
1972, 1950-1973. JNIH ABCC Life Span Study, Report 7, Hiroshima, Atomic Bomb 
Casualty Commission.
Morrow P, Gelein R, Beier H, Scott J, Picano J and Yuüe C. (1982) Inhalation and 
intravenous studies ofUF^/U02F2 in dogs. Health Phys. 43 859-873.
Moskalev YI, Kunitskaya and Buldakov LA. (1973) Late effects associated with damage 
by transuranium elements, pp 9-10 in Book o f Abstracts, IRPA Congress, Washington, 
DC.
Moskalev YI and Rudnitskaya El. (1970). Liver pathology under the action o f  
americium-241. Radiobiologiya 10 No 5. Enghsh Translation AEC-tr-7215.
Moskalev YI, Streltsova VN and Buldakov LA. (1969). Late effects o f  radionuclide 
dammage. pp 489-509 in Delayed effects o f bone seeking radionucHdes. Eds. CW Mays, 
WSS Jee and RD Lloyd. Univ. o f UTAH Press, Salt Lake City, Utah.
Moss ML. (1966) Bone, in Histology. Ed. RO Greep. New York: McGraw-Hill.
Müller WA, Gossner W, Hug O and Luz A. (1978) Late effects after incorporation o f  
the short-lived alpha-emitters ^^ R^a and^^^Th in mice. Health Phys. 35 33-55.
Müller WA, Luz A, Murray B and Linzner U. (1990) Induction o f  lymphoma and 
osteosarcoma in mice by single and protracted low a: doses. Health Phys. 59 305-310.
Muntz JA and Guzman Barron ES. (1951) The transport o f  uranium to the tissues, pp 
182-198 in Toxicology of Uranium. Ed. A Tannenbaum. New York: McGraw-Hill.
Myers DK, Jackson JS and Dunford DW. (1991) The relative biological effectiveness o f  
tritium beta rays fo r  causes o f  death other than myeloid leukaemia in male CBA/H mice. 
Atomic Energy Control Board Research Report Info 0384, Ottawa, Canada.
Nakashima E. (1994) Relationship o f  five anthroporhetric measurement at age 18 to 
radiation dose among atomic bomb survivors exposed in utero. Radiat. Res. 138 121- 
126.
References 310
NCRP. (1989) National Council on Radiation Protection and Measurements (NCRP): 
Exposure o f  the US population from occupational radiation. Report 101, Bethesda, 
Maryland.
NE A (1988) Nuclear Energy Agency. Gastrointestinal absorption o f  selected 
radionuclides. NEA, Paris: OECD.
Nenot JC, Masse R, Morin M and Lafuma J. (1972) An experimental comparative study 
o f the behaviour o f  neptunium-237, plutonium-238, plutonium-239, americium-241 and 
curium-242 in bone. Health Physics 22: 657-665.
Neuman WE. (1951) The distribution and excretion o f  uranium, pp 710-728 in The 
pharmacology and toxicity o f uranium compounds. Div VI, Vol 1. Eds. C Voegtlin and 
HC Hodge. New York: McGraw-Hill.
Neuman WE. (1953) Deposition o f  uranium in bone, pp 1911-1991 in Pharmacology and 
Toxicology o f Uranium Compounds. Eds. C. Voegtlin and HC.Hodge. New York / 
Toronto / London: McGraw-Hill, Parts I and II 1949, parts III and IV 1953.
Neuman WF. (1980) Bone material and calcification mechanisms, pp 83-107 in 
Fundamental and clinical bone physiology. Ed. MR Urist. JB Lippincott and Co, 
Philadelphia.
Neuman WF, Neuman MW and Muhyan BJ. (1948a) The deposition o f  uranium in bone. 
I. Animal studies. J. Biol. Chem. 175 705-709.
Neuman MW and Neuman WF. (1948b) The deposition o f  uranium in bone. II. 
Radioautographic studies. J. Biol. Chem. 175 711-715.
Neuman WF, Neuman MW, Main ER and Mulryan BJ. (1953) Deposition o f  uranium in 
bone: Animal studies, pp 1911-1991 in Pharmacology and toxicity o f uranium 
compounds. Div. IV. Vol. 1. Eds. C Voegtlin and HC Hodge. McGraw-Hill, New York: 
McGraw-Hill.
Nifatov AP, Buldakov LA and Matveen VI. (1972). Some late effects after a single 
inhalation of^^^Pu and Am in dogs. Health Physics 22 875.
NMpelov B, Lizlov A and Koshumikova N. (1990) Experience with the first Soviet 
nuclear installation: Radiation doses and health. Priroda 2 30-38.
Nilsson A. (1969) Dose-dependent carcinogenic effect o f  radiostrontium, pp 173-183 in 
Radiation Induced Cancer, IAEA Publication STI/PUB/228, International Atomic Energy 
Agency, Vienna.
Nilsson A. (1970) Pathologic effects o f  different doses o f  radiostrontium in mice. Dose 
effect relationship in ^^ Sr induced bone tumours. Acta Radiol. 9 155-176.
References 311
Nilsson A. (1972) Sr-induced malignancies in mice, pp 207-241 in Biomedical 
Implications o f Radiostrontium Exposure. Eds. M Goldman and LK Bustad, US Atomic 
Energy Commission, Office of Information Services Report CONF-710201, Oak Ridge, 
Tennasee, USA.
Nilsson A and Broomé-Kaulsson A. (1976). The pathology o f  americium-241. Acta 
Radial. Ther. Phys. Biol. 15 49-70.
Nilsson A and Ronnbach C. (1973) Influence o f  oestrogenic hormones on 
carcinogenesis and toxicity o f  radio-strontium. Acta. Radiol. Ther. Stockh. 12 209-228.
Okeanov AE, Cardis E, Antipora SI, Poluakov SM, Sobolev AV and Bazulko NV.
(1996) Health status andfollow-up o f  the liquidators in Belarus, pp 851-859 in The 
Radiological Consequences of the Chernobyl Accident. Eds A Karaglou, G Desmet, GN 
Kelly and HG Menzel. CEC Pubhcation EURl 6544EN, ECSC-EC-EAEC, Brussels- 
Luzembourg.
Oghiso Y, Yamada Y and lida H. (1994) Differential induction o f  bone and 
haematopoietic tumours in C3H mice after injection of^^^Pu citrate. Radiat. Res. 35 236- 
247.
Oghiso Y, Yamada Y and lida H. (1997) High frequency o f  leukaemia lymphomas with 
osteosarcomas but no myeloid leukaemias in C3H mice after ^^ P^u citrate injection. 
Radiat. Res. 38 77-86.
Okada S, Hamilton HB, Egami N, Okajima S, Russell WJ and Takeshita K. (1975) A 
review o f  thirty years study o f  Hiroshima and Nagasaki atomic bomb survivors. Radiat. 
Res. (Tokyo) 16 Suppl. 1-164.
Olds RJ and Olds JR. (1979) The colour atlas o f  the rat - dissection guide. Wolfe 
Medical Publications Ltd, London.
Olsen J, Andersson M and Boice JD. (1990) Thorotrast exposure and cancer risk.
Health Phys. 58 222-223.
Otake M, Fujokoshi Y and SchuU W. (1993) A longitudinal study o f  growth and 
development o f  stature among prenatally exposed atomic bomb survivors. Radiat. Res. 
134 94-101.
Overgarrd M. (1988) Spontaneous radiation-induced rib fractures in breast cancer 
patients treated with postmastectomy irradiation. A clinical radiobiological analysis o f  
the influence o f  fraction size and dose response relationships on late bone damage. Acta 
Oncol. 27117-122.
Pearson AE and Phelps TA. (1981) Radiation effects on mouse incisor teeth following 
whole body irradiation o f  up to 16 Gray. Int. J. Radiat. Biol. 39 409-417.
References 312
Parfitt AM. (1976) The actions o f  parathyroid hormone on bone: Relation to bone 
remodelling and turnover, calcium homeostasis, and metabolic bone disease. Part III o f  
IVparts; PTH and osteoblasts, the relationship between bone turnover and bone loss, 
and the state o f  the bones in primary hyperparathyroidism. Metabolism 25 1033-1069.
Parfitt AM. (1983) Physiologic and clinical significance o f  bone histomorphometric 
data, pp 143-224 in Bone Histomorphometry: Techniques and Interpretation. Ed. RR 
Recker. CRC Press, Boca Raton.
Parfitt AM. (1988) The composition, structure and remodelling o f  bone: A basis fo r  the 
interpretation o f  bone mineral measurements, pp 9-28 in Bone mineral measurements by 
photon absorptiometry: Methodological problems. Eds. JV Dequeker, P Geusens and HW 
Wahner. Leuven, Belgium: Leuven University Press.
Park JF. (1987) Inhaled plutonium oxide in dogs, pp 5-20 in Pacific Northwest 
Laboratory Annual Report for 1986 to the Office o f Energy Research, US Department o f  
Energy, Part 1. PNL-6100. Battelle Pacific Northwest Laboratory, Richland, Washington.
Pattengale PK and Taylor CR. (1983) Experimental models o f  lymphoproliferative 
disease: the mouse as a model fo r  human non-Hodgkin's lymphomas and related 
leukaemias. Am. J. Pathol. 113 237-265.
Peligot B. (1841) Cited by Greenwood NN and Eamshaw A. (1994) Chp. 31: The 
actinide elements, pp 1450-1486 in The Chemistry o f the Elements. Oxford: Pergamon 
Press.
Penneman RA, Coleman JS and Keenan TK. (1961) Alkaline oxidation o f  americium: 
Preparation and reactions o f  Am(IV) hydroxide. J. Inog. Nucl. Chem. 17 138-145.
Phalen RF, Cuddihy RG, Fisher GL, Moss OR, Schlesinger RB, Swift DL and Hsu-Chi 
YEH. (1991) Main features o f  the proposed NCRP Respiratory Tract Model. Radiat. 
Prot. Dosim. 38 179-184.
Pifer JW, Hempelmann LH, Dodge HJ and Hodges FJ 2nd. (1968) Neoplasms in the Ann 
Arbor series o f  thymus-irradiated children; a second survey. Am. J Roentgenol. Radium 
Ther. Nucl. Med. 103 13-18.
Polednak AP, Stehney AF and Rowland RE. (1978) Mortality among women first 
employed before 1930 in the US radium dial-painting industry. Am.J Epidemiol. 107 
179-195.
Popplewell DS and Boocock G. (1968) Distribution o f  some actinides in blood serum 
proteins, pp 45-55 in Diagnosis and Treatment of Deposited Radionuclides. Eds. HA 
Korgberg and WD Norwood. Excerpta Med. Found, Amsterdam
Popplewell DS, Stradling GN and Ham GJ. (1975) The chemical form  ofplutonium in 
urine. Radiat. Res. 62 513-519.
References 313
Preston D, Kusumi S and Tomonaga M. (1994) Cancer incidence in atomic bomb 
survivors. Part III: Leukamia, lymphoma and multiple myeloma 1950-1987. Radiat. Res. 
137 568-597.
Prichard JF. (1972) in The Biochemistry and Physiology o f Bone. Ed GH Bourne Vol 1.
Priest ND. (1981). Plutonium in bone: The effects o f  remodelling, pp 39-55 in Bone and 
Bone-seeking radionuclides: physiology, dosimetry and effects. Ed. V Volf. EULEP 
Symposium EUR 7168EN Harwood Academic, Chur, Switzerland.
Priest ND and Jackson S. (1977). Plutonium in bone: a high resolution autoradiographic 
study using plutonium-241. Int. J. Radiat. Biol. 32 325-350.
Priest ND, Howells G, Green D and Haines JW. (1982) Uranium in bone: Metabolic and 
autoradiographic studies in the rat. Human Toxicology 1 97-114.
Priest ND, Howells GR, Green D and Haines JW. (1983) The uptake o f  americium-241 
by the rat skeleton and its subsequent redistribution and retention: Implications fo r  
human dosimetry and toxicology. Human Toxicology 2 101-120.
Priest ND, Howells G, Green D and Haines JW. (1985) Initial deposition pattern o f  
actinides 91-96 in the skeleton o f the rat. pp 175-197 in Metals in Bone. Hingham, USA: 
MTP Press L td..
Prisyazhiuk A, Pjatak OA, Buzanov VA, Reeves GK and Beral V. (1991) Cancer in the 
Ukraine, post-ChemobyI. Lancet 338 1334-1335.
Radford EP, Doll R and Smith PG. (1977) Mortality among patients with ankylosing 
spondylitis not given X-ray therapy. New Eng. J. Med. 297 177-181.
Raymond KN and Smith WL. (1981) Actinide-specific sequestering agents and 
decontamination applications. Structure and binding. 43 159-186
Regen EM and Wilkins WE. (1936) On rate o f  healing offractures and phosphatase 
activity o f  callus o f  adult bone. J Bone Joint Surg. 18 69-79.
Robertson W, Butler M and D ’Angio G. (1991) Leg length discrepancy following 
irradiation fo r  childhood tumours. J. Pediat. Ortho. 11 284-287.
Rogers AW. (1979) Techniques o f  autoradiography. 3rd edition, Elsevier North- 
Holland Biomedical Press, Amsterdam.
Rosenthal MW and Lindenbaum A. (1967) Influence o f  DTPA therapy on long-term 
effects o f  retained monomeric plutonium. Radiat. Res. 31 506-521.
References 314
Rosenthal MW and Lindenbaum A. (1969) Osteosarcomas as related to tissue 
distribution o f  monomeric and polymeric plutonium in mice, pp 371-384 in Delayed 
effects o f bone seeking radionucHdes. Eds. CW Mays, WSS Jee and RD Lloyd. Univ. o f 
Utah Press, Salt Lake City, Utah.
Rosenthal MW, Marshall JH and Lindenbaum A. (1968) Autoradiographic and 
radiochemical studies o f  the effect o f  colloidal state o f  intravenously injected plutonium 
on its distribution in bone and bone marrow, pp 73-80 in Diagnosis and treatment of  
deposited radionucHdes. Proc. Symp. Richland 1967. Eds. HA Komberg & WD Norwood. 
Excerpta Medica Foundation, Monograph on Nuclear Medicine 2.
Rosenthal MW and Schubert J. (1957) Kinetics o f  body distribution as influenced by 
zirconium. Radiat. Res. 6  349-354.
Ross MH and RomreU LJ. (1989) Histology: A Text and Atlas. 2nd Edn. Baltimore: 
WilHams and Wilkins.
Rowland RE. (1964) Resorption and bone physiology, pp 335-351 in Bone 
biodynamics. Ed HM Frost, Little Brown and Co, Boston.
Rowland RE and Famham JE. (1968) The deposition o f  uranium in bone, pp 33-36 in 
Radiological Physics Division Report. Argonne National Laboratory, Argonne, Illinois. 
ANL-7489.
Rowland RE and Famham JE. (1969) The distribution o f  uranium in bone. Health 
Physics 17 139-144.
Rowland RE and Stehney AF. (1978) Radium-induced malignancies, pp 259-264 in 
Argonne National Laboratory Report. ANL-78-65, Part II.
Rowland RE, FaÜla PM and Keane AT. (1971) Tumour incidence in radium patients. 
Report 7860, Argonne National Laboratory, Argonne, lUinois.
Rowland RE, Stehney AF and Lucas HF. (1978) Dose-response relationships fo r  female 
radium dial workers. Radiat. Res. 76 368-383.
Rowland RE and Lucas HF. (1984) Radium dial workers, pp 231 -240 in Radiation 
Carcinogenesis: Epidemiolgy and Biological Significance. Eds. JD Boice and JE 
Fraumeni, Raven Press, New York.
Rowley JD. (1973) A new consistent chromosomal abnormality in chronic myelogenous 
leukaemia identified by Quinacrine florescence and Giemsa staining. Nature 243 
290-293.
Rubin P and Casarett GW. (1968) Clinical Radiation Pathology. WB Saunders, 
Philadelphia.
References 315
Rugh R. (1963) The impact o f  ionising radiations on the embryo andfetus. Amer. J. 
Roentgenol. 89 182-190.
Rydberg J and Rydberg B. (1956) Studies on the extraction o f  metal complexes. XIII. The 
complex formation between U(IV) and acetylacetone. Arkiv. Kemi. 9 81-94.
Sager R. (1989) Tumour suppressor genes: the puzzle and the promise. Science 246 
1406-1412.
Sankaranarayanan K. (1991) Ionising radiation and genetic risks III. Nature o f  
spontaneous and radiation induced mutations in mammalian in vitro systems and 
mechanisms o f  mutation. Mut. Res. 258 75-97.
Saunders CL and Kathren RL. (1983) Ionizing radiation: Tumorigenic and tumoricidal 
effects. Springer-Verlag, New York.
Saunders RD, EUender M, Kowalczuck Cl, Sienkiewicz ZJ and Wood NR. (1990) Dose- 
response relationships fo r  early and continuing health effects. NRPB-246, Chilton, 
London, HMSO.
Schales F. (1978) Problems and results o f  a new follow-up study. ^^ "^ Ra in adult 
ankylosing spondylitis patients, pp 30-36 in Biological Effects o f  ^ '^‘Ra. Benefit and Risk 
of Therapeutic Application. Eds. WA Müller and HG Ebert. Nijhoff Medical Division, The 
Hague.
Scheibel-Jost P, Pfeil J and Niethard F. (1991) Spinal growth after irradiation fo r  Wilm "s 
tumour. Int. Orthop. 15 387-391.
Schlenker RA, Pitman BG and Kathren RL. (1989) Bone surface deposition of^ ^^ A^m in a 
person with occupational exposure. Rad. Prot. Dosim 26 195-199.
Schubert J, Finkel MP, White MR and Hursch GM. (1950). Plutonium and yttrium  
content o f  the blood, liver and skeleton o f  the rat at different times after intravenous 
administration. J Biol. Chem. 182 635-642.
Schubert J, Fried JF, Rosenthal MW and Lindenbaum A. (1961) Tissue distribution on 
monomeric and polymeric plutonium as modified by a chelating agent. Radiat. Res. 15 
220-226.
Scrable HJ, Sapienza C and Cavanee WK. (1990) Genetic and epigenetic losses o f  
heterozygosity in cancer predisposition and progression. Adv. Cancer. Res. 54 25.
Seaborg GT, McMillan EM, Kennedy JW and Wahl A. (1940) Cited by Greenwood NN  
and Eamshaw A. (1994) Chp. SI: The actinide elements, pp 1450-1486 in The Chemistry 
o f the Elements. Oxford: Pergamon Press.
Seaborg GT, James RA, Morgan LG and Ghiorso A. (1944) Cited by Greenwood NN  
and Eamshaw A. (1994) Chp. 31: The actinide elements, pp 1450-1486 in The Chemistry 
of the Elements. Oxford: Pergamon Press.
References 316
Seki M, Yoshida K, Nishimura M and Nemoto K. (1991) Radiation-induced myeloid 
leukaemia in C3H/He mice and the effect o f  prednisolon acetate on leukaemogenesis. 
Radiat. Res. 127 146-149.
SeldinHM. (1955) Radio-osteomyelitis o f  the jaw . J. Oral Surg. 13 112-119.
Seltser R and Sartwell PE. (1965) The influence o f  occupational exposure to radiation 
on the mortality o f  radiologists and other specialists. Am. J. Epidem. 81 2-22.
Schlenker RA, Oilman BG and Cummins HT. (1976) Macroscopic distribution o f  
plutonium-239 distributed in bone from a human injection case, pp 321-328 in Health 
Effects o f Plutonium and Radium, Ed. WSS Jee, The JW Press, Salt Lake City, Utah.
Schoeters GR and Vanderborght OLJ. (1983) Relative effectiveness of^ '^^ Am vs ^^ R^a 
approached by haemopoietic stem cell studies in various bone marrow sites o f  
contaminated mice. Health Phys. 44 555-570.
Schoeters G and Vanderborght O. (1989) The comparative carcinogenicity of^ '^ ^Am 
versus ^^ R^a in various mouse strains, pp 503-513 in Low dose radiation: Biological basis 
of risk assessment. Eds. KF Baverstock and JW Stather, Taylor and Francis, London.
Schoeters GER, Maisin JR and Vanderborght OLJ. (1991) Toxicity of^ ^^ A^m in male 
C57BL mice: Relative risk versus ^^ R^a. Radiat. Res. 126 198-205.
Sharpe WD. (1974) Chronic radium intoxication: clinical and autopsy findings in long­
term New Jersey survivors. Environ. Res. 8 243-383.
Shouse SS, Waren SL and Whipple GH. (1913) Aplasia o f  marrow andfatal 
intoxication in dogs produced by roentgen irradiation o f  all bones. J. Exp. Med. 53 421.
Sikov MR and Mahlum DD. (1972) Age-dependance of239-plutonium metabolism and 
effect in the rat. pp 261-272 in Radiobiology of plutonium. Eds. BJ Stover and WSS Jee. 
The JW Press, Univ. o f Utah, Salt Lake City.
Smith GS, Walford RL and Mickey R. (1973) Lifespan and incidence o f  cancer and 
other diseased in selected long-lived inbred mice and their Fj hybrids. JNCI50 1195- 
1213.
Smith J, Davidson J and Glatmen G. (1982) Skeletal effects o f  orthovoltage and 
megavoltage therapy following treatment o f  nephroblastoma. CHn. Radiol. 33 601-613.
Smith PG, Doll R and Radford EP. (1977) Cancer mortality among patients with 
ankylosing spondylitis not given X-ray therapy. Br. J. Radiol. 50 728-734.
Smith P and Doll R. (1982) Mortality among patients treated fo r  ankylosing spondylitis 
after a single treatment course with X-rays. Br. J. Radiol. 284 449-460.
Smith VH, Ballou JE, Clarke WJ and Thompson RC. (1961) Effectiveness o f  DTPA in 
removing plutonium from the pig. Proc. Soc. Exp. Biol. (NY) 107 120-125.
References 317
Smith VH. (1964) Prevention o f  plutonium deposition by desferrioxamine-B. Nature 
204 899-900.
Sonis A, Tarbell N  and Valachovic R. (1990) Dentofacial development in long-term 
survivors o f  acute lymphomblastic leukaemia: A comparison o f  three treatment 
modalities. Cancer 66 2645-2652.
Sontag W. (1983) The early distribution of^^^Pu, ^^ A^m and^^^U in the soft tissues and 
skeleton o f  old rats. A comparative study. Human Toxicology 2 91-100.
Sontag W. (1984) Long-term behaviour of^^^Pu, "^^ A^m and in different bones o f
one-year-old rats: macrodistribution and macrodosimetry. Human Toxicology 3 469- 
483.
Spanner M, Müller WA and Atkinson MJ. (1992) The role o f  ferritin in the intracellular 
uptake o f  radionuclides, p 85 in Book o f Abstracts, 24th Annual Meeting o f the 
European Society for Ra^ation Biology. October 4-8,1992, Erfurt, Germany.
Spiers FW, Lucas HF, Rundo J and Anast GA. (1983) Leukaemia incidence in the US 
dial painters. Health Phys 44 Suppl. 49-72.
Speiss H. (1956) Schwere Strahlenschaden nach der Peteosthorbehandlung von 
Kindem. Dt. Med. Wschr. 81 1053.
Speiss H, Poppe H and Schoen H. (1962) Strahlenindizerte Knochentumoren nach 
Thorium X-Behandlung. Monatsshrift fur Kinderheilkunde 110 198-201.
Speiss H and Mays CW. (1970) Bone cancers induced by ^^ "^ Ra (Th X) in children and 
adults. Health Phys. 19 713-729 and addendum Heath Phys. 20 543-545, 1971.
Speiss H and Mays CW. (1973) Protraction effect on bone sarcoma induction of^ ^^ R^a in 
children and adults, pp 437-450 in Radiation Carcinogenesis, USAEC, Springfield, 
Viginnia.
Speiss H, Gerspach A and Mays CW. (1978) Soft-tissue effects following ^^Ra injections 
into humans. Health Physics 35 61-81.
Speiss F, Lucas H and Anast G. (1983) Leukemia incidence in the US Dial Workers. 
Health Phys. 44 Suppl 1, 65-72.
Stanley JA, Eidson AF and Mewhinney JA. (1982) Distribution, retention and dosimetry 
ofplutonium and americium in the rat, dog and monkey after inhalation o f  an industrial- 
mixed uranium and plutonium oxide aerosol. Health Phys. 43 521-530.
Stannard JN. (1988) Radioactivity and health: a history. National Technical Information 
Service, Springfield, Virginia.
References 318
Stather JW. (1974) Distributions off^P, "^ C^s, ^^ Sr and ^^ B^a as a function o f  age in the 
mouse skeleton. Health Phys. 26 71-79.
Stevens A and Lowe J. (1992) Histology. Gower Medical Pubhshing, London.
Stevens A and Lowe J. (1995) Pathology. Mosby, London.
Stevens W, Bruenger FW, Atherton DR and Stover BJ. (1971) pp 212 USAEC 
Document COO-119-244.
Stevens W, Bruenger FW, Bates D and Atherton DR. (1976) Retention and distribution 
o f  americium-241 (III): in neonatal beagles, pp 167-171 in Research in Radiobiology. 
Annual Report o f the Internal Irradiation Program, University o f Utah. COO-119-251.
Stevens W, Bruenger FW, Atherton DR, Smith JM and Taylor GN. (1980) The 
distribution and retention ofhexavalent^^^U in the beagle. Radiat. Res. 83 109-126.
Stevens W, Bruenger FW and Stover BJ. (1968) In vivo studies on the interactions o f  
PuIVwith blood constituents. Radiat. Res. 33 490-500.
Stover BJ, Atherton DR and KeUer N. (1959) Metabolism off^^Pu in adult beagle dogs. 
Radiat. Res. 10 130-147.
Stover BJ, Bruenger FW and Stevens W. (1968) The reaction o f  Pu(IV) with the iron 
transport system in human blood serum. Radiat. Res. 33 381-394.
Stover BJ, Atherton DR, Bruenger FW and Buster DS. (1962) Further studies o f  the 
metabolism off^^Pu in adult beagles. Health Phys. 8  589-597.
Stubbs JB. (1992) Results from a new mathematical model o f  gastrointestinal transit 
that incorporates age and gender-dependent physiological parameters. Radiat. Prot. 
Dosim. 41 63-69.
SuUivan MF, Hackett PL, George LA and Thompson RC. (1960) Irradiation o f  the 
intestine by radioisotopes. Radiat. Res. 13 343-355.
Svoboda V, Bubenikova D and Kotaskova Z. (1981) Myeloid leukaemia in ^^ P^u treated 
mice. J. Cancer Res. Clin. Oncol. 100 255-262.
Svoboda V and Bubenikova D. (1990) Hemoblastoses in mice contaminated with low 
activities off^^Pu. Neoplasma 37 639-646.
Takahashi S, Kitabatake T, Yamagata S, Miyakawa T, Masuyama M, Mori T, Tanaka T, 
Hibino S, Miyakawa M, Kaneda H, Okajima S, Komiyama K, Koga Y, Adachi T, 
Hashizume T and Hashimoto Y. (1965) Statistical study on thorotrast-induced cancer o f  
the liver. Tohoku J Exp. Med. 87 144-154.
Tannenbaum A, Silverstone H and Kozoil J. (1951) Tracer studies o f  the metabolism and 
excretion o f  uranium in mice, rats and dogs, pp 128-181 in Toxicology of Uranium. Ed.
A Tannenbaum. National Nuclear En^gy Series Div IV Vol 23. McGraw Hill, New York.
References 319
Taylor DM. (1962) Some aspects o f  the comparative metabolism ofplutonium and 
americium in rats. Health Phys. 8  673-677.
Taylor DM. (1972) Interactions between transuranium elements and components o f  cells 
and tissues. Health Phys. 22 575-581.
Taylor DM. (1973) Plutonium, chemical and physical properties, pp 323-347 in 
Uranium, Plutonium, Transplutonic Elements. Eds. HC Hodge, JB Stannard and JB Hursh. 
New York: Springer-Verlag.
Taylor DM. (1983) Interactions o f  plutonium with human saliva in vitro. In Proc. 7th 
Int. Congr. Radiat. Res. Vol. E; E5-17, Martinus NijhofFPublishers, Amsterdam.
Taylor DM and Bensted JPM. (1969) Long term biological dammage from  
plutonium-239 and americium-241 in rats, pp 357-370 in Delayed effects o f bone-seeking 
radionuclides. Eds. CW Mays, WSS Jee and RD Lloyd. Univ. of UTAH Press, Salt Lake 
City, Utah.
Taylor DM, Sowby ED and Kember NF. (1961) The metabolism o f  plutonium and 
americium in the rat. Phys. Med. Biol. 6  73-86.
Taylor GN, Dougherty TF and Christensen WR. (1978) Some aspects o f  internally 
depostited^^^Pu. pp 110-119 in Pathology of Irràdiation. Ed CC Berdjis. Williams and 
Wilkins, Baltimore, USA.
Taylor GN, Mays CW, Lloyd RD, Gardner PA, Talbot LR, McFarland SS, Pollard TA, 
Atherton DR, VanMoorhem D, Brammer D, Brammer TW, Ayoroa G and Taysum DH. 
(1983) Comparative toxicity of^^^Ra, ^^ P^u, and^^^Cf in C57Bl/Do black and
albino mice. Radiat. Res. 95 584-601.
Taylor GN, Thurman GB, Mays CW, Shabesturi L, Angus W and Atherton DR. (1981) 
Plutonium-induced osteosarcomas in the St. Bernard. Radiat. Res. 8 8  180-186.
Thomas P, Griffith K and Fineberg B. (1983) Late effects o f  treatment fo r  Wilm’s 
tumour. Int. J. Radiat. Oncol. Biol. Phys. 9 651-657.
Thomas RG, McCleUan RO, Thomas RL, Chiffelle TL, Hobbs CH, Jones RK, Mauderly 
JA and PickreU JA. (1972) Metabolism, dosimetry and biological effects o f  inhaled 
"^^ A^m in beagle dogs. Health Phys. 22 863-871.
Thome MC. (1977) Aspects o f  the dosimetry o f  alpha-emitting radionuclides in bone 
with particular emphasis on ^^ R^a and Pu. Phys. Med. Biol. 22 36-46.
Thurman GB, Mays CW, Taylor GN, Christensen WR, Rehfeld CE and Dougherty TF. 
(1971) Growth dynamics o f  beagle osteosarcomas. Growth 35 119-125.
References 320
Travis L, Kathren R and Boice JD. (1992) Cancer risk following exposure to thorotrast: 
Overview in relation to a case report. Health Phys. 63 89-97.
Triffitt JT. (1980) The organic matrix o f  bone tissue, pp 45-82 in Fundamental and 
Clinical Bone Physiology. Ed. MR Urist. JB Lippincott and Co, Philadelphia.
Trosko JE, Chang CC, Madhukar BV and Klaunig JE. (1990) Chemical, oncogene and 
growth factor inhibition o f  gap junction intercellular communication: An integrative 
hypothesis o f  carcinogenesis. Pathobiol. 58 265-278.
Tucker M, D ’Angio G and Boice JD. (1987) Bone sarcomas linked to radiotherapy and 
chemotherapy in children. New Engl. J. Med. 317 588-593.
Tucker M, Coleman C and Cox R. (1988) Risk o f  second cancers after treatment fo r  
Hodgkin’s disease. New Engl. J. Med. 318 76-81.
Turner GA and Taylor DM. (1968a) The transport o f  plutonium, americium and curium 
in the blood o f  rats. Phys. Med. Biol. 13 525-536.
Turner GA and Taylor DM. (1968b) The binding o f  plutonium to serum proteins in 
vitro. Radiat. Res. 36 22-30.
Tyror JG. (1989) The medical implications o f  nuclear power plant accidents, pp 1-36 in 
Medical Response to Effects o f Ionising Radiation. Eds. WA Crosbie and JH Gittus. 
London: Elsevier Apphed Science.
Uhberg S, Nelson A, Kristoffersson H and Engstrom A. (1962) Distribution o f  
plutonium in mice. Acta Radiologica 58 459-471.
UNSCEAR. (1977) United Nations Scientific Committee on the Effects o f Atomic 
Radiation (UNSCEAR) Sources and effects o f  ionising radiation. United Nations,
New York.
UNSCEAR. (1988) United Nations Scientific Committee on the Effects o f Atomic 
Radiation (UNSCEAR) Sources, effects and risks o f  ionising radiation. United Nations, 
New York.
UNSCEAR. (1993) United Nations Scientific Committee on the Effects o f Atomic 
Radiation (UNSCEAR) Genetic and somatic effects o f  ionising radiation. United 
Nations, New York.
Upton AC. (1990) Radiobiology and radiation protection: The past century and 
prospects fo r  the future, pp 199-231 in Radiation Protection Today - The NCRP at Sixty 
years. NCRP Proceedings No 11. National Council on Radiation Protection and 
Measurements, Bethesda, Maryland, USA.
References 321
USDE. (1996) International radiobiology archives o f  long-term animal studies. Vol 1. 
Descriptions o f  participating institutions and studies. GB Gerber, CR Watson, T 
Sugahara and S Okada. DOE/RL-96-72/EUR 16954. US National Technical Information 
Service, Springfield, Virginia.
Van den Heuvel R, Gerber GB, Leppens H, Van der Plaetse and Schoeters GER. (1995) 
Long-term effects on tumour incidence and survival from exposure o f  the BALB/c 
mouse in utero and during adulthood. Int. J. Radiat. Biol. 6 8  679-686,
van Kaick G, Muth H, Kaul A, Wesch H, Immich H, Liebermann D, Lorenz WJ, Luhrs H, 
Scheer KE, Wagner G and Wagner K. (1986) Report on the German Thorotrast study. 
Strahlentherapie 80 Suppl. 114-118.
van Kaick G, Muth H and Kaul A. (1984) The German thorotrast study. Report o f  the 
Commission o f the European Communities, EUR 9504, EN, CEC Luxembourg, Brussels.
van Kaick G, Wesch H, Luhrs H, Lieberman D, Kaul A and Muth H. (1989) The German 
thorotrast study - report on 20 years o f  follow-up. pp 98-104 in Risks from Radium and 
Thrortrast. Eds. DM Taylor, CW Mays, GB Gerber and RC Thomas, British Institute o f  
Radiology, London.
van Putten LM. (1961) Treatment o f  radiostrontium intoxication in mice. II. Survival 
and bone tumour frequency. Int. J. Biol. 5 477-484.
van Putten LM and de Vries. (1962) Stronium-90 toxicity in mice. J. Natl. Cancer. Inst. 
28 587-598.
Vaughan JM. (1970) The physiology o f  bone. C\dXQnàonVvQss,OySoxé.
Vaughan JM. (1973) The effects o f  irradiation on the skeleton. Clarendon Press, Oxford.
Vaughan JM, Bleaney B and Taylor DM. (1973) Distribution, excretion and effects o f  
plutonium as a bone seeker, pp 349-502 in Uranium, plutonium, transplutonium elements. 
Eds. HC Hodge, JN Stannard and JB Hursh, Springer-Verlag, Berlin.
Voelz GL, Hempelmann LH and Lawrence JN. (1979) A 32 year medical follow-up o f  
Manhattan project plutonium workers. Health Phys. 37 445-485
Watson WA, PMlipson T and Oates PJ. (1981) Numerical analysis: the mathematics o f  
computing. Edward Arnold, London.
Weinberg RA. (1991) Tumour suppressor genes. Science 254 1138-1146.
Weller RL, Buschbom RL, Dagle GE, Ragan HA and Park JF. (1995) Hepatic effects o f  
inhaled plutonium dioxide in beagles. Radiat. Res. 144 73-81.
Wick R and Gossner W. (1983) Follow-up study o f  late effects in ^^ '^ Ra treated 
ankylosing spondylitis patients. Health Phys. 44 Suppl. 187-195.
References 322
Wick R, Chmelevsky D and Gossner W. (1986) Risk to bone and haematopoietic
tissue in ankylosing spondylitis patients. Strahlentherapie 80 Suppl. 38-44.
Wick R and Gossner W. (1989) Recent results o f  the follow-up of^ '^ '^ Ra treated 
ankylosing spondylitis patients, pp 25-28 in Radium and Thorotrast. Eds. DM Taylor,
CW Mays, GB Gerber and RC Thomas. BIR Report 21. British Institute o f Radiology, 
London.
Williams PA and Peacocke AR. (1965) The physical properties o f  a glycoprotein from  
bovine cortical bone. Biochim. et Biophys. Acta. 101: 327-335
Williamson M. (1963) The sites o f  deposition o f certain radioactive isotopes which 
concentrate in bone. Thesis, Oxford University.
WiUiamson M and Vaughan JM. (1964) A preliminary report on the sites o f  deposition 
ofY, Am and Pu in cortical bone and in the region o f  the epiphyseal plate, pp 71-83 in 
Bone and tooth symposium. Ed. HJJ Blackwood. Pergamon Press, Oxford.
Wilkinson WD. (1962) Uranium metallurgy. Vol I. Uranium Process Metallurgy. 
Interscience Publishers, New York.
White MR and Schubert J. (1952) The action o f  salts o f  zirconium and other metals on 
plutonium and yttrium distribution and excretion. J Pharmacol. Exp. Ther. 104 317-324.
White RG, Raabe OG, Culbertson MR, Parks NJ, Samuels SJ and Rosenblatt LS. (1994) 
Bone sarcoma characteristics and distribution in beagles injected with radium-226. 
Radiat. Res. 137 361-370.
Wilson JD and Nossal GJV. (1971) Identification o f  human T and B lymphocytes in 
normal peripheral blood and in chronic lymphocytic leukaemia. Lancet 2 788-791.
Woodard H, Huvos A and Smith J. (1988) Radiation-induced malignant tumours o f  bone 
in patients with Hodgkin *s disease. Health Phys. 55 615-620.
Wronski TJ, Smith JM and Jee WSS. (1980) The microdistribution and retention o f  
injected ^^ P^u on trabecular bone surface o f  the beagle: Implications fo r  the induction o f  
osteosarcomas. Radiat. Res. 83 74-89.
Yuile CL. (1973) Animal experiments, pp 165-196 in Uranium, plutonium, transplutonic 
elements: Handbook o f experimental pharmacology 36. Eds. HC Hodge, JN Stannard and 
JB Hursh. Berlin: Springer-Verlag.
Yuspa SH and Poirier MC. (1988) Chemical carcinogenesis: from animal models to 
molecular models in one decade. Adv. Cancer Res. 50 25-70.
Zalikin GA, Moskalev YI, Petrovich IK and Rudnitskaya EL (1969) Biological effects o f  
americium-241. Radiobiologiya 9 599-603. English Translation AEC-tr-7109.
Animal Technology (1993) Vol. 44, No.3 247
Husbandry procedures and health problems 
associated with a long-term mouse study
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SUMMARY
In most breeding colonies mice are usually sacrificed at approximately 8 months of 
age. In the majority of experimental studies on the biokinetics of radiouclides, mice 
are killed before they are 18 months of age. For this toxicity study comparing the 
effects of incorporated radionuclides it was important that the CBA/H strain mice 
were kept for their full lifespan of approximately three years. Treatment, age and 
strain related problems are reported here.
INTRODUCTION
The study was designed to determine the relative toxicity of three radiouclides, 
plutonium-239, americium-241, and uranium-233, with respect to their ability to 
induce osteosarcoma and leukaemia. All three radionuclides are bone seeking alpha 
particle emitters which deposit on bone surfaces. Where the bone surface is adjacent 
to red bone marrow then some irradiation of both bone and bone marrow will occur, 
in which case osteosarcoma and/or leukaemia may result. If  the bone surface is not 
adjacent to red bone marrow then only sensitive cells in the bone will be irradiated 
and in this case only osteosarcoma is likely to occur.
The onset of either osteosarcoma or leukaemia would not be expected until about 
18 months post-treatment and often, particularly for osteosarcona, nearer to 24 months 
post-treatm ent. The mice were kept for as long as possible so that the life -tim e . 
iiicidence o f osteosarcom a and leukaem ia Could be com pared in the d ifferen t 
treatment groups.
METHODS
Experimental Protocol
The CBA/H mouse strain used in these experiments has been m aintained at the 
Medical Research Council (MRC) Radiobiology Unit, (Chilton, Didcot, Oxon, 0X11 
ORD) for 24 years and has no spontaneous incidence o f either osteosarcom a or 
leukaemia. It does, however, have a 60% incidence of hepatoma.
A total of 900 twelve week old male mice were used in this study. The animals 
were consigned to one of ten experimental groups, as indicated in Table 1. Each 
experimental group was divided into smaller groups of about 5-10. These sub-groups 
were treated with radionuclides at 12 weeks of age and were entered sequentially over 
an 18 month period in order to spread the work load generated at post mortem.
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Table 1
Injection d o se s  and size  of experimental groups.
Nuclide Group Injection d ose  
KBq kg '
No of animals
239RU High 5 50
Medium 15 60
Low 25 100
'"'Am High 6 50
Medium 17 75
Low 29 100
233U High 40 50
Medium 118 60
Low 197 100
Control Saline 0 100
M ice in each sub-group were injected intraperitonealy w ith one of the three 
radionuclides, plutonium -239, americium-241 or uranium-233, given as a citrate 
solution at low, medium or high dose levels; a further control group received normal 
saline. Administered activities at each dose level were adjusted to give equivalent 
average bone doses. A t 500 days these were 0.52 Gy (high dose level), 0.31 Gy 
(medium dose level) and 0.104 Gy (low dose level). Uranium-233 was administered 
to each animal by repeated injection over a three week period in order to avoid toxic 
effects in the proximal convoluted tubules o f the kidney. Similar procedures were 
adopted for the other groups. Intraperitoneal administration was the preferred route 
for repeated injections. In previous experiments, this route had been shown to result in 
a similar radionuclide distribution within the body when compared with animals given 
radionuclides by intravenous injection.'
In addition to the main toxicity study, groups of animals were killed at intervals up 
to 448 days to enable radiochemical analysis to be carried out on the retention and 
distribution of radionuclides in individual bones. Once these animals had been killed, 
their carcasses were placed with a colony of Dermestes maculatus beetles. These 
beetles strip the flesh from the bones in approximately 48 hrs. The bones were then 
collected and analyzed for the presence of radioactivity (Figure 1). These data will be 
compared with the incidence of osteosarcoma in different regions of the skeleton.
HUSBANDRY
The CBA/H mice were housed in small groups in polypropylene cages on sawdust 
bedding. Cages and bottles were cleaned once weekly and food and water given ad  
libitum. Animal care and handling conformed to the Animals (Scientific Procedures) 
A ct 1986. A ll mice were visually checked at least once daily. Each anim al was 
individually identifiable (by ear marking) within its cage group and had its own record
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Figure 1. Mouse bones ready for radiochemical analyses following defleshing using 
Dermestes maculatus beetles.
sheet on which all observations were recorded. Problem animals were identified by 
coloured tags on the cages and their numbers were written in the diary for more 
frequent checking.
HEALTH
The overall protocol for monitoring health is shown in Figure 2.
Up to 8 months post-treatment, the health sereening consisted of a visual check 
during cage changing. No treatment, strain or age related problems were expected 
during this tim e. Some m ice did develop abscesses in the abdom inal region, 
particularly round the penis and testes. The causal organism was Corynebacterium  
species which is present in the mouths of these mice. The abscesses were believed to 
be caused by fighting and were very slow growing. Where neeessary abscesses were 
lanced, cleaned and a small amount of antiseptic cream applied to aid healing.
From 8 months post-treatment, the animals received a weekly visual check and 
also an abdominal palpitation to check for the onset of hepatomas. These tumours are 
initially detected by a “thickening” of one or more lobes of the liver. They grow over 
a period of many months and may become large, hard and knobbly, although they 
may remain smooth. The mice showed no sign of discomfort or ill health during this 
period. The criteria for saerifice of the mice were any of the following:
1 ) Red feet -  denoting possible cardiovaseular problems eaused by congestion of the liver
2) Pale feet denoting possible internal bleeding
3) Respiratory distress and “D” shaped thorax denoting pressure on the diaphragm
4) Very distended abdomen and loss of eondition
5) Diseomfort during palpation
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Figure 2. Protocol for health monitoring.
From 18 months post-treatm ent, there was the possibility that leukaemia and/or 
osteosarcoma may develop. Outward signs of possible leukaemia were pale feet, nose 
and tail and a sudden loss o f condition. An enlarged spleen was also a sign of 
leukaemia and the mice were palpated to check for the presence of enlarged spleens 
during their weekly check. As soon as an enlarged spleen was detected, the mouse 
was humanely killed immediately to enable fresh blood and spleen tissue to be taken 
for confirm ation of the leukaem ia. M yeloid leukaem ia in the CBA/H mouse is 
characterised by the presence of metam yelocytes in the blood, m yeloblasts and 
promyelocytes (blood precursor cells) may also be present; these cells are normally 
only found in the bone marrow (Figures 3 and 4). Blood counts and blood smears 
were carried out to look for increased numbers of white blood cells and abnormal cell 
types. Spleen tissue was passaged to untreated animals. The passage of spleen tissue 
was carried out by homeogenising 0.1 g of the affected spleen with 5 cm^ of Earle’s 
balanced salts medium (Gibco); 0.5m l of this solution was then injected intra­
peritonealy  into 10-12 w eek old fem ale CBA /H  m ice. The passaged anim als 
developed leukaemia within a few weeks if the cells taken from the sacrificed mouse 
w ere m alignan t. Fem ale m ice w ere used fo r passag ing  so that chrom osom e 
karyotyping could be performed to confirm whether the malignant tissue originated 
from the male or the female mouse. The presence of deletion or rearrangement of 
chromosome 2 was also looked for as there is a high degree of correlation between 
this and myeloid leukaemia in these animals.^
Osteosarcoma of the limb was usually first detected by stiffening of the joints, 
followed by a swelling and sometimes paralysis. Tumours of the spine were more 
difficult to detect and often only became apparent if the mouse showed signs of 
paralysis in the hind quarters. Once a bone tumour was suspected the mice were 
monitored very carefully for signs of debilitation and paralysis; when these occurred 
the animal was humanely killed immediately. A diagnostic X-ray (Figure 5) was taken 
along with histological samples to confirm the diagnosis.
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F igure 3. Blood smear from CBA/H mouse showing a lymphocyte (small dark cell) 
and a metamyelocyte (large cell with central hole in nuclei).
' '  '
F igure 4. Blood smear from CBA/H mouse showing a promyelocyte (large cell with 
an irregularly shaped nuclei).
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From  24 m onths post-treatm ent, o ther age and treatm ent rela ted  problem s 
occurred. The mice commonly suffered breakage and loss of incisor teeth; therefore 
all teeth were checked weekly from this time onwards. If  loss did occur, animals were 
fed daily with a wet mash made from their regular diet which was ground to a powder 
and mixed with sufficient water to make a very stiff paste. In addition, teeth were 
clipped if lack of the grinding process caused them to grow too long.
Gut, kidney and lung tumours occurred either naturally or due to métastasés from 
other tumours. Gut tumours were detected by palpation and often led to weight loss 
and/or diarrhoea. Kidney tumours were also detected by palpation and caused weight 
loss and a general loss of condition. Lung tumours were not detectable by palpation, 
the observable signs were usually weight loss, rapid breathing and sometimes a “D” 
shaped thorax.
Animals could also become preapistic, evident as a permanently extruded penis. 
This was only a problem if the penis became sore and inflamed as the mouse was then 
reluctant to urinate and a large bladder could be palpated. The animal would be 
humanely killed as soon as any of the above became apparent.
Some animals developed eye abscesses which became apparent when the eye 
started to bulge slightly in the socket. These animals were humanely killed as soon as 
there was any sign of abnormality in the eye. Post mortem examination showed that 
the abscesses developed behind the eye, in the socket.
Finally, as the mice became older their bones became more fragile. Extra care had 
to be taken when handling and manipulating them to avoid stress fractures.
Post mortem
As each of the mice were killed or died they were given a post mortem examination. 
A diagnostic X-ray was taken as soon as possible after death to detect any developing 
osteosarcomas. Samples for histology were routinely taken from the lungs, liver, 
kidney, spleen, the left knee joint, lumbar vertebrae and sternum as well as from any 
tissues or organs which appeared abnormal.
RESULTS AND DISCUSSION
This study is still in progress and there are approximately 250 mice remaining alive. 
The CBA/H mice used in these experiments have a high natural hepatoma incidence 
of about 60% of which a proportion are fatal. The expected life-span of the animals is 
about 2-3 years. Figure 6 shows the age at death, the peak age for death being 
approximately 2.5 years old; the oldest mouse so far is 3.5 years old.
To date , e igh teen  bone tum ours have been observed , 10 in anim als given 
plu tonium . The expected  incidence o f osteosarcom a follow ing treatm ent w ith 
plutonium-239 in these experiments is 30% for the high dose group, 15% for the 
middle dose group and 7.5% for the low dose group.^ Taylor and Bensted'* found in 
rats that americium-241 caused less osteosarcoma than plutonium-239 by about a 
factor of three. No published data are as yet available for the incidence of osteosarcoma 
following the administration of uranium.
Eight myeloid leukaemias have been identified and several additional suspected 
m yelo id  leukaem ias are curren tly  being evaluated . The incidence o f  m yeloid 
leukaemia in these mice is between 20 and 25% following 3 Gy of X-irradiation.^ An
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Figure 5. Diagnostic X-ray of a CBA/H mouse showing a large tumour of the femur.
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Figure 6. Life span o f animals.
incidence of 7.5% is expected in the low dose plutonium group.^ No work is as yet 
published regarding the incidence of myeloid leukaemia in animals treated with 
americium or uranium.,
O f the animals that have been sacrificed or have died to date, about 49% had 
hepatomas, 6% had hepatocellular carcinoma with secondaries in the lung, 2% had 
hepatocellular carcinoma with secondaries in the gut, 14% had enlarged spleens 
denoting possible lymphoma or myeloid leukaemia, 4% had suspected osteosarcomas 
which are currently being histologically evaluated, 3% had bladder tumours, 2% had 
kidney tumours, 1% had adrenal tumours, 11% had eye abscesses, 3% had abdominal 
abscesses, 4% died immediately post injection and 1% died from unknown causes. It 
has been established that with good husbandry it is possible for these animals to live 
for long periods. Careful monitoring and accurate record keeping are essential to 
ensure that the animals do not suffer and are humanely killed at the appropriate time.
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Osteosarcoma induction in mice by the alpha-emitting nuclides, plutonium-239, 
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Introduction
Following either occupational or environmental exposure of individuals to alpha-emitting isotopes of 
plutonium (Pu), americium (Am) or uranium (U), tiieir entry into the bloodstream will result in long-term 
retention in the skeleton and a consequent risk of osteosarcoma and leukaemia. The International 
Commission on Radiological Protection (ICRP) has recently adopted models for the behaviour of 
radionuclides in the skeleton which take account of the physiological processes of bone remodelling and 
growth (1,2). The models treat Pu and Am similarly, allowing for burial of surface deposits during 
mineral deposition and transfer to the marrojv and release to the circulation during bone resoiption (1). 
Thus, the models predict that “ ®Pu and ^ "'Am are similarly effective in inducing osteosarcoma and 
leukaemia. Uranium behaves more like calcium and the aUraline earth elements and the model assumes 
more rapid transfer from surfaces to bone volume (2). Because a greater proportion of alpha energy from 
U isotopes is deposited harmlessly in bone mineral, they are predicted to be less effective in causing 
malignancy. No changes have been made to the assumptions that the sensitive cells for osteosarcoma 
induction are uniformly distributed on endosteal bone surfaces and those for leukaemia induction are 
uniformly distributed through red bone marrow. Furthermore, radionuclides are assumed to initially 
deposit uniformly on endosteal bone surfaces.
A number of finding are at variance with model predictions. E?q)erimental studies using rats (3) and mice 
(4) have shown that ^ Tu is about three times as effective as ^ '^Am in inducing osteosarcoma per unit 
average skeletal dose. Autoradiographic studies of mouse (5) and rat (6) bone have shown differences in 
the initial distribution of “®Pu, ^ ‘”Am and as well as their subsequent behaviour. The induction of 
osteosarcoma but absence or very low incidence of leukaemias in humans given radium isotopes suggest 
that alpha irradiation from bone surfaces may be ineffective in causing leukaemia, possibly due to 
heterogeneity in the distribution of sensitive cells in the marrow (7).
This paper presents results from a stucfy of the comparative toxicity of^Tu, "^'Am and in mice, 
comparing tumour incidence and the distribution of alpha dose within the skeleton. Completed results for 
osteosarcoma induction are reported; leukaemia diagnoses are not yet complete.
M a t e r i a l s  a n d  M e t h o d s
Male CBA/H mice were obtained from the Medical Research Council (MRC) Radiobiology Unit,
Chilton, Didcot, Oxon, 0X11 ORD. This strain a very low spontaneous incidence of osteosarcoma and 
leukaemia. Groups of 5 mice were housed together. Food (tj^e RMI Expanded, Special Diet Services, 
Witham, Essex) and water were freely available at all times. Animal care and handling conformed to tiie 
UK Animals (Scientific Procedures) Act 1986.
Groups of 12 week old mice (50-100) were given intraperitoneal injections of “®Pu, "^'Am or as the
Citrate complexes. Each nuclide was administered to three groups of animals at levels of activity 
^Miated to give average bone doses of about 0.2-0.3 Gy, 0.5-1.0 Gy and 1.3-1.6 Gy, calculated to 500 
administration; a further control group (100) were given inactive solution. To avoid chemical 
wMcity to the kidneys from each nuclide was administered as 9 injections over a 3 week period. All 
WCTe treated similarly. The mice were followed for their life-span and either died or were killed 
^ ^ n  moribund or a visible tumour was present. Osteosarcomas were identified by x-ray examination of 
vtUc death and the tumours confirmed by histological examination. Other organs and tissues
^ e n  for histological examination as appropriate.
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Results
Table 1 summarises tumour diagnoses for each group of animals, counting all observations including 
cases where individual animals were shown to have more than one tumour or tumour type. High 
incidences of liver and lung tumours were observed for all experimental groups and the control group, as 
expected with this mouse strain (8,9). A variety of other soft tissue tumours were identified with low 
incidences (see footnotes to Table 1). Small numbers of blood cell tumours were also observed; final 
diagnoses are in progress.
Table 1. Number of tumours by type
Group “ ’Pu “ 'Am 233u Control
Average dceletal dose to 500 days (Gy) 0.2 0.5 1.3 0.3 0.9 1.6 0.3 0.9 1.3 0
N o o f  animals 100 60 50 100 75 50 100 60 50 100
Osteosarcoma 2 5 14 0 3 10 2 1 2 1
Other skeletal tumours* 0 1 5 3 4 0 3 0 0 6
Leukaemias /  lynçhomas'’ 5 6 1 6 0 0 2 1 1 2
Other haemopoietic disorders* 2 1 1 3 4 1 4 2 3 5
Liver tumours' 94 76 48 86 69 43 83 66 42 80
Lung tumours* 40 23 15 36 24 10 40 19 16 37
Other soil tissue tumours' 10 12 10 8 11 8 19 18 30 19
* skeletal haemangioma, baemangiosarcoma, osteoma, odontoma, sarcoma, mastocytoma ; *’ myeloid leukaemia, lymphatic leukaemia, malignant 
lynçhoma: ‘ histiocytic sarcoma, haemangiosarcoma, haemangioma; '  hepatocellular adenoma and carcinoma; * bronchiolo-alveolar adenoma 
and carcincana; ‘ islet adenoma and carcinoma, tubular adenoma and carcinoma, adrenal cortical adenoma, adrenal phaeochromocytoma, 
neuroendocrine carcinoma, meningeal sarcoma, malignant paraganglioma, malignant schwaimoma, rhabdomyosarcoma, sarcoma, leiomyoma, 
trichoepithelioma and squamous cell carcinoma (dtin)
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Figure 1. Incidence of osteosarcoma following administration of^^Tu, '^"Am or
Osteosarcoma was seen in 2%, 8% and 18% of mice in the 0.2 Gy, 0.5 Gy and 1.3 Gy ^ ®^Pu groups (5, 
15 and 25 kBq kg '), respectively. The corresponding incidences of osteosarcoma in ^ '”Am groups were 
0,4% and 18%, respectively, and incidence in each group was about 2%. Only the highest dose 
groups had animals with more than one osteosarcoma, with one animal having two tumours in each 
nuclide group and 2 animals having three tumours in the ^ ®^Pu group. A difference was apparent in the 
location of osteosarcomas in the highest dose ^ ®^Pu and Am groups in that about 70% in the ^ ’^Pu 
group were in the appendicular skeleton, mainly femur, while a similar proportion in the ^ “'Am group 
were in the axial skeleton, mainly vertebrae. Osteosarcoma incidence as a fimction of dose was assessed 
using Poisson regression (Figure 1). Significance was tested by comparing changes in deviance with a 
distribution. Dose was found to have a significant effect on incidence (change in deviance = 20.34 on 1
4 - 6 8
p«0.001). However, the effect differed significantly between nuclides (change in deviance = 16.21 on 2 
d.f.; p<0.001). There was evidence for a difference in regression slopes for “ ®Pu and ^ '"Am (change in 
deviance = 3.86 on 1 d.f.; p=0.05) and a single slope for “®Pu and ^ '"Am differed significantly from a 
slope for (change in deviance = 12.35 on 1 d.f; p<0.001). For the slope was consistent with no 
effect of dose. A further analysis will take account of ages at death and competing causes.
Discussion
The observed incidences of “ ®Pu induced osteosarcoma in male CBA/H mice are consistent with reported 
incidences in females of the same strain of 7.5% and 30% after administration of 6 kBq kg ' and 19 kBq 
kg ' of “®Pu, respectively (8), and the observation that females were more sensitive than males to 
osteosarcoma induction by a factor of 3 -4 for ^ ®Pu and 4 - 6 for ^ R a (9). It is considered that the 
difference may be due to greater turnover of bone in females. The observed difference in osteosarcoma 
induction by “®Pu and ^ ""Am was smaller than reported previously. Bensted et al (4) reported that 17 out 
of 22 male rats given 108 kBq kg ' “®Pu developed osteosarcoma compared with 4 out of 19 given 92 
kBq kg ' '^"Am. Using small groups of animals (10 - 20), Taylor et al (3) showed a significantly greater 
incidence of osteosarcoma in male and female C57Bl/Do black mice given 105 kBq kg ' and 32 kBq kg ' 
of 239pu than in comparable groups given 102 kBq kg ' and 30-34 kBq kg ' of ^ '"Am. Similar studies 
using C57BL/DO albino mice showed greater osteosarcoma incidence with ^ ®Pu than ^ '"Am in female 
mice but no difference in male mice.
Autoradiographic studies have shown clear differences in the initial distribution of “ ®Pu and ^ '"Am on 
bone surfaces in rodents (5,6). While “ ®Pu is concentrated mainly on endosteal surfaces of trabecular and 
cortical bone, ^ "'Am is more widely distributed on bone surfaces including periosteal surfaces and internal 
cortical bone surfaces. Previous reports of greater sensitivity to osteosarcoma induction by “ ®Pu than 
“^"Am have been attributed to greater doses from “^ u  to trabecular surfaces (10). It is possible that 
differences in distribution and osteosarcoma incidence were accentuated by increased bone turnover 
caused by the deposited nuclides which is apparent, according to Loutit et al (9), at administered activities 
of 20 kBq kg ' and greater.
Uranium has been shown to deposit initially on bone surfaces, including endosteal and periosteal 
surfaces, concentrating on growing surfaces (5,6). The low toxicity of^^U compared with “ ®Pu and 
Am is consistent with more rapid burial of surface deposits, reflecting the chemical similarity of the 
uranyl ion and those of the alkaline earth elements, including calcium.
In conclusion, it would appear that the observed osteosarcoma incidences, although showing small 
differences between Pu and Am, are broadly consistent with ICRP model estimates of equivalent 
toxicity of “®Pu and ^ '"Am and lower toxicity of^^U.
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N e u t r o n - i n d u c e d  a u t o r a d i o g r a p h s  o f  f e m o r a l  b o n e  s h a f t s  t a k e n  f r o m  m i c e  i n j e c t e d  w i t h  4 0  k B q / k g  
p l u t o n i u m - 2 3 9 ,  a m e r i c i u m - 2 4 1  o r  u r a n i u m - 2 3 3 ,  1 ,  2 8  o r  2 2 4  d a y s  p r e v i o u s l y ,  w e r e  a n a l y s e d  
m o r p h o m e t r i c a l l y  i n  o r d e r  t o  p r e s e n t  a  c o m p a r i s o n  o f  t h e  c h a n g i n g  r a d i o n u c l i d e  d i s t r i b u t i o n  
p a t t e r n s .  M i c r o d o s i m e t r i c  m e t h o d s  w e r e  u s e d  t o  c a l c u l a t e  l o c a l i s e d  d o s e  r a t e s  t h r o u g h o u t  t h e  
b o n e  m a r r o w ,  a n d  h e n c e  t o  t h o s e  c e l l s  t h o u g h t  t o  b e  t a r g e t  c e l l s  f o r  l e u k a e m i a  i n d u c t i o n .  
I n i t i a l l y  a l l  t h r e e  r a d i o n u c l i d e s  w e r e  f o u n d  t o  b e  p r i m a r i l y  d e p o s i t e d  o n  t h e  e n d o s t e a l  s u r f a c e s  o f  
t h e  b o n e .  A m - 2 4 1  w a s  a d d i t i o n a l l y  d e p o s i t e d  o n  t h e  s u r f a c e s  o f  t h e  v a s c u l a r  c a n a l s .  P u - 2 3 9  
s u b s e q u e n t l y  b e c a m e  e i t h e r  b u r i e d  in  t h e  b o n e  m a t r i x  o r  r e s o r b e d  i n t o  m a c r o p h a g e s ,  w h i c h  b y  2 2 4  
d a y s  w e r e  s e e n  t o  h a v e  m i g r a t e d  t o w a r d s  t h e  c e n t r a l  v e n o u s  s i n u s .  A m - 2 4 1  d e p o s i t s  w e r e  a l s o  
p r e s e n t  i n  m a c r o p h a g e s ,  b u t  t o  a  l e s s e r  e x t e n t .  I n  c o n t r a s t  u r a n i u m  w a s  n o t  t a k e n  u p  i n t o  
m a c r o p h a g e s .
M e a n  d o s e  r a t e s  t o  t h e  a x i a l  r e g i o n  o f  m a r r o w ,  b e l i e v e d  t o  c o n t a i n  t h e  l e u k a e m o g e n i c  t a r g e t  c e l l s ,  
w e r e  c a l c u l a t e d  f o r  p l u t o n i u m  a s  0 . 1 1 , 0 . 0 7  a n d  1 6 . 7 8  m G y / d a y  a n d  f o r  a m e r i c i u m  a s  0 . 2 3 ,  5 . 1 9  
a n d  2 . 2 8  m G y / d a y  a t  1 ,  2 8  a n d  2 2 4  d a y s  r e s p e c t i v e l y .  F o r  u r a n i u m  a  d o s e  r a t e  o f  z e r o  w a s  
c a l c u l a t e d  a t  a l l  t i m e  p o i n t s .
Introduction
A p p a r e n t  c l u s t e r s  o f  l e u k a e m i a s  c e n t r i n g  a r o u n d  v a r i o u s  n u c l e a r  i n s t a l l a t i o n s  h a v e  l e d  t o  
m u c h  s p e c u l a t i o n  o f  a  p o s s i b l e  l i n k  b e t w e e n  e x p o s u r e  t o  a l p h a - e m i t t i n g  r a d i o n u c l i d e s  a n d  t h e  
i n d u c t i o n  o f  l e u k a e m i a ,  a l t h o u g h  n o  c a u s a l  l i n k  h a s  b e e n  e s t a b l i s h e d " '^ ' .  P l u t o n i u m - 2 3 9  a n d  
u r a n i u m - 2 3 3 ,  w h i c h  a r e  p r o d u c e d  a n d  u s e d  e x t e n s i v e l y  t h r o u g h o u t  t h e  n u c l e a r  i n d u s t r y ,  a r e  
p o t e n t i a l l y  l e u k a e m o g e n i c ,  a s  i s  a m e r i c i u m - 2 4 1 ,  w h i c h  I C R P  m o d e l s  s u g g e s t  s h o u l d  b e  s i m i l a r l y  
e f f e c t i v e  t o  p l u t o n i u m - 2 3 9  i n  l e u k a e m i a  in d u c t io n '® '.  I t  i s  k n o w n  t h a t  w h e n  s u c h  r a d i o n u c l i d e s  a r e  
t a k e n  i n t o  t h e  b l o o d ,  a  l a r g e  p r o p o r t i o n  i s  d e p o s i t e d  i n  t h e  s k e l e t o n ,  w h e r e  i t  c o n c e n t r a t e s  i n i t i a l l y  
o n  t h e  s u r f a c e  o f  t h e  b o n e ,  a n d  i s  r e d i s t r i b u t e d  t h r o u g h o u t  b o n e  a n d  b o n e  m a r r o w  o v e r  t i m e ,  a s  
a  r e s u l t  o f  b o n e  g r o w t h  a n d  r e m o d e l l i n g .  W h i l s t  i t  h a s  l o n g  b e e n  a s s u m e d  t h a t  t h e  l e u k a e m o g e n i c  
t a r g e t  c e l l s  a r e  r a n d o m l y  d i s t r i b u t e d  t h r o u g h o u t  a c t i v e  b o n e  m a r r o w " ' ,  m a r r o w  f r a c t i o n a t i o n  
s t u d i e s  h a v e  s h o w n  t h a t  i n  t h e  f e m o r a l  s h a f t  o f  t h e  m o u s e ,  t h e  m o r e  p r i m i t i v e ,  p l u r i p o t e n t  
h a e m o p o i e t i c  s t e m  c e l l s ,  b e l i e v e d  t o  b e  t h e  t a r g e t  c e l l s  f o r  m y e l o i d  l e u k a e m i a ,  a r e  c o n c e n t r a t e d  
t o w a r d s  t h e  c e n t r a l  o r  a x i a l  r e g i o n  o f  t h e  b o n e  m a r r o w ,  c l o s e  t o  t h e  c e n t r a l  v e n o u s  s in u s '® '.  T h i s  
s t u d y  p r e s e n t s  a  c o m p a r i s o n  b e t w e e n  t h e  d i s t r i b u t i o n  p a t t e r n s  o f  t h e s e  r a d i o n u c l i d e s  i n  t h e  b o n e  
a n d  b o n e  m a r r o w  o f  t h e  m o u s e  f e m o r a l  s h a f t  a n d  c a l c u l a t e s  r a d i a t i o n  d o s e  r a t e s  t o  t h e  a x i a l  r e g i o n  
o f  b o n e  m a r r o w ,  w h e r e  t h o s e  p r i m a r y  l e u k a e m o g e n i c  t a r g e t  c e l l s  a r e  b e l i e v e d  t o  b e  l o c a t e d '® '.
Materials and Methods
C B A / H  m i c e  a g e d  1 2  w e e k s  w e r e  i n j e c t e d  w i t h  4 0  k B q / k g  o f  P u - 2 3 9 ,  A m - 2 4 1  o r  U - 2 3 3  
c i t r a t e  s o l u t i o n ,  a n d  s a c r i f i c e d  a t  1 , 2 8  o r  2 2 4  d a y s  p o s t - i n j e c t i o n '^ ' .  F o r  m i c e  i n j e c t e d  w i t h  P u - 2 3 9  
o r  U - 2 3 3 ,  n e u t r o n - i n d u c e d  a u t o r a d i o g r a p h s  w e r e  p r e p a r e d  f r o m  a  5 p m  t h i c k  l o n g i t u d i n a l  s e c t i o n  
o f  f e m u r ,  w h i c h  h a d  b e e n  f i x e d  i n  e t h a n o l  a n d  e m b e d d e d  i n  S p u r r ’ s  r e s i n ' " " .  F e m u r  s e c t i o n s  w e r e  
s a n d w i c h e d  b e t w e e n  C R 3 9  p l a s t i c  s l id e s  a n d  i r r a d i a t e d  i n  t h e  5 M W  w a t e r - c o o l e d  n u c l e a r  r e a c t o r  
a t  t h e  M i n i s t r y  o f  D e f e n c e  ( P r o c u r e m e n t  E x e c u t i v e ) ,  A l d e r m a s t o n .  A f t e r  ‘c o o l i n g ’ t h e y  w e r e
e t c h e d  i n  6 . 2 5 M  s o d i u m  h y d r o x i d e  s o l u t i o n " ' .  F o r  A m - 2 4 1 ,  w h i c h  i s  n o t  f i s s i o n a b l e ,  a l p h a - p a r t i c l e  
i n d u c e d  a u t o r a d i o g r a p h s  w e r e  p r e p a r e d .  I m a g e  a n a l y s i s  o f  t h e s e  a u t o r a d i o g r a p h s  w a s  c a r r i e d  o u t  
u s i n g  a  Z e i s s  A x i o h o m e ,  a l l o w i n g  t h e  p o s i t i o n  o f  f i s s i o n  t r a c k s  r e l a t i v e  t o  t h e  b o n e  s u r f a c e  t o  b e  
m e a s u r e d .  T h e  o r i g i n  o f  t h e  t r a c k s ,  w h i c h  a r e  t e a r - d r o p  s h a p e d ,  w a s  a s s u m e d  t o  b e  l o c a t e d  o n e  
t r a c k  l e n g t h  f r o m  t h e  r o u n d e d  e n d  o f  t h e  t r a c k .  T r a c k s  w e r e  m e a s u r e d  i n  b o n e  a n d  b o n e  m a r r o w  
a c r o s s  2 5  t r a n s v e r s e  s e c t i o n s  o f  t h e  f e m o r a l  s h a f t .  T h e  p o s i t i o n s  o f  t h e  t r a c k  o r i g i n s  w e r e  g r o u p e d  
i n t o  2 p m  b i n s ,  a n d  d i s t r i b u t i o n  p a t t e r n s  p l o t t e d .  R a d i a t i o n  d o s i m e t r y  w a s  c a r r i e d  o u t  u s i n g  a n  
a p p r o x i m a t i o n  o f  s t o p p i n g  p o w e r  t o  a n  i n t e g r a b l e  m a t h e m a t i c a l  e q u a t i o n ,  a s  d e t e r m i n e d  b y  
S o n t a g " " ,  a l l o w i n g  c a l c u l a t i o n  o f  t h e  e n e r g y  d e p o s i t e d  i n  s u c c e s s i v e  2 p m  l a y e r s  f r o m  e a c h  
r a d i o n u c l i d e  d e p o s i t .  E n e r g y  w a s  c o n v e r t e d  i n t o  r a d i a t i o n  d o s e  r a t e  b y  i n c o r p o r a t i n g  t h e  
r a d i o a c t i v i t y  a n d  m a s s  o f  t h e  f e m u r ,  r e c o r d e d  a t  d i s s e c t i o n .
Results
I n i t i a l l y  a l m o s t  a l l  r a d i o n u c l i d e  d e p o s i t s  w e r e  l o c a t e d  o n  b o n e  s u r f a c e s .  P u - 2 3 9  a n d  U - 2 3 3  
s h o w e d  s u b s t a n t i a l l y  m o r e  d e p o s i t i o n  o n  e n d o s t e a l  s u r f a c e s ,  t h e  e n d o s t e a l  i p e r i o s t e a l  s u r f a c e  r a t i o s  
b e i n g  5 : 1 ,  3 : 2  a n d  1 : 2  f o r  P u - 2 3 9 ,  U - 2 3 3  a n d  A m - 2 4 1  r e s p e c t i v e l y .  P u - 2 3 9  a n d  A m - 2 4 1  a l s o  
s h o w e d  a  d i f i u s e  l o w  l e v e l  d e p o s i t i o n  t h r o u g h o u t  t h e  m a r r o w ,  n o t  o b v i o u s l y  a s s o c i a t e d  w i t h  a n y  
m a r r o w  s t r u c t u r e .  A t  2 8  d a y s  p o s t  i n j e c t i o n ,  s u r f a c e  d e p o s i t s  h a d  b e c o m e  b u r i e d  i n  t h e  b o n e  
m a t r i x ,  a l l  r a d i o n u c l i d e s  s h o w i n g  a  s i m i l a r  r a t e  o f  b u r i a l ,  t o  a r o u n d  6 0 p m  i n  t h e  f i r s t  m o n t h .  A g a i n  
p l u t o n i u m  a n d  a m e r i c i u m  s h o w e d  m a r r o w  d e p o s i t i o n ,  w i t h  e v i d e n c e  o f  p l u t o n i u m - l a d e n  
m a c r o p h a g e s  i n  c l o s e  p r o x i m i t y  t o  o n e  o f  t h e  b o n e  s u r f a c e s .  B y  2 2 4  d a y s ,  t h e  d i f f e r e n c e  i n  
d i s t r i b u t i o n s  h a d  b e c o m e  m o r e  p r o n o u n c e d .  A  p r o p o r t i o n  o f  t h e  p l u t o n i u m  w h i c h  w a s  i n i t i a l l y  
a s s o c i a t e d  w i t h  b o n e  s u r f a c e s  w a s  n o w  l o c a t e d  i n  s t a r - l i k e  p a t t e r n s ,  d i s t i n c t i v e  o f  m a c r o p h a g e s ,  
c l o s e  t o  t h e  c e n t r a l  v e n o u s  s i n u s ,  a s  w a s  a m e r i c i u m  b u t  t o  a  l e s s e r  e x t e n t .  I n  c o n t r a s t  a l m o s t  a l l  
u r a n i u m  h a d  u n d e r g o n e  b u r i a l ,  w i t h  v e r y  l i t t l e  r e m a i n i n g  i n  t h e  b o n e  m a r r o w .
F i g u r e  1 ,  w h i c h  v e r y  c l o s e l y  m i r r o r s  t h e  m e a s u r e d  t r a c k  d i s t r i b u t i o n s  d e s c r i b e d  a b o v e ,  
s h o w s  t h e  d i s t r i b u t i o n  o f  r a d i a t i o n  d o s e  r a t e  ( m G y / d a y )  t h r o u g h o u t  t h e  b o n e  m a r r o w  o f  t h e  
f e m o r a l  s h a f t  a t  e a c h  o f  t h e  t i m e  p o i n t s  f o r  P u - 2 3 9 ,  U - 2 3 3  a n d  A m - 2 4 1 .  A t  1 d a y  p o s t  i n j e c t i o n  
t h e  r a d i o n u c l i d e s  g a v e  m a x i m u m  d o s e  r a t e s  o f  2 9 ,  2 1  a n d  6  m G y / d a y  a t  t h e  e n d o s t e a l  b o n e  
s u r f a c e ,  f o r  P u - 2 3 9 ,  U - 2 3 3  a n d  A m - 2 4 1  r e s p e c t i v e l y .  T h e s e  d e c r e a s e d  t o  n e a r  z e r o  a p p r o x i m a t e l y  
4 0 p m  i n t o  t h e  m a r r o w  t i s s u e .  P u - 2 3 9  a n d  A m - 2 4 1  a l s o  s h o w e d  a  l o w  l e v e l  d o s e  r a t e  o f  l e s s  t h a n  
1 m G y / d a y  t h r o u g h o u t  t h e  r e m a i n d e r  o f  t h e  b o n e  m a r r o w .  A f t e r  2 8  d a y s  o n l y  t h e  4 0 p m  o f  b o n e  
m a r r o w  c l o s e s t  t o  t h e  b o n e  s u r f a c e  i n  t h e  u r a n i u m  s e c t i o n  r e c e i v e d  a n y  r a d i a t i o n  d o s e ,  t h i s  b e i n g  
u p  t o  2  m G y / d a y .  F o r  p l u t o n i u m - 2 3 9  a  d e g r e e  o f  a s y m m e t r y  h a d  d e v e l o p e d ,  w i t h  t h e  e n d o s t e a l  
s u r f a c e  o n  o n e  s i d e  o f  t h e  m a r r o w  c a v i t y  r e c e i v i n g  a  d o s e  r a t e  o f  1 0  m G y / d a y  a n d  t h e  e n d o s t e a l  
s u r f a c e  o n  t h e  o t h e r  s i d e  r e c e i v i n g  a  d o s e  r a t e  o f  l e s s  t h a n  5  m G y / d a y .  T h r o u g h o u t  t h e  b u l k  o f  
t h e  m a r r o w ,  i n  t h e  r e g i o n  f i r o m  8 0 p m  t o  8 6 0 p m ,  t h e  d o s e  r a t e  r e m a i n e d  a r o u n d  1 m G y / d a y .  A m -  
2 4 1  s h o w e d  h i g h e s t  d o s e  r a t e s  t o w a r d s  t h e  c e n t r e  o f  t h e  m a r r o w  ( 3 5 0 - 6 0 0  p m )  a n d  c l o s e  t o  t h e  
b o n e  s u r f a c e s ,  r e s u l t i n g  i n  d o s e  r a t e s  o f  u p  t o  5  m G y / d a y .  T h e  d o s e  r a t e  p a t t e r n ,  f o r  u r a n i u m  
c h a n g e d  v e r y  l i t t l e  f r o m  2 8  t o  2 2 4  d a y s ,  w i t h  o n l y  t h e  m a r r o w  c l o s e s t  t o  t h e  b o n e  s u r f a c e  
r e c e i v i n g  a n y  r a d i a t i o n  d o s e .  S i m i l a r l y ,  A m - 2 4 1  s h o w e d  l i t t l e  f u r t h e r  c h a n g e  i n  t h e  p a t t e r n  o f  
d i s t r i b u t i o n ,  w i t h  o n l y  a  s l i g h t  i n c r e a s e  i n  r a d i a t i o n  d o s e  t o  t h e  r i g h t  h a n d  s i d e  o f  t h e  m a r r o w .  T h e  
p l u t o n i u m  d i s t r i b u t i o n ,  h o w e v e r ,  c h a n g e d  d r a m a t i c a l l y  o v e r  t h e  s a m e  p e r i o d ,  p l u t o n i u m - l a d e n  
m a c r o p h a g e s  a c c u m u l a t i n g  a r o u n d  t h e  c e n t r a l  v e n o u s  s i n u s  i n  t h e  m a r r o w  r e s u l t e d  i n  d o s e  r a t e s  
o f  2 3  ±  1 2  m G y / d a y ,  a n d  a n  a v e r a g e  d o s e  r a t e  t o  t h e  w h o l e  m a r r o w  c a v i t y  o f  6  ±  2  m G y / d a y .
M e a n  r a d i a t i o n  d o s e  r a t e s  w e r e  c a l c u l a t e d  t o  t h e  r e g i o n  o f  m a r r o w  a d j a c e n t  t o  t h e  c e n t r a l  
v e n o u s  s i n u s ,  4 0 0 - 5 0 0 p m  i n t o  t h e  b o n e  m a r r o w ,  t h e  r e g i o n  t h o u g h t  t o  c o n t a i n  t h e  m o s t  p r i m i t i v e  
h a e m o p o i e t i c  s t e m  c e l l s .  T h e s e  a r e  s h o w n  i n  t a b l e  1 f o r  e a c h  o f  t h e  r a d i o n u c l i d e s .  E a c h  o f  t h e s e  
d o s e  e s t i m a t e s  c a n  b e  c o m p a r e d  w i t h  a v e r a g e d  d o s e  r a t e s  t o  t h e  f e m u r  f r o m  t h e  t h r e e  n u c l i d e s  
a f t e r  a d m i n i s t r a t i o n  o f  4 0  k B q / k g ,  t a k i n g  n o  a c c o u n t  o f  r e g i o n a l  d i s t r i b u t i o n ,  o f  4 - 6  m G y / d a y  f o r
P u - 2 3 9 ,  3 - 5  m G y / d a y  f o r  A m - 2 4 1  a n d  1 - 3  m G y / d a y  f o r  U - 2 3 3 ,  a p p l y i n g  t o  e a c h  t i m e  p o i n t .  
D i s c u s s i o n
T h e  i n i t i a l  d i s t r i b u t i o n  p a t t e r n s  o f  p l u t o n i u m ,  u r a n i u m  a n d  a m e r i c i u m  c o n f i r m  e a r l i e r  
d e s c r i p t i o n s  b y  a  n u m b e r  o f  a u t h o r s " ' " " ' " .  O n c e  i n i t i a l  s u r f a c e  d e p o s i t i o n  h a s  t a k e n  p l a c e ,  
r e d i s t r i b u t i o n  a p p e a r s  t o  b e  l a r g e l y  d e p e n d e n t  o n  b o n e  g r o w t h  a n d  r e m o d e l l i n g .  B u r i a l  o f  u p  t o  
6 0 p m  i n t o  t h e  b o n e  m a t r i x  a f t e r  2 8  d a y s  s u g g e s t s  t h a t  i n  r e g i o n s  o f  m a x i m u m  b o n e  g r o w t h ,  b u r i a l  
w o u l d  p r o c e e d  a t  a  r a t e  o f  a t  l e a s t  2 p m / d a y .  T h e  r e d i s t r i b u t i o n  o f  r a d i o n u c l i d e  d e p o s i t s  i n  t h e  
b o n e  m a r r o w ,  d u e  t o  b o n e  r e m o d e l l i n g ,  w a s  d i f f e r e n t  f o r  e a c h  o f  t h e  r a d i o n u c l i d e s .  U r a n i u m  w a s  
t o t a l l y  a b s o r b e d  o n t o  a n d  t a k e n  i n t o  t h e  b o n e  s t r u c t u r e ,  l e a v i n g  l i t t l e  o r  n o  m a r r o w  d e p o s i t  a f t e r  
t h e  f i r s t  f e w  d a y s .  A  p r o p o r t i o n  o f  P u - 2 3 9  a n d  A m - 2 4 1  d e p o s i t s  b e c a m e  r e d i s t r i b u t e d  t o  t h e  
m a r r o w  d u r i n g  t h e  p r o c e s s  o f  b o n e  r e m o d e l l i n g .  T h e i r  t r a n s f e r  t o  t h e  a x i a l  r e g i o n  o f  t h e  m a r r o w  
p r e s u m a b l y  i n v o l v e d  t r a n s f e r  f r o m  o s t e o c l a s t s  o n  o r  n e a r  b o n e  s u r f a c e s  t o  m a c r o p h a g e s  w h i c h  
a r e  m o b i l e  w i t h i n  m a r r o w  t i s s u e .  W h i l e  t h e  a x i a l  m a r r o w  r e c e i v e s  n o  r a d i a t i o n  d o s e  f r o m  U - 2 3 3 ,  
t h e  d o s e  r a t e  t o  t h i s  r e g i o n  d u e  t o  P u - 2 3 9  d e p o s i t i o n  i n  t h e  m a r r o w  i n c r e a s e s  w i t h  t i m e  t o  a  l e v e l  
w h i c h ,  i f  a p p l i e d  o v e r  a  p r o l o n g e d  p e r i o d ,  w o u l d  r e s u l t  i n  a  s u b s t a n t i a l  c u m u l a t i v e  r a d i a t i o n  d o s e .  
A m - 2 4 1  d e p o s i t s  in  t h e  m a r r o w ,  a l t h o u g h  n o t  a s  s u b s t a n t i a l  a s  t h o s e  f o r  P u - 2 3 9 ,  w o u l d  s t i l l  r e s u l t  
i n  a  s i z e a b l e  r a d i a t i o n  d o s e .  E s t i m a t e d  c u m u l a t i v e  d o s e s  ( u p  t o  2 2 4  d a y s )  t o  t h i s  a x i a l  r e g i o n  
s h o w e d  t h e  r a n k i n g  P u - 2 3 9 > A m - 2 4 1 > U - 2 3 3 ,  w i t h  c a l c u l a t e d  v a l u e s  o f  1 .6  +  0 . 8 ,  0 . 8  +  0 . 3  a n d  
0 . 0  G y .
E U e n d e r  e t  a l . ' " ’’®’ h a v e  u n d e r t a k e n  a  l i f e - s p a n  s t u d y  o f  t h e  e f f e c t s  o f  P u - 2 3 9 ,  A m - 2 4 1 a n d  
U - 2 3 3  i n  C B A / H  m i c e .  E a c h  r a d i o n u c l i d e  w a s  a d m i n i s t e r e d  t o  t h r e e  g r o u p s  o f  a n i m a l s  ( 5 0 - 1 0 0 )  
a t  l e v e l s  o f  a c t i v i t y  r a n g i n g  f r o m  5 - 2 7  k B q / k g  f o r  P u - 2 3 9 , 6 - 3 3  k B q / k g  f o r  A m - 2 4 1  a n d  3 6 - 2 1 1  
k B q / k g  f o r  U - 2 3 3 .  I n c i d e n c e s  o f  a c u t e  m y e l o i d  l e u k a e m i a  ( A M L )  i n c r e a s e d  w i t h  i n c r e a s i n g  d o s e  
r a t e  f r o m  P u - 2 3 9  a n d  A m - 2 4 1 ,  f r o m  a b o u t  4 %  i n c i d e n c e  i n  t h e  l o w e s t  d o s e  g r o u p s  t o  a b o u t  9 -
1 0 %  i n  t h e  h i g h e s t  d o s e  g r o u p s  i n  b o t h  c a s e s .  O s t e o s a r c o m a  i n c i d e n c e s  i n c r e a s e d  w i t h  i n c r e a s i n g  
d o s e  r a t e  f r o m  P u - 2 3 9  a n d  A m - 2 4 1  f r o m  0  -  2 %  i n  t h e  l o w e s t  d o s e  g r o u p s  t o  1 6  -  1 9 %  i n  t h e  
h i g h e s t  d o s e  g r o u p s .  T h e r e  w a s  n o  s i g n i f i c a n t  d i f f e r e n c e  b e t w e e n  P u - 2 3 9  a n d  A m - 2 4 1  i n  t h e  
i n d u c t i o n  o f  A M L  a l t h o u g h  t h e  e f f e c t  p e r  u n i t  d o s e  a p p e a r e d  s l i g h t l y  g r e a t e r  f o r  A m - 2 4 1 .  F o r  U -  
2 3 3 ,  i n c i d e n c e s  o f  A M L  a n d  o s t e o s a r c o m a  w e r e  l o w  i n  e a c h  g r o u p  a n d  t h e  e f f e c t s  w e r e  n o t  
s i g n i f i c a n t  c o m p a r e d  w i t h  c o n t r o l s .
T h e  r e l a t i v e  e f f e c t s  o f  P u - 2 3 9 ,  A m - 2 4 1  a n d  U - 2 3 3  i n  t e r m s  o f  A M L  i n d u c t i o n  o b s e r v e d  
b y  E U e n d e r  e t  a l . '" " ® ' c a n  b e  c o n s i d e r e d  t o  b e  c o n s i s t e n t  w i t h  o u r  p r e l i m i n a r y  e s t i m a t e s  o f  d o s e s  
t o  t h e  a x i a l  m a r r o w .  F o r  P u - 2 3 9  a n d  A m - 2 4 1 ,  n e i t h e r  t h e  d o s e  n o r  A M L  i n c i d e n c e  w e r e  
s i g n i f i c a n t l y  d i f f e r e n t  a n d  t h e  l o w  t o x i c i t y  o f  U - 2 3 3  r e f l e c t s  t h e  n e g l i g i b l e  d o s e  t o  t h e  m a r r o w .  
H o w e v e r ,  e s t i m a t e d  a x i a l  m a r r o w  d o s e s  w e r e  i n  t h e  o r d e r  P u - 2 3 9  >  A m - 2 4 1  >  U - 2 3 3  w h i l e  t h e  
t r e n d  i n  A M L  i n d u c t i o n  w a s  A m - 2 4 1  >  P u - 2 3 9  >  U - 2 3 3 .  F u r t h e r  a n a l y s e s  a r e  p l a n n e d ,  u s i n g  
a u t o r a d i o g r a p h s  p r e p a r e d  f o r  o t h e r  t i m e  p o i n t s  a f t e r  a d m i n i s t r a t i o n .  D o s e s  t o  o t h e r  r e g i o n s  o f  t h e  
b o n e  m a r r o w  a n d  t o  b o n e  s u r f a c e s  w i l l  b e  c o m p a r e d .
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The distribution and retention of plutonium, 
americium and uranium in CBA/H mice
M .  E U e n d e r ,  J . W .  H a i n e s  a n d  J . D .  H a r r i s o n
N a tio n a l R a d io log ica l P rotection  B oard, C hilton , D idcot, O xfo rdsh ire , O X l l  ORQ, UK
G ro u p s  o f  m a le  a n d  fe m a le  C B A /H  m ic e  w e re  g iv e n  
in tra p e r ito n e a l in jec tio n s  o f  40 kB q kg"^ o f  ^^^Am
a n d  c itra te  so lu tio n s an d  the  re ten tio n  an d  d is tr ib u ­
tio n  o f  th e  th re e  ra d io n u c lid e s  co m p a re d  a t  tim es u p  to 
448 d a y s . S im ila r  re s u lts  w e re  o b ta in e d  fo r m a le s  a n d  
fem ales a n d  sh o w ed  that:
1 W hole body  re te n tio n  a t 448 days w as very  s im ila r fo r 
239pu a n d  ‘^‘^Am, acco u n tin g  fo r ab o u t 20%  o f  in jec ted  
a c tiv ity  fo r e a c h  n u c lid e ; re te n tio n  o f  w as m u ch  
low er a t ab o u t 3%.
2 T h e  sk e le to n  a c c o u n te d  fo r 85%  o r  m o re  o f  re ta in e d  
239puj 241 A m  a n d  ac tiv ity  from  6 w eeks a fte r in jec­
tion .
3 T he g rea te s t co n cen tra tio n s  o f each  ra d io n u c lid e  w ere  
m e a s u re d  in  th e  m a in  bo d y  o f th e  sp in e , lim b g ird le s  
a n d  rib s, w ith  low est co n cen tra tio n s in  the  p aw  bones, 
h ead  bones a n d  c a u d a l verteb rae . T he inhom ogeneity  o f  
d is tr ib u tio n  w as  in  the  o rd e r  P u  > U > Am ; w ith  a  tre n d  
to  m ore  u n ifo rm  ac tiv ity  w ith  tim e.
4 A v e rag e  b o n e  d o se s  to  448  d a y s  w e re  c a lc u la te d  as
a b o u t 1.6 a n d  1.7 G y fo r ^^®Pu an d  '^‘^Am, respectively , 
a n d  0.3 G y fo r w ith  ran g es for in d iv id u a l bones o f 
0 .7 -3 .0  Gy, 1 .1 -2 .5  G y a n d  0 .1 -0 .6  Gy, re sp e c tiv e ly . 
A v e ra g e  l iv e r  d o se s  to  448  d a y s  w e re  c a lc u la te d  as 
a b o u t 0.9 Gy, 0.6 Gy a n d  0.007 Gy for ^^®Pu, ‘^**Am an d  
233jj respective ly , w h ils t th e  dose to the  k idney  for 
w as  ab o u t 0.1 Gy.
5 A u to r a d io g r a p h ic  s tu d ie s  o f  th e  d is t r ib u t io n  o f  th e  
n u c lid e s  in  th e  fem u r sh o w ed  d ifferences in  th e ir  in itia l 
d is tr ib u tio n  a n d  su b se q u e n t m ovem ent. In itia lly , c o n ­
c e n t r a t io n s  o f  2^®Pu w e re  g re a te r  o n  e n d o s te a l  th a n  
p e rio s te a l su rfaces  w h ile  ^^^Am d is trib u ted  m ore even ly  
on  b o n e  su rface s . T h e  in i t ia l  d ep o sitio n  o f  on  a ll 
su rfa c e s  w as  u n e v e n  w ith  c o n cen tra tio n s  p ro b ab ly  on 
ac tiv e  su rfaces . B u ria l o f  a ll th ree  nu c lid es  in  a rea s  o f 
b o n e  g ro w th  w a s  o b se rv ed . T ran sfe r o f  a c tiv ity  to the  
m a rro w  w as  g rea te s t fo r ^^^Pu a n d  least for
K ey w o rd s : p lu to n iu m , a m eric iu m ; u ran iu m ; bone doses
an d  au to rad iog raphy
Introduction
F o l l o w i n g  e i t h e r  o c c u p a t i o n a l  o r  e n v i r o n m e n t a l  
e x p o s u r e  o f  i n d i v i d u a l s  t o  a l p h a - e m i t t i n g  i s o t o p e s  
o f  p l u t o n i u m  ( P u ) ,  a m e r i c i u m  ( A m )  o r  u r a n i u m  ( U ) ,  
t h e i r  e n t r y  i n t o  t h e  b l o o d s t r e a m  w i l l  r e s u l t  i n  l o n g ­
t e r m  r e t e n t i o n  i n  b o n e  a n d  a  c o n s e q u e n t  r i s k  o f  
o s t e o s a r c o m a  a n d  l e u k a e m i a . ^ ’^  T h e  t a r g e t  c e l l s  f o r  
o s t e o s a r c o m a  i n d u c t i o n  a r e  t a k e n  t o  b e  i n  a  1 0  p m  
l a y e r  o n  e n d o s t e a l  b o n e  s u r f a c e s  w h i l e  t h o s e  f o r  
l e u k a e m i a  a r e  t h e  h a e m o p o i e t i c  s t e m  c e l l s  t a k e n  t o  
b e  e v e n l y  d i s t r i b u t e d  t h r o u g h o u t  r e d  b o n e  m a r -  
r o w . ^ ’2 T h e  I n t e r n a t i o n a l  C o m m i s s i o n  o n  
R a d i o l o g i c a l  P r o t e c t i o n ^  d e v e l o p e d  a  d o s i m e t r i c  
m o d e l  o f  t h e  s k e l e t o n  i n  w h i c h  e l e m e n t s  w e r e  c l a s ­
s i f i e d  a s  e i t h e r  ‘s u r f a c e  s e e k e r s ’ o r  ‘v o l u m e  s e e k e r s ’ . 
F o r  P u  a n d  A m ,  t h e  m o d e l s  a s s u m e d  t h a t  t h e i r  
r a d i o i s o t o p e s  w o u l d  b e  d e p o s i t e d  u n i f o r m l y  o n  
e n d o s t e a l  b o n e  s u r f a c e s  a n d  r e t a i n e d  t h e r e  w i t h  a  
h a l f - t i m e  o f  5 0  y e a r s . ^  F o r  U  i s o t o p e s ,  h o w e v e r ,  u n i ­
f o r m  d i s t r i b u t i o n  t h r o u g h o u t  t h e  b o n e  m i n e r a l  f r o m  
t h e  t i m e  o f  i n i t i a l  d e p o s i t i o n  w a s  a s s u m e d .  U s i n g  
t h e s e  m o d e l s  t h e  c o m m i t t e d  e q u i v a l e n t  d o s e  t o  
b o n e  s u r f a c e s  a c c o u n t s  f o r  a b o u t  3 0 %  o f  t h e  c o m ­
m i t t e d  e f f e c t i v e  d o s e  ( C E D )  f r o m  t h e  i n g e s t i o n  b y
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a d u l t s  o f  e i t h e r  ^ ^ ^ P u ,  ^ ^ ^ A m  o r  S i m i l a r l y ,  t h e  
c o m m i t t e d  e q u i v a l e n t  d o s e  t o  r e d  b o n e  m a r r o w  
a c c o u n t s  f o r  a b o u t  3 0 %  o f  t h e  C E D  f r o m  ^ ^ ^ P u  a n d  
^ ^ ^ A m  a n d  2 0 %  o f  t h e  C E D  f r o m  T h e  I C R P  v a l ­
u e s  o f  t h e  C E D  p e r  B q  i n g e s t e d  a n d  c o n s e q u e n t l y  
t h e  o v e r a l l  r i s k  o f  c a n c e r ,  a r e  t h e  s a m e  f o r  ^ ^ ^ P u  a n d  
2 ^ ^ A m ;  t h e  v a l u e  f o r  i s  m o r e  t h a n  a n  o r d e r  o f  
m a g n i t u d e  l o w e r  d u e  t o  i t s  m o r e  r a p i d  e x c r e t i o n  
a n d  i t s  a s s u m e d  d i s t r i b u t i o n  t h r o u g h o u t  t h e  b o n e  
v o l u m e .  I n  t h e  c a l c u l a t i o n  o f  d o s e s  f r o m  i s o t o p e s  o f  
P u  a n d  A m ,  I C R P , ^  h a v e  n o w  a d o p t e d  a  d y n a m i c  
m o d e l  d e v e l o p e d  b y  L e g g e t t '* ’^  w h i c h  t a k e s  a c c o u n t  
o f  a g e - d e p e n d e n t  b o n e  r e m o d e l l i n g ,  t h e  b u r i a l  o f  
s u r f a c e  d e p o s i t s  w i t h  t i m e  a n d  t h e  t r a n s f e r  o f  a c t i v i t y  
t o  t h e  m a r r o w .  I n  p r a c t i c e ,  t h e  u s e  o f  t h i s  m o d e l  
r e s u l t s  i n  o n l y  s m a l l  d i f f e r e n c e s  i n  e s t i m a t e d  s k e l e ­
t a l  d o s e s  f r o m  ^ ^ ^ P u  a n d  ^ ^ ^ A m .  C o m m i t t e d  e q u i v a ­
l e n t  d o s e s  t o  b o n e  s u r f a c e s  i n  a d u l t s  r e m a i n  e s s e n ­
t i a l l y  u n c h a n g e d ;  d o s e s  t o  r e d  b o n e  m a r r o w  a r e  
d e c r e a s e d  b y  a b o u t  3 5 %  f o r  ^ ^ ^ P u  a n d  5 0 %  f o r
A  n u m b e r  o f  e x p e r i m e n t a l  f i n d i n g s  a r e  a t  v a r i ­
a n c e  w i t h  t h e  a s s u m p t i o n s  m a d e  i n  t h e  I C R P  m o d ­
e l s .  E x p e r i m e n t s  w i t h  r a t s  h a v e  i n d i c a t e d  t h a t  2 3 o p ^  
i s  a b o u t  t h r e e  t i m e s  a s  e f f e c t i v e  a s  ^ '^ A m  i n  c a u s i n g  
o s t e o s a r c o m a  i n  t e r m s  o f  a v e r a g e  d o s e  t o  b o n e ;* ^ ’^  n o  
i n f o r m a t i o n  i s  c u r r e n t l y  a v a i l a b l e  f o r  
A u t o r a d i o g r a p h i c  s t u d i e s  h a v e  s h o w n  d i f f e r e n c e s
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between ^^ P^n and in their deposition on
bone surfaces. Plutonium is concentrated preferen­
tially on endosteal bone surfaces, while americium 
is deposited more uniform ly on endosteal and 
periosteal surfaces and also in the Haversian canals 
of cortical bone. ~^^  ^ It has also been shown that 
deposits initially on bone s u r f a c e s .T h e  main 
pathological effect following the deposition of alpha 
emitters in bone is the production of osteosarco- 
ma.7.17-20 Myeloid leukaemia has been observed in 
mice^° and rats^  ^ following administration of ^^ P^u; 
no information is available on the induction of 
leukaemia by ^^ ^Am or
Studies are in progress in CBA/H mice with the 
aim of relating the distribution and incidence of 
osteosarcoma resulting from intakes of ^^ P^u, ^^ ^Am 
and with the pattern of alpha-particle energy 
d ep osition . The in c id en ces  of acute m yelo id  
leukaemia are also being compared. In this paper, 
the distribution of ^^ ^Pu, '^^ A^m and in the 
skeleton and soft tissues at times up to 448 days 
after adm in istration  as citrate com p lexes is  
described, autoradiographic studies of the distribu­
tion of the nuclides in bone are also presented.
M aterials and m ethods
Animals
Male and female CBA/H mice were obtained from 
the MRC Radiobiology Unit, Chilton, Didcot, Oxon, 
0X11 ORD. Groups of five animals were housed  
together. They were used at 12 weeks of age, weigh­
ing 30 ± 3 g. Food (type RMI Expanded, Special 
Diet Services, Witham, Essex) and water were freely 
available at all times. Animal care and handling 
conformed to the Animals (Scientific Procedures) 
Act 1986.
Preparation and adm inistration o f radionuclide  
solutions
Stock solutions of ^^ P^u (IV) nitrate in 3 m  HNOg, 
2^^ Am (III) nitrate in 3 m  HNOg and ^^ U^ (III) nitrate 
(uranyl: ^^ U^Og (NOg)J in 3 m  HNOg were obtained 
from Amersham International pic, Amersham, 
Bucks. Aliquots of stock solutions were evaporated 
to dryness, redissolved in 0 .0 1 m  HNOg and an equal 
volume of 70 mM trisodium citrate solution added 
to give a final pH of about 6.5. Before administra­
tion the solutions were filtered through a 25 nm 
Millipore filter.
Mice were given intraperitoneal injections of 40 
kBq kg-  ^ of either ^^ P^u, ^^ ^Am or ^^ U^ citrate solu­
tions. Intraperitoneal injection was used after estab­
lishing in a preliminary study that the tissue distri­
bution of the three radionuclides was not signifi­
cantly different to the distribution after intravenous 
injection.
Radiochemical analysis and autoradiography 
In the preliminary study, groups of 5 mice were 
given either intraperitoneal or intravenous injec­
tions of 40 kBq kg“^  of either ^^ P^u, ^^ ^Am or ^^ U^ 
citrate solutions and killed after 7 and 28 days. 
Total retention and distribution between major tis­
sues were not significantly different (P < 0.02).
Groups of 12 mice were killed 1,7,14,28,56,112, 
224 and 448 days after intraperitoneal injection of 
the radionuclides. Five animals were dissected for 
separate analysis of liver, kidneys, adrenals, spleen, 
gastrointestinal tract, gonads, femora, humeri and 
remaining carcass. Five anim als were used for 
radiochemical analysis of individual bones; the ani­
mals were skinned, internal organs removed and 
the carcasses placed in a colony of Derm estes 
beetles {Dermestes malculatus) which strip the soft 
tissue from the bones. The bones were removed 
from the beetles and radiochemical analysis was 
undertaken separately for the skull, m andibles, 
groups of cervical, thoracic, lumber, sacral and 
caudal vertebrae, sternum, ribs, scapulae, humeri, 
radii, ulnae, pelvis, femorae, fibiae, tibiae, patellae 
and paws. Femora were removed from two further 
animals for autoradiographic analyses of radionu­
clide distribution.
For radiochemical analyses, tissues were reduced 
to a carbon-free ash by dry ashing at 500°G, dissolv­
ing in 8 m  HNOg, and re-ashing the dried-down  
residue. Ashed samples containing either ^^ P^u or 
233U were dissolved in 4M  HNOg and quantitatively 
extracted into an organic solvent/scintillant mixture 
for scintillation c o u n tin g .T h e  ^^ ^Am content of 
samples was determined by gamma counting.
For autoradiography, bones were fixed in 40% 
ethanol, dehydrated using graded alcohols and 
polypropylene oxide and em bedded in Spurr’s 
resin. Sections (5 pm) were cut from the plastic 
blocks containing the bones and placed on CR39 
plastic slides for a-track autoradiography. The 
slides were exposed from 1 month to 1 year. After 
exposure the slides were etched using 6.25 M NaOH 
solution at 60°G for up to 3-4 h to enable the a- 
tracks to be viewed in the plastic.
Results
Male and female GBA/H mice were killed at eight 
time intervals between 1 and 448 days following a 
single intraperitoneal injection of 40 kBq kg"  ^ of 
either ^^ P^u, ^^ ^Am or ^^ U^ as the citrate complexes. 
The whole-body retention of ^^ P^u and ^4iAm were 
similar with values of about 80% and 70% respec­
tively, after 1 day, falling to about 50% and 45% after 
4 weeks and about 25% and 20% after 448 days 
(Figure 1). The total retention of ^^ U^ was consider­
ably lower, falling from about 15% after 1 day to 
about 5% after 4 weeks and about 3% after 448 days.
39
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40 Table 1 The tissue distribution of 24iAm and in male CBA/H mice after intraperitoneal injection as the citrate
Tissue Nuclide % Injected activity at time (d): X  ± s.e.°
1 7 26 112 448
Liver 239pu 50.9 ± 2.04 40.6 ± 0.49 12.4 ± 0.22 3.06 ± 0.10 2.79 ± 0.16
^^ ^Am 54.2 ± 0.99 31.8 ± 0.77 13.0 ± 0.99 1.55 ± 0.10 0.71 ± 0.10
233U 0.18 ± 0.04 0.12 ± 0.13 0.05 ± 0.001 0.02 ± 0.003 0.01 ± 0.003
Femorae 239pu 2.60 ± 0.19 2.97 ± 0.09 2.83 ± 0.12 2.08 ± 0.11 1.61 ± 0.09
24iAm 1.18 ± 0.12 1.45 ± 0.05 1.71 ± 0.09 1.67 ± 0.06 1.06 ± 0.05
233U 0.73 ± 0.06 0.54 ± 0.08 0.53 ± 0.03 0.30 ± 0.02 0.25 ± 0.03
Humeri 239pu 1.64 ± 0.10 1.72 ± 0.16 1.17 ± 0.10 1.01 ± 0.12 0.83 ± 0.10
2«Am 0.46 ± 0.06 0.57 ± 0.04 0.95 ± 0.11 0.77 ± 0.07 0.57 ± 0.06
233U 0.35 ± 0.04 0.23 ± 0.02 0.34 ± 0.03 0.20 ± 0.02 0.11 ±0.02
Testes 239pu 0.17 ± 0.04 0.07 ± 0.04 0.08 ± 0.004 0.08 ± 0.004 0.08 ± 0.001
2^ ^Am 0.06 ± 0.01 0.09 ± 0.009 0.07 ± 0.002 0.08 ± 0.009 0.05 ± 0.004
Kidneys 233U 4.84 ± 1.08 0.40 ± 0.06 0.16 ± 0.02 0.02 ± 0.004 0.11 ± 0.02
Carcass^ 239pu 19.8 ± 0.76 20.2 ± 0.92 33.0 ± 0.99 24.9 ± 0.56 18.6 ± 0.82
^^ ^Am 11.1 ± 0.59 25.5 ± 0.62 26.9 ± 1.16 22.4 ± 1.38 17.9 ± 1.43
233U 8.93 ± 0.57 5.76 ± 0.78 4.42 ± 0.28 3.12 ± 0.17 2.16 ± 0.27
Totah 239pu 78.5 ± 2.16 67.6 ± 0.97 50.7 ± 0.90 31.7 ±0.62 24.5 ± 0.73
2^ ^Am 70.2 ± 1.24 61.9 ±0.96 44.2 ± 1.43 29.1 ± 1.24 20.7 ± 1.25
233U 15.5 ± 1.20 7.16 ± 0.71 5.55 ± 0.25 3.60 ±0.15 2.56 ± 0.24
“n = 5.
^Carcass sample = remaining tissue, ie hone, muscle and pelt.
'^ Total including adrenals, spleen, gastrointestinal tract, kidneys (^ ^^ Pu and and testes analysed separately.
Table 1 shows results obtained for the tissue dis­
tribution of 2^ P^u, Am and in male mice up 
to 448 days after injection. Results obtained at cor­
responding times for female mice were similar and 
are not shown. For each nuclide, the skeleton was 
the major site of long-term retention. The results 
show that at one day after injection of ^^ P^u, ahout 
50% of injected activity was retained in the liver 
and about 24% in the skeleton; the skeleton was 
taken to he the sum of the femora, humeri and 
remaining carcass for which activity is very largely
in bone with little activity in associated muscle tis­
s u e .W ith  time, the level of activity present in the 
liver decreased while retention in bone increased 
over the first month after injection and subsequently 
decreased. The distribution of americium in mouse 
tissues was very similar to that of plutonium. The 
initial uptake of americium in the skeleton was less 
than for plutonium  (13% of injected activity cf. 
24%) while uptake in the liver was similar. As for 
plutonium, the level of americium activity in the 
liver decreased rapidly w hile retention in bone
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Figure 1 Retention of ^^ P^n, ^^ ^Am and in CBA/H mice 
after intraperitoneal injection as the citrate.
Figure 2 Skeletal retention of ^^ ®Pu, ^^ ^Am and in the 
CBA/H mouse after intraperitoneal injection as the citrate.
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Figure 3 Percentage total body activity retained by liver and 
skeleton in CBA/H mice.
increased over the first month and subsequently 
decreased. The maximum retention in the skeleton, 
at 28 days after injection, accounted for 30% of 
administered americium compared with 37% of 
plutonium but retention after 448 days accounted 
for about 20% of injected activity for both nuclides 
(Figure 2). Total retention of at one day after 
injection accounted for 16% of administered activity, 
with about 10% in the skeleton and about 5% in the 
kidneys. Retention in the kidneys decreased rapidly 
while skeletal retention decreased progressively, 
accounting for 2.5% of injected activity after 448 
days. Figure 3 compares the percentage of whole 
body activity of ^^ P^u, ^^ ^Am and retained in 
the liver and skeleton . In itia lly , the skeleton  
accounted for 30%, 18% and 65% of retained ^^ P^u, 
2‘^ ^Am and respectively, increasing to 85%,
88% and 97% respectively, after 56 days; the corre­
sponding values after 448 days were 86%, 94% and 
99%, respectively.
The distribution of ^^ P^u, '^^ A^m and between 
the individual bones of the skeleton of male mice at 
7 and 448 days after injection are given in Tables 2 
and 3, respectively. The general pattern of distribu­
tion of the radionuclides was similar, with higher 
concentrations being seen in the thoracic, lumbar 
and sacral vertebrae and sternum and lower concen­
trations in the paw bones, radii, ulnae and clavicles. 
For the ^^ P^u animals at 7 days, the concentration of 
activity in the main body of the vertebrae was about 
four times greater than that in the bones with lowest 
concentrations and about twice the average skeletal 
concentration; differences in concentration were 
reduced by 448 days (Table 3). For ^^ ^Am and 
the initial differences in concentration and change 
with time were less than for ^^ P^u. The inhomo­
geneity function, which describes the deviation of 
the relative concentration (% injected activity g~^  in 
bone / % injected activity g~^  in skeleton) of the 
nuclides in individual bones from the concentration 
in the whole skeleton, was calculated using the for­
mula:
IF = ^fIWn(l-Cn}^
where Wn is a weighting function which is equal to 
the relative mass of the individual bones / bone 
group and Cn is the corresponding value of relative 
concentration. Figure 4 shows the inhomogeneity of 
distribution in the skeleton for the three radionu­
clides up to 448 days after injection. Inhomogeneity 
was greatest for ^^ P^u and lowest for ^^^Am. For 
2^ ®Pu, inhomogeneity decreased progressively from 
0.6 to about 0.4 after 448 days. The comparative
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Table 2 Distribution of and between the individual bones of male CBA/H mice 7 days after intraperitoneal injection
as the citrate
Bone % Injected activity: X  ± s.e.“ % Injected activity g-^  a sh :X ±  s.e.°
239pu ^^Mm 233 U 239pu 233 U
Skull 4.06 ± 0.22 4.75 ± 0.14 0.91 ± 0.05 37.6 ± 5.59 29.5 ± 1.41 5.70 ±0.31
Mandibles 0.74 ± 0.04 1.35 ± 0.05 0.31 ± 0.01 23.5 ± 4.59 22.2 ± 1.11 5.03 ±0.27
Cervical vertebrae 1.36 ± 0.09 0.97 ± 0.03 0.20 ± 0.01 81.1 ± 8.02 46.3 ± 3.59 9.30 ± 0.81
Thoracic vertebrae 2.87 ±0.15 1.59 ± 0.05 0.41 ± 0.04 100.2 ± 8.7 52.0 ±4.39 11.6 ± 0.79
Lumbar vertebrae 3.81 ± 0.37 2.00 ± 0.07 0.50 ± 0.05 95.1 ± 12.7 49.4 ± 3.01 11.3 ± 0.89
Sacral vertebrae 1.33 ± 0.21 1.16 ± 0.04 0.21 ± 0.02 92.9 ± 10.4 54.9 ±4.48 10.0 ± 0.93
Caudal vertebrae 1.50 ± 0.26 2.46 ± 0.14 0.44 ± 0.03 22.8 ± 2.96 25.8 ± 1.83 4.67 ± 0.37
Sternum 0.50 ± 0.03 0.36 ± 0.01 0.08 ± 0.01 86.3 ± 7.23 58.1 ± 2.21 13.1 ± 0.80
Ribs 1.94 ± 0.14 1.48 ± 0.16 0.45 ± 0.03 59.8 ± 5.21 43.9 ± 2.95 11.1 ± 0.72
Scapulae 0.76 ± 0.05 0.71 ± 0.03 0.17 ± 0.01 59.3 ± 4.00 48.6 ± 6.41 9.98 ± 0.55
Clavicles 0.14 ± 0.01 0.07 ±0.02 0.02 ± 0.03 45.2 ± 7.82 28.8 ± 6.72 6.39 ± 1.65
Humeri 1.23 ± 0.07 0.82 ± 0.03 0.25 ± 0.02 62.9 ± 8.09 31.5 ± 2.83 9.05 ± 0.42
Radii/Ulnae 0.20 ± 0.03 0.25 ± 0.01 0.05 ± 0.01 29.1 ± 2.47 30.6 ± 7.47 4.76 ± 0.67
Pelvis 2.07 ±0.12 1.38 ± 0.04 0.38 ± 0.03 65.0 ± 5.65 34.2 ± 2.07 8.84 ±0.75
Femorae 2.13 ± 0.15 1.48 ± 0.06 0.48 ± 0.03 59.7 ± 7.45 27.8 ± 1.69 8.50 ± 0.54
Fibiae/Tibiae 1.02 ± 0.15 1.19 ± 0.04 0.36 ± 0.02 41.3 ± 6.16 25.3 ± 1.47 7.27 ±0.48
Paws 0.61 ± 0.04 1.12 ±0.15 0.08 ± 0.01 14.4 ± 1.29 23.4 ± 2.15 1.64 ± 0.20
Total skeleton 30.4 ± 1.74 23.5 ± 0.83 5.38 ± 0.32 47.7 ± 5.17 32.3 ± 1.93 7.03 ± 0.40
'‘n  = 5.
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Table 3 Distribution of and between the individual bones of male CBA/H mice 448 days after intraperitoneal injection
as the citrate
Bone % Injected activity: X  ± s.e.° % Injected activity ash: X ±  s.e.°
239pij 2«Am 239pJ^ 2«Am
Skull 3.81 ±0.23 4.23 ± 0.15 0.69 ± 0.02 22.8 ±4.18 22.2 ± 1.15 3.37 ±0.17
Mandihles 0.72 ± 0.03 0.93 ± 0.04 0.24 ± 0.01 13.8 ± 3.30 12.5 ±0.59 3.22 ±0.16
Cervical vertebrae 0.94 ± 0.05 0.87 ± 0.05 0.13 ± 0.008 37.3 ± 7.00 33.3 ± 3.12 5.31 ± 0.43
Thoracic vertebrae 1.36 ± 0.08 1.18 ± 0.07 0.14 ± 0.004 38.8 ± 5.41 34.7 ±2.66 4.20 ± 0.14
Lumbar vertebrae 1.57 ± 0.06 1.29 ±0.07 0.20 ± 0.008 34.4 ±4.82 28.8 ±2.59 4.26 ± 0.24
Sacral vertebrae 1.02 ±0.07 0.81 ± 0.03 0.12 ± 0.002 38.4 ±4.55 34.3 ± 3.38 4.98 ± 0.16
Caudal vertebrae 1.98 ± 0.09 2.52 ± 0.09 0.62 ± 0.07 16.7 ±0.73 20.6 ± 1.05 5.05 ± 0.86
Sternum 0.25 ± 0.01 0.26 ± 0.02 0.03 ± 0.003 27.4 ± 2.03 40.8 ± 5.43 5.00 ± 0.49
Ribs 1.31 ± 0.06 1.36 ± 0.16 0.16 ± 0.01 25.5 ± 5.72 25.0 ± 2.13 3.00 ± 0.15
Scapulae 0.61 ± 0.02 0.65 ± 0.03 0.12 ± 0.006 32.0 ±6.86 27.7 ± 9.02 6.99 ± 0.69
Clavicles 0.10 ± 0.01 0.12 ±0.02 0.02 ± 0.003 22.0 ±2.60 35.7 ± 6.08 6.12 ± 0.82
Humeri 0.83 ± 0.05 0.70 ± 0.04 0.17 ± 0.006 32.2 ±4.02 23.4 ± 1.63 5.42 ± 0.39
Radii/Ulnae 0.22 ±0.01 0.22 ± 0.06 0.06 ± 0.002 19.2 ± 2.41 22.8 ± 2.65 5.80 ± 1.16
Pelvis 1.13 ± 0.05 1.07 ± 0.06 0.20 ±0.01 29.2 ±4.04 24.3 ± 2.34 4.40 ± 0.24
Femorae 1.45 ± 0.10 1.15 ± 0.05 0.41 ± 0.02 27.9 ±4.33 19.2 ± 0.97 6.35 ±0.45
Fibiae/Tibiae 1.08 ± 0.04 1.04 ± 0.03 0.27 ±0.02 21.4 ±2.03 19.0 ± 0.86 4.78 ± 0.33
Paws 0.62 ± 0.08 1.25 ± 0.21 0.09 ± 0.009 14.7 ± 0.96 23.6 ± 2.90 1.77 ±0.11
Total skeleton 19.4 ± 0.89 20.1 ± 1.17 3.74 ± 0.15 23.4 ±4.16 22.2 ± 1.70 4.17 ± 0.29
“n = 5.
reduction for was from 0.46 to 0.36, w hile  
valu es w ere in  the range 0 .3 -0 .3 5  and 
showed no trend with time.
The accumulation of average skeletal dose is 
shown in Figure 5. The average doses to the skele­
ton from 239p  ^ and ^^ ^Am were very similar with 
values of about 1.6 and 1.7 Gy after 448 days 
respectively; although doses to individual bones 
(Table 4) reflect the greater inhomogeneity of distri­
bution of 239pu^  w ith  ranges of 0 .7 -3 .0  Gy and 
1.1—2.5 Gy after 448 days respectively. The cumula­
tive dose to the skeleton for was estimated as 
0.3 Gy with a range of 0 .1- 0.6 Gy.
The micro-distribution of ^^ P^u, ^^ ^Am and 
in the femurs of mice has been studied autoradi- 
ographically using GR39 plastic detectors at 1, 28,
224 and 448 days after administration. Initially, 
239?  ^ was deposited predominantly on endosteal 
bone surfaces and to a lesser extent on periosteal 
surfaces (Figure 6). By 224 days some burial of ^^ P^u 
had occurred, particularly in cortical bone, seen as 
lines of activity within the bone (Figure 7); other 
areas showed a more diffuse pattern of activity. 
Bone growth led to the formation of a region of new  
metaphyseal bone with low concentrations of ^^ P^u. 
At later times, increasing amounts of ^^ P^u were 
seen to accumulate in the bone marrow. Initially 
2^ ^Am deposited fairly evenly on all bone surfaces 
including those of vascular canals in the cortical 
bone (Figure 8). At later times, some burial occurred 
in the form of lines of activity, particularly in corti­
cal bone (Figure 9). Some accumulation of ^^ ^Am in
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Figure 4 Change in inhom ogeneity values w ith time after 
intraperitoneal injection of ^^^Pu, '^^ A^m and citrate in  
CBA/H mice.
Pu A m
Figure 5 Average skeletal dose following the intraperitoneal 
injection of ^ ®^Pu, ^^ ^Am and citrate in CBA/H mice.
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Figure 6 Autoradiograph of mouse femur 1 day after injection 
of 2-spu citrate showing an even deposition predom inantly on 
endosteal bone surfaces w ith some accum ulation on periosteal 
hone surfaces. There is also a low  concen tration  of activ ity  
throughout the marrow.
-U' - p  -.V- ?
Figure 9 Autoradiograph of mouse femur 224 days after injec­
tion of 2'*^Am citrate showing burial particularly in cortical hone, 
a region of new m etaphyseal bone w ith low concentrations of 
'^‘^ Am and some accumulation of activity in the bone marrow.
ft;
Figure 7 Autoradiograph of mouse femur 224 days after injec­
tion of 239py citrate showing burial of activity, particularly in cor­
tical bone, an accumulation of activity in the hone marrow and a 
region of new  m etaphyseal bone w ith  low concentrations of
239pu.
Figure 10 Autoradiograph of mouse femur 1 day after injection 
of 233JJ citrate showing uneven distribution of activity, on bone 
surfaces and some diffuse activity throughout the bone.
A  ■
■  ^  V —
_:Ua—  V
Figure 8 Autoradiograph of mouse femur 1 day after injection 
of 24iAm citrate showing an even deposition on all bone surfaces 
including those of vascular canals within the cortical bone.
Figure 11 Autoradiograph of mouse femur 224 days after injec­
tion of citrate showing uneven lines of buried activity and
small amounts of diffuse activity throughout the hone.
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44 Table 4 Cumulative doses (mGy) of ^^ P^u, ^^ ^Am and in 
bones and skeleton of male CBA/H mice 448 days after intraperi­
toneal injection as the citrate
Bone Cumulative dose (mGy): X  ± s.e.“
239pu 233 [;
Skull 1320 ± 60 1690 ± 190 306 ± 90
Mandibles 748 ± 60 1197 ± 150 307 ± 100
Cervical vertebrae 2644 ± 130 2555 ± 280 464 ± 120
Thoracic vertebrae 2940 ± 90 2650 ± 150 397 ± 110
Lumbar vertebrae 2760 ± 100 2359 ± 150 428 ± 120
Sacral vertebrae 2970 ± 150 2645 ± 140 418 ± 130
Caudal vertebrae 992 ± 190 1494 ± 150 311 ± 120
Sternum 2727 ± 130 2566 ± 180 390 ± 160
Ribs 1590± 100 1969 ± 220 323 ± 130
Scapulae 2070 ± 90 2447 ±170 5 3 1 ± 140
Clavicles 1815 ± 330 1859 ± 440 430 ± 220
Humeri 2230 ± 70 1807 ± 150 488 ± 110
Radii/Ulnae 1181± 153 1300 ± 247 3 3 1 ± 206
Pelvis 1870 ± 70 1803 ± 140 397 ± 110
Femorae 1913 ± 70 1680 ± 150 537 ± 110
Fibiae/Tibiae 1405 ± 80 1375 ± 180 416 ± 110
Paws 742 ± 120 1726 ± 190 125 ± 160
Total skeleton 1560 ± 60 1775 ± 140 287 ± 90
"n = 5.
the marrow was also observed but less than for 
The initial deposition of was on both 
periosteal and endosteal bone surfaces but the dis­
tribution was uneven with concentrations of activity 
in some areas (Figure 10). There was also evidence 
for diffuse distribution of activity in bone mineral. 
At later times some burial of surface deposits of 
233U was seen together with small amounts of dif­
fuse activity throughout the bone (Figure 11); little 
activity was seen in the marrow.
D iscussion
Long-term retention of Pu, Am and U is confined 
largely to the skeleton in all mammalian species 
s t u d i e d . T h e  dose from ^^ ®Pu, “^^^Am and 
to target cells for the induction of osteosarcoma 
and acute myeloid leukaemia will depend on their 
gross retention in the skeleton, the distribution 
between different parts of the skeleton and distribu­
tion within bone. Importantly, as discussed below, 
the radionuclides differ in their initial pattern of 
distribution on bone surfaces and in aspects of the 
subsequent burial and the proportion transferred to 
marrow.
The liver is also an important site of deposition 
for 239p  ^ and 18 ,2 6 -2 8  However, the elements
are quite rapidly lost from the liver of rats and mice 
such that, as show n in Figure 3, the skeleton  
accounts for more than 85% of the body content 
after about 56 days. The situation is different in 
humans in that retention in the liver is considerably 
longer w ith an estim ated half-tim e of about 20 
y ears. 2 Results consistent with longer retention half- 
times in the liver have also been obtained for ham­
sters and dogs.2^’2^  For the overall tissue reten­
tion is considerably lower than for ^^ P^u and ^^ ^Am 
due largely to rapid initial urinary excretion. 
15,30,31 only significant site of accumulation of 
other than the skeleton is the kidneys; the toxi­
city of natural U is due to its chemical damage to 
the kidneys.
Pu and Am ions are bound to the iron-transport 
protein, transferrin, in circulating blood, probably 
as Pu (IV) and Am (III).^ ~^^ ® A proportion of each 
elem ent w ill also be present in low  m olecular  
weight form, probably as the citrate complexes, and 
it is likely that this proportion will be greater for 
Am than Pu because the binding of Am to transfer­
rin is weaker than that of Pu.^ ~^^  ^ Uptake of both 
elements into the liver involves transfer from trans­
ferrin to the iron-storage protein, ferritin, in hépato­
c y t e s . ^^,39,40 pjjg association of Pu and Am with the 
longer-term storage protein, haemosiderin, in liver 
reticuloendothelial cells has also been demonstrat- 
ed,39-4i The reasons for species differences in the 
hepatic retention of Pu and Am are not understood 
but may relate to d ifferen ces in  transfer to 
haemosiderin, or differences in uptake into lyso- 
somes and transfer to bile.^^
In bone, the binding of Pu and Am to plasma 
transferrin w ill lead to their delivery to reticulo­
cytes the main destination of iron transport, for the 
synthesis of haem. However, as shown in Figures 6 
and 8, the initial distribution of ^^ P^u and ^^ ^Am in 
bone is largely inconsistent with association with 
cells in the marrow although some diffuse distribu­
tion of 239py^  in the marrow is apparent. The main 
site of deposition, as established in previous stud­
ies, is the bone surfaces,®’^  ^ indicating the presence 
of molecules with a higher binding affinity for Pu 
and Am than transferrin. It has been suggested that 
the binding molecules are glycoproteins or proteo­
glycans, constituents of the osteoid layer of unmin­
era lised  new  bone on grow ing surfaces. 
However, this suggestion is not consistent with the 
presence of ^^ P^u and ^^ ^Am on all types of bone 
surface, including resting and resorbing areas, and 
the observation that ^^ P^u on growing surfaces is 
largely concentrated on the surface of the miner­
alised bone.^  ^ Other studies have implicated phos- 
phoproteins, demonstrating the ability of molecules 
in mineralising rat dentine to bind lanthanum;^® 
binding to phospholipids has also been suggested.^^ 
Recently, uptake of radium from transferrin and 
incorporation into ferritin in osteoblasts has been 
dem onstrated .U ptake into osteoblasts may also 
occur for ^^ P^u and ^^ ^Am with important implica­
tions for their potential to induce osteosarcoma.
Differences are apparent in the initial pattern of 
distribution of ^^ P^u and '^^ A^m in the skeleton. As 
shown in Figures 6 and 7, 2S9p^  deposits preferen­
tially on endosteal surfaces while ^^ ^Am deposits 
more evenly on endosteal and periosteal surfaces
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and within vascular canals. These differences may 
reflect quantitative rather than qualitative differ­
ences in their binding to transferrin and ligands in 
bone. Binding to periosteal surfaces and the walls of 
vascular canals in vo lves  passage through the 
endothelium of blood vessels and may therefore 
favour 2^ ^Am in comparison with ^^ P^u because of 
weaker binding to plasma transferrin retained with­
in the vessels. The sinusoidal nature of marrow 
does not present the same barrier to endosteal depo­
sition.
Uranium is present in blood as the hexavalant 
uranyl ion, (UO^P ,^ binding to transferrin with a 
proportion circulating as U(V1) b ic a r b o n a te .T h e  
rapid early urinary excretion of the major propor­
tion of U reaching the circulation is indicative of 
weak protein binding. In the skeleton, uranyl ions 
replace Ca^ + on the surface of the hydroxyapatite 
crystals of mineral bone.^ >^^  ^ The size of the (U02)^+ 
ions are thought to prevent inclusion in the internal 
domain of the crystal lattice and it then remains on 
the crystal surfaces, subject to ion exchange reac­
tions. As shown in Figure 10, the initial pattern of 
distribution of ^^ U^ in mouse bone is uneven. This 
observation is consistent with previous findings^® 
and is thought to be due to preferential binding to 
growing surfaces by coprecipitation with Ca^ + dur­
ing bone formation. While the highest ^^ U^ concen­
trations were associated with bone surfaces, a pro­
portion of the activity in bone appeared to be dif­
fusely distributed throughout the bone mineral.
A comparison of the long-term retention of ^^ P^u,
Am and ^^ U^ in the skeleton of rats has been  
reported by Sontag. 2^,53 The animals used were over 
a year old at the time of injection. As in the present 
study using mice, skeletal retention of ^^ P^u and 
^^ ^Am in the rats was several times greater than that 
of 2^ U^ (2-4 times greater in rats; 5-6 times greater 
in mice). However, in contrast to the results for 
mice, a difference in retention between male and 
female rats was shown for ^^ ^Am and ^^ U^ although 
not for 239Pu. At one week after injection, the skele­
ton accounted for 17% and 29% of administered 
^^ ^Am in female and male rats, respectively, with 
corresponding values of 8% and 15% for ^^ U^; the 
skeleton retained about 40% of administered ^^ P^u 
in females and male animals. These differences 
between females and males for ^ l^Am and ^^ U^ were 
maintained over the duration of the study of more 
than one year.^  ^ In comparison, skeletal retention in 
mice showed no differences between females and 
males with values at 7 days after injection of about 
25-28%  of adm inistered activity for 239p  ^ and 
2^ ^Am and about 7% for ^^ U^. The observed differ­
ences may be a reflection  of different skeletal 
growth rates between old rats and young adult mice 
(12 weeks old) and between female and male rats. 
Comparison of the results obtained by Sontag^ -^^  ^
for female rats with data from short-term studies
using younger rats^ '^^ '^^  ^ show greater skeletal reten­
tion in the younger growing animals for ^^ ^Pu, 
^^ ^Am and ^^ U^. Sontag^^ showed that while the 
skeletal weight was proportional to body weight in 
old female and male rats, the skeletal weight of the 
female rats remained constant, whereas the skeletal 
and body weight of male rats increased progressively. 
That the difference between females and males 
applied to ^^ ^Am and ^^ U^ but not ^^ P^u suggests 
that skeletal uptake of ^^ P^u was relatively insensi­
tive to the greater skeletal turnover and growth in 
males. This may reflect a greater affinity of binding 
ligands in bone for ^^ P^u than for ^^ ^Am and ^^ U^.
Differences between ^^ ^Pu, ‘^^ ^Am and ^^ U^ in 
their distribution between individual bones of the 
skeleton in mice are consistent with results reported 
by Sontag 2^,53 distribution in rats. Thus, the gen­
eral pattern of distribution of the nuclides was simi­
lar in both species, with greater concentrations in 
the main body of the spine, limb girdles and ribs 
and lower concentrations in the paw bones, head 
bones and caudal vertebrae. The inhomogeneity of 
distribution was in the order Pu > U > Am in both 
species but with somewhat greater values in mice 
than in rats. For example, for ^^ P^u inhomogeneity 
changed from 0.6 to 0.4 (Figure 4) in mice over 448 
days while the corresponding change in rats was 
from 0.45 to 0.3. Data for the distribution for ^^ P^u 
and 2^ ^Am in the human skeleton, from four cases 
of long-term occupational exposure, have been com­
pared with data for baboons and monkeys by Lynch 
et As rodents, the greatest concentrations were 
in the thoracic and lumbar vertebrae and inhomo­
geneity was greater for ^^ P^u than for ^^^Am. It 
would appear that factors affecting distribution 
between different bones are the proportion of tra­
becular bone, and consequently the relative surface 
area for d ep osition , and d ifferen ces in  b lood  
supply.^ ’^^®
The high values obtained for the initial uptake of 
239pu and Am in the mouse liver of about 40-45%  
of injected activity are consistent with previous 
results for ^^ P^u in mice.^  ^ Comparison of ^^ P^u dis­
tribution in a number of strains of mice showed that 
uptake in the liver was particularly high in CBA/H 
mice, as used in the present study, and that skeletal 
retention was correspondingly lower due to direct 
competition for circulating ^^ P^u. CBA/H mice were 
used nevertheless, for comparisons of the biokinet­
ics and toxicity of ^^ P^u, ‘^^ ^Am and ^^ U^, because 
this strain provides a well studied model of radia­
tion-induced osteosarcoma and myeloid leukaemia 
in which the spontaneous incidence is practically 
z e r o . T h e  liver shows a spontaneous inci­
dence of benign tumours of around 60% in this 
mouse, but these are not a major cause of death.
The burial of surface deposits of ^^ P^u, ^^ ^Am and 
^^ U^ in areas of bone growth (Figures 7,9 and 11) is 
consistent with previous f i n d i n g s . T h i s
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46 process results in a reduction in radiation dose to 
sensitive cells in bone surfaces and in the bone mar­
row because of the short range of alpha-particles in 
bone of less than 30 pm. The current ICRP dosimet­
ric model for isotopes of Pu and Am  ^ takes account 
of burial of activity in bone although it does not 
take account of the differences in the initial distrib­
ution of the two elements on different bone sur­
faces. For autoradiographs (Figures 10 and 11) 
showed that a proportion of the activity in bone was 
diffusely distributed throughout bone mineral from 
one day after injection. At later times, burial of sur­
face deposits was observed but with no indication 
of a trend towards uniform distribution. The ICRP 
modeP for U assumes that long-lived isotopes are 
volume-seekers like the alkaline earth elements; 
that is, they are distributed throughout the volume 
of bone from the time of their initial deposition in 
the skeleton. However, the results obtained, together 
w ith other available data^ '^^ .^si suggest that the 
behaviour of U shows greater similarity to that of 
Am and Pu.
Transfer from bone to marrow is recognised as an 
important aspect of the behaviour of isotopes of Pu 
and is included in the ICRP model.^ Retention in 
the marrow is thought to be due to uptake in  
m acrophages.A utoradiographs show that trans­
fer of 244Am was less than that of ^^ P^u and accumu­
lation of in the marrow was negligible. Each of 
these observations is consistent with the behaviour 
of the nuclides in rats.^  ^ While the ICRP modeP 
includes accumulation in the marrow, the same 
parameters are applied to isotopes of Pu and Am 
and no account is taken of quantitative differences.
Sontag^" has used the results of autoradiographic 
studies of the distribution of ^^ P^u in the rat skele­
ton to determine the distribution of radiation dose. 
Doses increased in the order: marrow, bone mineral, 
periosteal surfaces, endosteal surfaces. Similar
R eferences
methods will be applied to the results obtained in 
the present study in order to compare the dose dis­
tribution of 2^ P^u, ^^ ^Am and
In conclusion, comparisons of the behaviour of 
239pu, and in CBA/H mice showed that
the skeleton was the principal site of deposition  
and long-term retention of each nuclide. No differ­
ences were established between males and females 
in  their sk eleta l uptake and reten tion  of the  
nuclides; previous results for old rats®^  probably 
reflect differences in skeletal growth. Within bone, 
all three nuclides were initially deposited on bone 
surfaces but with significant differences in their 
association with different types of surface and some 
diffuse distribution in bone mineral in the case of 
Surface deposits were buried in areas of bone 
deposition and transfer of activity to the marrow 
also occurred with ^^ P^u and to a lesser extent with 
Am. On the basis of these observations and cur­
rent assumptions regarding the distribution of sen­
sitive cells on bone surfaces and in the marrow,^ 
both cell types w ill receive different doses from 
each of the three nuclides and the dose rate w ill 
vary with time in each case. Studies are in progress 
with the aim of relating doses to sensitive cells with 
the distribution and incidence of osteosarcoma and 
the incidence of acute myeloid leukaemia. These 
data will be presented in a subsequent publication.
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